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Abstract 
The isolation and characterisation of MHC-presented peptides from CML-derived 
cell-lines, with a focus on post translational modification. 
Krishan N. Kapoor 
 
Phosphorylation is a key regulator of protein function and activity, and aberrant 
kinase activity is implicated in a wide range of malignancies, of which the bcr:abl 
fusion kinase found in chronic myeloid leukaemia is a classic example. As 
phosphopeptides are known to be presented by both the MHC class-I and class-
II pathways, against which specific CD4+ and CD8+ T cell responses may be 
generated, study of MHC-presented phosphopeptides may reveal unique cancer 
antigens with direct links to the neoplastic state. 
 
Mild acid cell-surface elution is a rapid and effective method for MHC class-I 
peptide capture, though complicated by contamination with non-MHC peptides 
and poor downstream compatibility, especially with IMAC, a popular method for 
phosphopeptide enrichment. As an alternative to the citrate-phosphate elution 
buffer, a TMA-formate elution buffer is proposed. This was developed for IMAC 
compatibility, and osmotically balanced and supplemented to minimise cell lysis, 
(assessed by several assays) and used with a pH 5.5 prewash to reduce non-
MHC peptide contamination. MALDI-MS/MS of MHC class-I peptides from K562-
A3 cells found a sequence with high homology to a known cancer antigen as the 
common peak for both citrate-phosphate and TMA-formate eluted cells. 
 
Currently there are no published mechanisms for cell-surface elution of MHC 
class-II peptides (immunoprecipitation is widely used), though previous work at 
NTU led to the development of an IMAC compatible MHC class-II protocol. This 
was also subjected to supplementation and optimisation, reducing cell death to a 
level corresponding to that of the widely accepted citrate-phosphate class-I 
protocol.  
 
Various chromatographic approaches were tested for phosphopeptide retention. 
Fe3+ IMAC remains optimal; methods were adjusted to increase peak fraction 
concentration (assessed by a modification the BCA protein assay improving 
suitability for peptides). Though further method development may be required to 
optimise mass spectrometry, a number of phosphopeptides were found in both 
MHC class-I and class-II eluates, many with known links to malignancy. It is 
hoped that these improved methods will be of use in the ongoing search for 
novel cancer antigens. 
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1.0 Introduction and Aims 
 
1.1  Cancer 
 
1.1.1  Definition and epidemiology 
 
Cancer may be defined as the uncontrolled proliferation of cells from a single cell 
of origin. Cell division is a tightly controlled event responsible for tissue growth 
and repair/turnover, with the uncontrolled tissue growth exhibited in cancer 
typically having lethal consequences if left untreated. Cancers are diagnosed in 
over 10 million patients per year, and account for approximately 12% of deaths 
worldwide (WHO, 2005); though this figure rises to 27 % for the UK 
(CancerStats, 2009). While deaths from cancer have fallen by 19.2 % in men, 
and by 11.4 % in women in the US between 1990/1-2005 (Jemal et al., 2009), 
this is largely due to improvements in detection/therapy for small subsets of 
common malignancies, and the incidence of cancer is expected to rise along with 
the mean age of western populations (Pal et al., 2010). 
 
 
1.1.2  Oncogenes and tumour suppressor genes 
 
It is believed that cancers generally arise due to genetic insult, typically from the 
accumulation of errors and mutations within an organism’s DNA over the course 
of its lifetime (Nordling, 1953; Lewin, 2000), though exposure to various agents 
such as carcinogens or ionising radiation may greatly increase the number of 
genetic errors over a short period of time (Westwood, 1999). As these errors 
accumulate they inactivate proteins or promoter regions, or (activate them via 
inactivation of their mediation pathways/proteins) until a point is reached at 
which the cell begins to replicate uncontrolled (Varmus and Weinberg, 1993). 
Hanahan and Weinburg (2000) laid out six characteristics that a cancer must 
acquire to develop into a tumour, namely: (1) independence from growth signal 
requirements; (2) insensitivity to antigrowth signals; (3) evasion of apoptosis; 
(4) limitless replicative potential; (5) sustained angiogenesis; and (6) tissue 
invasion/metastasis but there is no specific sequence for these events, and while 
the change in expression/functionality of a single gene may contribute to more 
than one of these steps, others may require alterations to multiple genes. It 
must be remembered that the potential causes for transformation of a cell from 
healthy to cancerous are legion, and far from exclusive (though some events are 
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common, such as loss of p53 function [Vousden and Lane, 2007]). Cancer stem-
cell theory further complicates this picture, and the relationship(s) between 
tumour, normal stem cell and cancer stem cell is still far from elucidated (Clarke 
et al., 2006), though it is thought that at least in the leukaemias limitless self-
renewal is restricted to a subpopulation of stem cells (Lane, et al., 2009). 
 
At the root of carcinogenesis lie two classes of genes: oncogenes and tumour 
suppressors. The discovery in the early 20th century that some tumour causing 
agents were transmissible, followed by the identification of cancer-causing 
oncoviruses fifty years ago (Epps, 2005) eventually led to the Nobel prize-
winning discovery that such genes were not originally viral in origin, but derived 
from mammalian genes that have become incorporated into a retroviral genome. 
The original genes, termed proto-oncogenes do not in the normal state of affairs 
lead to tumorigenisis, but are typically involved in cell division (Kwong et al., 
2007). However mutations, translocations, or gene amplification may lead to 
permanent activation of these genes, which in turn may initiate the cell into a 
proliferative state, or enhance the progression of an existing malignancy. Proto-
oncogenes may be divided into a range of functional groups including 
transcription factors (e.g. NOTCH1, mutated in the majority of T-ALL1 patients); 
epigenetic remodelers (e.g. chromosomal translocations involving ALL1, common 
in acute leukaemias); growth factors or growth factor receptors (reviewed for 
melanoma by Kwong et al., 2007); signal transducers (particularly kinase 
signalling pathways) or inhibitors of apoptosis (BCL-2 being a classical example) 
(Alfano, 2006; Croce, 2008; Palomero and Ferando, 2010). Nevertheless, 
oncoviruses remains implicated in approximately 12 % of cancers globally 
(Schiller and Lowy, 2010) with the majority accounted for by human 
papillomavirus, Epstein-Barr virus (EBV), hepatitis B and C, and Kaposi’s 
sarcoma–associated herpes virus. Helicobacter pylori infections are responsible 
for another 5.5 % of cancers (through activation of the Wnt/β-catenin signalling 
pathway) and the burden of infection-related (oncoviral or otherwise) 
malignancy is disproportionally borne by the developing world (Parkin, 2002). 
 
However, a mutation that converts a proto-oncogene into their oncogenic 
counterpart will not necessarily cause an immediate transformation to 
malignancy. Tumour suppressors, such as RB and p53, regulate cell division, and 
according to the two-hit hypothesis of malignancy2 the activity of such tumour 
                                                 
1
 T-cell acute lymphoblastic leukaemia. 
2
 Not to be confused with the two hit hypothesis of immunity (Moore et al., 1993; Murphy et al., 2004) 
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suppressors must also be disrupted if a cell is to proliferate uncontrolled 
(Knudson, 1971; DeCaprio, 2009). This theory states that if disruption of a 
tumour suppressor is to occur at the genetic level both copies of the gene 
usually must experience deactivation (Chan et al., 2004); this contrasts with 
oncogenes which are typically dominant over their non-mutated counterparts 
(Viallet and Minna, 1990). Typically tumour suppressors operate as DNA-damage 
linked checkpoints in the cell cycle, either preventing mitosis or initiating 
apoptosis if DNA damage is unrepairable (Sherr, 2004). A related set of genes 
known as metastasis suppressors operate to prevent tumour cells down-
regulating adhesion molecules (Vaidya and Welch, 2007). 
 
 
1.1.3  The Leukaemias 
 
1.1.3.1  Risk factors, classification and epidemiology 
 
As the potential molecular bases for a cancer are legion, classification tends to 
be primarily based on the apparent tissue of origin. The leukaemias (from the 
Greek leukoshaema or ‘white blood’), are cancers of the haematopoietic stem 
cells (HSC’s), a non-uniform (yet CD34+) pluripotent progenitor population 
contained in the bone marrow, with smaller numbers in the peripheral circulation 
(McKinney-Freeman and Goodell, 2004). These stem cells produce daughter cells 
which may be either committed myeloid or committed lymphoid progenitor 
(CMP/CLP) cells. While the former produce monocytes, neutrophils, basophils 
and eosinophils (as well as erythrocytes and platelets), the latter are the 
progenitors of B- and T-lymphocytes, and natural killer (NK) cells. Subsets of 
dendritic cells (DCs) may be produced by either progenitor class. 
 
The theory of cancer stem cells (CSC’s), that all the malignant cells within a 
tumour are derived from a single (un-differentiated or semi-differentiated) 
pluripotent cell with stem-cell like properties, is growing in acceptance, and in 
the case of CML and the other leukaemias is supported by a number of 
observations, including homogeneity of the bcr:abl (see 1.1.3.4) breakpoint 
amongst all leukaemic cells within a CML patient; the full or partial differentiation 
of these leukaemic cells into a range of hierarchical subtypes, all of which often 
carry the same chromosomal translocation (Haferlach et al., 1997). Further 
evidence includes the findings by Lapidot et al. (1994) that only transplantation 
of CD34+, CD38- acute myelogenous leukaemia (AML) cells led to the generation 
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of AML in SCID mice, where CD34- or CD38+ cells could not. As in bone marrow 
the CD34+, CD38- phenotype is expressed by immature haematopoietic 
progenitors, it is feasible that CSCs arise from mutations in normal stem or 
progenitor cells (which by definition are already in possession of the pluripotent 
capability) (Bannerjee et al., 2010). 
 
Leukaemias may therefore be divided into lymphoid and myeloid (in practise 
primarily granulocytes) subsets, though the malignant cells typically fail to 
demonstrate full maturation, especially in later stages (Altucci, et al., 2005). The 
World Health Organisation (WHO) recently reported that in 2004 (the most 
recent year for which they carry full epidemiological statistics) leukaemias were 
collectively responsible for over 263,000 deaths (3.7% of total cancer deaths) 
(WHO, 2004) with the majority of leukaemias occurring primarily in adults 
(Westwood, 1999). Risk factors include ionising radiation 3  (Moloney, 1987; 
Dropkin, 2009; Pelissari et al., 2009); some chemical agents, including 
cyclophosphamide, benzene, and chloramphenicol (Adamson and Seiber, 1981); 
chromosomal translocations (e.g. Faber and Armstrong, 2007; Caudell and Aplan, 
2008; Druker 2008; and Jamieson, 2008); as well as a variety of pre-existing 
conditions, including Down’s syndrome (Malinge et al., 2009; Rabin and Whitlock, 
2009), Fanconi’s anaemia (Andrea, 2003), and hyper-eosinophilia (Owen and 
Scott, 1979). Viral infection of HSCs/progenitor cells is also a strong risk factor 
for many leukaemias, particularly for retroviruses, for example the Friends 
Leukaemia Virus, the Moloney Murine leukaemia virus and the Human T-cell 
lymphotropic virus type 1 (reviewed in Bannerjee et al., 2010), while the (non 
retroviral) herpes-virus EBV is linked with childhood acute lymphoblastic 
leukaemia (ALL) (Tedeschi et al., 2007) and there is some evidence that it 
contributes to the progression of chronic lymphoblastic leukaemia (CLL) (Dolcetti 
and Carbone, 2010). Interestingly EBV infection is known to activate the human 
endogenous retrovirus HERV-K18 present in the genome (Sutkowski et al., 
2001), and it is possible that EBV may also employ this endogenous retrovirus as 
part of its life cycle, though how this may link with transformation is as yet 
unclear (Hsiao et al., 2006). However, the chronic myelogenous form of 
leukaemia (CML) which is the focus of this area of study has little in the way of 
recorded heritable components (Gunz, 1977; Lichtman, 1995). 
 
                                                 
3While a localized increase in CML incidences was a consequence of the 1945 atomic bomb 
detonations in Japan, a notably higher percentage of leukaemias in the Hiroshima survivors were 
diagnosed as CML than in Nagasaki (43.6 % c.f. 15 %) (Moloney, 1987). 
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Table 1.1 Breakdown of cancer diagnosis and mortality in the UK (total population) in 2007. 
Note that diagnosis and death often occur months to years apart, and therefore changes in 
therapy or prevention may allow a greater number of fatalities from a cancer than are 
diagnosed within the same year, as evidenced by pancreatic cancer (derived from 
CancerStats, 2009). Cancer accounted for approximately 27.31 % of the registered deaths 
in the UK in 2007 (ONS, 2008). 
 
 
 
 
 
Leukaemias Diagnosed (2006) 
Percentage 
of Total 
Leukaemias 
Mortality 
(estimated 
2010) 
Percentage 
of Total 
Leukaemias 
Chronic lymphocytic 
leukaemia 0  0
 
Acute monocytic leukaemia  0 	 0
	 
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Chronic monocytic leukaemia  0	 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Acute lymphocytic leukaemia  0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
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Other leukaemias 0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
Total 
	  
 
Table 1.2: Breakdown of diagnosis and mortality in the USA by leukaemia-subtypes. 
Diagnosis data for 2006 derived from Horner et al. (2006), estimated 2010 mortality figures 
derived from (LLS, 2010). Figures given are for total population, however the leukaemias 
account for a higher rate of mortality amongst males (WHO, 2004). 
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1.1.3.2  Chronic Myelogenous Leukaemia (CML) 
 
As may be seen from table 1.2, lymphocytic and myelogenous leukaemias make 
up the vast majority of leukaemia fatalities in the USA. These may be divided 
into chronic and acute forms. The latter involves the rapid accumulation of 
immature white blood cells within the bone marrow, inhibiting haematopoietic 
stem cell activity. The former, first identified in 1845 (Virchow, 1845; Bennett, 
1845; Cragie, 1845), typically involves the slower build up of (initially) normally 
maturing granulocytes in the bloodstream, though these cells showing 
increasingly poor chemotaxis as the disease progresses (Anklesaria et al., 1985). 
Unlike its acute counterpart, chronic myelogenous leukaemia (CML) may take 
years to progress (3-5 years to accelerated phase), and therefore immediate 
treatment is not always required. CML accounts for approximately 15% of adult 
leukaemias, affecting a global average of 10-20 individuals per million, per year, 
with the highest range between 40-60 years (the peak is 46-53 years), and like 
most leukaemias has a slightly higher prevalence in males4 (Cartwright, 1992; 
Faderl et al., 1999). Symptoms relating to the high white cell count include 
fatigue, anorexia/weight loss, hyperviscosity of blood, headaches, tinnitus, 
blurred vision and retinal hemorrhage, splenomegaly, haemomegaly, 
hyperuricaemia, and resulting gout and bladder stones, priapis, confusion and 
stupor (Quintás-Cardama and Cortes, 2006). 
 
Changes are usually observed in the white blood cells in the peripheral blood, 
with increases in basophils, eosinophils, myelocytes and neutrophils common, as 
well as potential increases in lymphocytes and platelets, the appearance of 
nucleated red blood cells may be observed, as may potential decreases in 
erythrocytes (Rodak et al., 2007). Within the bone marrow itself hypercellularity 
rapidly presents, along with depletion of fat and increasing fibrosis (Lorand-
Metze et al., 1987; Buesche et al., 2004). 
 
Chronic myelogenous leukaemia is bi- or tri-phasic, with the majority of patients 
diagnosed during the stable chronic phase, at which time ~40 % of patients are 
asymptomatic. This typically lasts for 3-5 years if untreated (Appleby et al., 
2005) giving way to accelerated phase (defined as a proportion of > 20 %5 
leukaemic cells in peripheral blood), in which the cancer shows increasing
                                                 
4
 The male-female patient ratio is 1.4:1 (Quintás-Cardama and Cortes, 2006) 
5
 Formerly 30 %. 
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Figure 1.1Global breakdown of mortalities from the leukaemias (per 100,000 inhabitants), standardised by age (WHOSIS, 2004) (image courtesy of 
Wikimedia Commons). The high rates of mortality in Iraq and Afghanistan are only partly due to the effect of the ongoing conflicts on the health service. In 
some regions of Iraq childhood leukaemia has more than doubled since 1995 (Hagiopan et al., 2010); while the cause of this has yet to be confirmed, 
public opinion largely ascribes this to the use of depleted uranium munitions in the 1990-1991 Gulf War. 
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genetic instability (Rivas et al., 2001) and the CML cell population shows reduced 
terminal  differentiation  (Mauro  and  Druker,  2001).   As  the  disease  progresses 
eosinophilia and basophilia are frequently observed, and Gaucher-like 
macrophage foam cells may be reported (Thiele et al., 1986). The activity of 
total leukocyte (or neutrophil) alkaline phosphatase is usually reduced, making 
this a common enzymatic assay (usually as a blood or bone marrow cell-count 
smear assayed under a microscope for a blue/violet colourimetric result) for 
indication of a potential leukaemic state (Ghanei and Vosoghi, 2002), prior to 
confirmation by cytogenetic or molecular approaches. 
 
The advanced stage culminates in blast crisis, the terminal stage (the risk of 
progressing from the advanced phase to blast crisis rises by approximately 4 % 
per year (Sokal et al., 1985)). This is symptomatically similar to acute 
myelogenous leukaemia (Faderl et al., 1999), and is defined as having greater 
than 20 % bone marrow composed of leukaemic blasts, or the presence of blast 
cells in peripheral blood, at which point median patient survival ranges from 6-9 
months depending on sensitivity to therapy. Death is typically from infection or 
complications related to bleeding (Shah et al., 2002; Appleby et al., 2005; 
Radich, 2007). 
 
As the condition progresses, 33% of patients in blast crisis exhibit cells with a 
lymphoid morphology expressing CD10 (a common acute lymphocytic leukaemia 
antigen also expressed in metastatic carcinomas [Velasquez et al., 2007]) CD19, 
and CD22. The remaining 67% exhibit a phenotype similar to acute myelogenous 
leukaemia (AML) expressing CD13, CD33, and CD117, with a small minority 
progressing to myelofibrosis, leading to bone marrow failure (Appleby et al., 
2005; Quintás-Cardama and Cortes, 2006). The French-American-British (FAB) 
classification system divides myelogenous leukaemia into seven stages, primarily 
by cell morphology (Bennett et al., 1976; 1981; Lilleyman, 1991), though this 
system has been supplanted by the more prognostic/diagnostic WHO approach 
(reviewed in Heaney et al., 2000 and Vardiman et al., 2002) which includes blast 
classification and differentiation, key chromosomal translocations and cell 
morphology.  
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1.1.3.3  Chromosomal translocations and BCR:ABL 
 
Abnormalities in chromosome structure, polyploidy and chromosome loss have 
been a commonly reported finding in cancer since the 1950’s, however it was not 
until the advances in basic molecular biology at end of that decade that these 
were recognised as being linked to the cancerous state (Rowley, 2008), and the 
subsequent and ongoing elucidation of the roles of oncogenes and tumour 
suppressors in neoplasticity (Hanahan and Weinburg, 2000). Of particular 
interest are the translocations commonly found in the leukaemias (amongst 
many other cancers), indeed, chronic myelogenous leukaemia (CML) is often 
toted as “a paradigm of early cancer” (Clarkson et al., 2003), partly due to the 
discovery that the majority (>90 %) of patients exhibit a consistent 
chromosomal abnormality known as the Philadelphia (Ph) chromosome (Nowell 
and Hungerford, 1960) 6 . This is formed from a reciprocal chromosomal 
translocation (Rowley, 1973), fusing the gene for c-ABL7 (Bartram et al., 1983), 
a proto-oncogene with non-receptor tyrosine kinase activity (from chromosome 
9) (Lugo at el., 1990) with BCR8 (Groffen et al., 1984), a hitherto unknown gene 
with serine/threonine kinase properties (from chromosome 22). 
 
The cause of the translocation is unclear, though Goldman and Melo (2003) 
suggested that this may be facilitated by close proximity between the two genes 
in interphase, however the resulting fusion-gene product is a deregulated 
cytoplasmic tyrosine kinase (Mauro & Druker, 2001)9. This fusion protein lacks 
the N-terminal sequence of abl, and the loss of a myristoylated glycine coupled 
with the disruption of the adjascent SH3 domain by bcr together significantly 
upregulate the kinase activity (and thus transforming activity) of abl (Franz et al., 
1989; Hanstschel et al., 2003). However Abl retains the actin-binding domain 
(enhanced by bcr coiled-coil and Grb-2-binding sequences which also enable 
dimerisation, and interaction with proteins such as Ras), nuclear localisation 
                                                 
6
 The remainder frequently exhibit mutations in the kinase Jak2, which is upstream of Ras, MAPK, 
Erk, PI3K, SHP-2 and STAT-5 (Tefferi and Gilliland, 2006; Kaushansky, 2007). Altered Jak2 activity 
is not specific to CML however, and Ph+ CML also often demonstrates altered JAK2 phosphorylation, 
especially with regard to c-myc upregulation (Xie et al., 2002). 
7
 c-ABL is the cellular homologue of the transforming protein v-ABL, from the Abelson murine 
leukaemia virus (Mauro and Druker, 2001), thought to be involved in cellular responses to oxidative 
stress, DNA damage, and integrin and (PDGF) signalling (Appleby et al., 2005).  
8
 BCR is a serine kinase with DBL (guanine nucleotide exchanger) homology and GTPase activating 
homology domains. Neutrophils of BCR-negative mice exhibit increased oxidative burst (Appleby et 
al., 2005), though the cause for this is undetermined.  
9
 Auto-tyrosine-phosphorylation down-regulates the kinase activity of the bcr region (Liu et al., 1996). 
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sequence and DNA-binding domain (Chung et al., 1996; He et al., 2002), further 
enhancing the activity of the fusion product. 
 
The fusion most commonly occurs between bcr exon 13 (also known as b2) or 14 
(or b3) and abl exon a2, producing a b2a2 or b3a2 fusion gene (Yaghmaie et al., 
2007), which in turn is transcribed into a 210 kDa cytoplasmic protein; though 
one 190 kDa form is known to be commonly produced by alternative splicing 
(Heisterkamp et al.,1985; Grosveld et al. 1986; Bernards et al., 1987; Melo, 
1996; ten Bosch et al. 1999; Mauro & Druker 2001). Alternative fusion points, 
such as b2a3 and b2a2 produce shorter (203 kDa) protein products (Yaghmaie 
et al., 2007), and similarly, additional splice variations have been found to 
produce shifts in reading frames and junction sequences which in turn may affect 
bcr:abl activity and produce differentially immunogenic sequences (Volpe et al., 
2007). The presence of a specific breakpoint in Ph chromosomes of all CML cells 
within a patient has been regarded as one of the primary pieces of evidence for 
CML’s clonal origin, and is supported by the activity of only one allele of glucose-
6-phosphate dehydrogenase in heterozygous female patients (Rodak et al., 
2007), the normal cells of whom express a heterogeneous phenotype. 
 
However BCR:ABL fusion is not exclusive to CML, and is also found in chronic 
neutrophilic leukaemia patients (Pane et al., 1996), as well as a minority of 
acute lymphoblastic (Westbrook et al., 1992) and acute myelogenous leukaemia 
(Kurzrock et al,. 1987), lymphoma (Mitani et al., 1990; Fuji et al., 1990) and 
myeloma patients (Van den Berge et al., 1979), though these occurrences 
frequently involve alternative fusion points, such as a fusion between exon 1 of 
bcr and abl exon 2 (e1a2), common in Ph+ ALL (and in CML in the later stages of 
blast crisis), or the a19a2 fusion common in chronic neutrophillic leukaemia 
(Yaghmaie et al., 2007). 
 
Other chromosomal translocations are also common in the leukaemias, such as: 
t(15:17) PML-RARα found in >90% of acute promyelocytic leukaemia10 (Altucci, 
et al., 2005); the t(8;21)(q22;q22)CBFT1-RUNX1 translocation (producing the 
AML1-ETO fusion protein) found in 10 % of AML (Schwieger et al., 2002). Also 
documented are the t(5:12)(q33:p13) TEL:PDGFRβ fusion commonly present in 
chronic myelomonocytic leukaemia (Golub et al., 1994); a TEL:AML1 
t(12;21)(p13;q22) translocation found in 25% of juvenile ALL (Golub et al., 
1995; McLean et al., 1996); the TEL:JAK2 t(9;12)(p24;p13) frequently occurring 
                                                 
10
 A subtype of AML. 
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in childhood T-cell leukaemia (Lacronique et al., 1997; Carron et al., 2000). 
Additional translocations include the t(5;10)(q33;q21)H4/D10S170:PDGFRβ 
translocation also found in (often bcr:abl negative) CML cases (Kulkarni et al., 
2000; Schwaller et al., 2001; Garcia et al., 2003; Drechsler et al., 2007) or the 
t(8;13)(p11;q11-12)/t(6;8)(q27;p11) translocations that fuse the fibroblast 
growth factor receptor (FGFR1) with ZNF198 or with the oncogene FOP 
respectively (Xiao et al., 1998; Popovici et al., 1999). Additional chromosomal 
abnormalities such as trisonomy 8 and duplication of the Ph chromosome are 
routinely detected in accelerated-phase patients (Quintás-Cardama and Cortes, 
2006). 
 
Further complicating the issue however, bcr:abl positive cells have been 
identified in the white blood cells of non-leukaemic patients (Biernaux et al., 
1995; Bose et al., 1998; Bayraktar and Goodman, 2010); the genes for two 
fusion kinases associated with anaplastic large cell lymphoma (ALCL): NPM:ALK 
and ATIC:ALK are found in non-malignant tissue belonging to ALCL and 
Hodgkin’s lymphoma patients (Maes et al., 2001),  and the AML1/ETO fusion 
gene is present in non-leukaemic stem cells of AML patients (Miyamoto et al., 
2000), and that such chromosomal translocations may occur prenatally (Mori et 
al., 2002). In these cases protein expression was not assessed however, and it is 
possible that the fusion proteins were either not properly expressed, that their 
activity might be inhibited by some unknown factor, that additional genetic 
events were required for malignancy, or that the occurrence of an (e.g.) t(9:22) 
chromosomal translocation in a non-stem cell cannot lead to self-renewing 
malignancy (Michor et al., 2006). Of these objections, the latter two are 
supported by the findings of Jaiswal et al. (2003) who found that the creation of 
an animal model which only expressed bcr:abl in non stem-cell myeloid cells led 
to myeloproliferative diseases in only a quarter of individuals, until the line was 
crossed with another strain lacking the pro-apoptosis gene BCL-2, whereupon 
50 % were found to present with leukaemias transplantable to w/t counterparts. 
 
The majority of these oncogenic fusion proteins are deregulated kinases like 
bcr:abl (as reviewed in Cross and Reiter, 2002), highlighting the role of 
phosphorylation within cancer (the remainder being typically transcription factors, 
or transcription regulatory factors). Though the human proteome is thought to 
contain over 10,000 phosphorylation sites on at least a third of the proteome, 
only around 2000 of these have been identified thus far (Zhang et al., 2002; 
Grimsrud et al., 2010), and altered expression or activity of kinases and 
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phosphatases has well documented links with cancer (Cantley et al., 1991; 
Capra et al., 2006) (see table 1.3 for some examples).  
 
 
1.2  Protein phosphorylation 
 
Protein phosphorylation may be broken down into O-linked (serine, threonine 
and tyrosine) (1800:200:1 respectively) (Hunter, 1998); N-linked (histidine, 
arginine and lysine); S-linked (cysteine); and acyl-linked (glutamic acid and 
aspartic acid) (Klumpp and Krieglstein, 2002; Barnouin et al., 2005; Han et al., 
2008).  To date, O-phosphorylation has received the lion’s share of analysis, 
primarily due to abundance: while the most common N-linked phosphorylation, 
phosphohistidine is thought to be 10-times more common than phosphotyrosine 
in yeast, studies on the mammalian proteome have produced far fewer results 
(reviewed in Klumpp and Krieglstein, 2002). While histidine phosphatases have 
been documented in the mammalian proteome (Klumpp et al., 2002; Ek et al., 
2002), the relative abundance of O-phosphorylation may however be a mirage 
produced by lower stability: surrounding amino acids have an immense impact 
on stability of (e.g.) histidine residue’s phosphate group, to the extent that 
dephosphorylation may in some cases be spontaneous, e.g. as a potentially 
ephemeral modification in enzyme catalytic sites (Klumpp et al., 2002; Ek et al., 
2002). Furthermore, the acid-lability of (e.g.) N-phosphorylation also renders 
analysis problematic by the mechanisms developed for O-phosphorylation (all 
non O-phosphorylations are acid labile, while phosphoarginine is unstable at 
either pH extreme), and currently no antibodies are available for detection of 
phosphorylated histidine residues (Klumpp and Krieglstein, 2002; 2005; Zu et al., 
2006). Despite this, histidine phosphorylation has been linked to a number of 
proteins of interest to cancer research (reviewed in Steeg et al., 2003). 
 
In all cases, phosphorylation may impact on protein activity, location and 
interaction (Zhang et al., 2002), and may result in the negatively charged 
phosphoryl group (which in the case of O-phosphorylation adds a mass of 80 Da 
to the amino acid in question [Mann & Jensen, 2003]) forming hydrogen bonds 
with positively charged amide groups (such as are found on asparagine, lysine or 
N-termini), or salt bridging to other residues (commonly arginine) (Petsko and 
Ringe, 2004). Such changes may then result in changes in protein conformation, 
bulk or charge; impacting either on function/activity, or creating recognition 
points for a second protein to bind (e.g. recognition of phosphotyrosine residues 
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by the highly conserved SH2 domain) (Campbell & Jackson, 2003). As the 
phosphate groups are removed by phosphatase enzymes these effects are often 
transient and reversible11. Phosphorylation, and its effects on protein structure 
and function is therefore a key factor in the activation or inactivation of enzymes, 
especially with regard to signalling cascades (Mann & Jensen, 2003) where it 
acts as a ‘molecular switch’ (Ishiai et al., 2003; Tournaviti et al., 2009). The 
kinase and phosphatase networks are therefore highly regulated (Mita et al., 
2002) and the ramifications of dysregulation on the cell cycle are well 
documented, and of continuing interest to research (Sharrard and Maitland, 
2007; Daub et al., 2008; Grimsrud et al., 2010). 
 
Enzyme Notes Reference 
RET/PTC3 
(RP3) 
Tyrosine kinase found in differentiated thyroid 
carcinomas, but also linked to inflammation 
Russell et al., 2003 
Protein Tyrosine 
Phosphatase γ 
Tumour suppressor phosphatase linked to kidney 
and lung adenocarcinomas, lung neoplasms.  
LaForgia et al., 
1991 ; Zheng et al., 
2000 
PRL-3 
Phosphatase 
Found in colorectal and ovarian cancers and gastric 
carcinomas; has strong links to metastasis. 
Polato et al., 2005, 
Miskad et al., 2004 
Syk Potential tumour suppressor kinase 
underexpressed in breast cancer. Widely expressed 
in haematopoietic cells. 
Li & Sidell, 2005 
Focal Adhesion 
Kinase (FAK) 
Regulates cellular adhesion, and upstream of ERK; 
expression correlates with Pancreatic tumour size.  
Sawai et al., 2005 
Furuyama et al., 
2006 
Protein 
Phosphatase 
A2 (PPA2) 
Broad specificity phosphatase with possible role as 
tumour suppressor. Inhibited by small t antigen of 
SV40 virus. Linked with various tumour types (in 
vitro/ex vivo). 
Gallego and Virshup, 
2005 
Janus kinase 2 
(Jak2) 
Tyrosine kinase frequently deregulated in cancer, in 
particular the haemopoeitic malignancies, and Ph- 
CML, but also breast, lung, pancreas, melanoma, 
and head and neck squamous cell carcinoma. Lies 
upstream from a number of key mitogenic signals, 
including MAPK, Ras, Erk and Pi3K. 
Ferrand et al. (2005) 
Tefferi & Gilliland, 
(2006); Godeny & 
Sayeski (2007); 
Kaushansky (2007);  
Wagner and Rui, 
(2008); Pfeiffer et al., 
(2009) 
Src Non-receptor tyrosine-kinase linked to melanoma, 
sarcoma, and breast/colon cancers. Cellular 
homologue of v-src (transforming gene found in 
Rous sarcoma virus). Inhibition leads to mitotic 
arrest.  
Moaser et al. (1999); 
Chong et al. (2005) 
Epidermal 
Growth Factor 
Receptor 
(EGFR) 
Tyrosine kinase over expressed in glioblastomas, 
oropharyngeal squamous cell carcinomas, bladder, 
breast, colorectal, lung prostate and ovarian 
cancers. Deletion of the extracellular domain can 
lead to constitutive activation (common mutation in 
some cancers, e.g.  glioblastomas). 
Lo & Hung (2006); 
Saloman et al. 
(1995); Nishikawa et 
al. (1994); Moscatello 
et al. (1995) 
Table 1.3: Examples of kinases and phosphatases with links to malignancy. 
                                                 
11A notable exception would be phosphorylation-dependent protein degradation, for example the 
cyclin-dependent kinase inhibitor protein p27, responsible for regulation of the cell cycle, is degraded 
(via ubiquitination) only once phosphorylated (Nickeleit et al., 2007; Varedi et al., 2010) 
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1.3  The role of the immune system in combating malignancy 
 
While the immune system is crucial for everyday defence against pathogens, it is 
also believed to play a vital role in destroying neoplasms at the oligocellular 
stage. The role of the immune system in tumour elimination was speculated at 
over a century ago (Erlich, 1908), though given the then immaturity of 
immunology and near non-existence of molecular biology it was largely 
overlooked until it was echoed by Burnet (1970), who hypothesised that: 
 
"…an important and possibly primary function of the 
immunological mechanisms is to eliminate cells which as a result 
of somatic mutation or some other inheritable change represent 
potential dangers to life[;] without immunological surveillance, 
cancer would be more frequent and occur at younger ages than it 
does, [and] immuno-suppressive agents (sic) [...] will increase 
the likelihood of neoplasia." 
Burnet (1970) in Schwartz (2000) 
 
Research with a range of immunocompromised knockout mouse models has 
indeed shown consistent relationships between loss of immune function and 
increased vulnerability to carcinogen-induced or spontaneous cancers, and that 
these cancers are more immunogenic than those that arise in immunocompetent 
strains (Schreiber et al., 2004). The hypothesis is supported by the increased 
risk of cancer found in patients receiving immunosuppressive treatments to 
prevent transplant rejection, and the positive correlation between tumour 
infiltrating lymphocytes and survival rates (Hoover, 1977; Birkeland, 1995; Dunn 
et al., 2002). 
 
This has in turn led to the modern theory that the immune system monitors the 
majority of tissues throughout the body for evidence of malignancy, with the 
exception of privileged areas such as (but almost certainly not limited to): the 
brain (Arshavsky2006); eye, ovaries and testis (Ferguson et al., 2002); foetus 
and placenta (Guller and LaChapell, 1999); liver (Crispe et al., 2006); and 
endothelial progenitor cell-derived endothelium (Ladhoff et al., 2010)12, and that 
as a malignancy comes to the attention of the immune system a form of natural 
                                                 
12
 Interesting, as there is conflicting data on the role of these cells in angiogenesis, which may feed 
through to another aspect of immune escape (Nolan et al., 2007; Purhonen et al., 2008; Ahn and 
Brown, 2009; Wickersheim, et al., 2009). 
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selection plays out (‘immunological sculpturing’) which either results in 
elimination of the cancer, or the generation of a non-immunogenic subpopulation 
which then develops into a tumour (Fassati and Mitchison, 2009). Therefore in 
addition to the six stages of cancer development laid out by Hanahan and 
Weinburg (2000), immune escape is also crucial to the development of any 
potentially harmful malignancy. 
 
 
1.3.1  The nonspecific/innate immune system 
 
The immune system is both complex and dynamic, and composed of cellular and 
humoral arms, each of which have innate and adaptive (‘specific’) components, 
with a high degree of cross-talk between them by way of cytokines. With the 
exception of natural killer (NK) cells, the innate cellular immune system has a 
limited role with regard to cancer immunosurveillance. While monocytes and 
macrophages are known to produce a range of tumouricidal responses 
(proinflammatory cytokines, and reactive oxygen species) when stimulated by 
CD4+ and CD8+ T cells (Bonnotte et al., 2001; Van Ginderachter et al., 2006), 
such environments may be pro-cancerous in the long term (de Visser et al., 
2006). Natural Killer cells target cells that lack expression of MHC class-I (see 
1.2.4.1), but may be evaded by expression of alternative MHC (or MHC-like) 
alleles in some tumours (Cretney et al., 1999; Godal et al., 2010) or possibly 
inactivated by regulatory T cells (Treg cells) (Ralainirina et al., 2007). 
Nevertheless, NK infiltration correlates with improved prognosis in a number of 
cancers (Villegas et al., 2002; Kondo et al., 2003; Kim et al., 2007). 
 
 
1.3.2  Tumour antigens 
 
Cancer antigens (molecules which may be recognised by either the humoral or 
cellular aspects of the adaptive immune system) may be broken down into 
tumour-associated or tumour-specific antigens (TAAs and TSAs) (Neville et al., 
1975). The former are expressed in a range of tissues, but with (often 
substantially) higher expression in malignancy (prostate specific antigen and 
HER2/neu are both classic examples), (Solvin, 2007; Hudis, 2007) and includes 
foetal and cancer-testis (C-T) antigens (such as HAGE), which are normally only 
expressed in immunoprotected tissues (Riley et al., 2009). Conversely tumour 
specific antigens are only found in malignant tissue, and include oncoviral 
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proteins (Khalili et al., 2008); frame-shifted sequences (Ishikawa et al., 2003); 
junction peptides from fusion proteins (Clarke et al,. 2001); and the idiotype for 
the T-cell or immunoglobulin receptors in T-cell or B-lymphocyte leukaemias 
(though of all the above these may be the least stable) (Davey et al,. 1986). 
While cancer antigens may be proteinaceous, carbohydrate or lipid; proteins 
tend to show higher immunogenicity (Westwood, 1999). 
 
However, down-regulation of tumour antigens in response to immunological 
pressure is a major factor in immune sculpturing / immunoediting (Fassati and 
Mitchison, 2009). If a protracted, panoptic and lasting immune response is to be 
mounted against a cancer, the tumour antigen(s) in question must ideally be 
linked to the malignant state and therefore to at least one of the factors outlined 
by Hanahan and Weinburg (2000). 
 
 
1.3.3  The humoral immune response 
 
While there is extensive evidence that the humoral system is capable of 
recognising cancer related antigens in a variety of cancers, including p53 
(though many of these antibodies do not discriminate between the w/t and 
mutant forms) (Soussi, 2000); and bcr and abl in CML patients (independently or 
fused, though not the fusion peptide) whether the production of endogenous 
antibodies against cancer-antigens can eliminate a tumour remains uncertain. 
Though monoclonal antibody therapy (e.g. trastuzumab/Herceptin®) may be 
highly successful (Hudis, 2007), many cancer antigens are not membrane bound 
(e.g. p53), and thus not accessible to circulating antibodies. When correlations 
between autoantibodies and prognosis exist, they tend to be negative (Soussi, 
2000; Tan, 2001; Volkmanna et al., 2003), suggesting that despite their small 
size and potential for tumour penetration, they have limited potential to lead to 
full remission. The role of regulatory B cells (or ‘Breg cells’) further complicates 
the issue (reviewed in Mizoguchi and Bahn, 2006). 
 
  
1.3.4 The CD4+ / CD8+ immune system and the Major Histocompatibility 
Complex (MHC) system 
 
The key to immune rejection of a tumour is therefore considered to be the 
CD4+/CD8+ immune response driven by CD8+ cytotoxic T lymphocytes and the 
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CD4+ T helper (Th) cells (Li et al., 2005; Riley et al., 2009). Whilst this system is, 
like the humoral response, specific and adaptive, it is also capable of recognising 
the presence of intracellular proteins and is therefore not restricted to receptors 
and ion channels in the plasma membrane. Antigen is made visible to T-cells by 
way of the Major Histocompatibility Complex (MHC). While MHC class-I and 
class-II molecules share structural similarities, both being transmembrane 
proteins composed of two subunits (α and β) and a peptide (which is integral for 
the stability of the complex) (Miller and Sant, 1995; Koopman et al., 1997; 
Pieters, 1997) they differ crucially in terms of structure, expression, and function. 
 
In simple terms, MHC class-I molecules are present on all healthy somatic cells, 
and present peptides derived from endogenously produced protein to CD8+ CTLs, 
while MHC class-II molecules are only present on a subset of cells, known as 
antigen presenting cells (APCs), and present exogenous peptide (acquired by 
phagocytosis) to CD4+Th cells, potentiating the specific immune response. Like B 
cells, T cells which recognise self-antigens are eliminated by negative selection in 
the thymus13,14 (Starr, et al., 2003). However not all peptides have an equal 
chance of being presented by the MHC molecules, the potential presentome is 
restricted at three points within the system, namely: selective cleavage by 
proteolysis, peptide loading, and binding of the peptides to specific MHC 
allelotypes. The different aspects of the MHC class-I and class-II, and these 
aspects of their antigen processing mechanisms are dealt with briefly below. 
 
 
1.3.4.1  Generation of MHC class-I peptides 
 
Be it due to requirements to regulate enzyme activity or because of simple wear 
and tear, all cellular proteins have a limited lifespan, primarily controlled by the 
ubiquitin system and proteasomal degradation (Yewdell, 2005). Prior to 
destruction proteins are tagged with the small (8.5 kDa) ubiquitin protein by way 
of lysine-glutamine cross-linking in an ATP dependent manner. Ubiquitinylated 
proteins are typically diverted to the 26S proteasome, a ~2 mDa protease 
complex composed of two 19S activator complex ‘gateway’ assemblies either 
end of a 700 kDa 20Sbarrel-shaped destruction chamber; a multicatalytic 
                                                 
13
 With the exception of CD25+ regulatory cells (Pacholczyk and Kern, 2008). 
14
 APCs within the thymus express a wide range of antigens normally found in a diverse array of 
tissues, through expression of the Autoimmune Regulator (AIRE), a master transcriptional regulator 
that activates a wide range of normally tissue specific genes, allowing the expression of normal 
antigens to naïve CD4+ and CD8+ T cells (reviewed in Cohn, 2009; Gardner et al., 2009). 
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protease composed of two seven-membered rings of α and β subunits (Golberg 
and Rock, 1992; Groll, 1997). 
 
The tagged proteins are then unfolded in an ATP-dependent process by the 19S 
activator complex (Liu et al., 2006), and fed into the 20S core, which breaks 
them down into short peptides by way of the proteolytic β subunits, each of 
which possess a different activity. Subunit β1 has a caspase-like activity, cleave 
primarily after acidic residues, subunit β2 cleaves after basic amino acids in a 
similar manner to trypsin; while subunit β5 has a chymotrypsin-like activity, 
cleaving after hydrophobic residues (Dick et al., 1998). Together these produce 
a range of peptides and polypeptides which may then be further metabolically 
degraded by peptidases (Yewdell et al., 2003). 
 
A subset of the proteasome: the immunoproteasome differs in structure from the 
constitutive complex. Not only does it associated with an alternative activator 
gateway (the 11S activator) (Förster et al., 2005); it also may have some or all 
of any of the following specialised subunits:β1i; β2i and β5i (Scheffler et al., 
2008; Guillaume et al., 2010), and β5t, (the latter of which is believed to be 
expressed solely in the thymus, and appears vital for CD8+ T cell development) 
(Murata et al., 2008). These changes allow the immunoproteasome to produce a 
much greater proportion of 8-12 amino-acid peptides (Flutter and Gao, 2004) 
and the expression of the immunoproteasome can be up-regulated by cytokine 
exposure; e.g. interferon (IFN)-γ (produced by activated T- and NK cells) (Falk 
and Rötzschke, 2003), which also up-regulates leucine aminopeptidase, an 
enzyme which is thought to cleave N-terminal flanking residues from otherwise 
antigenic peptides (IFN-γ also down-regulates thimet oligopeptidase, a 
metalloproteinase known to destroy many antigenic sequences) (York et al., 
1999). 
 
Following proteolytic cleavage many peptides are further processed by other 
peptidases (Reits et al., 2004). In particular Tripeptidylpeptidase II (TPPII), a 
large (5-9 MDa) oligopeptidase complex may play a crucial role trimming larger 
peptides, as it possesses both endo- and exo-peptidase functions (Geier et al., 
1999; Rockel et al., 2002; Reits et al., 2004). Indeed, the generation of some 
peptides may circumvent the immuno/proteasome entirely (Lankat-Buttgereit 
and Tampé, 2002), and that TPII may be able to target poly-ubuitinated proteins 
(Wang et al., 2000). 
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1.3.4.2   Loading of peptides into the MHC class-I complex 
 
In either case thepeptides produced are trafficked across the membrane of the 
endoplasmic reticulum by the TAP 1 / TAP 2 / ATP Binding Cassette system 
(Saveanu et al., 2001), bringing them into proximity with the newly synthesised 
MHC class-I molecules. These class-I molecules are a heterocomplex, partly 
made up of a 44 kDa heavy α-chain (containing three extracellular domains - α1, 
α2 and α3 - and a cytoplasmic tail, linked by a transmembrane domain), and a 
conserved smaller 11.5 kDa aβ-chain (β2-microglobulin), both of which are 
synthesised in the ER (with folding aided by chaperones such as ERp57 and 
calnexin) (Carpenter, 2001; Lankat-Buttgereit and Tampé, 2002; Zhang et al., 
2006), and glycosylated prior to encountering peptides. The α1 and α2 domains 
together form a structure of eight antiparallel β strands and two antiparallel α-
helices, the groove between these domains is the peptide binding site (Bjorkman 
et al., 1987). 
 
Each individual contains two copies of the MHC class-I haplotype (the three MHC 
class-I genes: A, B and C, found on the short arm of chromosome 6) inherited 
from each parent, and the expression of which are co-dominant (Choo, 2007). 
Unless homozygous, each individual therefore expresses six different class-I 
molecules (two MHC class-I A15, two B, two C) on their cells, each gene showing 
a high degree of polymorphism, resulting in a great variety in affinity for 
different peptides, and a high degree of heterogeneity in MHC complement (and 
corresponding ‘presentome’) between individuals. However, some MHC alleles 
are common among certain populations: e.g. >5 % of Caucasians carry the 
alleles for MHC class-I A1 and B8; the class-I A2 allele is common in Northern 
Europe but becomes progressively rarer as more southern populations are 
sampled; and the Cw*14 allele is rare in Indo-European populations, but more 
common in southern India. This linkage disequilibrium may be exploited by 
population geneticists to trace migrations (Thomas et al., 2004; Valluri et al., 
2005; Choo, 2007). Nevertheless, all MHC class-I molecule alleles share the 
common structure discussed above, with the majority of polymorphism being 
restricted to their peptide-binding sites (Bjorkman and Parham, 1990). 
 
Within the ER, short peptides with high binding affinity are loaded into the 
groove of the MHC by the peptide loading complex (TAP 1/2 and tapasin), aided 
                                                 
15
 In the HLA nomenclature, these are described as e.g. HLA-A*0201, HLA-A*03, HLA-B*4501 etc. 
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by various chaperones including calreticulin (Turnquist et al., 2002; Flutter and 
Gao, 2004; Wearsch and Cresswell, 2008; Del Cid, 2009), which by this point 
has replaced calnexin (Lankat-Buttgereit and Tampé, 2002). The binding/release 
of peptides by the TAP involves a significant and partially ATP-dependent 
reorganisation of the peptide loading complex (Neumann, et al., 2002; Chen et 
al., 2003). The components of this complex - TAP in particular - may influence 
peptide selectivity as binding is primarily influenced in favour of peptides with 
hydrophobic and basic residues towards the COOH termini (which are produced 
in higher numbers by the immunoproteasome than by the standard 26S 
proteasome) (Rock and Goldberg, 1999; Lankat-Buttgereit and Tampé, 2002), 
though the first three N-terminal residues may also influence TAP binding. 
However, while TAP will not transport peptides below 7 amino acids in length, 
the optimum peptide range is 8-16 residues, (Lankat-Buttgereit and Tampé, 
2002), and many peptides therefore require subsequent trimming by 
aminopeptidases before they may be loaded into the MHC peptide binding site 
(Saveanu et al., 2002; Yewdell et al., 2003). This may occur either in the ER, or 
following transport of the ‘reject’ peptides into the cytosol by the translocon 
(Koopman et al., 2000), after which they may be recycled back into the ER for a 
second (or possibly third) binding attempt (Roelse et al., 1994). 
 
 
1.3.4.3 Alternate pathways:  peptide editing and TAP-independent 
processing 
 
Other peptides, while of correct length, may have poor binding kinetics, and 
these are exchanged in a serial fashion for stronger-binding peptides, a process 
described as peptide editing. The role of tapasin in peptide editing is currently 
unclear; the majority of reports have suggested that tapasin deficient cell lines 
either express MHC bound peptides with poorer binding stability than wild-type, 
with greater spontaneous MHC-peptide disassociation on the cell surface, or in 
lysates (Garbi et al., 2000; Momburg and Tan, 2002; Tan et al., 2002; Williams 
et al., 2002; Howarth et al., 2004). In contrast Zarling et al. (2003) and Everett 
and Edidin (2007) demonstrated that for the MHC class-I B8 allele, the peptide 
repertoire did not differ between tapasin+/-cells (though these reports conflict 
with each other regarding whether greater spontaneous MHC-peptide 
disassociation occurs at the cell surface as a result of tapasin loss). However, 
Momburg and Tan (2002) note that the interactions between tapasin and the 
MHC heavy chain vary significantly depending on MHC gene and allele (Neisig et 
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al., 1996) and therefore it likely plays a greater role for some alloforms than 
others, while Wright et al. (2004) suggested that tapasin may be responsible for 
chaperoning peptide-binding, optimising binding kinetics while not significantly 
altering which peptides are expressed on the cell surface. A recent report by 
Praveen et al. (2010) using a intra-ER model suggests that tapasin allows the 
selective binding of low concentration high-affinity peptides in the presence of 
high (100-fold) concentrations of a lower-affinity peptide, by accelerating the 
disassociation of the low-affinity peptides when they are in a partially bound-
intermediary stage. It should be noted that this used a murine (class-I H-2Kb) 
MHC molecule and human tapasin (from a Rajii cell line) and that the above 
caveats regarding allovariation may still apply. The mechanism by which tapasin 
may increase the lability of these low-binding peptides is as yet undetermined. 
 
It is worth noting that peptide-MHC binding may also occur independent of TAP, 
(possibly via similar mechanisms that allow cross presentation between MHC 
class-I and class-II) (Jondal et al., 1996). The mechanisms by which this occurs 
are still under investigation: hydrophobic peptides containing or derived from 
signal sequences may enter the ER via the translocon, where they may be 
cleaved by ER peptidases, though this pathway cannot account for non-signal 
peptide presentation (Anderson et al,. 1991; Fromm et al., 2002), and 
expression of some signal sequences appears to be wholly TAP-dependent 
(Hombach et al., 1995). Song and Harding (1996) demonstrated that TAP-
independent processing was proteasome-independent, and postulated that 
binding of peptide by empty MHC class-I may conceivably occur anywhere along 
the pathway including on the cell surface itself. However Sigal and Lock (2000) 
demonstrated a pathway for viral peptides that they believed occurred in 
endocytic vacuoles, this was supported by supported by Fromm et al. (2002), 
who demonstrated that MHC expression in TAP deficient cells was sensitive to 
changes in endosomal pH, and by Shen et al. (2004) who demonstrated that it 
depends on cathespin-S, a protein normally associated with MHC class-II peptide 
processing, indicating that the pathway may be similar to that involved in cross-
presentation (see 1.3.4.6?). Furthermore there is evidence that TAP-independent 
processing may in some cases bear a relationship with the mechanisms of cell 
penetrating peptides (Brooks et al., 2010). 
 
Like the classical pathway, expression by the TAP-independent pathway is up-
regulated by IFN-γ, but in both cases this is largely a function of increased 
synthesis of MHC complex components rather than a selective effect (Fromm and 
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Erlich, 2001; Fromm et al., 2002). However while TAP-independent processing 
may be vital for presentation of some peptide vaccines (Sheikh et al., 2003), 
TAP-/- cells are less typically less efficient at presentation; they exhibit far fewer 
MHC molecules on their cell surface (possibly due to a higher ratio of MHC 
misfolding), and also have a higher proportion of empty surface MHC molecules 
(Jondal et al., 1996; Song and Harding, 1996; Sigal and Lock, 2000) underlining 
the crucial role for TAP in efficient antigen presentation. Accordingly, mutations 
in the TAP genes are one documented mechanism of achieving the MHC down-
regulation common in tumours, and tend to correlate poorly with prognosis 
(Fowler and Frazer, 2003; Mclusky et al., 2004).  
 
 
1.3.4.4 Transport of MHC class-I to the cell surface and interaction with 
CD8+ CTLs 
 
Once a strongly-binding peptide is loaded into the molecule, the heterotrimer is 
complete and is transported into the Golgi (Harter and Reinhard, 2000), where 
the complex is deglycosylated to allow TAP and calreticulin to disassociate 
(Turnquist et al., 2002), and following which it is trafficked to the cell surface. A 
simplified schematic of this pathway may be found in figure 1.3.A. 
 
Once upon the cell surface, α/β T-cells (CTLs) interact with the class-I molecule 
via the (highly conserved) CD8 receptor and their (hypervariable) T-cell receptor 
(TCR). If the TCR recognises the peptide antigen, and co-stimulation is found by 
way of CD28/CD80 binding (or cytokine stimulation from CD4+ T-helper cells), 
this leads to PI3K mediated activation of ERK to phosphorylate paxillin (Roberton 
et al., 2005), causing cytoskeletal reorganisation and polarisation of the CTL, 
and targeted release of granulysin, perforin, granzymes and tumour necrosis 
factor-α (TNF-α), as well as expression of the apoptosis-stimulating Fas-Ligand 
surface marker, followed by clonal expansion of the T cell population (Selleri et 
al., 2008; Hiroishi et al., 2010). 
 
As stated above, MHC class-I expression is near ubiquitous amongst nucleated 
diploid cells (excluding some cell populations in developing trophoblasts, 
especially prior to implantation) (Shomer et al., 1998). Under normal conditions, 
lack of MHC class-I expression triggers NK cell-mediated killing (Aptsiauri et al., 
2007), though this is not always the case; similarly the presence of MHC class-I 
may not result in CTL killing of a tumour cell for a number of reasons (Chang et 
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al.,2004). Nevertheless, infiltration of CD8+ T cells into tumours correlates with 
improved prognosis for many cancers (e.g. Schumacher et al., 2001; Zhang et 
al., 2003, Satoet al., 2005; Oble et al., 2008), reinforcing the theory that they 
may be the key to tumour elimination. 
 
 
1.3.4.5  MHC class-II synthesis and generation of peptides 
 
As has already been stated MHC class-II is only expressed on a subclass of cells 
known as antigen presenting cells (APCs)16, including B cells (Cheng et al., 1999), 
monocytes and macrophages (Ramachandra et al., 2009), and dendritic cells 
(DCs) (Leverkus et al., 2003), of which the latter are considered the most 
professional, and therefore potentially key to elimination of cancer by the 
immune system (Breckpot and Escors, 2009; Kalinski et al., 2009). The MHC 
class-II molecule is, like class-I, composed of an α- and β-chain; though in the 
case of MHC class-II these are of similar masses: 34 and 28 kDa respectively, 
and both contain transmembrane domains (Carpenter, 2001). Like class-I, each 
gene (HLA-DR, -DQ and –DP) is encoded on the long arm of chromosome 6; 
however for each class-II molecule both α- and β-chain show high variability, 
and as each chain is encoded individually, a wide range of combinations are 
possible across a population. 
 
The genes responsible for MHC class-II (including Ii, HLA-DM, and the β-chain of 
HLA-DO) all lie under the control of a master transactivator CIITA (class-II 
transactivator) (Chen and Jensen, 2008). This co-operates with a number of 
other transcription factors (TBP, RFX, X2BP/CREB and NF-Y) and coactivators 
(e.g. p300 and PCAF) leading to nucleosome acetylation and gene transcription 
(Boss, 2003). The promoter for CIITA varies by cell-type, and CIITA is also 
affected by dimerization, posttranslational modification and GTP-binding17 (Boss 
and Jensen, 2003). 
 
Following transcription, both α- and β-chain are synthesised in the ER in 
conjunction with the stabilising invariant chain (Ii) 18  (Cresswell, 1994) which 
                                                 
16
 Endothelial cells and T-cells may also be induced to express MHC class-II in response to INF-γ 
(Chen and Jensen, 2008) 
17The numerous modulators of activity may be crucial to differentiating CIITA’s other functions, as it 
is also implicated in increased expression of 40 other (non-MHC related) genes (Boss, 2003). 
18
 The invariant chain was originally believed to be a vital chaperone, without which class-II 
molecules would not fold properly. However this was later demonstrated to be allele-specific (Bikoff 
et al., 1995; Rajagopalan et al. , 2002). 
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dimerises with another MHC-class-II linked invariant chain forming a 
αβ3Ii3supercomplex. This is then trafficked to the MHC class-II compartment 
(MIIC), 19 (a multi-lamellar and/or multi-vesicular structure showing great 
regional homology in protein and lipid content) (Zwart et al., 2005) by way of 
the Golgi, where the invariant chain is cleaved sequentially by a number of 
peptidases (including Cathespin S), leaving individual MHC class-II molecules 
containing CLIP (class-II invariant chain peptide) in their binding groove 
(Chapman, 1998). The cleavage of CLIP disassociates the MHC from the 
cytoplasmic tail of Ii, which contains a targeting motif; without this the MHC is 
then free to be trafficked towards the cell surface. 
 
Simultaneously, exogenous material (ranging from polysaccharides, proteins and 
peptides to bacteria and tumour cells) is internalised by phagocytosis in a 
receptor-binding mediated (usually TLR-binding mediated) fashion (Blander, 
2008). Once internalised, this material moves from early endosomes through a 
series of increasingly acidic and proteolytic compartments, eventually being 
digested in lysosomes, which fuse with the MIIC (Chapman, 1998; Crotzer and 
Blum, 2009). Once here, peptides (12-30 amino acids in length) with strong 
binding affinity are then rapidly swapped for the CLIP peptide by way of the 
peptide editor20 and dedicated chaperone, HLA-DM; which shows great homology 
with MHC class-II, except in that it is non-polymorphic and does not bind peptide 
directly (Denzin and Cresswell, 1995). While mediated by low-affinity 
hydrophobic association (Zwart et al., 2005), the interaction with HLA-DM is 
crucial to stabilising MHC class-II as new peptides bind, and while the 
disassociation of CLIP is optimal in a low-pH environment (Kropshofer et al., 
1999), the chaperone function of HLA-DM is pH independent (Zwart et al., 2005). 
 
Though not originally synthesised into sphingolipid and cholesterol-rich 
membranes, the class-II molecule (with Ii or CLIP) is incorporated into these 
lipid rafts within the vesicle’s membranes during transport to the MIIC, and 
which will be anchored there by tetraspanins by the point at which the complex 
reaches the cell surface (Hitbold et al., 2003). Following binding of peptide 
antigen the complexes are trafficked with their raft to the cell surface in an IFN-γ 
stimulated manner (Poloso et al., 2004; Büning et al., 2005) (see figure 1.3.B.). 
                                                 
19 The MIIC is primarily composed of late endosomes, but also fuses with early endosomes, 
phagosomes, and the ER (Robinson and Delvig, 2002). 
20
 Though this primarily occurs in the MIIC, it is worth noting that in some cases MHC class-II-
peptide complexing may also occur in the Golgi, phagosomes, or on the cell surface itself (Robinson 
and Delvig, 2002). 
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Once there it interacts with the TCR of CD4+ Th or Treg lymphocytes (again in a 
lipid raft-dependent manner, as CD4 is also carried within a raft structure) 
(Machy et al., 2002; Handin et al., 2002), and if TCR recognition is coupled with 
costimulation (e.g. by CD28 binding to CD80/CD86 on the target cell) (Zhang et 
al., 2004), this leads to serial activation of Lyk and Fyn, both (semi-redundant) 
Src-family kinases. These phosphorylate CD3 and the tyrosine kinase ZAP-70, 
which goes on to phosphorylate LAT (Linker of Activated T-cells); setting off a 
cascade of signals via PLC and PKC (Groves et al., 1996; Handin et al., 2002; 
Kyung Chan et al., 2011) and causing release of cytokines (which vary 
depending on whether the CD4+cell is Th1, Th2 or Treg in nature), and which lead 
to either an immunostimulatory or immunoregulatory effect (Kaiko et al., 2008; 
Corthay, 2009). 
 
Given the tissue of origin in leukaemia (and lymphoma), many are unique 
amongst cancers in expressing not just MHC class-I but also MHC class-II (Diaz, 
et al., 2009), with CML blasts often showing a DC progenitor cell-phenotype. 
While these show (normally) poor lymphocyte stimulation, their replacement 
with normal DCs appears to be crucial to successful Imatinib-dependent (see 
section 1.4)  remission (Wang et al., 2004), and stimulation of AML blasts to 
form mature leukaemic-derived DCs has been presented as a possible route of 
immunotherapy (Tong et al., 2008; Kremser et al., 2010). Further investigation 
into the antigens these cells present may aid effective activation of the cellular 
immune system. 
 
 
1.3.4.6 HLA-DM, HLA-DO and MHC class-II peptide editing 
 
As well as stabilising the empty MHC molecule, HLA-DM is known to act as a 
peptide editor by altering the conformation of the class-II molecule and affecting 
conserved peptide bonds (in particular around the P1 binding pocket), thus 
allowing disassociation of bound peptide and reducing the inherent selectivity of 
the native MHC molecule, leading to a change in the peptide repertoire 
expressed (Busch et al., 2005; Narayan et al., 2009). Though there is evidence 
that HLA-DM may repeatedly bind to and disassociate from a class-II molecule, 
optimising the expression of high-binding peptides (Narayan et al., 2009), once 
a peptide with high binding kinetics has bound, the class-II molecule shows poor 
interaction with HLA-DM (Anders et al., 2011). 
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In some APCs (particularly mature B-cells and some DCs, depending on lineage) 
(Hornell et al., 2006) the activity of HLA-DM is modulated by a second 
chaperone, HLA-DO: another non-polymorphic class-II analogue21, though one 
which (like empty MHC class-II) lacks stability in the absence of HLA-DM (Chen 
and Jensen, 2008). The function of HLA-DO is not yet clear, it is known to 
typically down-regulate HLA-DM’s chaperone activity (in a pH-dependent manner) 
(Rocha and Neefjes, 2008), potentially resulting in lower cell surface MHC 
expression, a higher ratio of MHC-CLIP at the cell surface (common in mature B 
cells) (Chen et al., 2002) and a potential reduction in peptide editing. Indeed, 
the effect of HLA-DO is startlingly antigen-specific, with many experimental 
antigens showing cell-surface down-regulation, while others remain stable, or 
are even up-regulated (Fallas et al., 2004). Like HLA-DM, HLA-DO is only 
expressed intracellularly (though the murine homologue, H2O, can be trafficked 
to the cell surface) (Doueck and Altmann, 1997).  Interestingly the expression of 
the HLA-DOα and β chains appears to be independently regulated, leading to the 
postulation of a second (as yet unknown) role for HLA-DOα (Hornell et al., 2006). 
 
 
1.3.4.7  Cross-presentation 
 
The classical pathway of antigen presentation, where MHC class-I molecules 
present endogenous peptide and class-II present exogenous peptide is 
complicated by cross-presentation of antigens. First reported by Bevan (1975), 
this may occur in either direction, and on the whole does not appear to be reliant 
on any special processes, rather operating through many of the mechanisms 
involved in the classical presentation pathway. Whilst initially considered a minor 
curiosity of the phagocytotic cells, it has become apparent that cross-priming (i.e. 
of CD4+ cells against non-phagocytosed, or CD8+ against exogenous peptide) 
plays an important role in many aspects of T-cell mediated immunity, including 
auto-immunity, graft-rejection and tumour immunology (Amigorena and Savina, 
2010). 
 
                                                 
21
 Both HLA-DO and -DM show loss of conservation in the CD4+ binding region (Doueck and 
Altmann, 1997) 
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A B Figure 1.2: Simplified schematic of 
classical MHC class-I and class-II 
presentation. (A) Class I peptides are 
generated from endogenous/ 
intracellular protein and digested via 
the proteasome. Peptides are 
trafficked to the ER by TAP1/2 and 
loaded into the MHC class-I molecule 
with the aid of tapasin and calnexin, 
which then disassociate as the MHC 
class-I is then transported to the cell 
surface to interact with the TCR of 
CD8+ CTLs. (B) The MHC class-II 
molecule is synthesised in 
conjunction with an invariant chain, 
which leads to dimerisation with 
another class-II molecule. Upon 
transport to the MIIC, the invariant 
chain is cleaved and the resulting 
CLIP peptide swapped for an 
exogenous peptide (acquired via 
endocytosis and digestion in 
endosomes) by HLA-DM, before 
being transported to the surface to 
interact with the TCR of CD4+ T-
helper/Treg cells. 
 
It is important to note that cross 
presentation of class-I peptides by 
the class-II pathway, and vice versa, 
does occur by mechanisms which 
are still being elucidated. 
 
                (Modified from Barry, 2006) 
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1.3.4.7.1 Presentation of exogenous antigen by MHC class-I 
 
MHC class-I antigen presentation is not therefore solely restricted to 
endogenously produced peptides. The mechanisms by which exogenous material 
may lead to stimulation of CD8+ CTLs are varied, but can largely be broken 
down into antigens from a source with a unique ability to penetrate into the 
cytoplasm, e.g. bacterial disruption of membranes; antigens which may 
penetrate the membranes themselves such as cell penetrating peptides; 
antigens with high binding kinetics which displace and replace MHC-bound 
peptide on the cell surface, antigens passed between cells via gap junctions22 or 
antigens internalised by phagocytosis (Rock, 1996; Neijssen et al., 2005). This 
latter category is of greatest interest, given that it does not appear to be 
restricted to a particular peptide population, because of it’s probably involvement 
in vaccination (Groothuis and Neefjes, 2005), and because of the crucial role 
that phagocytotic APCs play in the immune system. Highlighting the importance 
of phagocytosis; cross presentation by class-I is considerably higher when 
antigen is bound to latex beads as compared to soluble antigen (Houde et al., 
2003), and a far less common phenomenon in non-phagocytic APCs such as B 
cells than in macrophages and DCs (Rock, 1996); though of the two cross-
presentation seems to be most crucial in DCs (Greer et al., 2009)23. 
 
In contrast with non-APC phagocytes such as neutrophils, and comparatively 
poor cross-presenting cells such as macrophages, both of which degrade 
phagocytosed material in an acid-dependent manner, the phagosomes of DCs 
may be maintained at a much higher pH for a prolonged period due to reactive-
oxygen species production of NADPH oxidase 2 (NOX2) (Mantegazza et al., 
2008)24. As NOX2 expression in myeloid cells is known to be modulated by a 
range of cytokines, including IL-6, TNF-α, or VEGF (Lechner et al., 2010), it is 
possible that the propensity towards cross-presentation may also be modulated 
                                                 
22These are inter-cytoplasmic connections between adjacent cells (often of different lineages) and 
especially commonly established by DCs and macrophages. They are established by connexins, and 
are capable of transferring molecules including peptides within the MHC class-I mass range. Tumour 
cells often close their gap junctions, potentially as another means of immune-evasion (Groothuis and 
Neefjes, 2005; Neijssen et al., 2005; Gafken and Lampe, 2006; Pang et al., 2009; Vyas et al., 2009).  
23
  Ironic given that in the mid 1990s it was unclear at to whether DCs truly cross-presented antigen, 
with some ascribing experimental data to macrophage contamination (Rock, 1996). 
24
 NOX2 and ROS levels only appear to affect cross presentation of antigens when peptide trimming 
is required; cross presentation of internalized shorter peptides is less affected by inhibition of NOX2 
function, suggesting a specific neutral pH-dependent peptidase may be at work (Mantegazza et al., 
2008) . ER-associated peptidase 1 and 2 appear to be potential candidates, though they are primarily 
found in the ER, not phagosomes. A phagosomal homolog, insulin-regulated aminopeptidase may 
instead be responsible (Rock et al., 2010) especially given its optimum activity is within the neutral 
pH range (Mizutani et al., 1982). 
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in part cytokinetically in monocyte-derived DCs, though it is important to note 
that the larger the mass of the internalized material, the greater propensity 
towards phagosome acidification (Tran and Shen, 2008), presumably to ensure 
elimination of live pathogens or biologically active proteins. 
 
Following internalisation and possibly enzyme-mediated hydrolysis, cross-
presentation of antigen by MHC class-I may be either TAP dependent 
(Kovacsovics-Bankowski and Rock, 1995) or otherwise. TAP-dependent 
processing requires that the peptides are transported via the cytoplasm25 (and 
possibly via the immunoproteasome, if not digested inside the phagosomes). The 
rate of transfer of peptides from phagosomes to cytoplasm is size dependent26 
(Tran and Shen, 2009), but given the distinct ion content of the ER and 
controlled pH commonly found in phagosomes, uncontrolled diffusion is unlikely. 
One mechanism responsible for this transfer is the bidirectional translocon Sec61 
protein channel complex (Römisch, 1999), part of the ER antigen-degradation 
pathway, present in both the ER and phagosomes, and capable of trafficking 
peptides across the membrane of either (Inaba and Inaba, 2005; Osbourne et al., 
2005; Rock, 2006). The complex is partly regulated by phosphorylation (Gruss et 
al., 1999) and is gated by the HSP chaperone BiP/Grp78, which requires ATP for 
activation along with numerous co-chaperones (Alder et al., 2005). 
 
TAP-independent processing from the cytoplasm to the ER (or other bodies) is as 
much of a possibility for cross-presented peptides as it is for endogenous 
antigens. For example, the bidirectional translocon/Sec61 protein channel is 
responsible appears to be responsible for trafficking peptides from phagosomes 
into the cytoplasm, it may also provide a pathway for trafficking into the ER 
(Inaba and Inaba, 2005; Osbourne et al., 2005). 
 
However a non-cytoplasmic cross-presentation route (‘the vaculolar pathway’) 
also exists, and for several years there has been debate on the exact route 
involved. While fusion of phagosomes (e.g. from autophagy – see 1.3.4.9) with 
the ER seems an obvious possibility, and is to some extent supported by 
experimental data (Ackerman et al., 2003), this theory is disputed by others (e.g. 
Touret et al., 2005, Groothuis and Neefjes, 2005); resolution of these conflicting 
viewpoints is problematic due to the difficulties of avoiding ER-contamination 
during phagosomes separation, as well as the potential for variation between cell 
                                                 
25
 TAP independent processing on the other hand may or may not be cytoplasmic. 
26
 No data is available on concentration dependence. 
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types (Lin et al., 2008; Vyas et al., 2009). It is also further complicated by 
evidence that phagosomes may also contain many proteins involved in class-I 
antigen processing, including TAP, calnexin, calreticulin and ERp57 (Houde et al., 
2003; Guermonprez et al., 2003), potentially giving phagosomes a role as ‘self-
sufficient cross-presenting organelles’ (Houde et al., 2003; Ramirez and Sigal, 
2004). Such ER-like bodies may go some way to explaining conflicting results on 
phagosomes-ER fusion (Ackerman et al., 2005), though again the existence of 
these bodies is also under debate. A third possible vacuolar route involves fusion 
of phagosomes with MHC containing endosomes (Greer et al., 2009) – an event 
which is relatively uncontroversial (Beron et al., 1995; Becken et al., 2010), 
though the extent to which this contributes to overall TAP-independent cross-
presentation is unclear. However, like classical presentation the cytosolic/TAP-
dependent route accounts for the overwhelming majority of cross-presented 
peptides (Shen et al., 2004; Rock and Shen, 2005). 
 
DCs are particularly noted for cross presentation of exogenous antigen via the 
class-I pathway (Robson et al., 2010), possibly reflecting in part the junction 
role they play between the MHC class-I, -II and nonspecific immune system. It is 
important to remember that cross-priming is also capable of stimulating CD4+ or 
CD8+ regulatory T cells, leading to cross-tolerance rather than cross priming 
(Greer et al., 2009). Indeed, given that defects in NOX2 expression are linked 
with autoimmunity, cross-presentation may be a crucial junction within 
immunoregulation (Mantegazza et al., 2008). 
 
 
1.3.4.7.2 Presentation of endogenous antigen by MHC class-II 
 
MHC class-II has also long been known capable of presenting endogenous 
material as well as that taken in by phagocytosis, and though the former 
represents a minority of the peptides presented by APCs, some antigens such as 
peptides from hen egg lysozyme (HEL) are expressed on MHC class-II with 
vastly higher efficiencies when transfected into their targets rather than provided 
exogenously (though the exact rates vary between cell types and plasmid 
promoter).  (Schnieder and Sercarz, 1997).  
 
Again however, the exact mechanisms involved are yet to be fully elucidated. In 
some cases cross presentation appears to be TAP dependent (Lechler et al., 
1996). Conversely however the addition of a four amino-acid ER-retention 
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sequence to HEL reduces the expression of five of the seven peptides cross-
expressed in transfected B-lymphoma cell lines (when compared with the wild-
type HEL plasmid) (Adorini et al., 1993). 
 
One potential route for endogenous material to access the class-II pathway is by 
autophagy; the engulfing and degradation of intracellular protein complexes and 
organelles by phagosomes (macroautophagy) or lysosomes (microautophagy) 
(Yorimitsu and Klionsky, 2005; Strawbridge and Blum, 2007). This was long 
thought to be a random process, upregulated by nutritional deprivation, infection 
or other stresses, but has since been demonstrated to be specific and (at least in 
some instances) a chaperone-mediated (CMA) process, regulated by GTP 
(Bandyopadhyay et al., 2010), and also influenced by cytokines, including IFN-γ-
mediated upregulation (Gutierrez et al., 2004), and TLRs (Vyas et al., 2008). 
Some forms of autophagy are organelle-specific, such as mitophagy, which 
degrades depolarised mitochondria in starvation conditions, or CMA, which 
largely targets proteins with a KFERQ motif (Li et al., 2008). The most-studied 
form: macroautophagy involves the formation of a double membrane which 
envelopes an area of the cytosol; while sometimes appearing random it is known 
to selectively target polyubiquitinylated protein aggregates in Parkinson’s (Webb 
et al., 2003) and Huntingdon’s (Shibata et al., 2006) diseases, while it is 
conceivable that the different forms of autophagy are more of a spectrum than 
discrete pathways, so each may have both selective and non-selective aspects 
(Li et al., 2008). 
 
Paludan et al. (2005) demonstrated that expression of an endogenous EBV-
related antigen was downregulated both by blocking lysosome acidification and 
by disrupting autophagy (with the type-1 PI3K inhibitor 3-methyladenine), with a 
reduction of between 30 and 70% expression on the cell surface, which along 
with the observation that autophagy is a constitutive function in APCs (Schmid et 
al., 2007), present as strong evidence for it’s role in cross-presentation. 
 
However, autophagy-deficient cell lines still cross-present peptides to the class-II 
pathway (Dani et al., 2004; Massey et al., 2006), suggesting that proteasomal 
(or immunoproteasomal) processing of protein may be another pathway to 
cross-presentation, following which the resulting peptides may be bound by 
class-II cross-presentation chaperones such as Hsp-40 and Hsp70 and 
transported to lysosomal-associated membrane protein (LAMP) 2a which traffics 
them into the lysosome; this in turn being bound for fusion with the MIIC (Zhou 
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et al., 2005; Strawbridge and Blum, 2007). It is believed that the degradation 
machinery may distinguish between long-lived (i.e. housekeeping) and short-
lived proteins either prior to, or following autophagy, and that the former may be 
degraded while the latter are more likely to be cross-presented (Li et al., 2009b). 
 
Thymic APC populations have a higher propensity towards cross presentation, 
highlighting its potential importance in immune-tolerance (Schnieder and 
Sercarz, 1997). A significant proportion of the peptides isolated from MHC class-
II molecules are apparently derived from cytosolin/incracellular proteins (Dongre 
et al., 2001), and this proportion is upregulated when autophagy is induced 
(Dengjel et al., 2005b). The link between TLRs and autophagy is one factor that 
has encouraged investigation of TLRs as therapeutic agents for cancer (reviewed 
in So and Ouchi, 2010). Cross-presentation of endogenous material may also be 
induced in non-APCs (melanoma cells) following transfection with MHC class-II 
(Chen et al., 1994). Of course these cells lack the phagocytic properties of APCs, 
and the corresponding cellular machinery, but interestingly in these cases cross-
presentation by MHC class-II is reduced if Ii is also expressed (Dissanayake et 
al., 2004). Crucially, the prime therapy for CML today, Imatinib mesylate (see 
1.1.4) appears to upregulate autophagy as a survival mechanism (Bellodi et al., 
2009), raising the possibility that cross-presentation may also be affected by the 
therapy. 
 
 
1.3.5  The CD1 lipid-antigen presentation system 
 
The CD1 processing system is a second antigen-presentation mechanism capable 
of stimulating a cellular immunity in an antigen-specific manner. There are five 
known CD1 isoforms, each with a structure similar to MHC class-I, being 
composed of a heavy chain with transmembrane domain, associated with β2-
microglobulin molecule (Polakova et al., 1993). Of the five isoforms, CD1a, b and 
c present exogenous (primarily bacterial) lipid antigens27 to α/β T cells, while 
CD1d presents endogenous lipid antigens to Natural Killer T cells (NKT cells: see 
1.3.6) (Paul, 2008). CD1e is not trafficked to the cell surface; instead it is 
cleaved from its transmembrane domains and is retained in soluble form within 
the Golgi, where it plays a chaperone role similar to HLA-DM (Maître et al., 
2008). Like the MHC system, the CD1d isoform is expressed by all cells, while 
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 Apolipoprotein E is implicated in uptake of lipid for CD1a-c presentation (van den Elzen et al., 
2005) 
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CD1a-c and e are primarily expressed by DCs (Moody and Porcelli, 2003). 
Further similarities may be found in assembly of the CD1 complex, which is also 
calreticulin and calnexin dependent, though also relying on endoplamsic 
phosphatidylinositol, which plays a key role similar to Ii in MHC clas-II 
presentation. Trafficking of CD1 to the plasma membrane is reliant on 
microsomal triglyceride transfer protein (Sagiv et al., 2007). Furthermore, it is 
believed that CD1d will associate with Ii, suggesting that their distribution, or 
that of MHC class-II may alter in the presence of one another (Paul, 2008). 
 
 
1.3.6  Alternative CD8+ T cell populations 
 
In addition to the α/β TCR expressing CTLs, another population carrying the non-
MHC γ/δ TCR also exists, making up 2-5 % of CD3+ T cells in the blood, but a far 
higher proportion in certain areas such as the skin and gastro-intestinal tract. 
The role of these cells is still being explored, but it is known that they also 
possess strong cytotoxic effector function, and secrete a range of cytokines, 
including IFN-γ and TNF-α (Hayday, 2000). These cells do not express CD4/CD8, 
and may be further subdivided into Vδ2+ (which make up 50-90 % of the total 
γ/δ T cell population) and Vδ2- (Vδ1+ or Vδ3+) populations. Of these, the latter 
do recognise MHC class-I chain-related molecules A and B (by way of the γ/δ 
TCR), and the UL16 binding proteins 1-3, all of which are up-regulated by heat 
shock or oxidative stress, leading to their constitutive expression in many 
epithelial tumours, as wells as and leukaemias and lymphomas (Groh et al., 
1999; Poggi et al., 2004). Vδ2- γ/δ T cells on the other hand do not, but instead 
recognise a range of non-peptidic phosphorylated metabolic intermediates from 
the non-mevalonate pathway of isoprenoid biosynthesis, as well as mitochondrial 
F1-ATPase and delipidated apolipoprotein A-I, all of which are commonly 
expressed in tumours (Kabelitz et al., 2007). 
 
The Vδ2+ population express MHC class-II and are capable of phagocytosis 
(Ichikawa et al., 1991; Wu et al., 2009), while the Vδ1+ population are capable 
of suppress CD8+ T cell responses and inhibit DC maturation, implying a 
regulatory function (Peng et al., 2007). Both populations are also capable of 
activation by NK receptors (which also recognise MHC class-I chain-related 
molecules A and B), tying them into the non-specific immune system (Rincon-
Orozco et al., 2005; Kabelitz et al., 2007). 
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Natural killer T (NKT) cells is an umbrella term for a range of T-lymphocytes 
which express Natural Killer receptors (NKRs), subsets of which also express the 
variant TCR chains Vα24 and/or Jα18 (and which may be CD8+/-). These TCRs 
recognise exogenous glycolipid antigens presented by the MHC-like CD1d 
molecule in a non hyper-variable manner (Peralbo et al., 2007), resulting in 
cytokine release and are capable of a memory-cell function. While these variant 
TCRs preclude recognition of peptide, the cells seem to play an important anti-
tumour role, with reduced numbers being recorded in numerous epithelial 
cancers, and which may also be useful for immunotherapy (reviewed in Molling 
et al., 2008). 
 
 
1.4  Therapies for cancer, and specifically CML 
 
1.4.1  Current and historical therapies for CML 
 
Though in general CML is largely chemotherapy-insensitive (Rivas et al., 2001) 
treatments for CML have historically relied on various chemotherapies such as 
Fowler’s solution, busulfan, hydrea/hydroxyurea, (which, due to their different 
mechanisms of action, may be applied individually or in combination) or 
sometimes radiotherapy (e.g.: spleenic irradiation) (Deininger and Druker, 2001). 
The first chemotherapeutic agent: Fowler’s solution (or black arsenic), is a weak 
potassium arsenite (arsenic trioxide) solution originally developed in the late 18th 
Century (though the use of arsenic as an anticancer agent dates back to the 1st 
Century AD) (Nicolis et al., 2009), but discontinued for therapeutic purposes 
(including at that time malaria and Hodgkin's lymphoma as well as the 
leukaemias) in the 1950’s due to toxicity and carcinogenicity associated with 
long-term use. The use of arsenite has however seen a resurgence in later years 
following trials with late-stage promyelocytic leukaemia (PML) patients, and was 
re-approved for therapy by the FDA in 2001 at 0.15 mg / kg body wt (Jun et al., 
2002; Nicolis et al., 2009). 
 
Busulfan (1,4-butanediol dimethanesulfonate) was introduced as an anticancer 
agent in the 1950’s. It is a DNA-alkylating and cross-linking agent known to 
affect stem cells, and typically able to control progression and symptoms of CML 
by reducing tumour burden for a minimum of three months, and extending 
patient lifespan to 3-4 years (Hehlmann et al., 1993; Iwamoto et al., 2004). It is 
usually prescribed at a daily dose of <0.1 mg/kg body weight, depending on 
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white cell count (Kolibab and Drucker, 2000) and may be used in combination 
with ‘classic’ chemotherapeutic agents such as cyclophosphamide (which also 
causes DNA-alkylation) (Kashyap et al., 2002) or fludarabine (which inhibits DNA 
synthesis) (de Lima et al., 2004). Side effects are severe however, including 
hepatic, pulmonary and cardiac fibrosis (potentially culminating in veno-
occlusion), as well as myelosuppression, and not only is the drug typically 
incapable of inducing cytogenetic remission, but busulfan resistance has also 
been documented in some patients (Stone, 2004; Valdez et al., 2008). 
Furthermore busulfan also has some mutagenic properties which may actually 
impair long-term survival (Hehlmann et al., 1993). 
 
Hydroxyurea, also known as hydroxycarbamide (CH4N2O2) is a small molecule 
capable of inhibiting the reduction of ribonucleotides crucial for DNA synthesis, 
and is typically prescribed in the 1-4 g/day range, depending on white blood cell 
count (Kolibaba and Drucker, 2000). Comparisons with busulfan have shown it 
to be a similar or superior therapeutic agent, with a greater survival advantage a 
lower toxicity profile (Hehlmann et al., 1993). Again while it is capable of 
producing a haematological response (Bubnoff and Duyster, 2010), it is rarely 
able to cure the patient (Garcia-manero et al., 2002), instead it extends patient 
lifespan and aid control of their symptoms (Faderl et al., 1999), and side effects, 
while usually haematological (Kolibab and Drucker, 2000) may also include 
nausea, skin atrophy and myelosuppression in the short term, and ulceration, 
gangrene, cutaneous squamous cell carcinoma and potentially lethal pulmonary 
effects following chronic use (Stone, 2004). Unfortunately as stated, all 
chemotherapeutic approaches to CML lack specificity and generally fail to 
produce true remissions in the majority of patients (blast crisis in particular 
tends to be refractive to chemotherapy), but to some extent alleviates suffering 
and/or prolongs patient lifespan (Deininger and Druker, 2001; Quintás-Cardama 
and Cortes, 2006). 
 
CML was also the first malignancy to be treated with (usually recombinant) IFN-α, 
a therapy which stimulates immune activity 28  through phosphorylation-
dependent activation of STAT-1, STAT-3, STAT-4, STAT-5a and -5b which all lie 
downstream of the IFN-α/β receptor, as well as augmenting the effect of many 
other cytokines, including IL-2 and increasing INF-γ and IL-12 expression in vivo 
(Maitikainen et al., 1999). The net result is an upregulation of T-cell function 
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 INF-α and INF-β, and their shared receptor are essential for clearance of viral infections. (Müller et 
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(Fausel, 2007), CTL proliferation and survival (Tough et al., 1996) and a 
promotion of the Th1 response (Roge et al., 1997). The therapy shows notably 
greater efficacy and survival rates than hydroxyurea (Chronic Myeloid Leukemia 
Trialists' Collaborative Group, 1997; Appleby, 2005); indeed, if deployed in the 
chronic phase INF-α is capable of producing haematological responses in up to 
80 % of patients, and complete cytogenetic responses (i.e. patients which are 
negative for fusion product transcript by PCR) in between 5 and 15 % (Bubnoff 
and Duyster, 2010). IFN-α has been shown to be especially effective when 
combined with Ara-C 29 (Guilhot et al., 1997) or hydroxyurea (Hehlmann et al., 
2003); unfortunately the key to IFN-α’s success is also the root of its toxicity – 
the therapy is often poorly tolerated (Kolibaba and Druker, 2000; Stone, 2004), 
rendering therapeutic doses less applicable. Side effects may include fatigue, 
prolonged flu-like symptoms, and depression (Fausel, 2007), and potentially 
lethal renal dysfunction, though this is usually only following chronic use (Colovic 
et al., 2006).  
 
Studies in the 1990’s illustrated that allograft bone marrow (stem cell) 
transplants30 (Apperley, 1998) and treatment with donor T lymphocytes can lead 
to remission and even complete cures of CML (Kolb et al., 1990; Collins et al., 
1997; Falkenburg et al., 1999), especially when combined with chemotherapy 
(Riddell et al., 2002). While transplants were originally thought to be most 
efficacious if carried out within the first twelve months following diagnosis, some 
studies have indicated that transplants carried out within three years may have 
as high a success rate (Gratwohl et al., 1993). Prognosis of the benefit of 
transplant is largely assessed using the scoring system developed by Sokal et al. 
(1985), though the development of therapeutic kinase inhibitors (see below) has 
to some extent undermined this system (Quintás-Cardama and Cortes, 2006). 
 
The primary hindrances to stem cell graft therapy are lack of suitable donors (for 
example only between one third – one half of patient siblings are suitable), and 
patient age, though obviously patient health / disease progression also factor 
heavily. The ideal conditions for transplant are otherwise healthy chronic-phase 
patients diagnosed less than one year ago and aged below 40, though even 
these have a post transplant mortality rate of up to 20 % (Peggs and Mackinnon, 
2003; Quintás-Cardama and Cortes, 2006). Even with matched unrelated donors 
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 Also known as cytarabine: a chemotherapeutic agent similar in structure to nucleosides which target 
dividing cells. 
30
 Studies which this author is proud to cite I.A. Dodi’s involvement. 
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taken into account, transplants are not an option for over 40 % of patients, 
though this figure is down from 80 % in the late 1990s, mostly due to kinase 
inhibitor therapy (see below) (Sawyers, 1999). 
 
Along with the risks typically implicit in surgery on cancer patients, one major 
complication of stem cell transplants is the risk of graft vs host disease (GvHD), 
where the immune cells which arise from the transplanted stem cells go on to 
reject the host’s tissues (Crough et al., 2002; Kolb et al., 1990). The risks of this 
condition may be significantly reduced by careful matching of patient and donor 
MHC class-I A, B C, and class-II Dr alleles, mismatching of any one of which may 
be a significant risk factor (MHC class-I C being the least vital) (Morishima et al., 
2002). When it does occur GvHD is usually controlled through corticosteroid 
therapy (Lee and Flowers, 2008), and has a strong negative correlation with CML 
relapse (Weiden et al., 1979; 1981), though this correlation is much weaker in 
AML and ALL (Horowitz et al., 1990).  
 
CML therapy was revolutionised a decade ago with the first therapeutic kinase 
inhibitor. Imatinib mesylate (or STI571)31, is a selective inhibitor for bcr:abl 
(Drucker and Lydon, 2000), and the first of a new family of small molecule 
inhibitors (reviewed in Zhang et al., 2009). Imatinib binds to the tyrosine kinase 
domain of bcr-abl in a competitive manner, stabilising the protein in an inactive 
conformation (Druker et al., 2001) and preventing ATP from accessing the active 
site (Quintás-Cardama and Cortes, 2006). It was designed based on the work of 
Yaish et al. (1988) in developing kinase-specific tyrphostins, and resulted from 
high throughput screening of the 2-phenylaminopyrimidine class kinase 
inhibitors. From these a number of compounds were selected and altered, until 
Imatinib was developed, initially as a platelet derived growth factor (PDGF) α/β 
inhibitor, but was also found to selectively inhibit abl kinases, and c-kit (Mauro 
and Druker, 2001). 
Phase-I clinical trials (with patients unsuitable for IFN-α therapy) demonstrated 
a complete haematological response in 98 % of patients receiving >300 mg 
Imatinib/day, with over 50 % also demonstrating a cytogenetic response. While 
no significant toxicity was observed with doses three times higher (mild 
myelosupppression was documented), dropping the dose to below 250 mg/day 
significantly reduced response rates (Druker et al., 2001). Similar results were 
observed in phase-II trials conducted on a largely late chronic-phase patient pool, 
dosed with 400 mg/day (now the standard dose, though subsequent trials have 
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 Developed by Novartis and marketed as Gleevec. 
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suggested benefits to raising this to 600 or 800 mg/day). As a result of this 
small molecule patient lifespans have been extended significantly, and when full 
cytogenetic responses occurred, they are maintained in 90% of these patients 
over three years later, though discontinuation of therapy often results in relapse 
(Quintás-Cardama and Cortes, 2006). 
 
However, within the reservoir of CML cells, post-transformative mutations in 
bcr:abl (often within the kinase domain) are frequent32 and may lead to Imatinib 
resistance (Corbin et al., 2003; Tauchi, et al., 2003). While newer small-
molecule inhibitors such as Nilotinib (>20-fold greater potency than Imatinib) 
and Dasatinib (>100-fold greater potency than Imatinib and which also inhibits 
Fyn, Lck, and Src kinase activity) have been developed to circumvent this 
(Quintás-Cardama and Cortes, 2006; Deguchi et al., 2008), resistance to these 
newer inhibitors has also been recorded (Soverini et al., 2007; Mahom et al., 
2008), especially amongst Ph+ stem cells (Copland et al., 2006; Jiang et al., 
2007; Konig et al., 2008) and the genetic instability typical of tumour cells may 
lead to the development of mutations which allow bcr:abl independent 
proliferation. As a result, Imatinib rarely succeeds in fully eradicating Ph+ cells 
from the body and therefore is typically a lifelong treatment (Appleby et al., 
2005). Indeed there are concerns that it may have immunosuppressive effects 
(Wolf et al., 2007) therefore additional therapeutic/preventative measures must 
be developed. As the overwhelming majority of cancers are destroyed by the 
immune system whilst still at the single cell-stage, successful malignancies must 
either escape from or be tolerated by the immune system (Khong and Restifo, 
2002). Therefore breaking immune tolerance may be the key to curing cancers, 
with the added benefit that such an approach may be performed without the 
high-toxicity of radio/chemotherapy. 
 
1.4.2  Cancer immunotherapy 
 
Immunotherapy against bacterial and viral diseases, starting in the modern age 
with Jenner’s cowpox-based vaccine for smallpox (then the cause of 10 % of 
mortality) has been a resounding success, and prophylactic vaccines are now 
readily available in Western society for a huge range of disease-causing agents, 
including: rabies; typhoid; cholera; plague; measles; varicella; mumps; 
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 Over 40 resistance-conferring mutations have been documented, each producing a different level of 
refractivity. Mutations in the glycine-rich P-loop, involved in ATP-binding are most common, and 
carry the poorest prognosis (Quintás-Cardama and Cortes, 2006). 
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poliomyelitis; hepatitis B and the tetanus and diphtheria toxins, many of which 
were previously fatal (Waldmann, 2003). However cancer immunotherapy is a 
far newer field, and is complicated by the immuno-sculpturing process that 
cancers undergo (typically long before diagnosis). The application of prophylactic 
vaccines is often prohibited by difficulty in identification of which tumours are 
likely to present in a currently disease-free patient; though one recent exception 
is the vaccine against human papillomavirus (HPV), some strains of which are 
sexually transmitted and responsible for 70 % of all cervical cancers (Lowy and 
Schiller, 2006). This vaccine is now given to adolescent females in numerous 
countries, with administration to males under consideration (Short et al., 2010; 
Yancey et al., 2010). 
 
Unfortunately, as previously stated oncoviruses play an etiological role in a 
minority of human cancers (Schiller and Lowy, 2010), therefore vaccines against 
other malignancies must be therapeutic in nature; i.e. aiming to reactivate and 
restimulate the immune system against an existing tumour (Waldmann, 2003).  
 
Unfortunately, as previously stated, oncoviruses play an etiological role in only a 
minority of human cancers (Schiller and Lowy, 2010), the remainder of which 
often lack a single major risk factor. As vaccines against other malignancies do 
not have such a direct link with an exogenous and immunogenic source, they 
must accordingly be therapeutic in nature; i.e. aiming to reactivate and 
restimulate the immune system against an existing tumour (Waldmann, 2003).  
 
 
1.4.2.1  Determination of cancer antigens 
 
A number of methods are available for determination of cancer antigens. While 
MHC elution and direct immunology is discussed in detail in section 4.1, a range 
of other options (reverse immunology) are available, each with specific strengths 
and weaknesses. One of the earliest approaches, autologous serological typing 
(e.g. Pfreundschuh et al., 1978; Ueda et al., 1979), and its successor, SEREX 
(serological analysis of recombinant cDNA expression libraries) (e.g. Chen 2004; 
Li et al., 2004) both rely on patient antibodies, which may represent a different 
set of antigens to the cellular immune response, while the T-cell equivalent (e.g. 
Kawakami et al., 1994) identifies T-cell epitopes, it may not take into account 
changes in reading frame or cryptic epitopes produced by translational 
modifications (Ho and Green, 2006), as well as requiring a known antigen to 
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begin with. Non-immune driven approaches tend to rely on differential 
expression of protein, as determined by (e.g.) protein microarrays (e.g. 
Gunawardana and Diamandis, 2007) or 2D-PAGE (though the latter is more 
commonly applied to serum reactivity) (Le Naour, 2001). These alone do not 
provide data on immunogenicity, and this data is usually acquired using peptides 
derived from in silico prediction of proteasomal digestion and MHC-binding for 
the protein of interest; though these algorithms are not perfect and may exclude 
peptides which are found in vitro (Pers. Comm., Dr Roger Horton, Nottingham 
Trent University), or include peptides which are not in fact naturally processed 
(Wang, 1997). Peptides which are predicted to be processed are then 
investigated using a variety of methods, including peptide binding assays, and 
the response (proliferation, cytokine release, and for class-I, the killing of target 
cells) of peptide-specific T cells33  to (e.g.) a cell line known to express the 
protein of interest and relative MHC allele(s). However these algorithms also do 
not currently account for post-translational modifications which may alter 
peptide immunogenicity or processing (see 1.4.4). 
 
 
1.4.2.2  MHC class-I antigens in leukaemia 
 
A number of MHC class-I epitopes have been identified with potential relevance 
to the leukaemias. Peptides from the bcr:abl fusion region which bind MHC 
alleles have been identified by a number of studies, many of which also 
demonstrated a CTL response (Bocchia et al., 1995; 1996; Grecoet al., 1996; 
Pinilla-Ibarz et al., 2000; Yotnda et al., 2000; and Clarke et al., 2001). Bocchia 
et al. (1995) demonstrated three peptides which bound well to MHC class-I A3 
and A11 and/or B8, while Posthuma et al. (1999) demonstrated that individuals 
with these MHC alleles showed a decreased risk of developing clinically 
detectable CML. Buzyn et al., (1997) demonstrated processing and 
immunogenicity of a peptide from the fusion protein’s counterpart abl:bcr. 
Vaccine trials with the bcr:abl peptides (either alone or in conjunction with 
Imatinib, cytokine therapy, or stem cell transplants) are ongoing, along with 
investigations into other antigens such as Wilms Tumour-1, Heat Shock Protein 
Peptide Complex 96; Proteinase 3 and Survivin, and have been recently 
reviewed in Dao and Scheinberg (2008) Guilhot et al. (2008), and Pinilla-Ibarz et 
al. (2009). 
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 Often generated by immunisation of a murine model with a peptide of interest and harvesting of 
(CD4+ / CD8+) T cells from the thymus a few days later. 
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1.4.2.3  Phosphopeptides as MHC antigens 
 
As the genetic instability typical of neoplasms may result in aberrant kinase 
expression and/or other proteins not normally expressed in the tissue 
(Gisselsson, 2005), phosphorylation patterns not seen in normal tissue may 
provide novel tumour antigens. If the kinase and substrate are not normally co-
expressed, such antigens may be tumour specific. 
 
Andersen et al. (1999) demonstrated that the MHC class-I antigen processing 
system was capable of presenting phosphorylated peptides and that CD8+ T cells 
could be generated that were specific for the phosphorylated form of the 
peptides, while Zarling et al. demonstrated that they occurred in vivo (2000) and 
that malignant cells present a different set of peptides from non-malignant 
(2006). However the phosphorylated peptides identified typically presented poor 
predicted binding scores in algorithms such as SYFPEITHI (mirrored by findings 
at NTU) and it was found that phosphorylation altered MHC binding as well as 
altering the antigenicity of the peptide (Mohammed et al., 2008; Petersen et al., 
2009). More recently phosphorylated peptides have also been shown to be 
presented by the MHC class-II complex and that again, the phosphate group 
alters binding to the complex (Depontieu et al., 2009; Li et al., 2010). 
 
Given the strong links between aberrant kinase activity and leukaemia, it is 
considered that phosphorylated peptides may present a novel class of tumour 
antigens when presented by both MHC class-I and class-II. As previous work at 
NTU has focused on the elution of MHC-presented peptides from class-I and 
class-II complexes direct from the cell surface, as well as the use of various 
chromatographic techniques to fractionation of MHC-presented peptides, the 
application of these approaches towards identification of MHC-presented 
phosphopeptides may generate novel candidate peptides for immunotherapy. 
 
 
1.5  Aims and Objectives 
 
The aims of this research focus on the peptidomic aspects of cancer immunology: 
namely isolation of MHC class-I and class-II peptides from the surface of 
leukaemic cell lines, and the use of chromatographic fractionation to isolate and 
Chapter 1.0: Introduction and Aims 
 42
concentrate the phosphorylated subpopulation, prior to identification of 
sequences by mass spectrometry. 
 
As will be discussed, this involved three main aspects of research: 
 
1) Modification of the BCA assay commonly used for protein quantification so 
as to improve applicability for estimation of peptide content. 
 
2) Alteration of the buffer components used for cell-surface elution of MHC 
peptides to minimise cell lysis. This involved utilisation of the BCA assay 
above as one determinant of cell death. 
 
3) Investigation into various chromatographic methods (both selective and 
generic) for concentration of phosphopeptides (using both synthetic 
peptides and tryptic digests of bovine casein), again heavily relying on 
the modified BCA assay for quantification. 
 
Following on from this, identification of MHC-presented phosphopeptides was 
performed by LC-ESI-MS/MS, though immunological significance is not 
determined at this stage. 
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2.0   Materials and Methods 
 
2.1  List of Materials 
 
2.1.1 List of plasticware, glassware and chromatographic stationary-
phases 
 
Reagent/material Supplier Notes 
   
Bond-Elut 18 SPE Columns Varian  
C18 SPE columns See ‘Bond-Elut’ and ‘Strata C18’ 
Cell culture plasticware Sarstedt T-25, and T-75 tissue 
culture flasks (vented), 
6-well plates, cryovials. 
 Greiner Bio-one T-175 tissue culture 
flasks (vented). 
FACS Test Tubes Tyco Healthcare  
HEA Hypercel Resin Pall  
HiLIC See HEA Hypercel, PPA Hypercel and Strata NH2. 
Hi-Trap Chelating HP 
columns (IMAC) 
GE Healthcare Iminodiacetate resin. 
IMAC columns See ‘Hi TrapChelating HP’ 
IMAC column dismantling 
tools 
Constructed by Mr Robert Davy, with thanks. 
Microplates (opaque) Fisher Scientific 96-wells, flat-bottomed. 
Microplates (transparent) Sarstedt 96-wells, flat-bottomed. 
Micro-pippette-tips  Sarstedt P 2 µl – P 10 ml 
PPA HyperCel resin Pall  
Screw-top tubes Sarstedt 15 and 50ml, rounded 
bottom 
 Sterilin 20 ml, flat bottomed. 
Sealed boiling (‘Eppendorf’) 
tubes 
Sarstedt 0.5, 1.5 and 2 ml 
   
   
Strata C8 SPE columns Phenomenex Strata C8 SPE columns 
Strata C18 SPE columns Phenomenex Strata C18 SPE columns 
Strata NH2 SPE columns Phenomenex Strata NH2 SPE 
columns 
Strata X SPE columns Phenomenex Strata X SPE columns 
Strata X-AW SPE columns Phenomenex Strata X-AW SPE 
columns 
Tissue culture flasks  See ‘cell culture’ 
 
 
2.1.2 List of reagents, solvents and media components 
 
Reagent/material Supplier Notes 
   
Acetic acid Fisher Scientific Reagent grade 
Acetone Sigma Aldrich HPLC grade 
Acetonitrile Fisher Scientific HPLC grade 
Adenylate kinase (AK) Sigma Aldrich 
(kindly donated by 
From chicken muscle. 
Foreign (non AK) 
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Dr.s John Dickenson 
and Laurice Fretwell.) 
activity below 1 %. 
Adenylate kinase detection 
reagent (AKDR) 
Lonza Biosciences includes luciferase and 
luciferin 
ATP Sigma Aldrich Supplied at 90 % 
purity. 
ATP detection reagent 
(ADR) 
Lonza Biosciences includes luciferase and 
luciferin 
Acrylamide Geneflow 30 (w/v) 29:1 
acrylamide:bis 
acrylamide 
Aldolase GE Healthcare From rabbit muscle. 
Ammonium bicarbonate Sigma Aldrich  
Ammonium persulphate Sigma Aldrich  
Ammonium sulphate Sigma Aldrich  
anti-β2 microglobulin 
antibody 
Sigma Aldrich Raised in mouse 
Ascorbic acid Sigma Aldrich  
Asparagine Sigma Aldrich  
BCA assay kit  Fisher Scientific 1 l kit. Includes 
bicinchoninic acid 
reagent (BCA 
component A) and 4 % 
(w/v) CuSO4 (B). 
BSA Sigma Aldrich  
Casein Sigma Aldrich Bovine 
Catalase GE Healthcare Bovine 
Citric acid Fisher Scientific  
Chloroform Fisher Scientific HPLC grade 
Coomassie Brilliant-Blue  Sigma Aldrich  
Copper Sulphate (CuSO4) Sigma Aldrich  
Deoxycholate Sigma Aldrich  
Diethanolamine (DEA) Fisher Scientific  
Dimethylsulphoxide (DMSO) Sigma-Aldrich Cell culture grade 
Ethanol (EtOH) Fisher Scientific  
Ethylenediamine-tetraacetic 
acid (EDTA) 
Sigma-Aldrich  
FeCl3 (Iron III chloride) Sigma-Aldrich  
Foetal Calf Serum Hyclone Cell culture grade 
Formic acid Fisher Scientific  
G-418 BD Biosciences  
Glucose (D-glucose) Sigma-Aldrich  
Glutamine / L-glutamine Lonza Biosciences 200 mM. Cell culture 
grade. 
Glutaraldehyde Melford Laboratories  
Glutathione (reduced) Sigma-Aldrich Hygroscopic. 
Glycerol Fisher Scientific  
Glycine Melford Laboratories  
Guinea pig liver Kindly supplied by Dr 
David Munoz  
HEPES Melford Laboratories  
Hydrochloric acid (HCl) Fisher Scientific HPLC grade 
Inositol Sigma-Aldrich Cell culture grade 
Isoton Beckman Coulter  
Laemelli sample buffer Sigma-Aldrich 2x concentration 
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Methanol (MeOH) Fisher Scientific HPLC grade. 
Anti-mouse (FITC 
conjugated) 
Sigma-Aldrich  
Anti-mouse (PE conjugated) Sigma-Aldrich  
NaCl Sigma-Aldrich  
Phosphate buffered saline 
(PBS) 
Lonza Biosciences Cell culture grade. 
Phosphoric acid (PA) Fisher Scientific HPLC grade 
Penicillin/streptomycin 
solution 
Lonza Biosciences 5000 
[units/ml]/[mcg/ml]. 
Cell culture grade. 
Peptides/phosphopeptides 
(synthetic) 
4mer (LSRH): NTU 
synthesised by Dr S 
Patwardhan. 
All synthesised to > 
80 % purity. 9-10mers: 
Pepceuticals 
20-27mers:  Alta 
Biosciences 
Potassium Chloride Sigma-Aldrich  
Pro-Q Diamond 
Phosphostain 
Invitrogen    
(Molecular Probes)  
Propidium idodide (PI) Sigma-Aldrich  
RPMI 1640  Lonza Biosciences Cell culture grade 
(without L-glutamine) 
Serine Sigma-Aldrich  
Sodium acetate Sigma-Aldrich  
Sodium doecyl sulphate 
(SDS) 
Melford Laboratories  
Sodium Hydroxide (NaOH) Sigma-Aldrich  
Sodium formate Sigma-Aldrich  
(di)Sodium Phosphate 
Na2HPO4 
Sigma-Aldrich  
Sucrose Sigma-Aldrich  
Tetramethyl 
Ethylenediamine (TEMED)   
Toxilight assay buffer Lonza Biosciences pH 7.5 
Tricine Fisher Scientific  
Trichloroacetic acid (TCA) Sigma-Aldrich  
Trifluoroacetic acid (TFA) Sigma-Aldrich  
Trimethylamine (TMA) Fisher Scientific 37 % (v/v) 
Tris Melford Laboratories  
Trypan blue suspension Sigma-Aldrich 0.4 % (w/v) in PBS 
Trypsin Sigma-Aldrich (Porcine) 
Tween 20 Fisher Scientific  
Ultra low weight marker 
(ULM) 
Sigma-Aldrich Peptide PAGE ladder 
(26.6 – 1.06 kDa MW)1 
W6/32 Antibody Kindly purified in-
house by Mr Stephen 
Reeder.  
 
 
                                                 
1
 Composed of: Rabbit Triosephosphate Isomerase (26.6 kDa); Horse Cardiac Myoglobin 
(17 kDa); Bovine Aprotinin (6.5 kDa); bovine Insulin Chain B (3.5 kDa) and Bradykinin (1.06 
kDa). 
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2.1.3  List of suppliers 
 
Supplier Address 
Alta Bioscience University of Birmingham, Edgbaston,               
Birmingham, B15 2TT. 
BD Biosciences 21 Between Towns Rd, Cowley, Oxon, OX4 3LY UK. 
Beckman Coulter 
UK, Ltd. 
Oakley Ct, Kingsmead Business Park, High Wycombe, 
Bucks, HP11 1JU. 
GE Healthcare. Pollards Wood, Nightingales Ln, Chalfont St Giles, Bucks, 
HP8 4SP. 
Fisher Scientific 
UK, Ltd. 
Bishop Meadow Rd, Loughborough, Leics, LE11 5RG. 
Geneflow, Ltd. Fradley Business Centre, Wood End Ln, Lichfield, Staffs, 
WS13 8NF. 
Greiner Bio-one, 
Ltd. 
Brunel Way, Stroudwater Business Park, Stonehouse, 
Gloucs, GL10 3SX.  
Hyclone UK, Ltd. Unit 9 Atley Way, North Nelson Industrial Estate, 
Cramlington, Northumb., NE23 1WA 
Invitrogen, Ltd.  3 Fountain Dr, Inchinnan Business Park, Renfrew, 
Renfrewshire, PA4 9RF 
Lonza Biosciences 
(Lonza Group Ltd.) 
Lonza Group Ltd. 228 Bath Rd, Slough, Berks, SL1 4DX 
Melford 
Laboratories Ltd. 
Bildeston Rd, Chelsworth, Ipswich, Suffolk, IP7 7LE 
Pall Life Sciences Europa House, Havant St., Portsmouth, Hamps, PO1 3TD 
Pepceuticals Ltd. Nottingham Biocity, Pennyfoot Street, Nottingham, NG1 
1GF 
Phenomenex Ltd. Melville House, Queens Av, Macclesfield, Cheshire SK10 
2BN 
Sarstedt Ltd. 68 Boston Rd, Beaumont Leys, Leicester, Leics, LE4 1AW 
Sigma Aldrich Sigma-Aldrich Company Ltd., The Old Brickyard, New Rd, 
Gillingham, Dorset, SP8 4XT. 
Sterilin, Ltd Angel Ln, Aberbargoed, Bargoed, Caerphilly, CF81 9FW. 
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2.2  Cell Culture  
 
Stock Solutions 
A: RPMI 1640 (as supplied) 
B: FCS (as supplied) 
C: L-glutamine solution: 200 mM (as supplied) 
D:  Penicillin/streptomycin solution: 5000 [units/ml]/[mcg/ml] (as supplied) 
E: Precept solution: 2 tablets dissolved in 500 ml dH2O, plus the addition of 
1 % (v/v) Tween (normal grade). 
F: DMSO. 
G: PBS: cell culture grade (as supplied) 
H: 0.1 % (w/v) Trypan blue: prepared by diluting 0.4 % (w/v) Trypan blue 
suspension fourfold with PBS. 
 
N.B.: All tissue culture was carried out using aseptic techniques in a 
Containment Level 2 laboratory. Solutions were all tissue culture grade unless 
stated otherwise. 
 
 
2.2.1  Preparation of cell culture media 
 
Culture media was prepared by the addition of the following per 500 ml bottle of 
RPMI 1640. Before addition to the media, foetal calf serum (FCS) was heat 
inactivated at 59 °C for 60 minutes.  
 
Component Stock 
concentration 
Volume 
added 
Final 
concentration Role 
Heat-
inactivated 
Foetal calf 
serum (FCS) 
100 % (v/v) 50 ml 10 % (v/v) 
Provides necessary  
growth factors and 
hormones 
L-glutamine 
solution 200 mM 5 ml 2 mM 
Essential amino acid and 
secondary energy source 
Pen/strep 
solution 
5000 units/ml 
potassium 
penicillin and 5000 
mcg/ml 
streptomycin 
sulphate 
5 ml 
50 units/ml 
potassium 
penicillin and 
50 mcg/ml 
streptomycin 
sulphate 
Penicillin: gram-positive 
bactericidal β-lactam 
antibiotic, Streptomycin: 
gram-negative bacteri-
cidal aminoglycoside 
antibiotic.2 
Table 2.1: Components added to RPMI 1640 cell culture media (500 ml), referred to 
hereafter as “complete RPMI 1640” 
 
                                                 
2
 Penicillin and streptomycin work synergistically, with penicillin enhancing the penetration of 
streptomycin into the bacterial cell wall (Winstanley & Hastings, 1989). 
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When necessary the antibiotic G-418 (prepared as a 500 mg/ml stock in PBS) 
was also added to a final concentration of 1 mg/ml for the culture of the 
transfected cell lines K562-A2, K562-A3 and T2.Dr4. G-418 is an aminoglycoside 
antibiotic toxic to mammalian cells lacking the gene APH 3‘ II (encoded as the 
reporter gene on the HLA-A2, HLA-A3 and HLA-Dr.4 plasmids), selectively killing 
those cells which have lost the gene of interest. 
 
 
2.2.2  Culture of frozen cells 
 
106 cells stored in a 1 ml aliquot of culture media (as above) plus 10 % v/v 
dimethylsulphoxide (DMSO) and frozen in liquid nitrogen were briefly thawed at 
room temperature and washed in 20ml RPMI 1640. The cells were then pelleted 
by centrifugation at 400 r.c.f. for 3 minutes using a refrigerated centrifuge 
(Eppendorf model 5702 R) and the supernatant discarded. Cell pellets were 
resuspended in 20 ml complete RMPI 1640 and seeded in a T-25 cell culture 
flask which was then cultured at 37 °C in a Heto Holten cellhouse 170 incubator 
supplied with a 5 % (v/v) CO2 atmosphere. Size and number of flasks were 
increased as required by the growth of the cells in question. Aside from 
incubation and centrifugation, all work took place within a Walker Safety Cabinet 
laminar flow hood, model 1290 CLII. 
 
 
2.2.3  Maintaining cell cultures 
 
Suspension cells lines JY, K562-A3, LAMA-84, T2.Dr4, & THP-1, were used for 
the course of experimentation. Cells were cultured in close contact and were 
typically passaged every 3-4 days, with a minimum period of 24 hours (for high-
confluency cultures) and a maximum period of no more than 9 days, due to the 
instability of glutamine, which has a half life of between 6.7-18 days (Ozturk & 
Palsson, 1990) and degrades into pyroglutamate and ammonium, which may be 
toxic to the culture depending on concentration (Schneider et al., 1996). The 
necessity to passage the cells was determined by the colour of the phenol red pH 
indicator present within the RPMI 1640. 
 
Culture media was replaced by one of two methods. Firstly, the cell suspension 
could be transferred to a 20 ml universal or a 50 ml falcon tube, and centrifuged 
at 400 r.c.f. for 3 minutes, using either an Eppendorf model 5702 R refrigerated 
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centrifuge or a MSE Falcon model 6/300 refrigerated centrifuge, following which 
the supernatant was discarded and the pellet resuspended in a fresh volume of 
media prior to being returned to the culture flask. Whilst this allows nearly 
100 % of the media to be changed per passage, it becomes a more demanding 
strategy in terms of time and disposable plasticware as culture volumes increase. 
 
Alternatively, and more conveniently for large numbers of cells, the flask could 
be placed in a vertical position and the cells allowed to settle by gravity over the 
course of 2-3 hours, following which the top 75-90 % (v/v) of the culture media 
was aspirated off (taking care not to disturb the cell sediment), and replaced 
with fresh complete RPMI 1640. 
 
Cells were sub-cultured 1:2 or 1:4 to maintain log phase growth (typically every 
8-12 days), either by centrifugation and division of the cell resuspension, or by 
transfer of 25 - 50 % v/v of the cell suspension from one flask to another, each 
of which was then brought to maximum culture volume by the addition of fresh 
media. Aside from incubation and centrifugation, all work took place within a 
laminar flow hood (Walker Safety Cabinet model 1290 CLII) and sealed flasks 
were cultured at 37 °C in a Heto Holten cellhouse 170 incubator supplied with a 
5 % (v/v) CO2 atmosphere. All waste was inactivated by incubating at a ratio of 
no greater than 1:4 with a Precept:H2O solution for > 1 hr at RT. 
 
 
2.2.4  Long-term storage of cells in liquid nitrogen 
 
When necessary cells were frozen in liquid nitrogen according to the following 
method: 
 
 
2.2.4.1  Preparation of freezing media (RPMI 1640) 
 
Freezing media was prepared by the addition of 2 ml 10 % (v/v) sterile DMSO 
(sterile filtered3, hybridoma tested) to a complete RPMI 1640, typically to a final 
volume of 20-50 ml depending on the number of cells required. It should be 
noted however that while this was suitable for those cell lines frozen during the 
course of this research, other cell lines (or fragile cultures) may benefit from a 
                                                 
3
 DMSO dissolves the plastic in most disposable filters; therefore DMSO pre-filtered by the 
manufacturer is required, and must be kept sterile for obvious reasons. 
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higher concentration of FCS in the freezing medium (90 % (v/v) FCS, 10 % (v/v) 
DMSO, 0 % (v/v) RPMI is not unheard of). 
 
 
2.2.4.2  Freezing cells 
 
Before freezing cells were counted by trypan exclusion (see section 2.4.4.1), 
washed once in RPMI 1640, and resuspended in freezing media at a 
concentration of 106 per ml. This was then transferred to 1.5 ml cryovials which 
were then frozen first at -80 °C for 3 hours, then transferred to liquid nitrogen 
storage (monitored and replenished as needed) until they were next required.  
 
 
 
2.3  Development of the BCA Peptide Assay 
 
2.3.1  BCA protein assay 
 
Stock Solutions 
A: Bicinchoninic acid (BCA) component A (as supplied) 
B: 4 % (w/v) CuSO4 (as supplied) 
C: 10 mg/ml BSA solution for standard curve preparation (as supplied) 
 
 
2.3.1.1 Unmodified BCA protein assay protocol 
 
A protein assay was performed by transferring 25 µl of each vortex-mixed 
sample to a clear, flat-bottomed 96-well microplate. When necessary the sample 
was diluted 1/5, 1/10, 1/20 or 1/50 in water or buffer (dilutions may be assayed 
as an alternative to, or in addition to the undiluted original) to compensate for 
high protein content, interfering substances, or a low pH. 
 
A standard curve was prepared using the ampoule of 10 mg/ml BSA provided 
with the BCA kit. Dilutions are made ranging from 0.1-1 mg/ml in a matrix 
appropriate for the samples to be assayed (along with blanks), and transferred 
in 25 µl volumes to the 96 well microplate. For all quantitative assays, replicates 
of no less than 3 were carried out for both the sample(s) and standard curve. 
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BCA standard working reagent was then prepared by mixing bicinchoninic acid 
reagent (BCA component A) with 4 % (w/v) CuSO4 (component B) in a ratio of 
50:1. A 200 µl volume of this coloured reagent was then added in a randomised 
pattern to each well that contained a standard or sample, before the microplate 
was covered with sealing film, and incubated at 37 °C for 30 minutes, following 
which the microplate was unsealed, and the absorbance read at 570 nm in a Bio 
Rad microplate reader (model 680).  
 
Where a time course was performed the plate was incubated unsealed within the 
microplate-reader (built-in incubator pre-warmed to 37 °C), and absorbances 
read every 5 minutes over a 120 minute period.  
 
 
2.3.2 Investigation into the applicability of the BCA assay for the 
quantification of peptides 
 
Stock Solutions: 
A: Bicinchoninic acid (BCA) component A (as supplied) 
B: 4 % (w/v) CuSO4 (as supplied) 
C: Synthetic peptide solutions (all to >80 % purity), dissolved in 100 % 
DMSO to 10 mg/ml. Sequences as per Table 2.3.1 
D: Protein solutions (aldolase, BSA casein and catalase) for tryptic digestion, 
dissolved in 10 mM Tris-acetate pH 8 to 25 mg/ml. 
E: Trypsin solution, dissolved in 10 mM Tris-acetate pH 8 to 10 mg/ml 
 
 
2.3.2.1 Preparation of synthetic peptide standards for BCA assay 
 
Synthetic peptide solutions in DMSO were diluted in appropriate reagents as 
required to produce working concentrations and standard curves from 0.015 – 1 
mg/ml. Samples were then assayed as per 2.3.1.1. See chapter 3, table 3.2 for 
details of peptide sequences and physical properties. 
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2.3.2.2 Tryptic digestion of standard proteins 
 
2.3.2.2.1 Preparation of tryptic digests of standard proteins for BCA peptide 
assay 
 
Rabbit muscle aldolase, bovine serum albumin, bovine casein and bovine liver 
catalase were dissolved at 25 mg/ml in 10 mM Tris-acetate pH 8 and tryptically 
digested by the addition of 1 % (w/w) porcine trypsin. Samples were incubated 
at 37 °C for 72 hours to achieve maximal digestion, following which standard 
curves ranging from 0.05 – 0.5 mg/ml were prepared from these digests by 
diluting in water, or other reagents as required. Samples were then assayed as 
per 2.3.1.1, with or without denaturing in SDS-NaOH (see 2.3.4). 
 
 
2.3.2.2.2 Preparation of low-concentration standard curves from tryptic 
digests of BSA to determine BCA peptide assay sensitivity 
 
Bovine serum albumin was digested as per 2.3.2.2.1 and standard curves 
ranging from 0.005 – 0.05 mg/ml were prepared from these digests by diluting 
in water, or other reagents as required. Samples were then assayed with or 
without denaturing in SDS-NaOH (see 2.3.4), as per 2.3.1, or with the 25:1 
bicinchoninic acid reagent (BCA component A):CuSO4 ratio as per 2.3.5.1. 
 
 
2.3.2.2.3 Preparation of weighted standards from tryptically digested casein 
 
Bovine casein was digested as per 2.3.2.2.1 and serial dilutions prepared. These 
were then denatured and assayed according to 2.3.4. The tryptic digests were 
then quantified against standard curves prepared from the 9-10mer peptides, 
and assigned the average concentrations from the pooled peptide standards. The 
weighted digests were then dispensed in to aliquots and frozen at -20 °C.  
 
In cases when a peptide subpopulation was expected, the weights were adjusted 
to reflect the relevant (e.g. phosphorylated) subpopulation. 
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2.3.3 Comparative solubilisation strategies for hydrophilic and 
hydrophobic peptides prior to BCA assay 
 
Two synthetic peptides, SQKGQESEY (hydrophilic score 0.9) and YISPLKSPY 
(hydrophilic score -0.5) were utilised to investigate potential BCA-compatible 
solubilisation methods prior to the assay, with the aim of reducing the variations 
in inter-peptide reactivity.  
 
Stock Solutions: 
A: Bicinchoninic acid (BCA) component A (as supplied) 
B: 4 % (w/v) CuSO4 (as supplied) 
C: Synthetic peptide solutions (all to >80 % purity), dissolved in 100 % 
DMSO to 10 mg/ml. Sequences as per Table 2.3.1 
D: 100 % (v/v) DMSO 
E: 100 % (v/v) methanol 
F:  0.18 % (w/v) deoxycholic acid solution  
G: 10 % (w/v) SDS solution  
H: 200 mM disodium phosphate solution  
G: 1 M sodium hydoxide solution  
 
 
2.3.3.1 Peptide Solubilisation  
 
Peptides were assayed at a final sample concentration of 0.2 mg/ml under the 
following conditions: (A) H2O; (B) 0.15 % deoxycholic acid*; (C) 1 % SDS; (D) 
5 % SDS*; (E) 1 % SDS + 10 % MeOH; (F) 5 % SDS + 10 % MeOH; (G) 50 
mM disodium phosphate*; (H) 100 mM disodium phosphate*; (I) 1 % SDS + 
0.1 M NaOH*; (J) 3 % SDS + 0.1 M NaOH*; (K) 5 % SDS + 0.1 M NaOH*; (L) 
1 % SDS + 10 % MeOH; (M) 5 % SDS + 10 % MeOH; (N) 1 % SDS + 50 mM 
Disodium phosphate + 10 % MeOH; (O) 5 % SDS + 50 mM Disodium phosphate 
+ 10 % MeOH; (P) 5 % SDS + 0.1 M NaOH + 10 % MeOH; (Q) 5 % SDS + 0.1 
M NaOH + 10 % DMSO; and (R) 5 % SDS + 0.1 M NaOH + 10 % MeOH + 10 % 
DMSO. 
 
The percentage concentration figures given represent (w/v) for SDS and 
deoxycholic acid, and (v/v) for DMSO and MeOH. * indicates treatment both at 
room temperature, and heat-denaturing for 5 minutes in a Biometric Uno 
Thermoblock set to 95 °C.  Samples were assayed as per 2.3.1. 
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2.3.3.2  Data Analysis and Statistical Evaluation 
 
In order to achieve cross-plate comparability, the absorbance for both the 
SQKGQESEY and YISPLKSPY peptide following each solubilisation regimen 
standardised against a third peptide (VHSATGFKQSSKALQRPVA-SD) at 0.3 
mg/ml in water. 
 
The adjusted absorbance values were then pooled and the standard deviation 
across both peptides calculated, under the hypothesis that a reduction in spread 
between the SQK and YIS would lead to a lower cross-peptide standard deviation. 
Once the final regime was decided upon (see 2.3.4), the comparative standard 
deviations of the pooled peptides with and without denaturing was compared 
using the student T-test to generate a statistically reliable result (n = 21). 
 
 
2.3.4  BCA peptide assay (final method) 
 
The following is the standard method adopted following the solubilisation 
experiments. 
 
Stock Solutions: 
A: Bicinchoninic acid (BCA) component A (as supplied) 
B: 4 % (w/v) CuSO4 (as supplied) 
C: 10 M NaOH 
D: 10 mg/ml synthetic peptide solutions (SQKGQESEY and YISPLKSPY 
peptides in DMSO) 
 
 
2.3.4.1 Preparation of SDS-NaOH for BCA peptide assay 
 
To prepare 20 ml of 2 % (w/v) SDS in 0.2 M NaOH (2x SDS-NaOH), 0.2 g SDS 
was dissolved in 15 ml pre-warmed dH2O, and 200 µl of 10 M NaOH stock added. 
The solution was then brought to 20 ml with warm dH2O, and filter-sterilised 
prior to storing in a sealed 20 ml sealed sample tube. The SDS-NaOH was pre-
warmed in a 37 °C water bath for 30 minutes and gently agitated, to ensure that 
SDS was fully dissolved prior to each use, following which samples were diluted 
1:1 with the 2x reagent and heat-denatured prior to analysis. 
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When a 1x solution was required this was prepared by diluting the X2 solution 
1:1 with ddH2O. This 1x solution was only used to dilute samples in a ratio 
of >20:1 SDS-NaOH : sample. 
 
 
2.3.4.2 Heat-denaturation of peptide samples in SDS-NaOH 
 
Sealed 500 µl microfuge tubes containing peptide samples diluted 1:1 in 2x SDS-
NaOH were vortex-mixed, pulse-centrifuged at 20,800 r.c.f. and heated to 95 °C 
for five minutes in a Biometric Uno Thermoblock. Samples were then vortex 
mixed before being assayed as per 2.3.1. 
 
 
 
2.3.5 Investigation of additional variations on the standard protocol 
  
2.3.5.1 BCA assay with increased-copper standard working-reagent 
 
In order to investigate the effect of higher CuSO4 concentrations on the peptide 
BCA assay, BCA standard working reagents was also prepared in a ratio of 25:1 
bicinchoninic acid reagent (BCA component A) to 4 % (w/v) CuSO4 (component 
B). Samples were then assayed as per 2.3.1.1. 
 
 
2.3.5.2 Analysis of samples over an incubation time course 
 
Where a 120 minute time course was pursued, samples were prepared in H2O or 
denatured in SDS-NaOH, and 25 µl transferred to a 96-well microplate in 
triplicate as previously described. However once BCA standard working reagent 
was added, the 96-well microplate was transferred directly to the Bio Rad 
microplate reader (model 680), where the built in incubator was pre-warmed to 
37 °C. Readings were then taken every 5 minutes over a two hour period.  
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2.3.5.3 Microwave incubation  
 
The method of Atkins and Tuan (1992) utilising microwave incubation as an 
alternative to the 37 °C incubation period was adapted to investigate its 
applicability to peptide quantification, and whether the period of microwave-
incubation could also simultaneously replace the heat-denaturing step. A 600 w 
Hinari ‘lifestyle’ model equipped with a rotating tray was utilised. 
 
The effect of empty wells on microwave incubation was determined by adding 
200 µl of H2O to 24, 46 or all 96 wells within a microplate, which was then 
visually observed when heated for up to 60 seconds on full power. The effect of 
microplate location on the rotating microwave tray was also investigated, with 
plates filled with 200 µl of H2O in all 96 wells placed in the centre or on the edge 
of the rotating tray, and again visually observed. 
 
The final method established for even heating of the microplate without boiling 
required all unused wells to be filled with 200 µl of H2O, following which the 
microplate was covered with sealing film and placed on the near edge of the 
microwave tray. The microwave was set to heat the microplate for 15 seconds, 
during which time the microwave tray would rotate though 180 °. The plate was 
then moved across the tray to its original position, with the result that the wells 
previously on the outer-edge of the rotating tray were now on the inner side, 
and subjected to a second 15 second incubation. Following this the plate was 
then allowed to cool to room temperature over the course of 2 minutes, then the 
seal removed4 and the absorbance read at 570 nm in a Bio Rad microplate 
reader (model 680). 
 
Using this method a tryptic digest of BSA, as well as the two synthetic peptides 
SQKGQESEY (hydrophilic score 0.9) and YISPLKSPY (hydrophilic score -0.5) were 
then assayed across a short standard curve of 0.1 - 0.5 mg/ml. Samples were 
assayed in water, or in SDS-NaOH (+/- heat denaturing), and the data analysed 
in a similar manner to 2.3.4. 
 
 
 
                                                 
4
 Care must be taken not to allow the microplate to boil, or the contents of the wells to expand to the point where 
capillary action draws liquid up out of the wells to mix on the underside of the seal, as this may alter both well 
volume, and lead to sample mixing, skewing results. Alternatively the microwave incubation may be attempted 
without the seal, however the effects of evaporation have not been evaluated. 
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2.3.5.4  Heat denaturation in BCA Reagent A + SDS 
 
Stock Solutions 
A: Bicinchoninic acid (BCA) reagent A (as supplied) 
B: 10 % (w/v) SDS solution 
C: 1 % (w/v) SDS solution 
D: 10 mg/ml synthetic peptide solutions (SQKGQESEY and YISPLKSPY in 
DMSO) 
E: 4 % (w/v) CuSO4 (as supplied) 
G: 2x SDS-NaOH (prepared as per 2.3.4) 
 
Two synthetic peptides were dissolved to 0.066 mg/ml (final assay concentration) 
in reagent A with increasing concentrations of SDS as per table 2.3.2.  Samples 
were aliquoted into three replicates of 250 µl, vortex-mixed, pulse-centrifuged at 
20,800 r.c.f. and heated to 95 °C for five minutes in a Biometric Uno 
Thermoblock. 
 
Both peptides (along with appropriate blanks) were also prepared to the same 
(final assay) concentration in water, and in SDS-NaOH and assayed with the 
other samples described above, as per 2.3.1 and 2.3.4 respectively. 
 
Final SDS 
concentration 
Synthetic 
Peptide Stock/ 
DMSO only 
10 % (w/v) 
SDS solution 
1 % (w/v) 
SDS solution 
H20 
BCA 
reagent A 
Final 
Volume 
0 % (w/v) 5 µl 0 µl 25.7 µl 92.5 µl 660 µl 757.5 µl 
0.05 % (w/v) 5 µl 0 µl 51.8 µl 66.8 µl 660 µl 757.5 µl 
0.01 % (w/v) 5 µl 20.6 µl 0 µl 40.7 µl 660 µl 757.5 µl 
0.25 % (w/v) 5 µl 41.3 µl 0 µl 71.9 µl 660 µl 757.5 µl 
0.50 % (w/v) 5 µl 82.5 µl 0 µl 51.3 µl 660 µl 757.5 µl 
1.00 % (w/v) 5 µl 82.5 µl 0 µl 10 µl 660 µl 757.5 µl 
Table 2.2: Preparation of synthetic peptides (and DMSO-only blanks) in BCA reagent A, with standard 
curve of increasing SDS concentration. Both  SQKGQESEY and YISPLKSPY peptides were prepared. 
 
CuSO4 (4.5 µl of 4 % w/v) was added to each well of a transparent 96-well flat-
bottomed microplate (excepting those wells required for BCA, which were plated 
out as per 2.3.1 or 2.3.4). To each of these wells 225 µl sample/blank was 
added, and the plate sealed and incubated at 37 °C for 30 minutes prior to 
reading absorbance at 570 nm as described in 2.3.1. 
 
 
Chapter 2.0: Materials and Methods 
 58
2.3.6 Peptide BCA of biologically-derived material 
 
Stock solutions 
 
A: 1 M Tris stock solution 
B: 20 mM Tris-acetate pH 8.0 
C: Guinea pig liver homogenate: (20 % w/v) in 20 mM Tris-acetate pH 8. 
D: 10 mM TMA-HCl pH 8 
E: Dubecco’s phosphate buffered saline (isotonic and sterile as supplied) 
F: 100 % Chloroform (as supplied) 
G: 100 % Methanol (as supplied) 
H: 37 % Hydrochloric acid (as supplied) 
I: Acidified chloroform:methanol (as per Jackowski and Rock (1989) 
J: 100 % Acetone (as supplied) 
K: 72 % (w/v) Trichloroacetic acid (TCA) 
L: Bicinchoninic acid (BCA) component A (as supplied) 
M: 4 % (w/v) CuSO4 (as supplied) 
N: SDS-NaOH (2x). 
 
 
2.3.6.1  Precipitation of protein by ammonium sulphate 
 
10 ml of a guinea-pig liver homogenate was transferred to a sterile 50 ml beaker 
and 8 g of ammonium sulphate crystals were added (final concentration 80 % 
w/v) and allowed to dissolve at 4 °C overnight. Precipitated material was 
collected by transferring this material to sealed 2 ml microfuge tubes and 
centrifuging at 10,000 r.c.f. at 4 °C for 45 minutes, after which the supernatant 
was discarded, the pellets transferred to sterile dialysis tubing and dialysed 
against a volatile digestion buffer (10 mM TMA-HCl pH 8) for 24 hours at 4 °C, 
during which time the buffer was changed regularly. 
 
 
2.3.6.2 Cell lysis and Precipitation of protein by acidified 
chloroform:methanol 
 
T2 and JY cell lines were cultured as per section 2.2 to populations of 
approximately 5 x 108. Cells were transferred to sealed 50 ml solvent-proof 
tubes and washed twice with PBS to remove serum proteins. Cellular protein was 
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then extracted by the method developed by Jackowski and Rock (1989); 25 ml 
acidified chloroform:methanol was added to the cell pellet and thoroughly 
vortex-mixed. Following this the lysate began to separate into two phases, a 
clear bottom-phase, and a debris-rich top-phase. Cell lysates were then 
centrifuged at 10,000 r.c.f. for 60 minutes at 4 °C to allow the formation of a 
protein plug between the two phases. The nucleotide-, peptide- and 
carbohydrate-rich methanolic top-phase was aspirated and frozen at -80 °C, and 
the plug removed with tweezers and washed twice in 20 ml ethyl acetate before 
being dried under inert gas (N2). The lipid-rich chloroform bottom-phase was 
discarded. 
 
Cell pellets were then transferred to sterile dialysis tubing and dialysed against a 
volatile digestion buffer (10 mM TMA-HCl pH 8.0) for 24 hours at 4 °C, during 
which time the buffer was changed regularly. 
 
 
2.3.6.3 Tryptic digestion of biologically derived material 
 
Once dialysis was complete the contents of the tubing was transferred to sealed 
20 ml tubes and the protein concentration estimated by protein BCA (see 2.3.1). 
Following this, 1 % (w/w) porcine trypsin was added and the samples incubated 
at 37 °C for 72 hours (see 2.3.2.2). 
 
 
2.3.6.4 Acetone precipitation of undigested material  
 
Following trypsinisation, undigested protein was precipitated by the addition of 9 
volumes of ice-cold acetone to the sample, which was incubated at -20 °C 
overnight, and then centrifuged at 10,000 r.c.f. for 20 minutes at 4 °C, following 
which the supernatant was dried under inert gas (N2), and the peptides weighed 
out and redissolved at 10 mg/ml in DMSO, before being stored at -80 °C pending 
dilution in water or SDS-NaOH for assaying by BCA. Following the absorbance 
being read at 570 nm, the data was analysed in a similar manner to 2.3.4, 
though T-tests were not performed. 
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2.3.6.5 Trichloroacetic acid-precipitation of polypeptides and proteins 
 
When necessary proteins and large polypeptides were removed from samples 
prior to assaying by the addition of 1 volume of 72 % (w/v) TCA stock : 9 
volumes of sample, bringing the final concentration to 7.2 % (w/v) TCA. 
Precipitated material was then removed by centrifugation at 10,000 r.c.f. for 10 
minutes at 4 °C, and the supernatant diluted 1:5 in ddH2O before being mixed 
1:1 with 2x SDS-NaOH, and assayed against a standard curve also containing 
0.72 % (w/v) TCA, diluted 1:1 in SDS-NaOH. 
 
 
2.4  Cell Surface Elution Methodology 
 
2.4.1 Preparation of MHC elution buffers 
 
N.B.: While dissolution of powdered reagents often took place either at RT or 
using ddH2O pre-warmed to higher temperatures, all solutions involved in MHC 
elution were brought to pH at 4 °C, and used at this temperature, on the 
principle that lower temperatures minimises membrane trafficking of receptors, 
and thus prevents or reduces MHC-internalisation during elution. 
 
 
2.4.1.1 Preparation of isotonic citrate-phosphate buffers (‘Storkus buffer’) 
for elution of MHC class-I or pH 5.5 prewash 
 
Stock Solutions: 
A: 0.131 M disodium phosphate (isotonic solution) 
B: 0.066 M citric acid (isotonic solution) 
 
Once both solutions were cooled to 4 °C, the disodium phosphate was brought to 
pH (typically pH 3.3) with citric acid, producing an isotonic buffer. This was then 
sterile filtered, and used within 4 hours of preparation. 
 
 
2.4.1.1.1 Supplemented citrate-phosphate 
 
A version of the isotonic citrate-phosphate pH 3.3 (“Storkus buffer”) and pH 5.5 
(“prewash buffer”) were also prepared containing those supplements added to 
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the TMA formate and sodium-formate buffers (excluding the sucrose and KCl). 
This was prepared as per 3.1.1, except with the addition of 10 mM D-glucose, 2 
mM myo-inositol and 1 mM reduced glutathione in each of the buffers. 
 
 
2.4.1.2 Preparation of TMA-formate MHC class-I elution buffer 
 
A 250 ml volume of elution buffer was prepared by mixing 0.998 ml (37 %) TMA 
(final concentration 25 mM); 25.67 g sucrose (final concentration 0.3 M); 8.39 g 
KCl (final concentration 0.45 M); 0.9 g D-glucose (final concentration 10 mM); 
0.18 g myo-inositol (final concentration 2 mM); and 0.08 g glutathione (final 
concentration of 1 mM) in 225 ml ddH2O. This solution was cooled to 4 °C, and 
the pH adjusted to 3.3 with formic acid before being brought to 250 ml with 
ddH2O. The buffered solution was then sterile filtered prior to use, which took 
place within 4 hours of preparation. 
 
 
2.4.1.2.1 TMA-formate MHC class-I elution buffer variants 
 
In developing the final minimal-lysis MHC class-I buffer, variations on this buffer 
composition were investigated, including various concentrations of the 
supplements as illustrated in table 2.3 below. 
 
Supplement Concentrations tested 
Sucrose 0, 0.075, 0.15, 0.3, 0.45 and 0.6 M 
KCl 0, 0.075, 0.15, 0.3, 0.45, 0.6, and 0.75 M 
Glucose 0, 0.5, 2, 5, 10, 20, 30 and 50 mM 
Inositol 0, 0.5, 1, 2, 4 and 5 mM 
Glutathione 0, 0.2, 0.5, 1, 2, 4 and 5 mM 
Ascorbic acid 0, 0.02, 0.05, 0.1, 0.2, 0.5, 1, and 2 mM 
Table 2.3: Range of supplement concentrations investigated for MHC class-I elution buffer. 
 
Apart from the differing concentrations of the supplements, these were prepared 
identically to the TMA-formate buffer described in 2.4.1.3. 
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2.4.1.3 Preparation of sodium-formate MHC class-II elution buffer 
 
A 250 ml volume of class-II elution buffer was prepared by dissolving: 0.85 g 
sodium-formate (final concentration 50 mM); 25.67 g sucrose (final 
concentration 0.3 M); 8.39 g KCl (final concentration 0.45 M); 0.9 g D-glucose 
(final concentration 10 mM); 0.18 g myo-inositol (final concentration 2 mM); and 
0.08 g glutathione (final concentration of 1 mM) in 225 ml ddH2O. This solution 
was cooled to 4 °C, and the pH adjusted to 2 with formic acid before being 
brought to 250 ml with ddH2O. The buffered solution was then sterile filtered 
prior to use, which took place within 4 hours of preparation. 
 
 
2.4.1.3.1 Sodium-formate MHC class-II elution buffer variants 
 
In developing the final minimal-lysis MHC class-II buffer, variations on this buffer 
composition were investigated, including various concentrations of the 
supplements as illustrated in table 2.4.2. 
 
Apart from the differing concentrations of the components, these were prepared 
identically to the sodium-formate buffer described in 2.4.1.3. 
 
Supplement Concentrations tested 
Sodium formate 50, 100 and 200 mM 
Sucrose 0, 0.15, 0.3, and 0.45 M 
KCl 0, 0.3, 0.45, and 0.6 M 
Glucose 0, 5, 10, and 20 
Inositol 0, 1, 2, and 4 mM 
Glutathione 0, 0.5, 1, and 2 mM 
Table 2.4: Range of supplement concentrations investigated for MHC class-II elution buffer 
 
 
2.4.2  Cell surface elution protocol 
 
In order to obtain enough material to identify peptide sequences by mass 
spectrometry, large numbers of cells are required. While this figure is ideally in 
excess of 1 x 109 (Bonner et al., 2002) smaller populations may be used if there 
is confidence that the peptide in question is highly expressed. Here all cultures 
were grown to > 1.8 x 109, in duplicate. In developing the minimum lysis buffers, 
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smaller figures of 1-10 x 106 cells were used in triplicate or greater, and the 
buffer volumes scaled down to the 1–2 ml range, but the eluate was not carried 
through to mass spectrometry. 
 
 
2.4.2.1 Elution of MHC class-I by isotonic citrate-phosphate pH 3.3 (‘the 
Storkus method’) 
 
Stock Solutions: 
A: Citrate-phosphate pH 3.3 
B: Cell culture-grade PBS. 
 
Following a cell count (see 2.4.4), the cell population is pooled by centrifugation 
at 500 RCF for three minutes into the minimum feasible number of sealed 50ml 
sample tubes and washed twice with sterile PBS. These washes are discarded 
and the citrate-phosphate buffer added to the cells and gently mixed by hand for 
one minute, before being centrifuged again. The supernatant is retained and 
stored at -80 °C. 
 
 
2.4.2.2 Elution of MHC class-I by TMA-formate minimal-lysis buffer 
 
Stock solutions 
A: Citrate-phosphate pH 3.3 
B: RPMI 1640 (as supplied by Lonza Biosciences) 
C: Isotonic saline solution (0.9 % v/v NaCl) 
D: 25 mM TMA-formate pH 3.3 MHC class-I elution buffer (prepared as per 
2.4.1.2, unless stated otherwise). 
 
Following a cell count, the cell population was pooled by centrifugation at 500 
RCF for three minutes into the minimum feasible number of sealed 50 ml sample 
tubes and washed with 25 ml isotonic citrate-phosphate pH 5.5 to lyse fragile 
cells and deplete potential contaminants. The cell suspension was then brought 
back to physiological pH by two washes with 50 ml RPMI 1640, and then de-
buffered by washing twice with isotonic saline. Following this, 15 ml MHC class-I 
elution buffer is added to each 50 ml tube, and the suspension gently mixed by 
hand for one minute, before being centrifuged again. The cells were not exposed 
to the elution buffers for a period of less than four, or greater than five minutes. 
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The supernatant was retained and transferred to 2 ml sealed boiling tubes before 
being clarified by centrifuging a second time at 20,800 RCF for fifteen minutes to 
remove any cellular debris or large protein complexes which may have carried 
over. The clarified supernatant was then repooled and stored at -80 °C until 
required. 
 
 
2.4.2.2.1 Elution of MHC class-I from adherent ALC cells by TMA-formate 
minimal-lysis buffer. 
 
These were eluted as per 2.4.2.2.1 with the following modifications. 2 x 108 
cells5 provided in T-75 tissue culture flasks were washed with 2x RPMI 1640, and 
de-buffered with 2x washes of isotonic saline. No prewash was performed. 30 ml 
supplemented 25mM TMA-formate pH 3.3 was added to the first flask, the cells 
gently washed with the buffer for 60 seconds, and then transferred to the second 
flask, and so on in a serial manner. This eluate was then centrifuged at 500 RCF 
for three minutes, and the supernatant then transferred to 2 ml sealed boiling 
tubes. These were then clarified by centrifuging a second time at 20,800 RCF for 
fifteen minutes to remove any cellular debris or large protein complexes which 
may have carried over. The clarified supernatant was then repooled and stored 
at -80 °C until required. 
 
 
2.4.2.3 Elution of MHC class-II by sodium-formate minimal-lysis buffer 
 
Stock solutions: 
A: Isotonic citrate-phosphate pH 5.5 
B: RPMI 1640 
C: Isotonic saline solution (0.9 % v/v NaCl) 
D: 50 mM sodium-formate pH 2 MHC class-II elution buffer 
E: 25 mM TMA-formate pH 3.3 MHC class-I elution buffer 
OR  Isotonic citrate-phosphate pH 3.3 
 
Following MHC class-I elution, above, 25 ml isotonic citrate-phosphate pH 5.5 
was added to each cell pellet, which is then disrupted by gentle agitation. The 
cell suspension was then brought to 50 ml with RPMI 1640, pelleted by 
centrifugation, and washed once more with 50 ml RPMI 1640. This process was 
                                                 
5
 Kindly donated by Dr Selman Ali and Ms Anisha Bannerjee (Nottingham Trent University) 
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repeated to ensure full pellet disruption, and the cell suspension was then de-
buffered by washing twice with isotonic saline. Following this, the MHC class-II 
peptides were eluted with 15 ml (per tube) sodium-formate and centrifuged to 
pellet the cell population (again the cells were not exposed to the elution buffer 
for a period of less than four, or greater than five minutes). The supernatant was 
retained and transferred to 2 ml sealed boiling tubes before being clarified by 
centrifuging a second time at 20,800 RCF for fifteen minutes to remove any 
cellular debris or proteins which may have carried over. The clarified supernatant 
was then repooled and stored at -80 °C until required. 
 
If class-I peptides are not required for analysis, isotonic citrate-phosphate pH 
3.3 may be utilised to elute them from the cell surface prior to class-II elution, 
instead of TMA-formate. This also eliminates the need for the pH 5.5 prewash 
steps. 
 
 
2.4.3 Flow cytometry analysis to confirm cell surface elution 
 
In order to determine whether the TMA-formate buffer leads to disruption of the 
MHC class-I complex, flow cytometry was utilised using the monoclonal α-MHC 
class-I antibody W6/32 (produced from hybridoma in-house, and kindly purified 
by Mr Steve Reeder), and a mouse anti-β2 microglobulin antibody.  
 
 
2.4.3.1  Cell surface elution and staining of cells for flow cytometry 
 
Stock Solutions: 
A: FACS Buffer 
B: W6/32 Primary monoclonal anti-MHC class-I antibody 
C: Anti β2M Antibody 
D: FITC-conjugated anti mouse secondary antibody 
E: MHC class-I elution buffers. Prepared as per 2.4.1 with the following 
modifications: The TMA-formate and isotonic citrate-phosphate buffers 
were prepared as per 2.4.1, except in 20 ml volumes along a pH gradient 
with the following pH values: 7.5; 7; 6.5; 6; 5.5; 5; 4.8; 4.6; 4.4; 4.2; 
4.0; 3.8; 3.6; 3.5; 3.4; 3.3; 3.2; 3.1; 3. 
F: Isotonic saline solution (0.9 % v/v NaCl). 
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The following elution protocols were investigated: 
1) An isotonic citrate-phosphate pH gradient with the K562-A3 cell line. 
2) A TMA-formate pH gradient with both the K562-A3 and JY cell lines. 
3) An untreated control for both K562-A3 and JY cell lines (washed with PBS 
only) 
 
For each buffer pH, 4 x 106 cells were eluted as per the relevant sections of 
2.4.2 (though the pH 5.5 prewash step was not utilised in this instance), and 
washed twice by centrifuging at 500 RCF for three minutes, then resuspending in 
PBS. Each cell suspension was then divided in two for staining against either 
MHC class-I expression or β2 microglobulin, and transferred to FACS tubes 
before being then washed twice in FACS buffer. 
 
The cell suspension was gently mixed and resuspended with 100 µl FACS buffer 
before 5 µl primary antibody was added, and the cells incubated on ice for 30 
minutes. 
 
Following this, the cells were washed 2x with FACS buffer, and then 20 µl of 
secondary antibody, a fluorescein isothiocyanate (FITC) conjugated (rabbit) anti-
mouse polyconal, was added and the cells again incubated on ice for 30 minutes, 
and protected from light. Once incubation was complete, the cells were again 
washed 2x with FACS buffer and resuspended in 1 ml isoton solution before 
being subjected to analysis by flow cytometry. 
 
 
2.4.3.2 Flow cytometry analysis of cells following elution 
 
Following staining the distribution of relative fluorescence within the cell 
resuspensions were analysed using a Beckman Coulter flow cytometer.   
 
 
2.4.4 Determination of cell viability following elution protocols 
 
In developing the minimum lysis MHC class-I and –II elution buffers, various 
methods of measuring cell death were employed. 
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2.4.4.1 Post-elution determination of cell viability by trypan blue exclusion  
 
In order to optimise the TMA-formate MHC class-I elution buffer for minimal cell 
death, trypan blue staining was utilised. 
 
TMA-formate buffers containing the range of supplement concentrations detailed 
in Table 2.4.1 were prepared as per 2.4.1.2.1. Two million cells were then eluted 
in replicates for each buffer as per the relevant sections of 2.4.2, washed twice 
with RPMI 1640 by centrifuging at 500 RCF for three minutes, then resuspended 
in 2 ml RPMI 1640. 
 
Following this, 20 µl of each cell suspension was assayed for viability by trypan 
blue exclusion, as per 2.4.4.1. The percentage dead cells within the 
haemocytometer was then calculated by the following formula: 
 
(Mean number of stained cells counted / total number of cells counted) x 100 
 
Again, each sample was eluted, washed, prepared and counted prior to 
preparation of the next, in order to minimise variations in Trypan exposure. 
 
Once the buffer supplements were optimised, the addition of these into the 
sodium-formate pH 2 MHC class-II elution buffer was also investigated, along 
with a reduction in buffer molarity from 200 mM to 50 mM, as per 2.4.1.3.1. 
 
 
2.4.4.2 Post-elution determination of cell viability by propidium iodide 
exclusion  
 
2.4.4.2.1 Preparation of a phycoerythrin-conjugated colour control 
 
In order to calibrate the flow cytometer to the excitation and emission spectra 
for PI, an appropriate colour control was prepared using a secondary antibody 
conjugated to the fluorochrome phycoerythrin (PE), which has a similar emission 
spectra to PI (575 nm, compared with 550 nm for PI). Cells were labelled with 
the W6/32 α-MHC class-I monoclonal antibody as detailed in 2.4.3.1 (no MHC 
elution steps were performed on this sample), with a PE-conjugated secondary 
antibody taking the place of the FITC-conjugated antibody described. 
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2.4.4.2.2 Analysis of cell viability by propidium iodide 
 
TMA formate and sodium-formate buffers (supplemented or unsupplemented) 
were prepared, along with isotonic citrate-phosphate buffers, pH 3.3 and 5.5, 
PBS and isotonic saline (see section 2.4.1). Cells were eluted as per the 
protocols detailed in 2.4.2, after which they were washed twice with FACS buffer, 
before being resuspended in 0.2 ml Isoton. Controls took the form of an 
untreated cell population and a heat-killed population heated to 95 °C for 20 
minutes, then cooled to room temperature. 
 
Twenty µl of a 100 µg/ml PI solution was added to each sample, which were 
then incubated on ice for 2 minutes, protected from light, after which the volume 
was brought to 1 ml with Isoton, the cells pelleted by centrifugation at 500 RCF 
for three minutes, the supernatant discarded, and the cell pellet resuspended in 
1 ml isoton solution (Beckman Coulter, UK) (again protected from light), before 
being analysed by flow cytometry using an excitation and emission wavelength 
of 488 and >550 nm respectively. 
 
 
2.4.4.3 Determination of peptide/protein loss during elution as a marker 
for cell damage 
 
Stock solutions 
A: Isotonic citrate-phosphate pH 3.3 
B: Isotonic citrate-phosphate pH 5.5 
C-D: 25 mM TMA-formate pH 3.3: unsupplemented (without  osmotic 
balancing)/osmotically balanced (without glucose, inositol or glutathione). 
E-F: 50 mM sodium-formate pH 2: unsupplemented (without osmotic 
balancing)/osmotically balanced (without glucose, inositol or glutathione). 
G: Isotonic saline solution (0.9 % v/v NaCl) 
H: Phosphate buffered saline 
 
 
2.4.4.3.1 Elution of MHC class-I and II 
 
Replicates of 10 x 106 cells were prepared in RPMI 1640, washed twice in PBS 
and eluted by the protocols illustrated in 2.4.2, with the following modifications: 
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PBS was utilised instead of RPMI 1640. The elution took place using a 600 µl 
volume, of which 400 µl was aspirated following cell centrifugation, and taken for 
analysis by peptide-BCA assay (see 2.4.4.3.2). 
 
 
2.4.4.3.2 Analysis by modified BCA 
 
For each replicate, 10 µl of the MHC elution supernatant was diluted in 40 µl 
ddH2O and this then mixed with 0.2M NaOH and 2 % (w/v) SDS in a 1:1 ratio. 
This 100 µl mixture was then heat-denatured and assayed as per Kapoor et al. 
(2009) (method detailed in section 2.3.4), with appropriate blanks and a 
weighted casein digest standard curve. 
 
 
2.4.4.4 Investigation into the applicability of the ToxiLight cell viability 
assay to determine cell death during MHC elution 
 
2.4.4.4.1 Denaturing and renaturing of adenylate kinase 
 
Stock solutions: 
A, B, C:  Isotonic citrate-phosphate pH 7.4, 5.5, and 3.3 
D, E, F:  25mM TMA formate (unsupplemented) pH 7.4, 5.5, and 3.3 
G:  RPMI 1640 cell culture medium (as provided; free of serum, L-
glutamine and penicillin/streptomycin. 
H:   2 mM HEPES pH 7.4 
I:   ToxiLight assay buffer (ass supplied) 
 
200 units of chicken muscle AK (Sigma Aldrich, UK) was dissolved in 100 µl of 2 
mM HEPES pH 7.4. Five microlitres of this solution was then vortex-mixed with 
20 microlitres of buffer (TMA-formate / citrate-phosphate or RPMI 1640 media), 
incubated at 4 °C for five minutes, and then brought back to pH 7.4 by diluting 
1:10 with ToxiLight assay buffer (optimal ratio predetermined using pH paper). 
This was then compared with a sample prepared in ToxiLight buffer alone. 
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2.4.4.4.2 Determination of renatured adenylate kinase activity 
 
Stock solutions 
A:  Adenylate kinase detection reagent (AKDR) 
 
25 µl of the rebuffered AK solution was then tranferred to a white opaque-
bottomed 96-well plate in triplicate. To this, 100 µl of AKDR was added, and the 
plate incubated for five minutes at 37 °C before being transferred to a Fluostar 
OPTIMA luminometer / fluorimeter, the sum luminescence was read over 10 
cycles (11.4 minutes) at 22 °C. 
 
 
2.4.4.5 Determination of ATP loss during MHC elution as a marker for cell 
damage 
 
Stock solutions 
A: Isotonic citrate-phosphate pH 3.3 
B: Isotonic citrate-phosphate pH 5.5 
C: Unsupplemented 25 mM TMA-formate pH 3.3 
D: Osmotically balanced 25 mM TMA-formate pH 3.3 
E: Fully supplemented 25 mM TMA-formate pH 3.3 
F: Unsupplemented 50 mM sodium-formate pH 2 
G: Osmotically balanced 50 mM sodium-formate pH 2 
H: Fully supplemented 50 mM sodium-formate pH 2 
H: Isotonic saline solution (0.9 % v/v NaCl) 
I: Cell-culture grade PBS (as supplied) 
J: 5 mM ATP stock 
K: 5 mM Tris acetate pH 7.8 
L: ATP detection reagent (ADR): stock solution 
M: ATP detection reagent (ADR): working solution 
 
 
2.4.4.5.1 Determination of relative intracellular ATP content 
 
In order to establish the intracellular ATP content of the four cell lines under 
investigation, 5 x 106 cells were washed twice with 2 ml 0.9 % (w/v) saline, 
before being resuspended in 2 ml ddH2O. These suspensions were then heat-
killed by immediately subjecting to 95 °C for ten minutes, then vortex-mixed for 
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one minute before being subjected to a second 95 °C incubation for another ten 
minutes, in a method similar to one of those employed by Bagnara and Finch 
(1972). Following this, the suspensions were clarified by centrifuging at 20,800 
RCF for thirty minutes, after which the top 1.5 ml of supernatant was aspirated 
and immediately transferred to -80 °C until the was required for analysis. 
 
Analysis was carried out using opaque 96-well microplates. Replicates of 5 µl 
were transferred to each well and mixed with 20 µl of 5 mM Tris-acetate pH 7.8. 
To this 175 µl of ADR working solution was added, and the plate gently agitated 
for 10 seconds before being loaded into a Fluostar OPTIMA set to incubate plate 
at 25 °C6, and the cumulative luminometry measured over 15 240-second cycles. 
 
 
2.4.4.5.2 MHC Elution for ATP assay 
 
The elution protocol was carried out as per 2.4.4.3.1, with the following 
modifications: 5 x 106 cells were utilised for each elution, in a 0.6 ml elution 
volume, and once the supernatant was aspirated it was clarified by centrifuging 
at 20,800 RCF for twenty minutes, following which the top 200 µl of supernatant 
was aspirated to a fresh 500 µl sealed boiling tube and immediately transferred 
to -80 °C. 
 
 
2.4.4.5.3 Choice of assay buffer 
 
Stock solutions: 
A - F: 0.02, 0.05, 0.1, 0.2, 0.5 and 1 M Tris-acetate pH 7.8 
G-L: 0.02, 0.05, 0.1, 0.2, 0.5 and 1 M HEPES-HCl pH 7.8 
M: 25 µM ATP 
N: ATP detection reagent (ADR): working solution 
 
Standard molarity curves of both Tris and HEPES buffers were assessed for 
compatibility with the Luciferase assay.  
 
5 µl of 25 µM ATP was transferred to each well of a white opaque 96-well flat-
bottomed microplate. This was followed by 120 µl of buffer (in triplicate), and 75 
µl of ADR working solution. The plate was then gently agitated for 10 seconds 
                                                 
6
 Optimum temperature for firefly luciferase (Gális & Jirásková, 1992) 
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before being loaded into a Fluostar OPTIMA set to incubate plate at 25 °C, and 
cumulative luminometry was measured over twenty 180-second cycles. 
 
 
2.4.4.5.4 Determination of optimum buffer : eluate ratios 
 
Stock solutions: 
A: 0.2 M HEPES-HCl pH 7.8 
B: 1 M NaOH 
C: Elution buffers (as 2.4.4.5) 
 
Volumes of unsupplemented elution buffers were titrated against 0.2 M HEPES, 
with or without the addition of different volumes of NaOH to increase pH above 
the pKA of the elution buffer. The resulting pH was then assessed first using 
universal indicator pH paper and then confirmed using a pH meter. Once the 
optimum ratios to provide a pH of 7.8 were determined, the ability to rebuffer 
the osmotically balanced and fully supplemented elution buffers were also then 
confirmed. To ensure full rebuffering the ratio of HEPES to buffer was then 
doubled before use with the assay. 
 
 
2.4.4.5.5 Compatibility of elution buffers with the luciferase-determined ATP 
assay 
 
Stock solutions: 
A: 0.2 M HEPES-HCl pH 7.8 
B: 25 µM ATP 
C: ATP detection reagent (ADR): working solution (2) 
D: Elution Buffers (as 2.4.4.5) 
 
MHC class-I TMA-formate buffers were diluted 1:4 in 0.2 M HEPES, while citrate-
phosphate buffers and MHC class-II sodium-formate buffers were diluted 1:9. In 
each of these buffer mixes standard concentration curves (0.1 – 0.5 µM) of ATP 
were prepared, along with an ATP-negative blank. 
 
25 µl of sample was transferred in triplicate to a white opaque 96-well flat-
bottomed microplate. Once all samples were laid out within the plate, they were 
followed by 175 µl ADR working solution. The plate was then gently agitated for 
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10 seconds before being loaded into a Fluostar OPTIMA set to incubate plate at 
25 °C, and cumulative luminometry was measured over twenty-five 180-second 
cycles. 
 
 
2.4.4.5.6 Luciferase-determined assay of MHC eluate ATP content. 
 
Stock solutions: 
A: 0.2 M HEPES-HCl pH 7.8 
B: 25 µM ATP 
C: ATP detection reagent (ADR): working solution (2) 
D: Elution Buffers (as 2.4.4.5) 
E: MHC class-I and class–II eluates (as 2.4.4.5.1) 
 
MHC eluates were diluted with 0.2 M HEPES as per 2.4.4.5.5. Again standard 
concentration curves (0.1 – 0.5 µM) of ATP were prepared in matching buffer 
mixes, along with ATP-negative blanks, and the opaque 96-well plates assayed 
for ATP as per 2.4.4.5.5. 
 
 
2.4.5  Potential to re-culture cells post elution  
 
Following on from determining cell viability, the possibility of re-culturing a cell 
population after elution of MHC class-I and/or class-II was investigated, with a 
view to the potential for a single population to provide multiple elutions. 
 
 
2.4.5.1 Reculture potential determined by media turnover 
 
Following on from determining cell viability, the possibility of re-culturing a cell 
population after elution of MHC class-I and/or class-II was investigated, with a 
view to the potential for a single population to provide multiple elutions. 
 
Stock solutions: 
A: Isotonic citrate-phosphate pH 3.3 
B: Isotonic citrate-phosphate pH 5.5 
C-E: 25 mM TMA-formate pH 3.3 (unsupplemented / osmotically 
balancede/fully supplemented) 
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F-H 50 mM sodium-formate pH 2 (unsupplemented / osmotically balancede/ 
fully supplemented) 
I: Isotonic saline solution (0.9 % v/v NaCl) 
J: Cell-culture grade RPMI 1640 
K: Complete RPMI 1640. 
 
Two x 106 cells were eluted in triplicate as per 2.4.2, producing cell populations 
which had been eluted for class-I by citrate phosphate or TMA-formate buffers 
(+/- supplements) and for class-II by first eluting MHC class-I in citrate-
phosphate pH 3.3, then eluting class-II in sodium-formate (+/- supplements). 
 
Once eluted, cells were washed once with citrate-phosphate pH 5.5, then twice 
with RPMI 1640, before being recultured in complete RPMI 1640 in covered six-
well culture plates incubated at 37 °C in a Heto Holten cellhouse 170 incubator 
supplied with a 5 % (v/v) CO2 atmosphere, and the plates monitored for a 
change in media colour over the next 7 days. 
 
 
2.4.5.2 Post-elution cell proliferation determined by [3H]-thymidine 
incorporation 
 
Stock solutions: 
A: MHC elution buffers (excluding the sodium-formate buffers) 
B: Cell-culture grade PBS 
C: ‘Complete’ RPMI 1640 
D: Tritiated thymidine solution 
E: Scintillation fluid 
   
One million cells were treated with MHC class-I elution protocols using citrate 
phosphate, or TMA-formate (+/- supplements) buffers in triplicate. Elutions took 
place as per 2.4.2, though in 1 ml volumes. These cells were then washed twice 
in RPMI 1640 and recultured in complete RPMI 1640 for 48 hours in 6 well plates, 
as per 2.4.5.1. 
 
Following this forty-eight hour period, cells were counted and resuspended in 
fresh complete RPMI 1640. From these resuspensions 1 x 103 cells from each 
treatment were plated out in triplicate into a 96 well microplate. Each well was 
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then treated with tritiated thymidine to a final concentration of 37 MBq/µl and 
incubated for 18 hours prior to harvesting. 
 
Following incubation cells were harvested onto a 96-well filter plate and 40 µl 
scintillation fluid added to each filter well, following which a Top-Count 
Scintillation counter was utilised to perform counts over 1 minute for each well. 
 
 
2.5  Optimisation of chromatography 
 
2.5.1  Immobilised Metal Affinity Chromatography (IMAC) 
 
2.5.1.1  Fe3+ IMAC 
 
Stock Solutions: 
A: 15 mM FeCl3 in ddH2O. 
B: Wash buffer (1): 25 mM TMA-formate, pH 3.3 (unsupplemented). 
C: Tryptic digests of casein (prepared as per 2.3.2.2) and brought to 25 mM 
TMA-formate, pH 3.3. 
D: Elution buffer (1): 100 mM DEA-HCl, pH 8.4. 
E: 50 mM EDTA. 
F: ddH2O 
G: Storage solution: 20 % (v/v) ethanol in ddH2O 
H: Wash buffer (2): 5 mM TMA-formate, pH 3.3 (unsupplemented). 
I: Elution buffer (2): 100 mM DEA-HCl, pH 9.0. 
J: Elution buffer (3): 50 mM DEA-HCl, pH 9.0. 
K: Elution buffer (4): 100 mM DEA, pH 10.45. 
 
N.B: Unless stated otherwise, each wash of change in solution took place 
using >5 ml (five column volumes) to ensure full alteration of intra-column 
conditions. With the exception of the sample each solution was sterile filtered 
prior to use. Flow rates were maintained at 0.5 ml/min. 
 
 
2.5.1.1.1 Standard method 
 
Hi-Trap-chelating HP IMAC columns were connected to a Gilson MiniPulse 
eVolution peristaltic pump and the flow rate adjusted to 0.5 ml/min. The 
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columns were washed with ddH2O and charged with 1 ml 15 mM FeCl3. Unbound 
metal ions were washed away with ddH2O and the column equilibrated with wash 
buffer (1) before the sample was applied. Unbound material was washed away 
with wash buffer and bound material eluted using elution buffer (1), and 
collected in 1 ml fractions which were then quantified by peptide BCA (see 2.3.4). 
 
Buffer was then washed away using ddH2O and metal ions removed using 50 mM 
EDTA, which was in turn removed using ddH2O. Following this the column was 
either subjected to a second wash and re-charged with metal ions for a second 
sample, or washed with 20 % (v/v) EtOH and stored at 4 °C.  
 
 
2.5.1.1.2 Increased elution pH 
 
Performed as per 2.5.1.1.1, with the exception of elution, which took place using 
elution buffer (2) (100 mM DEA-HCl pH 9.0). This was then followed with 10 
column volumes of elution buffer (4) (100 mM DEA pH 10.45), and again 1 ml 
fractions collected. 
 
Performed as per 2.5.1.1.1, with the exception of elution, which took place using 
elution buffer (2) (100 mM DEA-HCl pH 9.0).  
 
 
2.5.1.1.3 Addition of a low-molarity wash stage. 
 
Performed as per 2.5.1.1.2, with a second 5 mM wash stage (wash buffer 2) 
after the wash with 25 mM TMA-formate pH 3.3 (wash buffer 1).   
 
 
2.5.1.1.4 Reduction in elution buffer strength 
 
Performed as per 2.5.1.1.3, with the exception of elution which took place using 
elution buffer (3) (50 mM DEA-HCl pH 9.0).  
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2.5.1.1.5 Addition of a second column 
 
A second IMAC column was attached in line with the first and chromatography 
was performed as per 2.5.1.1.4, except that the volume of each solution applied 
to the column was increased by a factor of 2.5. 
 
 
2.5.1.2  Cu2+ IMAC 
 
Stock Solutions: 
A: 15 mM CuSO4 in ddH2O. 
B: Wash buffer (1): 100 mM HEPES-NaOH, pH 7.2. 
C: Tryptic digests of casein (prepared as per 2.3.2.2) and brought to 25 mM 
TMA-formate, pH 3.3. 
D: Elution buffer (1): 0.1 % (v/v) TFA in ddH2O. 
E: 50 mM EDTA. 
F: ddH2O 
G: Storage solution: 20 % (v/v) ethanol in ddH2O 
H: Wash buffer (2): 5 mM HEPES-NaOH, pH 7.2. 
I: Elution buffer (3): 50 mM DEA-HCl, pH 9.0. 
 
N.B: Unless stated otherwise, each wash of change in solution took place 
using >5 ml (five column volumes) as per 4.4.1.1 and with the exception of the 
sample each solution was sterile filtered prior to use. 
 
 
2.5.1.2.1 Standard method 
 
Hi-Trap-chelating HP IMAC columns were connected to Gilson MiniPulse eVolution 
peristaltic pump and the flow rate adjusted to 0.5 ml/min. The columns were 
washed with ddH2O and charged with 1 ml 15 mM CuSO4. Unbound metal ions 
were washed away with ddH2O and the column equilibrated with wash buffer (1) 
before the sample was applied. Unbound material was washed away with wash 
buffer and bound material eluted using elution buffer (1), and collected in 1 ml 
fractions which were then quantified by peptide BCA (see 2.3.4). 
 
Buffer was then washed away using ddH2O and metal ions removed using EDTA, 
which was in turn removed using ddH2O. Following this the column was either 
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subjected to a second wash and re-charged with metal ions for a second sample, 
or washed with storage solution and stored at 4 °C.  
 
 
2.5.1.1.2 Increased elution pH 
 
Performed as per 2.5.1.1.1, with the exception of elution, which took place using 
elution buffer 2 (0.5 % (v/v) TFA in ddH2O).  
 
 
2.5.1.1.3 Addition of a low-molarity wash stage. 
 
Performed as per 2.5.1.1.2, with a second 5 mM wash stage after the 100 mM 
HEPES-NaOH pH 7.2  
 
 
2.5.2  Reversed-phase (RP) chromatography 
 
N.B: Unless stated otherwise, each wash of change in solution took place 
using >1 ml (five column volumes) to ensure full alteration of intra-column 
conditions. With the exception of the sample each solution was sterile filtered 
prior to use. Application was performed by hand using a 1 ml syringe, at a flow 
rate of 1 ml/min (visually assessed). 
 
 
2.5.2.1  Choice of resin 
 
Stock Solutions: 
A: Phosphopeptide solutions: 0.2 mg/ml in 0.1 % (v/v) TFA. 
B: Conditioning/wash solution: 0.1 % (v/v) TFA. 
C: Acetonitrile 80 % (v/v) in ddH2O. 
D: Acetonitrile 100 % (v/v). 
E: Non-chromatographic standards: 0.2 mg in 82.5 % (v/v) ACN.  
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2.5.2.1.1 Chromatography 
 
Varian Bond-Elut C18, and Strata C8 and C18 50 mg SPE columns were activated 
with 2 ml of 80 % (v/v) ACN and conditioned using 1 ml 0.1 % (v/v) TFA. 
Samples (0.2 mg in 1 ml) were loaded onto the column and unbound material 
removed by washing with 1 ml 0.1 % (v/v) TFA. Bound peptides were then 
eluted using 1 ml 80 % (v/v) ACN, followed by 0.5 ml 100 % ACN. Eluted 
fractions were all collected in 1.5 ml volumes stored in 2 ml sealable boiling 
tubes and spiked with 20 µl DMSO. 
 
Non chromatographic standards were prepared by the addition of 20 µl synthetic 
peptide stock solution (in DMSO) to 1.5 ml 82.5 (v/v) ACN.  
 
 
2.5.2.1.2 Rotary evaporation 
 
Eluates and standards were then placed in a Juan Rotary Evaporator and dried to 
below 50 µl (the presence of DMSO prevents full evaporation), following which 
they were brought to 200 µl with ddH2O and the peptide content assayed by 
peptide BCA (as per section 3.1.4). Recovery of phosphopeptides following RP-
chromatography was then calculated as a percentage of the non-
chromatographic standards. 
 
 
2.5.2.2  Alteration of sample acidification 
 
Stock Solutions: 
A-I: Acidified ALR(p) phosphopeptide solutions: 0.2 mg/ml in TFA, HCl or 
phosphoric acid (PA) at 0.1, 0.5, 1 % (v/v). 
JR-: Conditioning/wash solutions: TFA, HCl or PA as above (without peptide). 
C: Acetonitrile 80 % (v/v) in ddH2O. 
D: Acetonitrile 100 % (v/v). 
E: Non-chromatographic standard: 0.2 mg ALR(p) in 82.5 % (v/v) ACN.  
 
Varian Bond-Elut C18 50 mg SPE columns were activated with 2 ml of 80 % (v/v) 
ACN and conditioned using 1 ml conditioning solution. Samples (0.2 mg ALR(p) 
acidified as above in 1 ml) were loaded onto the column and unbound material 
removed by washing with 1 ml of the corresponding wash solution. Bound 
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peptides were then eluted using 1 ml 80 % (v/v) ACN, followed by 0.5 ml 100 % 
ACN. Eluted fractions were all collected in 1.5 ml volumes stored in 2 ml sealable 
boiling tubes and spiked with 20 µl DMSO. 
 
Non chromatographic standards were prepared by the addition of 20 µl synthetic 
peptide stock solution (in DMSO) to 1.5 ml 82.5 (v/v) ACN.  Samples were then 
dried by rotary evaporation, brought to volume and assayed by peptide BCA as 
per 2.5.2.1.2. 
 
 
2.5.2.3  Inclusion of salt in loading conditions 
 
Stock Solutions: 
A-E: Tryptic digests of casein (0.3 mg/ml) in 0.2 mM Tris-acetate pH 8 (15 
mg/ml digest diluted 1/50), acidified with 0.5 % (v/v) TFA containing: 0, 
0.1, 0.2, or 0.5 M KCl or 20 µl DMSO. 
F-I: Wash solution (1) 0.5 % (v/v) TFA containing: 0, 0.1, 0.2, or 0.5 M KCl. 
I: Conditioning/wash solution: 0.5 % (v/v) TFA. 
J:  Acetonitrile 80 % (v/v) in ddH2O. 
K:  Acetonitrile 100 %. 
 
Varian Bond-Elut C18 50 mg SPE columns were activated with 2 ml of 80 % (v/v) 
ACN and conditioned using 1 ml 0.5 % (v/v) TFA (+/- KCl). Samples (0.3 mg 
casein in 1 ml 0.5 % (v/v) TFA +/- KCl) were loaded onto the column and 
unbound material removed by washing with 1 ml of wash solution. Bound 
peptides were then eluted using 1 ml 80 % (v/v) and 0.5 ml 100 % ACN. These 
were spiked with 20 µl DMSO and subjected to rotary evaporation and assayed 
by peptide BCA as per 2.5.2.1.2 against a non-chromatographic standard. 
 
 
2.5.2.4  Final method 
 
Stock Solutions: 
A: 80 % Acetonitrile. 
B: Conditioning/wash solution 0.5 % (v/v) TFA. 
 
Varian Bond-Elut C18 SPE columns (500 g) were activated with 8 ml of 80 % (v/v) 
ACN and conditioned using 8 ml 0.5 % (v/v) TFA. Samples (in MHC elution 
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buffers – see 2.4) were diluted 1:1 in ddH2O, acidified by the addition of 0.5 % 
(final volume) TFA and loaded onto the column7. Unbound material was removed 
by washing with 8 ml of wash solution and bound peptides eluted using 8 ml 
80 % (v/v) and 3 ml 100 % ACN. These were assayed by peptide BCA as per 
2.3.1. 
 
 
2.5.3  Mixed mode and ion exchange resins 
 
Again, these were investigated using the hydrophilic SQK(p) and the 
hydrophobic YIS(p) phosphopeptides. 
 
N.B: Unless stated otherwise, each wash of change in solution took place 
using >1 ml (five column volumes) to ensure full alteration of intra-column 
conditions. With the exception of the sample each solution was sterile filtered 
prior to use. Application was performed by hand using a 1 ml syringe, at a flow 
rate of 0.5 drops per second (visually assessed). 
 
 
2.5.3.1  Strata X 
 
Stock Solutions: 
A: Phosphopeptide solutions: 0.2 mg/ml SQK(p)/YIS(p) in 2 % (v/v) 
phosphoric acid. 
B: 2 % (v/v) phosphoric acid. 
C: 25 % (v/v) MeOH in ddH2O. 
D: 50 % (v/v) MeOH in ddH2O. 
E: 50 % (v/v) MeOH in acetonitrile. 
F: 100 % acetonitrile. 
G: ddH2O 
E: Non-chromatographic standards: 0.2 mg in 82.5 % (v/v) ACN.  
 
Strata X 50 mg SPE columns were activated with 2 ml of 100 % ACN and 
conditioned using 1 ml ddH2O and 1 ml 2 % (v/v) phosphoric acid. Samples (0.2 
mg in 1 ml) were loaded onto the column and washed with 1 ml 2 % (v/v) 
phosphoric acid; followed by 1 ml 25 % (v/v) MeOH in ddH2O and 1 ml 50 % 
                                                 
7
 In cases where two-rounds of C18 SPE was used, the peak fraction(s) from the first round were 
diluted 1:19 with 0.5 % (v/v) TFA and applied to a fresh column. 
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(v/v) MeOH in ddH2O. All three wash/elution stages were retained for analysis. 
Bound material was then eluted with 1 ml 50 % (v/v) MeOH in ACN and 1 ml 
100 % ACN. Solvent washes and eluates were collected in 1 ml volumes stored 
in 2 ml sealable boiling tubes and spiked with 20 µl DMSO. 
Non chromatographic standards were prepared by the addition of 20 µl synthetic 
peptide stock solution (in DMSO) to 1 ml 50 (v/v) MeOH in ACN. These and the 
methanolic fractions were then subjected to rotary evaporation and assayed by 
peptide BCA as per 2.5.2.1.2 against the standards. 
 
 
2.5.3.2  Strata X-AW 
 
Stock Solutions: 
A: Phosphopeptide solutions: 0.2 mg/ml SQK(p)/YIS(p) in 2 % (v/v) 
phosphoric acid. 
B: 2 % (v/v) phosphoric acid. 
C: 20 mM sodium acetate, pH 5.0. 
D: 50 % (v/v) MeOH in ddH2O. 
E: 50 % (v/v) MeOH in acetonitrile. 
F: 100 % methanol. 
G: 2 % ammonium bicarbonate, 0.5 % TFA in MeOH. 
E: Non-chromatographic standards: 0.2 mg in 82.5 % (v/v) ACN.  
 
Strata X-AW 50 mg SPE columns were activated with 2 ml of 100 % ACN and 
conditioned using 1 ml ddH2O and 1 ml 2 % (v/v) phosphoric acid. Samples, 
either SQK(p) or YIS(p) (0.2 mg in 1 ml) were loaded onto the column and 
washed with 1 ml 20 mM sodium acetate pH 5 and then with methanol, followed 
with 1 ml 2 % (w/v) ammonium bicarbonate, 0.5 % (v/v) TFA in MeOH. Both the 
sodium acetate and methanolic fractions were collected in 1 ml volumes stored 
in 2 ml sealable boiling tubes and spiked with 20 µl DMSO. 
 
Non chromatographic standards were prepared by the addition of 20 µl synthetic 
peptide stock solution (in DMSO) to 1.5 ml 50 (v/v) MeOH in ACN. These and the 
methanolic fractions were then subjected to rotary evaporation and assayed by 
peptide BCA as per 2.5.2.1.2 against the standards. 
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2.5.4  Hydrophilic Ligand Interaction Chromatography (HiLIC) 
 
A form of normal-phase chromatography, Hydrophilic Ligand Interaction 
Chromatography (HiLIC) may be considered the opposite of reversed-phase 
chromatography: samples are loaded in a non-polar solvent, and bind to a resin 
with hydrophilic components, before they are eluted in a polar (typically aqueous) 
medium.  
 
N.B: Unless stated otherwise, each wash of change in solution took place 
using >1 ml (five column volumes) to ensure full alteration of intra-column 
conditions. With the exception of the sample each solution was sterile filtered 
prior to use. Unlike the previous chromatographic approaches, the work with 
HiLIC involved both small-volume (< 200 µl) SPE cartridges loaded by syringe 
(at a flow rate of 1 ml/min), and 1 ml HPLC-compatible columns, loaded by 
peristaltic pump (at a flow rate of 0.5 ml/min). With the exception of the Strata 
NH2, these were all packed in-house. 
 
Stock Solutions: 
A: Synthetic peptides/phosphopeptides: 10 mg/ml in DMSO. 
B: Casein digest: 25 mg/ml in 50 mM DEA pH 9.0. 
C: Post-IMAC phosphopeptide enriched casein digest: typically > 4 mg/ml in 
50 mM DEA-HCl pH 9.0. 
D: 20 % (v/v) ethanol (storage solution). 
 
 
2.5.4.1  Comparison of resins 
 
Stock Solutions: 
A: ALR(pS)NFERI: 0.2 mg in 2 ml 90 % ACN (+ 1 % v/v DMSO8). 
B-F:  90.0; 75.0; 50.0; 25.0; 0 % (v/v) ACN  
 
 
2.5.4.1.1 Preparation of columns 
 
Phenomenex Strata-NH2 columns were used as supplied. HEA (hexylamine) and 
PPA (phenylpropylamine) HyerCel columns (Pall, UK) were constructed from 
used Varian Bond-Elut C18 cartridges. The C18 resin was removed from these 
                                                 
8
 A result of the peptides being stored at 10mg/ml in 100 % DMSO. 
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columns by a combination of back pressure applied through the nozzle with a 
steel rod, and use of a slender spatula to fish out the filter-frits and dry resin. 
Filters and columns were cleaned with detergent and hot water, and then by 
sonication in 1 % (v/v) SDS in 0.1 M NaOH, before final rinses in 100 % ACN 
and 100 % ddH2O. End frits were then placed back into the columns, and HEA or 
PPA HyperCel resin suspensions (in 20 % v/v EtOH) added in 0.3 ml volumes 
until the bed volume appeared similar to the Strata-NH2 columns, at which point 
the top-frits were replaced atop the resin and the column washed with water and 
then with 20 % EtOH as a storage solution. Columns were used for a maximum 
of 10 analytical runs before the resin was removed and repacked. 
 
 
2.5.4.1.2 Application of material 
 
Columns were activated with ddH2O and equilibriated with 90 % (v/v) ACN. The 
synthetic phosphopeptide ALR(p) was loaded onto each column in 2 ml (~ 5 
column volumes) and the column eluted with a stepwise elution from 90.0, 75.0, 
50.0, 25 and 0 % (v/v) ACN, with fractions of ~250 µl collected for analysis by 
peptide BCA. These were diluted 1:5 in ddH2O before being mixed 1:1 with 2x 
SDS-NaOH, heat denatured (see 2.3.4.2) and analysed by the peptide BCA assay 
(Kapoor et al., 2009), as per 2.3.1. 
 
 
2.5.4.2  Effect of DMSO 
 
Stock Solutions: 
A: ALR(pS)NFERI: 0.2 mg in 2 ml 90 % ACN (1 % v/v DMSO). 
B-E: 90.0; 75.0; 50.0; and 25 % (v/v) ACN (+/- 1 % v/v DMSO) 
F: ddH2O 
 
HEA columns were prepared as per 2.5.4.1.1. Casein digests were clarified by 
centrifugation at 20,800 r.c.f. for 15 minutes and the supernatants loaded onto 
the column. Unbound material was washed away with 90 % (v/v) ACN, and a 
stepwise elution gradient applied from 75 to 25 % (v/v) ACN (+/- 1 % v/v 
DMSO). Finally each column was washed with ddH2O. Fractions of ~0.33 µl were 
collected throughout and were analysed by peptide BCA in a similar manner to 
2.5.4.1.2. 
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2.5.4.3  HPLC setup 
 
2.5.4.3.1 Preparation of column 
 
A 1 ml volume HEA HyperCel column was prepared from a used Hi-Trap-
chelating HP IMAC cartridge. End caps were removed using tools built in-house9 
and filter/frits and resin removed and the filters and cartridge cleaned in a 
similar manner to 2.5.4.1.1. The column was packed with HEA HyperCel under a 
flow rate of 0.2 ml/min ddH2O using a peristaltic pump connected as per 
2.5.1.1.1, and the top-frit replaced. The column was then washed with 10 ml 
ddH2O and then with 5 ml 20 % EtOH as a storage solution. Columns were used 
for a maximum of 10 analytical runs before the resin was removed and repacked. 
 
 
2.5.4.3.2 HPLC methodology 
 
The HEA HyperCel columns were connected to an ÄKTA FPLC platform (GE 
Healthcare) and subjected to a flow rate of 0.1-0.5 ml/min. A maximum 
pressure of 40 psi was set, and a UV absorbance of 210 nm. Analyte-free runs 
were performed using a gradient from 90 – 0 % (v/v) ACN in the presence or 
absence of 1 % (v/v) DMSO though increases in pressure beyond the maximum 
tolerance of the resin were experienced and method development further 
optimised using quantification via peptide BCA (see 2.3.4).  
 
Columns were subsequently connected to a PerkinElmer series 200 HPLC under 
similar conditions to the above and phosphopeptide enriched digests of casein 
loaded at 75 % ACN. Issues with TFA absorbance of UV led to a second return to 
BCA-determined elution, and investigation into maintenance of a continuous TFA 
concentration (2.5.4.7), or the use of TFA/alternative acid gradients to 
fractionate bound material (2.5.4.8). 
 
 
2.5.4.4  Selectivity for casein or BSA 
 
Stock Solutions: 
A-C: 75.0; 50.0; and 25 % (v/v) ACN. 
                                                 
9
 Tools designed and created by Mr. Robert Davey, with thanks. 
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D-I: BSA or casein dissolved in 75.0; 50.0; and 25 % (v/v) ACN to a 
concentration of 5 mg/ml. 
J: ddH2O 
K: 0.1 % (v/v) TFA. 
 
In order to determine the applicability to isolate phosphorylated protein, BSA 
and casein were both prepared in varying amounts of ACN: 75.0; 50 and 25 
(v/v)10 and 2 ml applied to 1 ml volume HEA HyperCel columns using a Gilson 
MiniPulse eVolution peristaltic pump at 0.5 mg/ml. Again, a stepped gradient to 
ddH2O was employed, followed by a 0.1 % (v/v) TFA wash. Fractions of 1 ml 
were collected and peptide concentration determined by BCA as 2.5.4.1.2. 
 
 
2.5.4.5  Selectivity for casein IMAC eluates 
 
Stock Solutions: 
A-C: 75.0; 50.0; and 25 % (v/v) ACN. 
D: Post-IMAC phosphopeptide enriched casein digest, typically > 1 mg/ml in 
75 % (v/v) ACN, 12.5 mM DEA-HCl pH 9.0. 
E: ddH2O 
F: 0.1 % (v/v) TFA. 
 
Following on from the casein and casein digest experiments, a phosphopeptide 
enriched fraction from a Fe3+-IMAC of trypsinised casein was employed to 
determine the potential for HEA and PPA HyperCel to fractionate a 
heterogeneous phosphopeptide population. Peptides were loaded at 75 % (v/v) 
ACN and the columns subjected to a stepwise gradient to ddH2O followed by a 
0.1 % (v/v) TFA wash. Again 1 ml fractions were collected and analysed by 
peptide BCA as 2.5.4.1.2. 
 
    
2.5.4.6  Inclusion of TFA in mobile phase 
 
Stock Solutions: 
A-F: 75.0; 50.0; and 25 % (v/v) ACN, +/- 0.1 % (v/v) TFA. 
G: Post-IMAC phosphopeptide enriched casein digest, typically > 0.5 mg/ml 
in 75 % ACN (v/v), 12.5 mM DEA-HCl pH 9.0. 
                                                 
10
 Problems with solubility were experienced at 90 % ACN. 
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H: ddH2O 
I: 0.1 % (v/v) TFA. 
 
To determine if the inclusion of TFA might allow peptide fractionation along a 
solvent gradient the above experiment (2.5.4.6) was repeated with HEA 
HyperCel only, with or without the inclusion of 0.1 % TFA in the mobile phase. 
Peptides were loaded at 75 % (v/v) ACN and the columns subjected to a 
stepwise gradient to ddH2O following which a 0.1 % (v/v) TFA wash was applied 
to both columns. Again 1 ml fractions were collected and analysed by the peptide 
BCA assay as per 2.5.4.1.2. 
 
 
2.5.4.7  Elution with acid-gradients and use of alternative acids 
 
Stock Solutions: 
A: 75 % (v/v) ACN. 
B: ddH2O 
C-D: 0.001 % (v/v) TFA; HCl. 
E-H: 0.01 % (v/v) TFA; HCl; formic acid; phosphoric acid. 
I-L: 0.1 % (v/v) TFA; HCl; formic acid; phosphoric acid. 
M-P: 1 % (v/v) TFA; HCl; formic acid; phosphoric acid. 
Q: Post-IMAC phosphopeptide enriched casein digest, typically > 0.5 mg/ml 
in 75 % ACN, 12.5 mM DEA-HCl pH 9.0. 
 
To determine if an acid gradient with TFA or alternative acids might facilitate 
fractionation of a heterogeneous phosphopeptide population (2.5.4.6) was 
repeated with HEA HyperCel only, and a range of concentrations of four 
commonly utilised acids. Peptides were loaded at 75 % (v/v) ACN and the 
columns washed with ddH2O following which a logarithmic acid gradient was 
applied (0.001 – 1 % v/v), following which remaining peptide was eluted using 
1 % (v/v) TFA followed by 90 % (v/v) ACN. Again 1 ml fractions were collected 
and analysed by the peptide BCA assay as 2.5.4.1.2. 
 
 
2.5.4.8  Evaluation of binding potential for synthetic (phospho/)peptides 
 
Stock Solutions: 
A-B: 75.0; 50 % (v/v) ACN. 
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C: ddH2O 
D: 0.5 % (v/v) TFA. 
E: 0.01 % (v/v) TFA; HCl; formic acid; phosphoric acid. 
F: Phosphopeptide mix: 1 ml containing 0.2 mg of each of the following: 
ALR(p); SQK(p); TVE(p); YIS(p) in 75 % (v/v) ACN.  
G: Non-phosphopeptide mix: 1 ml containing 0.2 mg of each of the following: 
ALR(x); SQK(x); TVE(x); YIS(x) in 75 % (v/v) ACN. 
 
To determine whether the HiLIC eluates contain phosphorylated, 
unphosphorylated, or mixed peptides, a mixture of peptides (phosphorylated or 
not) were applied to a 1 ml HEA column at 75 % (v/v) ACN, and the column 
subjected to a stepwise elution protocol to 0.5 % (v/v) TFA. Again, 1 ml fractions 
were collected and analysed by the peptide BCA assay as 2.5.4.1.2. 
 
 
2.5.5  Peptide PAGE 
 
The peptide-PAGE methods below are based on Yim et al. (2002)’s modification 
of the method developed by Schagger & von Jagow (1987). 
 
 
2.5.5.1 Preparation of 18 % polyacrylamide tricine gel buffer 
 
Stock Solutions: 
A: Acrylamide: 30 % (w/v) solution (29:1 acrylamide:bis-acrylamide). 
B:  5x Buffer/electrolyte solution (0.6 M tris-HCl; 500 mM tricine; 2.5 % 
(w/v)  glycerol and 0.5 M each of serine, glycine, and asparagine. 
C: 10 M NaOH. 
 
To prepare 500ml 18% acrylamide peptide gel buffer 100 ml of (room 
temperature) solution B was mixed with 300 ml 30 % (w/v) acrylamide. The pH 
was adjusted to 7.4 with 10 M NaOH and the volume brought to 500 ml with 
ddH2O. 
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2.5.5.2  Gel polymerisation 
 
Stock Solutions: 
A: 18 % (w/v) acrylamide gel buffer (see 2.5.5.1). 
B: 1 % (w/v) Ammonium persulphate (APS) 
C: Tetramethylethylenediamine (TEMED) 
D: Running buffer: 3.27 g Trizma Base, 15.014 g glycine, and 1.00 g SDS in 
100 ml ddH2O, pH 8.3 with HCL. 
 
To 20 ml of acrylamide gel buffer, 150 µl of APS and 15 µl of TEMED were added, 
swiftly mixed and transferred to the gel plates along with the well-combs. Once 
polymerisation was complete the gel kits were rinsed with ddH2O to remove any 
unpolymerised acrylamide, and transferred to the gel tanks. Running buffer was 
then added to both inner and outer chamber. 
 
 
2.5.5.3 Sample preparation and electrophoresis 
 
Stock Solutions: 
A: 2x Laemlli sample buffer. 
B: Ultra-low weight marker/ladder (ULM) in 2x Laemlli sample buffer. 
 
Following quantification by the peptide BCA assay, sample volumes were 
adjusted with ddH2O to ensure equal loading and mixed 1:1 with 2x Laemlli 
sample buffer and denatured by heating to 95 ºC before each well was loaded 
with no more than 100 µg total peptide. One well was loaded with 10 µg ULM to 
show molecular weights. Electrophoresis was performed at 45 v/gel for 
approximately 3 hours, following which gels were removed from the gel plates 
and placed in shallow ~ 40 ml volume covered trays and briefly rinsed twice with 
ddH2O to remove excess tris/SDS. 
 
 
2.5.5.4 Pro-Q Diamond Staining 
 
Stock Solutions: 
A: 5 % (v/v) Glutaraldehyde  
B: Pro-Q Diamond phosphostain. 
C: Pro-Q Diamond destain: 20 % (v/v) ACN , 50 mM Na-acetate, pH 4.0. 
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Gels were incubated on a gel shaker with 10 ml 5 % (v/v) glutaraldehyde for one 
hour to fix peptides within the gels, following which the gel was washed 
repeatedly in ddH2O over 36 hours to dialyse out any remaining glutaraldehyde. 
The gel tray was then wrapped in foil before the addition of 20 ml Pro-Q 
Diamond and incubated on a gel shaker for 150 mins under protection from light. 
This was then poured off and the unbound stain removed by incubating with 20 
ml destain solution for 3 x 30 min periods. Following two washes in ddH2O the 
gels were then imaged using a Fujifilm, FLA-5100 gel scanner armed with a cye-
5 laser. 
 
 
2.5.5.5 Coomassie blue staining 
 
Stock Solutions: 
A: Coomassie blue gel stain: 1 mg/ml Coomassie Brilliant-Blue powder in 
45 % MeOH and 10 % acetic acid (both v/v) in ddH2O. 
B: Gel destain: 45 % MeOH and 7 % acetic acid (both v/v) in ddH2O. 
 
Gels were incubated on a gel shaker for one hour with 20 ml 5 % (v/v) 
coomassie blue stain, following which the gel was rinsed twice in ddH2O and 
incubated overnight on a gel shaker with destain solution and a small twisted 
piece of tissue paper to bind coomassie stain as it disassociates from the gel. 
Following this a digital photograph of the gel was taken in a UVLtec gel imager 
equipped with a light-box and visible-range bulb. 
 
 
 
Mass Spectrometry 
 
2.6.1  MALDI-TOF Mass Spectrometry 
 
Stock Solutions: 
A: α-Cyano-4-hydroxycinnamic acid solution (CHCA): 5 mg/ml in 50 % (v/v) 
ACN, 0.05 % (v/v) TFA. 
B: Peptide standard calibrant II [Bruker pt no 222570] (700-4000 Da) 
mg/ml in 33.3 % (v/v) ACN, 0.066 % (v/v) TFA. 
C: MHC class-I peptide eluates: ~1 mg/ml in 80 % (v/v) ACN (HPLC grade) 
(following C18 RP SPE). 
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N.B:  Unless stated otherwise, all reagents are mass-spectrometric grade. 
 
MALDI mass spectrometry was performed in a similar manner to Matharoo-Ball 
et al. (2007) and Vafadar-Isfahani et al. (2010) Following desalting using C18 RP 
SPE columns (as per 2.5.2.4) 1  µl of sample was mixed with 1 µl of CHCA 
solution on-plate. Standard calibrants were prepared in the same method, 
excluding the RP stage, and at a ratio of 1 calibration spot : 4 sample spots. 
These were air dried at RT and the plates loaded into the Bruker Ultraflex III 
TOF/TOF MALDI mass spectrometer. Peptide-CHCA complexes were then fired 
upon, and data from 2000 pulses per spot collected in positive reflectron mode, 
and the mass spectra from 500 – 4000 Da analysed in Flex Analysis software 
(Bruker). 
 
 
2.6.2  LTQ-ESI-MS/MS 
 
Stock Solutions: 
A: 5 % (v/v) ACN, 0.1 % (v/v) formic acid, 0.005 % (v/v) 
heptafluorobutyric acid (HFBA) in H2O. 
B: 0.1 % (v/v) formic acid, 0.005 % (v/v) heptafluorobutyric acid (HFBA) in 
95 % (v/v) ACN. 
C: Heptatitis B standard peptide (TPPAYRPPNAPIL128-140) 
D: Sample: diluted to 1 fmol/µl in 0.1 % (v/v) formic acid in H2O. 
 
N.B:  Unless stated otherwise, all reagents are mass-spectrometric grade. 
 
 
2.6.2.1  HPLC fractionation 
 
 
HPLC and ESI-MS/MS were performed in a similar method to Clarke et al. (2001). 
Samples were chromatographically analysed on a Dionex U3000 nanoflow LC 
system equipped with a Dionex C18 20 mm 300 µ trap column to desalt analytes, 
and a Dionex Pepmap (15 cm length; 15 µ internal diameter; 3 µ particle size) 
analytical column for sample fractionation. 
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Twenty µl of each sample/standard at 1 fmol/µl was loaded by injection loop 
onto the trap column at a 30 µl/min flow rate. After desalting the flow was 
redicrected by means of a 10-port switching valve and the flow-through from the 
trap column directed onto the analytical column at 300 µl/min. The columns 
were subjected to an A:B gradient of 100:0 – 30:70 A:B (40 mins) and from 
30:70 – 0:100 A:B (2 mins) at 300 µl/min. This was then held for 5 mins before 
a reverse gradient to 100:0 A:B (1 min) was applied. Columns were then 
reequilibriated in (A) for 32 mins (total run time of 80 mins). 
 
 
2.6.2.2  Sample ionisation and fragmentation 
 
Upon elution from the column samples were ionised across a unconditioned glass 
capilliary 10 µ ESI tip with a 1.8 kV charge held at 200 °C (typical injection time 
400 ms, total microscans 3) and introduced to the Finnegan linear quadruple ion 
trap (LTQ) mass spectrometer (Fisher, Thermo Scientific), running in positive 
mode. The signal was tuned with LTQ autotune and the synthetic Heptatitis B 
MHC class-II restricted peptide TPPAYRPPNAPIL standard, and fragmentation 
carried out with relative collision energy of 35 % (automatic gain control was 
used and an isolation width of 3 Da set). Data-dependent acquisition was carried 
out on the top 5 tandem mass spectra throughout the run. 
 
 
2.6.3  Identification 
 
Tandem mass spectra RAW files were either analysed with Bioworks Browser 
(Thermo) or later with Proteome Discoverer (Thermo) using the MASCOT search 
algorithm to search the SwissProt protein database against the (unless indicated) 
Homo sapiens (hereafter: Human) Proteome catalogue. Post-translational 
modifications included were phosphorylation on serine, threonine, and tyrosine, 
or for Cu2+ IMAC samples, oxidation of methionine.  
 
 
2.6.4  Database design 
 
A simple non-relational database of peptide sequences was created using 
Microsoft Access (version 2003). Fields were created using Table design view, 
primarily using either text boxes (maximum field size 255 chars) or Boolean 
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checkboxes, with the SwissProt accession numbers of the suggested protein 
sources used as a key field. A mononumeric “potential significance” field allows 
users to score the peptide from 0-9, while Boolean checkboxes allow sorting by 
protein function(s), links with different cancers, and possible roles within cancer. 
Data is entered manually at this time. 
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3.0:  Modification of the BCA assay for 
quantification of peptide content 
 
3.1  Introduction 
 
The accurate measurement of peptide in solution is vital to developing 
appropriate protocols for sample fractionation, isolation, and analysis. As 
reproducible analytical chromatography and mass spectrometry both require 
accurate loading of sample prior to fractionation/analysis, knowledge of sample 
concentration is crucial. While the majority of peptide analyses involve tryptic 
digests of (often precipitated, weighed and reconstituted) proteins, estimation of 
peptide concentration may usually be circumvented. However as the samples 
obtained by mild acid elution of MHC complexes contain peptides rather than 
proteins, measurement of peptide concentration is highly desirable. 
 
With the rise in peptidomics over the last few years, it is curious that though 
there are a wide range of methods for estimating protein concentration, far 
fewer approaches are available for quantifying the peptide content of a sample. 
Whilst UV absorbance at 280 or 200 nm is often recommended for synthetic 
peptides, it is far from ideal for biochemical samples since at 280 nm absorbance 
is strongly influenced by aromatic rings (e.g. those found in the side chains of 
Trp and Tyr, as well as purines and pyrimidines), whilst absorbance at 200 nm 
may be complicated by many other compounds, especially those with carbon-
carbon or carbon-oxygen bonds (Stoshcheck, 1990). Fujinari et al. (1994) 
increased the accuracy of this approach by combining UV-absorbance with 
chemiluminescent detection of nitrogen in HPCL eluates, though this is a difficult 
approach to apply to crude biological samples. Conversely amino acid analysis, 
whilst highly accurate, usually requires significant and lengthy sample cleanup 
prior to analysis, and full hydrolysis of amino acids from peptide may take 
anywhere from a few hours to several days (Kaspar et al., 2009).  
 
Alternatively a number of fluorescent approaches to protein and peptide 
quantification have been put forward, for example, Fluorescamine (4’-phenyl-
spiro [furan-2(3H),1’-phthalan]-3,3’-dione) (Udenfriend et al., 1972), o-
phthaldialdehyde (OPA) (Goodno et al., 1981) and 3-(4-Carboxybenzoyl) 
quinoline-2-carboxaldehyde (CBQCA) (Liu et al., 1991; You, et al. 1997) are all 
nonfluorescent compounds that become fluorescent when conjugated to primary 
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amines (such as N-termini and lysine residues), rendering them suitable for 
sensitive detection of peptide and protein. However, these assays may be 
strongly influenced by changes in frequencies of different amino acids between 
samples (e.g. lysine), and changes in the order of some residues (especially 
those with terminal prolines) (Schiltz et al., 1977). They are also susceptible to 
false positives from other primary amines; e.g. glycine, and to an extent Tris 
buffers, or amino sugars such as sialic acid (Goodno et al., 1981; You, et al. 
1997). The fluorescent agents are often light sensitive, and some, such as 
fluorescamine, are rapidly degraded in aqueous solutions or hydroxylic solvents 
(e.g. methanol, ethanol, propanol) (Böhlen et al., 1973; De Bernado et al., 
1974). The assays’ tolerance for other compounds also varies considerably, and 
though most are quite compatible with lipids, the secondary structure of proteins 
and peptides can affect sensitivity, and limited compatibility with detergents and 
thiols means that they cannot be easily denatured (an exception being CBQCA, 
where the addition of Triton-X may actually enhance sensitivity) (Haughland, 
1996; You, et al. 1997; Molecular Probes, 2001a, C6667).  
 
Similarly, epicocconone, the basis for the LavaPrepTM assay (Veal, 2007) and 
Deep PurpleTM protein stain, is also applicable to peptide quantification, but is 
highly selective for histidine, arginine and lysine residues (Bell et al., 2003; 
Coghlan et al., 2005), leading to problems with interpeptide variability, as well 
as being complicated by free amino acids. It also exhibits very limited tolerance 
for detergents and acids (Veal, 2007; Interchim, 2008). 
 
Two alternative fluorescent assays, Nano-Orange and the Quant-iT protein assay, 
bind through hydrophobic-interactions with the sample protein (Molecular Probes, 
2001b; 2007). While this reduces specific amino acid-based variations in 
fluorescence proteins, it may present a greater issue with regard to peptides, 
especially for the Nano-Orange assay, given that there is a notable difference in 
the reactivity between proteins of different sizes (Dr. P. Roach, University of 
Nottingham, pers. comm. 2009). Additionally given that these assays operate by 
hydrophobic binding, they present limited compatibility with detergents and 
lipids, and therefore sample cleanup may be required prior to use. A third assay, 
the EZQ Protein Quantitation Kit (Molecular Probes, 2005), is performed on a 
dot-blot after washing to remove contaminants, and may therefore be 
problematic for small molecules such as heterogenous peptide populations, 
which may bind poorly to the membrane. Alternatively relative/semi-quantitation 
by way of mass spectrometry is also an option, though this has its own obstacles 
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in terms of time, cost and convenience, and is far more applicable to specific 
peptides (ideally sequences known prior to analysis) within a sample rather than 
total peptide content. It also requires the inclusion of an appropriate internal 
standard, and may be complicated by chromatographic losses (Zhu and 
Desiderio, 1996). 
 
However, there are no standard colourimetric approaches to peptide 
quantification. With regard to colourimetric protein assays, both modern forms of 
the biuret assay: (a) the Lowry (Lowry et al., 1951) and (b) the bicinchoninic 
acid (BCA) (Smith et al., 1985) assays are occasionally utilised to quantify 
peptide (Hua & Scheller, 2001; Faber et al., 2003; Saleem et al., 2005), though 
neither is recommended for such. The other ‘classic’ colourimetric protein assay, 
the Bradford method, is sequence specific (Stoscheck, 1990), and not applicable 
to peptides below 3 kDa (Pierce, 2005). 
 
The BCA assay, which has largely replaced the older Lowry method due to its 
convenience, compatibility, linearity and comparatively lower inter-protein 
variability (Stoshcheck, 1990) is based on two reactions. Firstly the co-ordination 
and reduction of a Cu2+ ion by 4-6 peptide bonds to form a complex, which 
allows the reduction of the copper to Cu1+ (the biuret reaction). The reduced 
copper is then chelated by two BCA molecules, producing a shift in absorbance 
to 562 nm (in practice 540-570 nm may be utilised) (Olsen and Markwell, 2007). 
There is also a sequence-specific reduction of copper involving tryptophan, 
tyrosine, cysteine and cystine residues, but as this is temperature independent 
(unlike the peptide-backbone reaction), sequence specific effects may be 
reduced by carrying the experiment out at higher temperatures (Wiechelman et 
al., 1988). Given that biuret-based assays react primarily with the peptide bonds 
in anything larger than a tripeptide, rather than the NH+ terminus or a reaction 
specific to functional groups, the BCA assay is theoretically applicable to 
reproducible estimation of peptide content, in a range consistent with the 
requirements for prep chromatography and peptide PAGE; however, despite the 
examples of this cited above, there is little published data on its practical 
applicability to peptide quantification. 
 
This chapter details evaluation of the BCA assay for analysis of total peptide 
concentration within a sample, and a modification to the standard BCA protocol 
to improve applicability to estimation of peptide content. Synthetic peptides and 
tryptic digests were both evaluated, as well as the effect of phosphorylation as a 
Chapter 3: Results 
The BCA peptide assay 
 97
relevant post-translational modification. The most significant results were 
published in Kapoor et al., 2009. 
 
 
3.2  Suitability of the BCA assay for estimating the peptide content of  
a sample 
 
Previous work has suggested that the BCA assay, normally restricted to the 
quantification of protein, would also be applicable to quantifying peptides. This 
work was based around a single peptide from BCR-ABL, 
VHSATGFKQSSKALQRPVASD (hereafter: ‘VHS’), and a reproduction of this assay 
demonstrated that a calibration curve could be generated using standards 
ranging from 16.25 to 250 µg/ml (see Figure 3.1). The peptide was prepared 
and assayed by BCA as per section 2.3.1, producing a repeatable and linear 
standard curve implying potential viability for assaying peptide concentration. 
However, inter-sample variability remained uninvestigated. 
 
 
 
 
 
 
Figure 3.1: A typical BCA assay calibration curve generated using VHSATGFKQSSKAL-
QRPVASD peptide standards from 0.0163 – 0.25 mg/ml. Peptide dilutions were prepared 
in water and 25 µl transferred to a 96 well plate in triplicate. 200 µl of BCA working 
reagent was then added to each well, and the plate incubated for 15 minutes at 37 °C 
before the absorbance was read at 570 nm. n = 4, error bars indicate SD. 
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3.3   Inter-sample variability for peptide BCA 
 
Tryptic digests of BSA and casein were prepared in 10 mM Tris pH 8 (as per 
2.3.2.2), and a standard curve of dilutions prepared, and then assayed as per 
the BCA protein assay protocol (2.3.1) (see Figure 3.2).  
 
 
 
This illustrated a notable difference in BCA reactivity between BSA and casein 
peptides. Whilst according to their sequence data, the two should both render 
peptides of broadly similar lengths when digested (with marginally larger 
peptides produced from the caseins), peptide gel electrophoresis indicates that 
the BSA is not readily trypsinised, but consistently produces fragments of a 
larger length than the caseins (see Figure 3.3), potentially reflecting the function 
of casein as a performed on undigested BSA and casein, a similar pattern is seen 
to the digests (see figure 3.4). 
 
As the BCA assay is known to be influenced by sequence-specific effects 
(Wiechelman et al., 1988), it is conceivable that the difference between BSA and 
casein reactivity may be due to the higher incidence of cysteine, tyrosine and 
tryptophan in BSA compared with the caseins (see table 3.1), but given the 
temperature independent nature of these reactions and the large difference in 
 
Figure 3.1.2: Representative BCA assay calibration curves generated using tryptic 
digests of BSA and mixed caseins from 0.05 – 0.5 mg/ml. Digests were diluted in water 
and 25 µl transferred to a 96 well plate in triplicate. 200 µl of BCA working reagent was 
then added to each well, and the plate incubated for 30 minutes at 37 °C before 
absorbance was read at 570 nm. Similar observations were found with multiple digests. n 
= 4, error bars indicate SD. 
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reactivity between the two proteins it was believed that other factors were 
involved. 
 
 
 
ULM Casein BSA 
 
 
 
Figure 3.3: Coomassie-blue stained 18 % (v/v) acrylamide peptide PAGE (prepared as 
per Yim et al., 2002, see: 2.5.5) containing tryptic digests of casein and BSA (prepared as 
per 2.3.2.2) along with an ultra low-weight marker (ULM), illustrating differential digestion 
between the two proteins. Similar staining patterns were observed for numerous digests. 
 
Figure 3.4: Typical BCA assay calibration curves generated from undigested BSA and 
mixed caseins from 0.12 – 1 mg/ml. Protein solutions were diluted in water and 25 µl 
transferred to a 96 well plate in triplicate. 200 µl of BCA working reagent was then added 
to each well, and the plate incubated for 30 minutes at 37 °C before absorbance was 
read at 570 nm. n = 4, error bars indicate SD. 
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In order to further investigate this aspect of the assay, 13 synthetic peptides 
(including 4 phosphopeptides and their non-phosphorylated counterparts, all 
with high predicted binding scores to MHC class-I A2 or A3 alleles, as determined 
by the SYFPEITHI algorithms) were utilised (see table 3.2 for sequences and 
physical characteristics), all from proteins with known links to leukaemia or 
malignancy. 
 
Peptide sequence Size pI HPS 
Sequence 
Source 
Short 
name 
 a.a. Da.     
LSRH 4 511.6 11 0.3 TP53BP1 LSRH 
ALRSNFERI 9 1105.3 10.9 0.3 bcr ALRx 
ALR(pS)NFERI 9 1185.2 10.9 0.3 bcr ALRp 
SQKGQESEY 9 1055.1 4.3 0.9 SHP-1 SQKx 
SQKGQESE(pY) 9 1135 4.3 1.1 SHP-1 SQKp 
YISPLKSPY 9 1067.3 9.5 -0.5 Rb protein YISx 
YI(pS)PLKSPY 9 1147.2 9.5 -0.5 Rb protein YISp 
TVEAVAYAPK 10 1048.2 6.9 -0.1 hRad51 TVEx 
TVEAVA(pY)APK 10 1128.2 6.9 0.1 hRad51 TVEp 
LYGFNLVIVHSATGFKQSSK 20 2196.5 10.2 -0.5 bcr:abl LYG 
QAGILARNLUPMVATVQGQN 20 2080.4 11 -0.5 GP64 QAG 
VHSATGFKQSSKALQRPVASD 21 2214.5 10.6 0.2 bcr:abl VHS 
VIVHSATGFKQSSKALQRPVASDFEPQ 27 2928.3 9.9 0 bcr:abl VIV 
Table 3.2: Synthetic peptide sequences utlised to determine the suitability of the BCA assay 
for peptide quantification and in development of the modified assay. Physical properties 
derived from the online peptide property calculator at http://www.innovagen.se/. All are from 
human protein sequences, with the exception of QAG (derived from human herpes virus 5). 
Key: a.a., amino acids; Da, molecular weight in Daltons; pI, isoelectric point; HPS, hydrophillic 
score. All 9-10 amino acid peptides have high predicted MHC class-I A*201 and A*301 
binding scores. 
 
Protein 
No of residues per protein molecule 
Cysteine Tryptophan Tyrosine 
BSA 35 3 21 
Casein α S1 1 2 10 
Casein α S2 3 2 12 
Casein β 1 1 4 
Table 3.1: Relative incidence of BCA-reactive amino acids (as defined by 
Weichelman et al., 1988) in BSA and bovine caseins. Sequence data 
derived from the ExPASy proteomics server (www.expasy.ch). 
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Peptide concentration curves from 0.125 – 1 mg/ml were prepared (as Figure 
3.5) and samples assayed as per the method outlined in section 2.3.2.1. The 
divergent standard curves produced illustrate the diverse ability of assorted 
peptides to react with the BCA standard working reagent. A time course of BCA 
reactivity over 120 minutes indicate that this difference is not primarily based 
around differential rates of reaction, but a near-absolute difference in reactivity. 
While the inter-peptide variation was found to decrease over time, a linear 
regression curve extrapolated from the final 30 minutes of the time course 
indicated that inter-peptide variation would require an incubation of over eight 
hours to drop below 10 %, and therefore merely extending the incubation period 
was not a realistic solution (data not shown). 
 
However when the effect of the peptides’ physical properties on BCA reactivity 
was investigated, a non-parametric correlation co-efficent of 0.788 became 
apparent between peptides’ hydrophilic scores (HPS) and BCA reactivity, rising 
to 0.83 if phosphorylated peptides are excluded, and 0.907 if the sample is 
restricted to non-phosphorylated peptides of 9-10 amino acids in length, though 
neither phosphorylation status nor peptide length correlated well with BCA 
reactivity (even if peptides were divided into subgroups according to HPS). 
Furthermore, larger peptides appeared to show a greater sensitivity of BCA 
reactivity to changes in hydrophilicity (see Figure 3.6), though this may be an 
artefact of the small population studied. 
 
 
3.4 Reducing interpeptide variability in BCA reactivity through peptide 
solubilisation 
 
As the prime determinant of BCA reactivity appeared to be hydrophilicity, 
attempts were made to solubilise peptides by a variety of regimens, including 
addition of NaOH, SDS, deoxycholate, disodium phosphate, DMSO and methanol, 
alone or in various combinations (see 2.3.3). Two peptides with widely divergent 
hydrophobicities were utilised: YISPLKSPY (YISx, HPS -0.5) and SQKGQESEY 
(SQKx, HPS 1.1) and following solubilisation the peptides were assayed by the 
standard BCA protocol (see section 2.3.1) at 0.5 mg/ml. The absorbance of both 
peptides was pooled and standard deviation calculated to determine spread 
between the two samples, compared against assaying both in water (see Figure 
3.7). A comparison of these solubilisation methods indicated that while many 
approaches led a to decrease in spread between the two peptides, boiling the 
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sample in 1 % (w/v) SDS in 100 mM NaOH provided the greatest reduction in 
interpeptide variability. 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: BCA assay calibration curves generated from 9 synthetic peptides (all non-
phosphorylated) from 0.12 – 1 mg/ml. Peptide dilutions were prepared in water and 25 µl 
transferred to a 96 well plate in triplicate. 200 µl of BCA working reagent was then added 
to each well, and the plate incubated for 15 minutes at 37 °C before the absorbance was 
read at 570 nm. n = 4, error bars indicate SD. 
Peptide Trendline Equation     R2 
ALRSNFERI Y = 1.2922x + 0.2393     0.9985 
SQEGQESEY y = 1.8948x + 0.3055     0.9905  
TVEAVAYAPK y = 0.7149x + 0.2958     0.9719 
YISPLKSPY y = 0.2366x + 0.2221     0.9839 
VHSATGFKQSSKALQRPVASD y = 3.0076x + 0.3236     0.9931 
LSRH y = 0.1146x + 0.1929     0.9326 
VIVHSATGFKQSSKALQRPVASDFEPQ y = 0.6263x + 0.1978     0.9983 
LYGFNLVIVHSATGFKQSSK y = 0.8056x + 0.2198     0.9983 
QAGILARNLVPMVATVQGQN y = 0.0813x + 0.2104     0.9977 
 
      Peptide of 9-10 amino acids         Peptide of > 20 amino acids 
      Peptide of 4 amino acids         Trendline 
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Figure 3.6: Scatterplots of peptide hydrophilic score (HPS) and BCA reactivity for 13 
synthetic peptides (n = 4) when assayed by the standard BCA protocol at 0.5 mg/ml, 
including trendlines for total peptide population and subpopulations divided by peptide 
length and phosphorylation status (hence symbol overlap). Peptides were prepared in 
H2O and 25 µl transferred to a 96 well plate in triplicate. 200 µl of BCA working reagent 
was then added to each well, and the plate incubated for 30 minutes at 37 °C, following 
which the absorbance was read at 570 nm. HPS derived from the peptide property 
calculator at http://www.innovagen.se. 
 
Peptide 
Population 
Population 
Size 
Mean 
Absorbance Mean HPS 
Spearmans’ 
Rho (P value) 
All peptides 13 0.42 0.03 0.788 
 (0.00)** 
9-10mer 
subpopulation 8 0.45 0.2 
0.762 
 (0.00)** 
9-10mer 
Phosphorylated             
subpopulation 
4 0.4 0.25 0.734 
   (0.007)** 
9-10mer Non-
phosphorylated     
subpopulation 
4 0.49 0.15 0.907 
 (0.00)** 
> 20mer 
subpopulation 4 0.45 -0.18 
0.777 
 (0.03)* 
All non-
phosphorylated 
peptides 
9 0.43 -0.1 0.83 
  (0.00)** 
Spearmans Rho correlation co-efficients for the relationship between synthetic peptide 
BCA reactivity and hydrophillic score (HPS). 
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Figure 3.7: Cross-peptide standard deviation following various solubilisation regimens. 
Attempts were made to increase the solubility of two peptides YISPLKSPY (HPS -0.5) and  
SQKGQESEY (HPS 1.1) by various means (n = 3), following which 25 µl of each sample 
was transferred to a 96 well plate and 200 µl of BCA working reagent added to each well 
before the plate was incubated at 37 °C for 30 minutes, and the absorbance read at 570 
nm. Following this absorbances (n = 3 or greater) were normalised against a water control 
and the standard deviation calculated across all absorbances for each solubilisation 
regimen. This indicated that whilst many approaches led to a reduction in spread between 
the two peptides when compare with the non-solubilised control, heating the samples for 
five minutes at 95 °C in the presence of 1 % (w/v) SDS in 0.1 M NaOH prior to the addition 
of BCA working reagent gave the greatest reduction in interpeptide variation. 
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This solubilisation method was then reapplied to the wider synthetic peptide 
population and a reduction in spread of 32.12 % was found, rising to 52.46 % 
when the assay was restricted to nonamers and decamers. When the trypsinised 
samples were analysed was found to only reduced the spread of standard protein 
digests (rabbit aldolase; BSA, bovine casein and catalase) by 11.5 %; while 
digests of protein isolated from guinea pig liver, and two suspension cell lines 
(the EBV-immortalised JY line and the T2 hybridoma line) showed a greater 
reduction in intrersample variation of 34.63 % (full graphical and numerical 
information is available in figures 3.8 – 3.10). Reproducible linear standard 
curves were achievable in all cases. Surprisingly however the reduction in spread 
was not achieved solely by increasing the reactivity of  hydrophobic peptides, but 
also  by reducing the absorbance of formerly highly-reactive peptides (especially 
notable in the case of the VHS peptide, though also for SQKx, and to some 
extent for ALRx and VIV), leading to a notable reduction in the mean absorbance 
for each peptide pool, though the median absorbance was not dramatically 
altered, indicating that peptides of medium to low-reactivity were not similarly 
affected. 
 
 
3.5 Investigation into addition of SDS directly to BCA reagent A 
 
In was hypothesised that the number of reagents required could be streamlined 
by the addition of SDS and the peptide sample directly into BCA reagent A, 
which itself contains 100 mM NaOH. This mixture could then be heat-denatured 
prior to mixing with the CuSO4 required for the BCA reaction. Once again the 
hydrophobic YISPLKSPY (YISx, HPS -0.5) peptide and the hydrophilic 
SQKGQESEY (SQKx, HPS 1.1) peptide were utilised to test the feasibility of this 
approach. These were included at a fixed concentration (0.5 mg/ml) in the 
preparation of two standard curves (one for each peptide) of SDS concentration 
in BCA reagent A (0.05 – 1 % w/v SDS). Both standard curve preparations were 
then heat-denatured and added to a 96-well microplate containing 4 µl of CuSO4 
in each well, following which the plate was incubated for 30 minutes at 37 °C 
and absorbance measured as previously. The absorbance of both peptides was 
pooled and the cross-peptide standard deviation calculated to determine spread 
between the two peptides, compared against assaying both in water, or by 
denaturing in the previous SDS-NaOH protocol (see Figure 3.11).  
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Figure 3.8: Typical standard calibration curves for synthetic (1) unphosphorylated 9-10mer and (2) 4 and >20mer peptides (in each case n = 4). Peptides 
were assayed by BCA in (A) water or (B) following heat-denaturing in 1 % (w/v) SDS in 0.1 M NaOH. Standard curves of peptide concentration were 
prepared and 25 µl assayed in a 96 well plate in triplicate by addition of 200 µl of BCA working reagentand  incubated for 30 minutes at 37 °C prior to 
reading absorbance at 570 nm. Linear standard curves were achieved for each peptide, with heating in SDS-NaOH reducing inter-peptide variation 
by >32 %, by both reduction in reactivity of formerly re peptides, and increases in reactivity of hydrophobic peptides. Error bars indicate SD. 
1-B 1-A 
2-A 2-B 
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Figure 3.9: Typical standard calibration curves for tryptic digests of (1) standard proteins (aldolase, BSA, casein and catalase) and (2) biologically derived 
material (protein from guinea pig liver, and the JY and T2 suspension cell lines) (in each case n = >3). Digests were assayed by BCA in (A) water or (B) 
following heat-denaturing in 1 % (w/v) SDS in 0.1 M NaOH. Standard concentration curves were prepared and 25 µl assayed in a 96 well plate in triplicate by 
addition of 200 µl BCA working reagent and incubated for 30 minutes at 37 °C prior to reading absorbance at 570 nm. Linear curves were achieved for each 
peptide, with heating in SDS-NaOH reducing inter-peptide variation by 11.5 % for the standard proteins, and 34.63 % for the biologically derived material. 
Error bars indicate S.D. 
2-A 
1-A 1-B 
2-B 
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Figure 3.10: Box and whisker plot indicating total data spread and interquartile range of 
synthetic and tryptically-derived peptide populations assayed by the standard BCA (Smith 
et al., 1985), or by denaturing in SDS-NaOH prior to assay. Standard proteins: aldolase, 
BSA, catalase and casein. Biological material: protein extracts from guinea pig liver, and 
JY and T2 suspension cell lines. Data is expressed as a percentage of mean absorbance 
for that population when assayed by the standard BCA method. In each case n = 3. 
 
Sample 
Assayed in H2O Assayed in SDS-NaOH Percentage 
reduction SD median mean (±SD) median mean (±SD) 
Synthetic peptides 
(n=13) 0.6685 
0.8656        
(± 0.5811) 0.647 
 0.671         
(± 0.3944) 32.12% 
Synthetic 9-10mer 
peptides (n=8). 0.0582 
0.0829        
(± 0.0539) 0.0544 
 0.0651       
(± 0.0256) 52.46% 
Standard protein 
digests (n=4) 0.417 
 0.4368        
(±  0.1289) 0.4025 
 0.41           
(± 0.1141) 11.5% 
Biological material 
digests  (n=4) 0.0795 
 0.0812      
(± 0.0137) 0.0677 
0.065          
(± 0.009) 34.63% 
Median and mean A570 nm (± standard deviations) for synthetic and tryptically-derived peptide 
populations assayed by the standard BCA or by heat-denaturing in SDS-NaOH prior to assay. 
Standard proteins: aldolase, BSA, catalase, and casein. Biological material: protein extracts from 
guinea pig liver, and JY & T2 suspension cell lines. Synthetic peptides as previously detailed. 
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It was found that this method resulted in inter-peptide variation comparable to 
the standard BCA approach, with the absorbances for SQKx being similar across 
the standard curve, often without any statistically significant difference in 
absorbance. However a slight and statistically significant increase in absorbance 
for the YISx peptide was observed across the standard curve. Though this was 
highest for reagent A containing 0.1 % (w/v) SDS, it was statistically 
indistinguishable from that achieved using reagent A in the absence of SDS, 
implying that heat denaturing YISx within reagent A may be the determining 
factor (similarly SQKx also showed small but a statistically significant increase in 
absorbance when heated in reagent A in the absence of SDS).  
 
Overall however there is little reduction in inter-peptide spread when compared 
with the standard BCA approach, while heat-denaturing the peptides in 1 % (w/v) 
SDS in 0.1 M NaOH prior to mixing with working reagent was again shown to 
reduce inter-peptide variation by over 50 % (Kapoor et al., 2009). 
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Figure 3.11: Assessment of SDS addition into Reagent A. Absorbance of two peptides 
(and cross-peptide mean) (n = 5) at 0.5 mg/ml following heat-denaturing in BCA reagent A 
in the presence of increasing concentrations of SDS, following which samples were mixed 
with CuSO4 (at a 50:1 ratio of reagent A:CuSO4), incubated at 37 °C for 30 minutes, and 
the absorbance read at 570 nm; compared with peptides assayed in H2O, or following 
heat-denaturing in 1 % (w/v) SDS in 0.1 M NaOH. As can be seen SQK and YIS 
absorbances are largely constant across the increasing SDS concentrations, while heat 
denaturing in 1 % (w/v) SDS in 0.1 M NaOH dramatically reduces interpeptide spread, as 
indicated by the error bars (S.D.). 
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3.6 Determination of assay sensitivity following modification 
 
In order to determine to what extent the modified assay conditions may have 
impacted upon sensitivity, standard curves from 5 – 50 µg/ml were prepared 
from tryptic digests of BSA as per 2.3.2.2, and assayed as per 2.3.1 and 2.3.4, 
with both the 50 : 1 BCA reagent A : CuSO4 ratio described in 2.3.1 and the 25 : 
1 ratio described in 2.3.5.1. It was found that at concentrations of 10 µg/ml and 
above, linear standard curves were achievable, but below this absorbances were 
statistically indistinguishable from the blank for both the unmodified and 
modified BCA at the 50:1 ratio of BCA working reagent (see Figure 3.12). As 
expected, the 25:1 ratio of BCA working reagent gave a minor increase in 
absorbance to the standard BCA assay, though without increasing the sensitivity 
of the assay, while this ratio appeared to impart a reduced sensitivity to the 
modified assay, rendering the 10 µg/ml BCA peptide standard statistically 
indistinguishable from the blank, and barely distinguishable from 20 µg/ml. 
Regression co-efficient (R2) values of 0.98 or greater were achievable in all cases 
apart from the modified assay when carried out with the 25:1 ratio of BCA 
working reagent (R2 = 0.67). 
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Figure 3.12: Typical standard BCA assay calibration curves for BSA digests (n = 4) over 5 
– 20 µg/ml to determine the limits of assay sensitivity. BSA tryptic digests were assayed in 
a standard calibration curve: either in H2O, or following heat-denaturing in 1 % (w/v) SDS 
in 0.1 M NaOH. 25 µl of each sample was transferred to a 96 well plate in triplicate and 
200 µl of BCA working reagent (prepared at either 50 : 1 or a 25 : 1 ratio of reagent A to 
4 % (w/v) CuSO4) was added to each well. The plate was then incubated for 30 minutes at 
37 °C, and the absorbance was read at 570 nm. The higher concentration of CuSO4 in the 
25:1 working reagent produces a decrease in sample reactivity when peptides were were 
heat denatured in SDS-NaOH prior to the assay. Error bars indicate S.D. 
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3.7 Applicability of microwave incubation to replace either the heat-
denaturing step or the 37 °C incubation step 
 
In order to determine whether the microwave-incubation proposed by Akins and 
Tuan (1992) was transferable to replace the 30 minute 37 °C incubation required 
for the modified assay, and furthermore, whether it might also be utilised to 
simultaneously replace the heat-denaturing step at 95 °C, the two peptides 
previously utilised for solubilisation studies: YISPLKSPY (YISx, HPS -0.5) and 
SQKGQESEY (SQKx, HPS 1.1) were exploited. Short standard curves over the 
0.1 – 0.5 mg/ml range were prepared from each peptide, either in H2O, or in 
1 % (w/v) SDS in 0.1 m NaOH (+/- heat denaturing) as per 2.3.4. 
 
Before the incubation could take place, control microplates containing only water 
were microwave-incubated in a number of positions on the revolving tray. These 
were then heated to boiling and visually observed. It was found that placing the 
microplate in the centre of the revolving tray lead to rapid boiling, but this only 
occurred in the centre of the microplate. Offsetting the microplate lead to those 
wells closest to the centre heating to the greatest degree, while the most even  
 
incubation was achieved by moving the microplate to the edge of the revolving 
tray, allowing it to complete a 180° revolution over 15 seconds, then pausing the 
incubation and moving it to the opposite edge of the tray (thereby alternating 
which wells are on the inside of the revolving tray) before continuing the 
incubation for a further fifteen seconds (see 2.3.5.3). It was also observed that 
the fewer wells of the 96-well microplate that contained aqueous sample, the 
more rapidly those wells that were utilised would reach boiling point, therefore 
for purposes of standardisation, 200 µl of dH20 was added to any unutilised wells. 
 
Once this was optimised, incubation of a 96-well microplate containing the 
peptide standard curves and BCA working reagent were subjected to the 
microwave incubation and the reduction in data spread calculated as previously 
described (see Figure 3.13). 
 
While standard curves could be produced using the microwave method, it was 
found that inter-well variability was higher when plates were incubated by this 
method, and the R2 values lower than usually observed. 
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Figure 3.13: Microwave incubation of BCA assay. Standard calibration curves of SQKx and YISx 
peptides and a tryptic digest of BSA (all n = 4) following 2 x 15 second microwave incubations in 
place of the 30 minute incubation at 37°C. Samples were assayed in (A) water, or 1 % (w/v) SDS 
in 0.1 m NaOH without (B) or with (C) heat-denaturing at 95 ° prior to the assay. 25 µl of each 
sample was transferred to a 96 well plate in triplicate and 200 µl of BCA working reagent then 
added to each well. The plate was then incubated for two 15 second periods on a rotating 
microwave tray as per 2.3.5.3 and absorbance read at 570 nm. Error bars indicate S.D. (D) Cross-
peptide standard deviation was used to determine inter-peptide variation, which indicated that 
whilst the inclusion of SDS-NaOH lead to a reduction in inter-peptide variation, the microwave 
incubation step was not sufficient to replace heat-denaturing the samples at 95 ° prior to the 
assay. 
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The inclusion of 1 % SDS in 0.1 M NaOH within the peptide matrix was found to 
reduce inter-peptide variation by approximately 5 % when compared with the 
peptides assayed in ddH2O. Curiously this was less than the reduction found in 
unheated samples incubated at 37 °C, where it was reduced by 26 % (see figure 
3.7). This may be a function of the higher inter-well variability which is believed 
to be a consequence of non-uniform heating of each well (despite the 
repositioning of the microplate within the microwave), or possibly a longer 37 °C 
incubation in SDS-NaOH provides greater solubilisation and linearisation than the 
brief microwave incubation allows. In either case, it is clear that microwave- 
incubation is not sufficient to replace heat denaturing prior to incubation, which 
produced a reduction in inter-peptide variation of 38.6 % (though this is a 
smaller improvement than the 52.46 % reduction achieved by a 30 minute 
incubation at 37 °C). 
 
 
3.8 Investigation into the effect of peptide phosphorylation on BCA 
reactivity 
 
Finally, given the overall aims of selectively, the effect of phosphorylation on the 
BCA peptide-assay was briefly investigated using the four 9-10mer 
phosphopeptides and their non-phosphorylated counterparts. When the reactivity 
of the phosphorylated and non-phosphorylated forms of these peptides are 
compared a clear discrepancy is observed (see figure 3.14), in that the 
phosphate group appears to produce a reduction in BCA reactivity (significant to 
P <0.05) in three of the four peptides (ALR, SQK and TVE), though to differing 
degrees, irrespective of whether the peptides are heated in 1 % (w.v) SDS in 0.1 
M NaOH or not. A very minor increase in BCA reactivity is apparent in the final 
peptide (YIS), though this was not statistically significant if heat-denatured in 
SDS-NaOH. 
 
It is notable that in the case of the ALR peptide, phosphorylation only reduces 
BCA reactivity by approximately 12 % (when assayed in SDS-NaOH), while in 
the case of SQK and TVE, this rises to 45% and 35% respectively. Conversely, 
the hydrophobic YIS peptide shows a minor statistically insignificant increase in 
reactivity when phosphorylated. As the SQK and TVE peptides are tyrosine 
phosphorylated, it is conceivable that this may be linked to the sequence-specific 
temperature independent secondary reaction noted by Wiechelman et al. (1988). 
Though within the peptide pool studied tyrosine-rich peptides were not found to  
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Figure 3.14: Differential BCA reactivity of four peptides with and without phosphorylation. 
Peptides were assayed at 0.125 mg/ml (A) in water or (B) following heat denaturing in 
1 % (w/v) SDS in 0.1 m NaOH. 25 µl of each sample was transferred to a 96 well plate in 
triplicate and 200 µl of BCA working reagent then added to each well. The plate was then 
incubated for 30 minutes at 37 °C, following which the absorbance was read at 570 nm. 
See table Y.2 for peptide sequences. For all but the most hydrophobic peptide, 
phosphorylation appears to produce a statistically significant reduction in BCA reactivity, 
for both denatured and native peptides (in each case n = 4). * = significant to a P value of 
<0.05, ** = significant to a P value of <0.01. 
A 
B 
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have a statistically greater reactivity than those without this residue, the range 
of peptide lengths and hydrophilicities, combined with a small overall sample 
pool may have hidden such sequence specific effects. As another post-
translational modification, sulphation, may also occur to tyrosine residues 
(Huttner, 1982), it is conceivable that this may have similar effects, as may 
modification of tryptophan or cysteine, which are targets for glycoslation 
(Schnaebel et al., 2004), and prenylation/palmitoylation respectively (Marshall, 
1993; Deitrich and Ungermann, 2004). 
 
Conversely, ALR and YIS are both serine phosphorylated, and while a slight 
reduction in BCA reactivity is noted in the phosphorylated form of ALR compared 
with the unphosphorylated control, there is no known role for serine in the 
secondary BCA reaction. In this case it is conceivable that a phosphoserine may 
simply interfere sterically with the co-ordination and reduction of the Cu2+ to 
Cu1+, though in the case of the highly hydrophobic YIS peptide, this may be 
balanced against a possible increase in solubility imparted by the phosphate 
group. 
When peptides are assayed by the standard BCA protocol (i.e. without SDS-
NaOH) the differences in absorbance between phosphorylated and 
nonphosphorylated peptides is greater for the serine-phosphorylated peptides 
(ALR, YIS), but smaller for the tyrosine phosphorylated peptides (SQK, TVE).  
The reasons behind this are unclear; while the purpose of the SDS-NaOH is to 
linearise and solubilise the peptides prior to the assay, unphosphorylated 
tyrosine containing peptides showed relative reduction in reactivity compared to 
their phosphaorylated counterparts. Therefore it is not due to a resulting 
increase in the accessibility of the naked tyrosine residues and concurrent 
increase of the secondary (sequence specific) BCA reaction compared with the 
native controls. It is possible that the same solubilisation and linearization may 
reduce the steric hindrance of the phosphoserine residues on Cu2+ reduction or 
co-ordination, leading to a concomitant ablation of the differences in BCA 
absorbance. Analysis of the interpeptide variation reveals that spread between 
the phosphorylated peptides is less than 50 % of that found between their non-
phosphorylated counterparts. This naturally leads to the hypothesis that the 
modified BCA assay may potentially show even greater accuracy when the 
content of a phosphopeptide enriched sample is analysed (assuming an 
appropriate phosphorylated standard is utilised). However given the limited 
phosphopeptide population utilised these hypotheses are difficult to verify, and 
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will require further evaluation before their accuracy and applicability may be fully 
determined. 
 
 
3.9  Discussion 
 
While in theory a wide number of assays are available for the measurement of 
peptide and protein concentration, in practice many of these require extensive 
sample clean-up, lengthy assay time, specialised equipment, or are heavily 
influenced by sequence-specific effects. The versatility and robustness of the 
BCA protein assay, along with its rapidity and convenience has lead to and 
maintained its widespread use as one of the leading protein assays for several 
decades (Stoscheck, 1990). While not designed for the determination of peptide 
concentration, these qualities - along with the fact that it does not primarily rely 
on a sequence-specific reaction - have lent it to adoption in the assay of peptides 
and polypeptides (Hua & Scheller, 2001; Faber et al., 2003; Saleem et al., 2005). 
 
However, it is evident that there is a wide variation in inter-peptide BCA 
reactivity; though some variations in reactivity between samples is not unusual 
and generally accepted in protein assays (see: Gornall et al., 1949; Smith et al., 
1985); this is usually minimised by choice of appropriate standards. In this case 
it is apparent that the variations were primarily due to differences in peptide 
hydrophilicity (which was implicated in 90 % of the variation in 
nonphosphorylated peptides of the same length) and, it is presumed, solubility. 
Therefore using two peptides of differing hydrophilicities, attempts were made to 
solubilise the peptides by a variety of means, many of which reduced this 
variation to some extent, with boiling the sample in 1 % (w/v) SDS in 0.1 M 
NaOH prior to mixing with working reagent showing the greatest reduction. 
When this protocol was applied to a variety of peptide populations: both 
synthetic and tryptic digests from purified proteins (aldolase, BSA, casein and 
catalase) or biological samples (lysates of guinea pig liver and the JY and T2 cell 
lines), a reduction in data spread was achieved in each case, ranging from 
11.5% - 52.5%, with a mean of 32.7%; a variation well within that accepted for 
the original protein BCA assay. This modification did not appear to significantly 
impact negatively on the assay’s linearity, optimum incubation period, 
applicability of microwave-incubation, or the lower limits of the overall assay 
sensitivity, though some reduction in hydrophilic peptide reactivity was observed. 
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When investigating solubilisation strategies it was apparent that combination 
treatments were, for the most part, more effective than any single reagent. It is 
therefore conceivable that the inter-peptide variation could be further reduced 
by also including methanol, DMSO, or other peptide solubilising reagents. 
However, it is assumed that each addition to the assay will likely reduce the 
tolerance of the assay for complicating reagents. 
 
The effect of post-translational modification – specifically phosphorylation, while 
normally of minor interest with regard to the protein assay, was also 
investigated. Our data suggests that phosphorylation notably reduces BCA 
reactivity, and that this effect is more pronounced in the case of tyrosine 
phosphorylation, possibly due to the sequence-specific secondary BCA reaction. 
Furthermore the effect of tyrosine phosphorylation was increased when peptides 
were heat-denatured in SDS-NaOH, highlighting the need for appropriate 
standards when samples are assayed. The effect of other post-translation 
modifications (e.g. glycosylation or prenylation) are at this point unknown, 
however it is considered likely that some effect would be observed, if only due to 
steric hindrance. 
 
Of particular note is an effect which might be called the hydrophilic elasticity of 
reactivity by length: changes in overall peptide hydrophilicity had a greater 
impact on reactivity in longer peptides than in shorter ones. While this may 
seem a semi-obvious observation, for a 20–amino acid peptide to increase in 
hydrophilicity to the same extent as 10-amino acid one, the effect on the amino 
acid(s) itself must be greater. Similarly, one would therefore expect a single 
phosphorylation point to have a lesser effect on reactivity in longer peptides than 
shorter, though this hypothesis is as yet untested. 
 
In conclusion, a simple modification to the BCA assay protocol markedly 
improves its applicability to peptide quantification. Despite this, some inter-
peptide variation remains, and appropriate standards (including any expected 
post-translational modifications) must be used to generate an accurate result. 
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4.0:  MHC cell-surface elution buffers 
(development of minimal-lysis IMAC-
compatible MHC elution buffers)  
 
4.1   Introduction 
 
As previously discussed (see 1.3.4), the CD8+ and CD4+ T-cell responses are the 
cornerstone of the specific immune system, and rely on the expression of 
peptides by surface MHC molecules (which in humans are often termed HLA). 
MHC class-I expression is near universal in healthy nucleated cells, and involves 
the expression of short peptides primarily derived from intracellular protein 
(Clarke, et al., 2001), which are monitored by a circulating antigen-specific CD8+ 
CTL population. MHC class-II is normally found only on typically phagocytotic 
antigen presenting cells (APCs), and displays longer peptides usually derived 
from exogenous protein, and monitored by the antigen-specific CD4+ T-cells, 
which regulate other elements of both the specific and non-specific immune 
system (Assudani et al., 2006). Numerous groups have attempted to develop 
immunotherapy strategies against a range of cancers (using peptides/peptide 
constructs, whole proteins, plasmids, or attenuated cells) and whilst there has 
been a significant degree of success in vitro and using animal (typically murine) 
models, most human trials have shown little success (Parish, 2003). 
 
There are numerous theories for why this is the case, including but not limited to 
immunoregulatory functions, and our limited understanding and control of the 
patient immune system, the late stage of many patients, the need to striate 
patient groups/move towards a more personalised approach, and a requirement 
for improvements in the vaccines themselves (the target, the delivery 
mechanism, and the adjuvant), (Copier et al,. 2009). This last category may also 
be paired with the need to investigate combination therapies (including chemical 
inhibitors, and when applicable, allogenic stem cell therapies for leukaemia 
patients) (Barret & Rezvani, 2007; Dao and Scheinberg, 2008) hopefully leading 
to improvements in the success rate of T-cell mediated tumour immunotherapy. 
Identification of putative vaccines is therefore an important aspect of both 
general cancer immunotherapy, and the personalised approach which may 
become more dominant in future (Castelli et al., 2004). 
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The methods used when searching for vaccines may be divided into two primary 
categories: namely direct or reverse immunology. Reverse immunology 
(discussed in 1.4.3) involves the development of a peptide-based vaccine 
typically from a gene or protein known to be commonly expressed/over-
expressed in the tumour of interest (e.g. tumour associated antigens, fusion 
proteins or cancer-testis antigens). This was initially achieved using overlapping 
peptides from the protein of interest, but was later aided by algorithms such as 
Pcleavage and SYFPEITHI, which predict likely points of cleavage by the 
immune-proteasome, and strength of binding to different MHC-alleles 
(Rammensee, et al., 1999; Bhasin and Raghava, 2005); and confirmed using 
MHC binding assays. Peptides likely to be presented are then assessed by CTL-
mediated killing assays of the target cells (Osanto, 1997). Currently however the 
limited data regarding the effects of phosphorylation on peptide processing and 
the strength of binding to MHC molecules makes a predictive approach difficult 
to achieve. 
 
Direct immunology involves identification of naturally occurring MHC-associated 
peptide epitopes direct from the cell surface, typically though not exclusively 
from malignant or virus-infected cells/cell lines. The method stems originally 
from the work of Sugawara et al. (1987) who determined that treatment of 
either primary or cultured cells with isotonic citrate-phosphate pH 3.3 
supplemented with 1 % (w/v) BSA led to elimination of MHC class-I mediated 
antigenicity in a pH dependent manner, without affecting either MHC class-II or 
non MHC antigens, and with minimum cytoloysis. This approach was later taken 
up by Storkus et al. (1993a) to elute MHC-associated peptides from a range of 
cell lines, and following fractionation of an eluate from an influenza-A infected 
Mel-624 cell line (MHC class-I A2-positive) by reverse-phase HPLC on a C18 
column, they were able to confirm the presence in the eluate of a previously 
identified immunogenic peptide (Hogan et al,. 1988) by a CTL-mediated specific 
cytolysis assay. This approach was then used to identify immunogenic HPLC 
fractions from the surface of a number of melanoma cell lines (Storkus et al., 
1993b), and six months later the first of these peptides was characterised using 
tandem mass-spectrometry (Cox et al., 1994), a pairing of methods which would 
become the accepted paradigm for direct immunology, and would be utilised by 
Jimenez et al. (1996); Ostankovitch et al., 1998 ; Herr, et al. (1999) ; 
Nakatsuka et al. (1999); Fan, et al., (2000); Santin et al. (2000); Clark et al. 
(2001); Ishii et al. (2003); Chromik et al. (2005); Gannage, et al., 2005; 
Gebreselassie et al. (2006); Pend et al. (2007) and Antwi et al. (2009). 
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However the pH 3.3 isotonic citrate-phosphate buffer is known to cause between 
5 - 10 % cell death as determined by trypan-blue staining (Storkus et al., 1993a 
and 1993b; Fan et al., 2000; Clark et al., 2001), which may contaminate eluates 
with intracellular peptides not associated with MHC molecules (Bonner et al., 
2002). As the chelating properties of the citric acid render it incompatible with 
on-line mass spectrometry, samples eluted from cells must be desalted and 
concentrated by (e.g.) C18 SPE or cation-exchange chromatography prior to 
subfractionation and analysis (Clark et al., 2001), following which candidate 
peptides may be chosen, and assessed for their immunogenicity (routinely using 
synthesised counterparts). While the direct immunology method requires a 
higher degree of sample handling and data analysis than reverse immunology, it 
does not restrict the search to peptides from a (usually single) known target 
(Greten and Jaffee, 1999), and ensures that the peptide is not only present on 
the cell surface, but is processed and presented efficiently; a potential weakness 
of the reverse immunological approach (Dao and Scheinberg, 2008). 
Furthermore direct elution of MHC peptides also prevents the products of 
unexpected variations in proteasomic cleavage from being disregarded, and may 
also be used to determine the presence of post-translationally modified peptides 
within the MHC presentome. 
 
The most common alternative, papain cleavage of MHC molecules or membrane 
solubilisation and subsequent capture of MHC class-I molecules onto an 
immunoaffinity column is both expensive, and in the case of papain digestion 
risks cleavage of peptides and hydrolysis of esters and amides within the 
peptides’ functional groups (Kato et al., 1987; Meos et al,. 1995)1.  
 
Direct elution of class-II peptides has long been thought to be problematic. 
Whilst it has previously been shown that the MHC class-II molecule will 
destabilise at pH 2.2 (Schneider and Secarz, 1997), high cell lysis has been 
observed at this pH (Bonner et al., 2002; Kessler et al., 2003). Therefore the 
primary approaches for acquisition of class-II restricted peptides again tend to 
involve either papain cleavage (Gorga et al., 1991; Nag et al., 1994) or 
                                                 
1
 Though the deamidation function of papain has an optimum pH of 10.0, at pH 7 it has only fallen to 
25 % and the protein shows optimum deamidation activity at 20 °C (c.f. 50 °C for the protolytic 
activity). The esterfication activity has a optimum of pH 6-7. While C-terminal hydrophobic residues 
are important for MHC-binding (MHC consortium, 1999), Meos et al. (1995), also report that the 
presence of terminal hydrophobic residues are important for papain activity. 
Chapter 4.0: Results 
MHC cell-surface elution buffers 
 121
membrane solubilisation, followed by immunoprecipitation and elution (e.g. 
Tomlinson et al. 1996a 1996b and 1997). Again however, papain cleavage risks 
damage to peptides prior to their analysis, and furthermore unlike the class-I 
molecule which may be cleaved from the cell surface within 20 minutes, 
approximately 90% of class-II molecules remain uncleaved after a 3 hour 
incubation, even with a 1:3 ratio of papain:membrane protein (Kaufman and 
Strominger, 1979)2. Membrane solubilisation also presents problems in that a 
proportion (ranging up to 50 %) of MHC class-II molecules remain lipid insoluble 
(Poloso et al., 2004), impacting on immunoprecipitation and the subsequent 
elution Poloso et al., 2004. However this population may include the majority of 
molecules from the MIIC and so poorly bound peptides which would not normally 
be trafficked to the cell surface may be depleted from the eluate as a result 
(Poloso et al., 2004), it may also be enriched in those peptides which stimulate a 
Th1 response (Buatois et al., 2003), an effect which may be beneficial to the 
search for Th2 stimulating epitopes, and also contain the majority of cell-surface 
class-II molecules presenting CLIP (Goebel, 2002). An alternative method, using 
noble-metal complexes to displace class-II antigens has been described by De 
Wall et al. (2006), though no subsequent information has become available, and 
compatibility with protein cleanup/fractionation techniques has yet to be 
assessed. 
 
Recent work within NTU involved research into the elution of MHC class-II 
peptides direct from the cell surface using a pH 2 buffer compatible with a broad 
range of chromatographic methods, including IMAC and ESI-MS/MS (Barry, 
2006). This was performed using the TAP and HLA-DM deficient T2 cell line 
transfected with MHC class-II DRB1*0401. As a result of HLA-DM deficiency, the 
class-II molecules present on the cell surface largely present the CLIP peptide 
(LPKPPKPVSKMRMAATPLLMQA). Flow cytometric staining against class-II and 
CLIP revealed disassociation of the peptide from the MHC at pH 2 (see figure 
4.1.A), and this was confirmed by ESI LC MS/MS (figure 4.1.B).  
 
As the importance of CD4+ Th1 in potentiating the CD8
+ CTL response is well 
documented (Kaiko et al., 2008), it is conceivable that this may allow an 
alternate route for development of class-II peptide vaccines by direct 
immunology.  Alternatively and as discussed previously (1.2.4.2) unlike the        
z 
                                                 
2
 As determined by radio immuno-assay. 
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Figure 4.1: Confirmation of CLIP elution from MHC class-II of T2.Dr4 cells determined by 
(A) flow cytometry and (B) tandem mass spectrometry for the CLIP peptide (from Barry, 
2006). 
B 
A 
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majority of tumours, MHC class-II expression is reasonably common in the 
leukaemias (Guy et al., 1986; Drexler et al., 1988, Yunis, et al., 1989) it may be 
coupled with the use of MHC class-II expression by leukaemic cells themselves 
as the basis for a cell-based vaccines, similar to the method of transfecting 
tumour cells or cell lines with class-II as a means of stimulating activation of Th1 
CD4+ cells to cause an anti-tumour CD8+ response leading to rejection of a 
tumour or metastases (Ostrand-Rosenberg et al., 1990; Baskar et al., 1995; 
Armstrong et al., 1997; Pulaski and Ostrand-Rosenberg, 1998; Dolan et al., 
2004). 
 
In a similar vein, previous work carried out at NTU indicates that a 25 mM TMA-
formate buffer pH 3.3 may be an IMAC compatible substitute for the isotonic 
citrate-phosphate Storkus’ buffer, and the potential for a pre-elution wash with a 
low pH buffer to remove membrane-associated serum peptides prior to MHC 
elution (see table 4.1) (Barry, 2006). This chapter describes the development 
and optimisation of these novel buffers for the elution of class-I and class-II 
peptides direct from the surface of numerous cell lines with minimal cell lysis, 
reducing the time required for sample processing and purification.  
 
 
No prewash. Following prewash. 
Peptide sequence Proposed Source Peptide sequence Proposed Source 
TLAAHLPAEFTPAVHASLDKF Haemoglobin LSGITGARNLAVS
QVVHKVVS 
Alpha-1 antichymotrypsin 
pre-cursor 
YQKVVAGVANALAHKYH Haemoglobin QNLKLFRH Protein kinase AMP-
activated alpha 2 catalytic 
subunit 
LSFPTTKTYFPHF Haemoglobin FVSNHAY Fructose bisphosphate 
aldolase 
SPADKTNVKAAWGKVGAHAG
EYG 
Haemoglobin HDSFLKAVPSQKR
T 
S100 calcium binding 
protein – calgizzarin 
DAHKSEVAHRFKDLGEENFK Human Serum 
Albumin 
FGPKGFGRGGEA
SHTFK 
Cysteine Rich Protein 1 
PGHLQEGFGCVVTNRFDQL PAI-1 mRNA 
binding protein 
MAHMASKE Glyceraldehyde 3-
phosphate 
dehydrogenase 
TLAAHLPAEFTPAVHASLDKF Haemoglobin ECQSHKLTVE Proteosome Subunit 
Table 4.1: Highest confidence peptides eluted from LCL-BM cell line MHC class-II with 
unsupplemented 50 mM sodium formate pH 2 with or without first washing the cells with a pH 
5.5 prewash, and isolated by Cu2+ IMAC prior to ESI MS/MS (from Barry, 2006). 
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4.2 Confirmation of MHC class-I elution by citrate-phosphate or TMA 
formate elution buffers 
 
Previous work at NTU suggested that a TMA-formate buffer at pH 3.3 would be 
capable of causing disassociation of peptide from the MHC class-I complex in a 
pH dependent manner similar to the citrate-phosphate elution protocol devised 
by Storkus et al. (1993), while remaining compatible with a wide variety of 
downstream chromatographic approaches such as IMAC. In order to confirm this, 
populations of 4 x 106 JY and K562-A3 cells were treated with TMA-formate and 
citrate-phosphate elution buffers as per section 2.4.2, washed and rebuffered in 
PBS, and treated with the W6/32 anti-MHC class-I monoclonal antibody or an 
anti-β2 microglobulin monoclonal antibody and then treated with the FITC 
conjugated secondary antibody prior to analysis by flow cytometry, as described 
in section 2.4.3.  
 
This illustrated comparable disassociation of β2 microglobulin from the MHC 
class-I complex with TMA-formate or citrate-phosphate (see Figure 4.2), and 
that despite research which suggests different MHC alleles may present tighter 
or looser global association with their presentomes (Gebreselassie et al., 2006), 
at pH 3.3 the effect was not limited to a single MHC allele. While the 
disassociation at pH 3.4 and above seemed to be greater for the citrate-
phosphate buffer over the TMA-formate, this is probably due to the greater 
capacity and broader buffering range of the citrate-phosphate buffer. The pH 5.5 
citrate-phosphate buffer appears to have no appreciable effect on MHC 
expression or β2 microglobulin retention, and is thus a suitable prewash medium. 
 
Though this data does not document MHC expression levels following buffer 
treatment, any internalisation of the MHC complex is expected to take place 
after the disassociation of the peptide, especially given that the buffers used 
were pre-cooled to 4 °C, and the rate of MHC internalisation is known to be 
temperature dependent (Tse and Pernis, 1984). 
 
 
Chapter 4.0: Results 
MHC cell-surface elution buffers 
 125
 
Figure 4.2: Confirmation of pH–dependent β2-microglobulin elution by FACS (expressed as a percentage of the range between stained / unstained 
untreated controls). FITC stained K562-A3 and JY cell populations analysed by flow-cytometry following treatment with citrate-phosphate or TMA-formate 
buffers prepared across a pH range (displayed as % expression on untreated cells). 4 x 106 cells were subjected to TMA-formate or citrate-phosphate 
elution buffers across a pH range from 3 to 7.5. Following treatment, cells were stained with a monoclonal murine antibody against β2-microglobulin, 
washed, and stained with an FITC-conjugated α-mouse secondary before being analysed by flow cytometry, as per 2.4.3. The data indicates β2-
microglobulin disassociation occurs between pH 3.4 and pH 3.3 with both TMA-formate and citrate-phosphate buffers, illustrating a pH-dependent 
mechanism for eluting bound peptide from the MHC class-I complex. No significant differences appear to exist between the disassociation pH of the MHC 
class-I A*0201 presenting JY cell line, and the K562 cell line transfected with MHC class-I A*0301. Finally, washing with pH 5.5 citrate-phosphate has no 
apparent effect on β2-microglobulin integrity. Main graph illustrates the pH scale from 3 to 4.0, while the full pH scale is visible in the inset (bottom-right). 
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4.3 Optimisation of minimal-lysis elution buffers using trypan-blue 
staining as an indicator of cell mortality 
 
The trypan blue dye was introduced by Nobel laureate Paul Ehrlich in 1904 (Ruis 
and Muir, 2005), and is routinely used within the context of cell culture to 
differentiate between viable and non-viable mammalian cells, as non-viable cells 
lack the membrane integrity required to exclude the dye and thus prevent cell 
staining. It was first applied to leukocytes by Evans and Schulemann (1914) and 
lymphocytes by Pappenheimer (1917), where it was demonstrated to rapidly 
stain damaged or traumatised cells. Its advantages are the speed and 
convenience with which it may be used, cells require little preparation prior to 
staining, and no specialised equipment beyond a microscope with (x)10 or (x)40 
objective lens and a haemocytometer, as well as its reproducibility, low cost, and 
low acute toxicity (Pappenheimer, 1917). 
 
 
4.3.1 Osmotic balancing and supplementation of TMA-formate elution 
buffer 
 
While the pH gradient experiments illustrate that MHC class-I elution is pH 
dependent, the unsupplemented TMA-formate buffer was found to cause high 
cell death, raising concerns with regard to sample contamination by intracellular 
peptides, proteases, kinases and phosphatases, which may alter or mask those 
peptides which are derived from the MHC complex. It is suggested that this was 
primarily due to the high water potential of the 25 mM buffer leading to 
osmotically determined cell lysis, osmotic balancing of the buffer with sucrose 
and KCl was attempted. Cell lysis was determined by trypan blue exclusion as 
per 2.4.4, and an optimum concentration of 0.3 M sucrose, and 0.45 M KCl found 
to produce 8.4 % (± 2.72) trypan-staining staining for JY cells (see figure 4.3). 
 
This was then confirmed with the K562-A3 and THP-1 cell lines using a limited 
sucrose/KCl matrix, producing a similar pattern of trypan staining, with a 
minimum value of 8.69 (± 1.68) % cell death at 0.3 M sucrose, 0.45 M KCl (see 
Table 4.2). 
 
The osmotic balancing brought trypan-determined cell lysis within the ~ 10 % 
range described by Storkus et al. (1993) and others (Clark et al., 2001; Bonner, 
et al., 2002), and a Mann-Whitney U test failed to find a statistical difference in   
z 
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Figure 4.3: Trypan staining of the JY cell line (n = 6) following treatment with pH 3.3 
25mM TMA-formate elution buffers with varying concentrations of sucrose and potassium 
chloride included as osmotic agents. 2 x 106 cells were washed in PBS, treated with 
elution buffers, and centrifuged to pellet the cells, following which cells were washed 
twice and re-suspended in PBS. To determine percentage cell death, 20 µl of each cell 
suspension was then mixed with 180 µl of 0.1 % (w/v) trypan blue, and the stained and 
total number of cells counted using a haemocytometer. An optimum concentration of 0.3 
M sucrose and 0.45 M KCl was determined to reduce the proportion of cell-staining to 8.4 
(± 2.72) %. Numerical data is detailed below, and reproduced for other cell lines in table 
3.2.2 overleaf. 
 
Percentage post-elution trypan staining of JY cell population when treated with 25 mM TMA-
formate (pH 3.3) elution buffers containing various concentrations of sucrose and KCl as 
osmotic agents (± values indicate standard deviation). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Su
c
ro
se
 
(M
) 
 
                  KCl (M) 
 0 0.15 0.3 0.45 0.6 
0 76.71 (± 5.07) 
48.05 
(± 8.54) 
58.53 
(± 8.2) 
22.86 
(± 9.02) 
19.6 
(± 2.05) 
0.15 33.8 (± 16.01) 
23.02 
(± 10.10) 
17.69 
(± 1.65) 
11.19 
(± 2.49) 
10.79 
(± 1.99) 
0.3 16.8 (± 4.56) 
11.57 
(± 1.76) 
8.53 
(± 1.72) 
8.40 
(± 2.72) 
8.96 
(± 3.93) 
0.45 16.06 (± 3.32) 
10.39 
(± 1.68) 
13.39 
(± 5.39) 
14.64 
(± 3.56) 
15.09 
(± 2.98) 
0.6 28.63 (± 4.89) 
12.97 
(± 2.57) 
18.47 
(± 5.72) 
20.75 
(± 4.67) 
23.99 
(± 3.87) 
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Su
cr
o
se
 
(M
) 
               KCl (M) 
 
0.3 0.45 0.6 
JY K562-A3 THP-1 JY K562-A3 THP-1 JY K562-A3 THP-1 
0.15 17.69 (± 1.65) 
19.7 
(± 2.59) 
17.46 
(± 1.27) 
11.19 
(± 2.49) 
12.23 
(± 1.26) 
8.47 
(± 1.61) 
10.79 
(± 1.99) 
11.27 
(± 2.26) 
10.45 
(± 1.1) 
0.3 8.53 (± 1.72) 
9.03 
(± 1.22) 
8.85 
(± 1.09) 
8.4 
(± 2.72) 
8.69 
(± 1.68) 
7.66 
(± 1.41) 
8.96 
(± 3.93) 
8.85 
(± 1.64) 
7.96 
(± 1.59) 
0.45 13.39 (± 5.39) 
14.05 
(± 3.14) 
13.21 
(± 1.32) 
14.63 
(± 3.56) 
14.85 
(± 1.81) 
13.66 
(± 1.13) 
15.09 
(± 2.98) 
16.7 
(± 0.99) 
15.7 
(± 1.29) 
 
Table 4.2: Percentage post-elution trypan staining of the JY, K562-A3 and THP-1 cell lines 
following treatment with pH 3.3 25mM TMA-formate elution buffers, with varying concentrations of 
sucrose and potassium chloride as osmotic agents across a narrow molar range. 2 x 106 cells were 
washed in PBS, treated with elution buffers, and centrifuged to pellet the cells, following which cells 
were washed twice and re-suspended in PBS. To determine percentage cell death, 20 µl of each 
cell suspension was then mixed with 180 µl of 0.1 % (w/v) trypan blue, and the stained and total 
number of cells counted using a haemocytometer. An optimum concentration of 0.3 M sucrose and 
0.45 M KCl was found in each case. ± values indicate standard deviation, and in all cases n = 6. 
 
trypan staining between osmotically balanced TMA-formate and isotonic citrate-
phosphate for either the JY or K562-A3 cell lines (see figure 4.4). 
 
It was also noted that trypan-blue staining was marginally lower for both K562-
A3 and JY cell lines when they were re-buffered in RPMI 1640 c.f. PBS following 
elution (see figure 4.5), echoing the results of Pappenheimer (1917), who noted 
that lymphocytes produced lower staining counts when the trypan blue was 
prepared in Locke’s solution (an isotonic buffer containing NaCl, KCl, CaCl2, and 
a sodium bicarbonate buffer pH 7.4) rather than isotonic saline. 
 
It was therefore determined to investigate whether the components of the RPMI 
1640 culture media might improve survival under elution conditions, as the 
media was itself designed primarily for the culture of lymphocytes, albeit within 
a physiological pH range. Amongst other components, the RPMI 1640 culture 
media contains: 11.1 mM D-glucose; 194 µM myo-inositol and 3.25 µM reduced 
glutathione (Moore et al., 1967), each of which was tested at a range of 
concentrations to determine the effect on immediate post-elution cell viability. 
All proved to provide some benefit to cell survival (see figure 4.6.A), with 
optimum concentrations determined to be 10 mM D-glucose, 2 mM myo-inositol, 
and 1 mM reduced glutathione, each of which reduced post elution trypan 
staining of the JY cell line from 8.44 % (± 2.77) to between 3.79 – 5.36 % (with 
z  
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standard deviations of between 1.49 and 2.4). The anti-oxidant ascorbic acid 
was also tested, and though this too offered a minor benefit with regard to cell 
survival (reducing trypan staining of the JY cell line to 6.47 %), it proved 
incompatible with Fe3+ IMAC and was therefore not carried forward. 
 
The benefits provided by the D-glucose, inositol and reduced glutathione proved 
at least semi-cumulative, and their addition in combination reduced post-elution 
trypan-determined cell death to 1.17 (± 0.35) %, 2.31 (± 1.06) % and 2.12 (± 
1.06) % for the JY, K562-A3 and THP-1 cell lines respectively (see figure 4.6.B). 
Not only were these staining levels significant statistically (P value = <0.01) 
when compared by Mann-Whitney U test with an unsupplemented osmotically 
balanced buffer, but it brought staining within each cell line to a point 
statistically indistinct from the untreated populations. 
 
 
Figure 4.4 Trypan staining of the JY and K562-A3 cell lines (n = 12) following treatment 
with pH 3.3 isotonic citrate-phosphate or 25mM TMA-formate (osmotically balanced with 
0.3 M sucrose and 0.45 M KCl). 2 x 106 cells were washed in PBS, treated with elution 
buffers, and centrifuged to pellet the cells, following which cells were washed twice and 
re-suspended in PBS. To determine percentage viability, 20 µl of each cell suspension 
was then mixed with 180 µl of 0.1 % (w/v) trypan blue, and the stained and total number 
of cells counted using a haemocytometer. Both student T-tests and Mann-Whitney U 
tests indicated no statistical difference apparent between the isotonic citrate-phosphate 
and osmotically balanced TMA-formate treated populations for either cell line (to P < 
0.05).  Error bars indicate S.D. 
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Though the approach of Sugawara et al. (1987) included 1 % BSA in the citrate-
phosphate buffer to stabilise cell viability, this was excluded from the methods of 
Storkus et al. (1987) and our own procedures for the simple reason that the 
contamination of bovine serum peptides would complicate sequencing of MHC-
derived peptides. Similarly, the amino acids and phosphate ions found in RPMI 
1640 were not considered as potential supplements as it was feared they would 
complicate isolation, quantification and identification, however the addition of 
these to the elution buffer may reduce cell death further, as may the inclusion of 
metal ions such as calcium or magnesium. 
 
 
Figure 4.5: Post-elution trypan staining of the JY and K562-A3 cell lines following 
rebuffering to pH 7.5 with either PBS or RPMI 1640. 2 x 106 cells were washed in PBS, 
treated with elution buffers, and centrifuged to pellet the cells, following which cells were 
rebuffered in either PBS or RPMI 1640. Percentage viability was determined by mixing 20 
µl of each cell suspension with 180 µl of 0.1 % (w/v) trypan blue, and the stained and 
total number of cells counted using a haemocytometer. In each case a Mann Whitney U 
test found statistical differences between PBS and RPMI 1640 rebuffered populations, to 
P < 0.05 (signified by *). Error bars indicate S.D. 
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Figure 4.6: Trypan determined post-elution cell death of (A) JY cell line eluted with 
osmotically balanced 25mM TMA-formate buffers (pH 3.3) containing a range of 
concentrations of either D-glucose, myo-inositol, reduced glutathione or ascorbic acid. 
The level of cell staining observed in the unsupplemented buffer is denoted by the dotted 
level line. (B) JY, K562-A3 and THP-1 cell lines eluted with osmotically balanced 25mM 
TMA-formate buffers containing serial supplementation with 10 mM glucose, 2 mM 
inositol and 1 mM glutathione (each of which proved statistically distinct from the 
unsupplemented osmotically-balanced buffer). In each case 2 x 106 cells were washed in 
PBS, treated with elution buffers containing the various supplements/concentrations, 
before the cells were washed twice and re-suspended in PBS. Percentage viability was 
determined by mixing 20 µl of each suspension with 180 µl of 0.1 % (w/v) trypan blue, 
and the stained and total number of cells counted using a haemocytometer. An elution 
buffer containing all three supplements reduced post-elution trypan-determined cell death 
to 1.17 (± 0.35) %, 2.31 (± 1.06) % and 2.12 (± 1.06) % for the JY, K562-A3 and THP-1 
cell lines (significant to P < 0.01 when compared with the unsupplemented buffer, n = 5). 
B 
A 
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4.3.2 Effect of osmotic balancing, adjustment of molar concentration, 
and further supplementation of sodium-formate MHC class-II 
elution buffer 
 
It was noted that the MHC class-II elution buffer originally designed at NTU 
provided an extremely high buffering capacity, however when cells were 
rebuffered in RPMI 1640, the phenol red did not present the standard reddish 
colouration indicative of pH 7.4 until at least the third or fourth wash leading to 
concerns that the high cell staining - 30.9. (± 0.55) % for the JY cell line, 35.7 
(± 0.75) % for THP-1, might be a result of prolonged exposure to a low pH. 
When investigated, reductions in the concentration of the buffer were found to 
reduce trypan staining to 22.4 (± 0.81) % for the JY cell line and 24.2 (± 
0.84) % for THP-1 at 50 mM sodium formate (see figure 4.7), each to a 
statistically significant degree. Furthermore, a Spearman’s rho of -0.945 (to a P 
value of <0.01) was found between buffer strength and trypan staining. 
 
While cell staining - and by implication, cell lysis - remained high with the 50 mM 
buffer, the 200 mM buffer required a much higher concentration of formic acid to 
bring to pH 2.0. Though following clarification eluates are stored at – 80 °C, high 
formic acid concentrations may result in formylation of peptides, or degradation 
of aromatic amino acids, especially if samples are to be stored for extended 
periods (Beavis and Chait, 1990; Morrison et al., 1990).  
 
Although initial research on the 200 mM sodium-formate buffer had indicated a 
similar optimal range of KCl and sucrose to the TMA-formate buffer, this was 
confirmed using the MHC class-II positive JY and T2.DR4 cell lines, treated with 
50 mM sodium-formate buffers across a limited sucrose/KCl gradient. This 
produced a similar pattern of trypan staining to the TMA-formate buffer, with a 
minimum value of 11.97 (± 1.0) % cell staining for the JY cell line, 13.63 (± 
1.16) % for the T2.Dr4 hybridoma line, and 14.58 (± 1.18) % for the THP-1 cell 
line at 0.3 M sucrose, 0.45 M KCl (see Table 4.3). 
 
The inclusion of short concentration ranges of glucose, inositol or glutathione in 
the pH 2 buffer were assayed by trypan-blue staining, and demonstrated a 
similar pattern to Figure 4.6.A. This was followed by the serial addition of 10 mM 
glucose, 2 mM inositol and 1 mM glutathione, which again provided a cumulative 
benefit to post-elution trypan-exclusion, reduced cell staining to 1.17 (± 0.35) % 
and 2.31 (± 1.06) % for the JY and K562-A3 cell lines respectively (see figure     
z 
Chapter 4.0: Results 
MHC cell-surface elution buffers 
 133
 
 
 
 
Su
cr
o
s
e 
(M
) 
               KCl (M) 
 
0.3 0.45 0.6 
JY K562-A3 THP-1 JY K562-A3 THP-1 JY K562-A3 THP-1 
0.15 18.18 (± 1.81) 
19.81 
(± 0.87) 
21.62 
(± 1.03) 
16.73 
(± 1.07) 
17.94 
(± 0.92) 
19.44 
(± 0.97) 
15.61 
(± 0.97) 
16.49 
(± 1.26) 
18.78 
(± 1.12) 
0.3 13.66 (± 1.15) 
15.28 
(± 1.06) 
15.28 
(± 1.37) 
11.97 
(± 1.0) 
13.63 
(± 1.16) 
13.56 
(± 1.43) 
12.96 
(± 1.43) 
14.58 
(± 1.18) 
14.51 
(± 1.59) 
0.45 14.96 (± 0.88) 
15.31 
(± 1.06) 
15.53 
(± 0.99) 
15.76 
(± 0.92) 
16.55 
(± 0.91) 
16.87 
(± 1.84) 
16.48 
(± 1.21) 
18.21 
(± 1.07) 
18.7 
(± 1.29) 
 
Table 4.3: Percentage post-elution trypan staining of the JY, T2.Dr4 and THP-1 cell lines 
following treatment with pH 2 50 mM sodium-formate elution buffers, with varying 
concentrations of sucrose and potassium chloride as osmotic agents across a narrow molar 
range. 2 x 106 cells were washed in PBS, treated with elution buffers, and centrifuged to 
pellet the cells, following which cells were washed twice and re-suspended in PBS. To 
determine percentage cell death, 20 µl of each cell suspension was then mixed with 180 µl 
of 0.1 % (w/v) trypan blue, and the stained and total number of cells counted using a 
haemocytometer. An optimum concentration of 0.3 M sucrose and 0.45 M KCl was found in 
each case. ± values indicate standard deviation, and in all cases n = 6. 
 
Figure 4.7: Trypan determined post-elution cell death of JY and THP-1 cell lines eluted 
with unsupplemented sodium formate pH 2 at decreasing buffer molarity. 2 x 106 cells 
were washed in PBS, treated with elution buffers containing the various 
supplements/concentrations, and centrifuged to pellet the cells, following which cells were 
washed five times and re-suspended in PBS. To determine percentage viability, 20 µl of 
each cell suspension was then mixed with 180 µl of 0.1 % (w/v) trypan blue, and the 
stained and total number of cells counted using a haemocytometer. Each reduction in 
buffer strength led to a statistically significant drop in trypan-blue staining for both the JY 
and THP-1 cell lines (in each case with a P value of 0.05 or greater) , and an inverse 
Spearman’s rank correlation of -0.945 (to a P value of 0.01) was found for both cell lines 
between cell death and buffer strength. At 50 mM staining of JY and THP-1 cell line was 
reduced to 22.4 (± 0.81) % and 24.2 (± 0.84) % respectively (n = 6). 
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4.8). Again, these staining levels were statistically significant when compared by 
Mann Whitney U test with an unsupplemented osmotically balanced buffer, 
though in the case of THP-1 cell line treated with the class-II elution buffer 
containing 10 mM glucose, this significance was only apparent at a P value of 
<0.05. 
 
 
 
 
 
 
 
Figure 4.8: Trypan determined post-elution cell death of JY, T2.Dr4 and THP-1 cell lines 
eluted with osmotically balanced 50 mM TMA-formate buffers (pH 2.0) containing serial 
supplementation with 10 mM glucose, 2 mM inositol and 1 mM glutathione (each of which 
was statistically distinct by ANOVA from the unsupplemented osmotically-balanced buffer 
for every cell line). In each case 2 x 106 cells were washed in PBS, treated with elution 
buffers containing the various supplements/concentrations, and centrifuged to pellet the 
cells, following which cells were washed twice and re-suspended in PBS. To determine 
percentage viability, 20 µl of each cell suspension was then mixed with 180 µl of 0.1 % 
(w/v) trypan blue, and the stained and total number of cells counted using a 
haemocytometer. Treatment with an elution buffer containing all three supplements 
reduced post-elution trypan-determined cell death to 5.82 (± 0.35) %, 6.29 (± 1.06) % and 
6.25 (± 1.06) % for the JY, T2.Dr4 and THP-1 cell lines respectively, and the addition of 
each supplement was statistically significant (to a P value of at least <0.05) against the 
unsupplemented but osmotically balanced buffer treatment. 
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4.3.3 Supplementation of isotonic citrate-phosphate with non-osmotic 
supplements 
 
Once ideal concentrations of the additional supplements were confirmed, the 
effect of their addition into the isotonic citrate-phosphate buffers at pH 5.5 and 
3.3 was tested; while no significant effect was apparent at pH 5.5, surprisingly a 
minor increase in mean cell staining for each of the cell lines was observed at pH 
3.3 (see figure 4.9), though this was only statistically significant (to a P value of 
<0.05) for the K562-A3 line. As these buffers are already isotonic with regard to 
the contents of the suspension cell lines tested, this may be due to osmotic 
effects, though Rous and Turner (1916), noted that the survival of erythrocytes 
in media containing agents such as glucose was modulated by citric acid on a 
concentration dependent scale. Furthermore, as one of the aims of this research 
was to replace the citrate-phosphate elution buffer with one directly compatible 
with the IMAC approach for selection of phosphorylated or histidine-containing 
peptides, supplementation of the citrate-phosphate buffer would do little to 
achieve these goals, as the same sample clean-up steps would be required. 
 
 
4.3.4 Comparative post-elution trypan staining following treatment with 
MHC class-I and class-II buffers 
 
Finally, comparative trypan staining of cells was performed following MHC class-I 
(figure 4.10) and MHC class-II (figure 4.11) elution with the buffers developed 
above. In the case of the MHC class-I buffers, elution was performed with and 
without the pH 5.5 prewash step, while for MHC class-II elution was performed 
with and without elution of MHC class-I peptides, either by isotonic citrate-
phosphate pH 3.3, or by prewashing with isotonic citrate-phosphate pH 5.5 then 
eluting MHC class-I with the complementary (osmotically balanced or fully 
supplemented) TMA-formate buffers prior to class-II elution. Results were 
compared with MHC elution by the isotonic citrate-phosphate approach utilised 
by Storkus et al. (1993a/b). This confirmed a reduction in cell lysis with 
progressing supplementation of the pH 3.3 TMA-formate and pH 2 sodium-
formate buffers. 
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Figure 4.9: Trypan determined cell death of K562-A3, JY and THP-1 cell lines following 
treatment with isotonic citrate phosphate buffers with (‘supplemented’) or without 
(‘unsupplemented’) the addition of 10 mM glucose, 2 mM myo-inositol and 1 mM 
glutathione. 2 x 106 cells were washed in PBS, treated with buffers, and centrifuged to 
pellet the cells, following which cells were washed twice and re-suspended in PBS. To 
determine percentage viability, 20 µl of each cell suspension was then mixed with 180 µl 
of 0.1 % (w/v) trypan blue, and the stained and total number of cells counted using a 
haemocytometer. While little difference was observed between the pH 5.5 buffers, at pH 
3.3 the mean cell staining increased for all three cell lines when supplements were added 
to the isotonic citrate-phosphate, and the K562-A3 cell line exhibited a statistically 
significant difference in trypan staining between supplemented and unsupplemented pH 
3.3 buffers. Also interesting to note is the comparative staining of the three cell lines, 
particularly THP-1 which seems to show increased resistance to the citrate-phosphate 
buffer at pH 3.3 relative to K562-A3 and JY, but comparative or higher cell staining at pH 
5.5 when compared with the other cell lines. 
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It also indicated that prewashing the cells with isotonic citrate-phosphate at pH 
5.5 prior to MHC class-I elution did not significantly increase the levels of cell 
staining except in the case of the osmotically balanced and fully supplemented 
TMA-formate buffer, where trypan staining increased, but became statistically 
indistinguishable from the prewashed-only controls. Indeed, when trypan 
staining levels at the preceding stages are taken into account, it appears that 
prewashing with citrate phosphate leads to a reduction in cell lysis at the MHC 
class-I elution stage, potentially by lysing the more fragile elements of the 
subpopulation prior to the pH 3.3 stage. As a result the resultant trypan staining 
for each prewashed cell line following exposure to the optimised TMA-formate 
buffer is calculated to be under 1 % (see figure 4.10). 
 
For MHC class-II elution (figure 4.11) the situation appears slightly more 
complex. When MHC class-I elution by TMA-formate (with a pH 5.5 prewash) 
took place prior to MHC class-II elution, mean staining increased, but remained 
statistically insignificant from populations subjected to class-II elution only. 
When class-I peptides were removed by citrate-phosphate pH 3.3 (without a 
prewash), mean cell staining increased even further and became statistically 
significant (P <0.05) when compared with cells where MHC class-I peptides were 
not removed, though this result remained statistically insignificant when 
compared with those which had undergone a pH 5.5 prewash and TMA-formate 
elution prior to MHC class-II elution. Again, when the trypan staining levels of 
the populations which had undergone either the prewash followed by TMA-
formate or the citrate-phosphate elution were accounted for it was found that 
both led to a reduction in cell staining after the pH 2 treatment, with citrate-
phosphate pH 3.3 producing a greater reduction in staining than the prewash 
followed by TMA formate buffer. 
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Figure 4.10: Trypan-determined cell death of K562-A3, JY and THP-1 cell lines (n = 6) following treatment with the buffers used in MHC-class-I elution, 
and variants thereupon. 2 x 106 cells were washed in PBS, treated with buffers, and centrifuged to pellet the cells, following which cells were washed twice 
and re-suspended in PBS. To determine percentage viability, 20 µl of each cell suspension was then mixed with 180 µl of 0.1 % (w/v) trypan blue, and 
percentage staining determined with a haemocytometer. The osmotically balanced TMA-formate buffer produces trypan staining levels statistically 
indistinguishable from citrate-phosphate at pH 3.3, while the fully supplemented buffer is indistinguishable from untreated cells (P <0.05). Prewashing at 
pH 5.5 led to a slight rise in mean trypan staining, though this was only statistically significant to (P <0.05) for the osmotically balanced and fully 
supplemented buffer. * indicates no statistical difference to untreated controls (to a P value of <0.05); + indicates no statistical difference to pH 5.5 
prewash-only controls (to P <0.05). 
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Figure 4.11: Trypan determined cell death of JY and THP-1 cell lines following treatment with the buffers used in MHC class-II elution, and variants 
thereupon. 2 x 106 cells were washed in PBS, treated with buffers, and centrifuged to pellet the cells, following which cells were washed twice and re-
suspended in PBS. To determine percentage viability, 20 µl of each cell suspension was then mixed with 180 µl of 0.1 % (w/v) trypan blue, and the 
percentage staining determined with a haemocytometer. As with the TMA-formate this confirms the decreasing cell staining observed with osmotically 
balancing and supplementing the sodium-formate buffers (significant to P <0.05), and that the osmotically balanced and fully supplemented class-II elution 
buffer produces trypan staining levels statistically indistinguishable from isotonic citrate-phosphate at pH 3.3. Additionally treatment of cells with isotonic 
(0.9 % w/v) saline produced no increase in cell staining compared with untreated controls. * indicates no statistical difference to Storkus et al. (1993) pH 
3.3 citrate-phosphate buffer for elution of MHC class-I (to P <0.05). 
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4.4 Measurement of cell death by propidium iodide exclusion and flow 
cytometry 
 
Following on from trypan exclusion, a second cell stain, propidium iodide (PI) 
was employed to confirm minimal cell death and comparative staining between 
buffers. Like trypan blue, this fluorescent dye is excluded by live cells with intact 
membranes, but unlike trypan, the fluorescence of PI increases dramatically 
when intercalated between the guanine-cytosine base pairs of DNA or RNA 
(Suzuki et al., 1997, Le Goff, et al., 1992), and the non-visual assessment 
offered by flow cytometry reduces subjectivity. It was first utilised in conjunction 
with flow cytometry by Nicoletti et al. (1991) to determine apoptosis, though 
subsequent work indicated that it does not fully differentiate between apoptosis 
and necrosis, it is less sensitive to necrotic cell death due to the occurrence of 
random DNA fragmentation (Lecoeur, 2002). 
 
The viability of the three cell lines: K562-A3, JY and THP-1 were assessed by 
propidium iodide exclusion and flow cytometry following elution of MHC class-I 
class-II peptides by isotonic citrate-phosphate, and the TMA-formate and 
sodium-formate buffers (unsupplemented, osmotically balanced, or fully 
supplemented) (see figure 4.12). The resulting data largely supported that 
gathered by trypan exclusion, in that progressive supplementation of the TMA-
formate and sodium-formate buffers reduced the mean level of cell staining, 
though the levels of cell staining for the unsupplemented TMA-formate and 
sodium-formate buffers were significantly lower and higher than that found by 
trypan exclusion, while that observed in the untreated controls was significantly 
higher. Despite this, osmotic balancing of the TMA-formate buffer resulted in a 
level of mean cell staining comparable to that caused by isotonic citrate-
phosphate pH 3.3, while full supplementation brought mean cell staining close to 
that of the untreated controls, and below that caused by citrate-phosphate 
elution. Full supplementation of the sodium formate buffer also brought cell 
staining to a level statistically indistinguishable from the level caused by MHC 
class-I elution with citrate-phosphate pH 3.3. 
 
 
Whilst this data appears to support that gathered from the earlier trypan blue 
exclusion experiments, both assays rely on penetration and retention of a dye 
introduced after MHC-elution and rebuffering. It is conceivable that any 
significant damage to membrane integrity during MHC elution may be repaired
Chapter 4.0: Results 
MHC cell-surface elution buffers 
 141
 
Figure 4.12: Post-elution staining of K562-A3, JY and THP-1 cell lines with propidium iodide as determined by flow cytometry. 4 x 106 cells were washed 
in PBS, treated with elution buffers (JY and THP-1 were treated with both MCH class-I and class-II elution protocols, K562-A3 with class-I only), and 
pelleted by centrifugation, following which cells were washed twice in FACS buffer and re-suspended in 0.2 ml Isoton. 20 µl of 100 µg/ml propidium iodide 
was added to each cell suspension and incubated at room temperature (protected from light) for 2 minutes, prior to being washed by centrifugation and 
resuspension in Isoton prior to analysis by flow cytometry (calibrated with cells stained with W6/32 (MHC class-I) and a phycoerythrin-labelled secondary 
antibody as a positive colour control). Supplementation of buffers reduced cell staining to 8.6 – 10.1 % for the MHC class-I TMA formate buffer (significant 
to P < 0.05 when compared with unsupplemented or osmotically balanced buffers for each cell line), and 11.6 – 21.9 % for the MHC class-II elution buffer 
(significant to P < 0.05 when compared with unsupplemented buffers for both cell lines, and in the case of THP-1 when compared with the osmotically 
balanced buffer). This may be compared with the citrate-phosphate buffer (pH 3.3) which produced 9.8 – 16.8 % cell staining. * indicates no statistical 
difference to untreated controls (to a P value of <0.05); + indicates no statistical difference to pH 5.5 prewash-only controls (to a P value of <0.05). 
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by this point, or that the stress of a low pH environment may leave a 
subpopulation of cells in a fragile or proapoptotic state. Either could lead to a 
misreporting of cell integrity, and therefore an erroneous estimation of 
intracellular peptide contamination.  
 
 
4.5 Determination of relative protein and peptide loss as a marker for 
cell viability 
 
In order to further and more accurately determine relative cell integrity during 
MHC elution, and the benefits conferred by buffer supplementation, the modified 
BCA assay for estimation of peptide concentration (as detailed in chapter 3) was 
utilised to determine the relative proteinaceous content of MHC eluates from four 
cell lines (see figure 4.13).  
 
As stated in 3.1, the BCA assay largely relies on the co-ordination and reduction 
of Cu2+ to Cu1+ by the peptide bonds of a protein or peptide, leading to a 
concentration-dependent shift in absorbance at 562 nm. Therefore any agents 
which alter the rate of CuSO4 reduction will cause a variation in the final results. 
Unfortunately, the inclusion of glucose (a reducing sugar) and glutathione (a 
tripeptide) in the fully supplemented buffer lead to high peptide-independent 
levels of copper reduction that proved unfeasible to blank out, and therefore only 
the unsupplemented and osmotically balanced IMAC compatible buffers were 
compared with the isotonic citrate-phosphate elution buffer. The results largely 
corresponded with previous data, insofar as the osmotic balancing appeared to 
reduce the mean levels of peptide/protein loss (to a P value of <0.05) for both 
the TMA-formate and the sodium-formate buffers (except in the case of MHC 
class-II elution of the THP-1 cell line, following a prewash). Furthermore, the use 
of a pH 5.5 prewash step also reduced the levels of protein/peptide loss (to P 
<0.05) for all samples, with the exception of the K562-A3 cell line which 
exhibited an increase from 96.7 (± 2.6) µg/ml to 132.7 (± 2.5) µg/ml. 
 
Unfortunately as stated earlier, exact quantification of protein/peptide loss is 
difficult. This is partly due to inter-protein/peptide variation in BCA reactivity: as 
figure 3.9 in chapter 3.5 shows, tryptic digests of protein derived from the JY 
and T2.Dr4 cell lines show a minor difference, even after heat-denaturing in 
SDS-NaOH; and is further complicated by the lack of a 100 % accurate standard. 
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Figure 4.13: Peptide and protein loss from JY, K562-A3, T2.Dr4 and THP-1 cell lines 
following treatment with MHC elution buffers, including isotonic citrate-phosphate pH 3.3 
and the IMAC compatible TMA-formate pH 3.3 and sodium-formate pH 2 buffers 
(unsupplemented or osmotically balanced) either without (A) or with (B) first treating the 
cells with a pH 5.5 isotonic citrate-phosphate prewash. 10 x 106 cells were washed in 
PBS, treated with 0.6 ml of the elution buffers, and following centrifugation to pellet the 
cells the top 0.4 ml was aspirated and assessed for proteinaceous content by diluting 1:4 
in water and then mixing 1:1 with 2 % (w/v) SDS in 0.2 M NaOH, prior to heat-denaturing 
and analysis by peptide BCA (see chapter 3) against standards prepared in appropriate 
matrices. In each case osmotic balancing of class-I and class-II buffers significantly 
reduced intracellular peptide-loss from each cell line (to P < 0.05, n = 3), and the 
osmotically balanced buffers exhibited significantly lower peptide loss than treatment with 
the isotonic citrate-phosphate pH 3.3 (excepting MHC class-II elution of THP-1). * 
indicates statistical difference to unsupplemented results (P <0.05). 
B 
A 
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Additionally, the susceptibility of the BCA assay to reducing agents also raises 
the problem that loss of any intracellular reducing agents, including glucose and 
many intermediate products of the respiratory pathway, glutathione, and some 
ions such as magnesium (Lucarini and Kilikian, 1999), may lead to erroneous 
quantification of the proteinaceous content of each sample. Such variations are 
however characteristic of most protein/peptide assays and while the figures 
given for peptide-loss are therefore approximate, internal comparability is still 
valid. 
 
As citric acid is a chelating agent, known to interact with Cu2+ ions (Molinari et 
al., 2004) it is conceivable that this could also impair the assay results, however 
the linearity of the standard curves obtained (R2 values were obtained of 0.99 for 
the isotonic pH 5.5 buffer and 0.984 for the pH 3.3 buffer) imply that accurate 
measurement is possible. Furthermore, if the chelating properties of citric acid 
were to play a role, one would expect a drop in reactivity and a subsequent 
underestimation of peptide loss. In fact the comparative standard curves for pH 
3.3 and pH 5.5 indicate that the pH 5.5 buffer actually showed a lower BCA 
reactivity than the pH 3.3, producing an A570nm of 0.245 (SD ± 0.016) c.f. 0.284 
(SD ± 0.005), despite the lower ratio of citric acid : sodium phosphate3. This 
may be due to either a buffering effect between the sodium phosphate and the 
components of the BCA assay (in order of concentration: sodium carbonate; 
bicinichoninic acid; sodium-bicarbonate; NaOH; and sodium tartrate) or possibly 
due to an ionic interaction between the negatively charged phosphate groups 
and the positively charged sodium tartrate, which may in turn impair the 
solubilisation of the Cu1+ by the sodium tartrate, leading to a marginally lower 
colour formation. Though in either case the absorbance of the standard curves 
prepared in the other buffers were in a similar range, demonstrating that the 
citric acid is unlikely to be a major source of error. However, the unfortunate 
inability of the assay to compare the osmotically balanced buffers with the fully 
supplemented versions required further experimentation to confirm the trypan 
and PI staining data. 
 
 
 
                                                 
3
 As demonstrated in 3.1.3, the presence of sodium phosphate produces a higher inter-
peptide variation between the SQKx and YISx peptides (see figure 3.2.7), which may also go 
some way to explaining the difference observed between these two buffers. 
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4.6 Applicability of the ToxiLight Assay to determine cell permeability 
during MHC elution 
 
In order to further determine relative cell integrity during MHC elution, the 
ToxiLight non-destructive cell toxicity assay kit (Lonza Biosciences) was assessed 
for its applicability to measure cell-permeability during MHC elution. The assay 
operates on the principle of ATP production from ADP by adenylate kinase (AK) 
derived from cell culture supernatants, and subsequent measurement of ATP 
concentration using firefly luciferase and luciferin (Lonza, 2007). Therefore the 
difference in luminescence between samples is - cēterīs paribus - dependent on 
differential AK concentrations between samples and therefore differences in cell 
lysis or permeability. 
 
Human AK has an optimal pH of 7.4 – 7.5 (Hamada et al., 1982; Sheng, 1999), 
however, though most AKs have a reasonably broad pH range (Dinbergs and 
Lindmark, 1989; Ulschmid et al., 2004) it was uncertain whether the enzyme 
released into the elution buffer medium (pH 5.5, 3.3 and 2.0) would show 
compromised activity, and whether it would fully renature when brought back to 
pH 7.4. To test this, a solution of 200 units chicken muscle AK was mixed with 
isotonic citrate-phosphate and (unsupplemented) 25 mM TMA-formate buffers at 
pH 7.4, 5.5, and 3.34, and incubated at 4 °C for five minutes before being 
rebuffered to pH 7.4 with ToxiLight assay buffer (RT). 
 
Following exposure to the isotonic citrate-phosphate and 25 mM TMA-formate 
buffers at pH 3.3 a notable drop in AK activity was observed (see Figure 4.14). 
This was more pronounced in the case of the isotonic citrate-phosphate buffer, 
which dropped to 5.73 (SD ± 5.2) %, while the pH 3.3 TMA-formate buffer only 
dropped to 23.07 (SD ± 7.9) %. At pH 5.5 the difference between the two was 
similarly pronounced, with exposure to the citrate-phosphate buffer reducing AK 
activity to 60.57 (SD ± 15.5) % when rebuffered to pH 7.4, while the TMA-
formate was 82.78 (SD ± 9.5) %. Despite the broad pH range it appears that 
the AK fails to re-nature following exposure to low-pH buffers, making it less 
than ideal for the purposes of this assay, hence the supplemented and class-II 
elution buffers were not investigated. 
 
                                                 
4
 Note that pH 7.4, and 5.5 lie more than the 1 pH point outside the pKa of the TMA formate 
buffer, and thus a relatively poor buffering effect might be expected at these pHs.  
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The difference between the TMA-formate and isotonic citrate-phosphate buffers 
was investigated further by comparing the enzyme treated with pH 7.4 buffers 
(i.e. without a pH denaturing effect) with those treated with RPMI 1640 or the 
ToxiLight buffer alone. At pH 7.4 the 25 mM TMA-formate buffer demonstrated 
no statistically significant difference to the RPMI 1640 and ToxiLight buffer only 
controls, however the isotonic citrate-phosphate buffer displayed only 72.63 (SD 
± 5.4) % activity (to P <0.01). This, and the relatively lower activity displayed 
by all the isotonic citrate-phosphate buffers, might be due to both the relative 
strength of the isotonic citrate-phosphate buffer compared to the 25 mM TMA-
formate, and the broader pKa range of the citrate-phosphate buffers (the 
phosphate has multiple acidic groups and thus three dissociation constants). The 
isotonic citrate phosphate is therefore a much greater buffer at pH 7.4 and pH 
5.5, and has a higher concentration (and thus buffering capacity) throughout the 
pH range examined, and so it may be argued that this allowed it to fully 
denature the AK, while the TMA-formate failed to do so. 
 
However, the isotonic citrate-phosphate buffer also possesses chelating 
properties which, given that the luciferase assay is magnesium-dependent, may 
be ablating the assay luminescence, and would explain why the assay failed to 
show full AK activity following exposure to the citrate-phosphate buffer even 
when the buffer pH matched the optimum activity. As the pH of the buffer drops, 
the citric acid concentration increases, producing a greater impact on the 
luciferase assay as well as denaturing the AK enzyme, and reducing its activity. 
This double-effect complicates adoption of the assay for the purpose of 
determining cell permeability during MHC elution, and it was therefore decided 
not to pursue the ToxiLight assay any further. Furthermore there were concerns 
that measurement of AK-loss may not be comparable between different cell lines 
without first quantifying and identifying the activity and distribution of the 
different isoforms within each cell line studied (which may change as a result of 
stress, for example as a response to alteration of the cell membrane potential, 
e.g. when subjected to mild acid elution) (Abanese, et al., 2009), and that use of 
AK as a marker for cell permeability may lead to underestimation of intracellular 
peptide contamination, given the relative size of the adenylate kinases (194 – 
562 amino acids depending on the isoform) (von Zabern et al., 1976; Van 
Rompen et al., 1999) compared with MHC class-I and class-II peptides. 
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Figure 4.14: Luciferase-determined post-elution adenylate kinase (AK) activity assayed 
by the ToxiLight cell viability assay. 0.455 units of AK (n = 4) was denatured in either 
TMA-formate or citrate-phosphate buffers across a pH range, and brought back to pH 7.4 
by diluting in ToxiLight assay buffer. This was then mixed with AK detection reagent, 
incubated for five minutes at 37 °C, and the sum luminescence read using a FluoStar 
OPTIMA fluorimeter / luminometer set to gain 3 over 10 cycles (11.4 minutes) at 22 °C. 
Data is expressed as a percentage activity of that treated with pH 7.4 buffers. Error bars 
indicates SD, * indicates statistical significance at P < 0.05) as determined by Mann-
Whitney U-test. 
 
Figure 4.15: Luciferase-determined adenylate kinase (AK) activity assayed by the 
ToxiLight cell viability assay following exposure to three buffers at pH 7.4. 0.455 units of 
AK (n = 6) was exposed to RPMI 1640, 25 mM TMA-formate or isotonic citrate-phosphate 
buffers all at pH 7.4, and then diluted in ToxiLight assay buffer (also pH 7.4). This was 
then mixed with AK detection reagent, incubated for five minutes at 37 °C, and the sum 
luminescence read using a FluoStar OPTIMA fluorimeter / luminometer set to gain 3 over 
10 cycles (11.4 minutes) at 22 °C. Error bars indicates SD, ** indicates statistical 
significance at P <0.01) as determined by ANOVA. 
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4.7 Use of ATP leakage as a marker for cell permeability during MHC-
elution 
 
It was therefore decided to measure ATP-loss directly using the ATP-monitoring 
reagent found in the ViaLight cell cytotoxicity assay (Lonza Biosciences). While 
this assay is normally applied to lysates to determine total cellular ATP, it was 
considered that any permeability of the plasma membrane large enough to allow 
intracellular peptides to contaminate a MHC eluate would also be large enough to 
allow the relatively much smaller ATP molecules to migrate from the cytoplasm 
to the supernatant. Firefly luciferase bioluminescence is considered a fast and 
highly sensitive ATP assay with high reproducibility (Karl, 1980; Zhao and 
Haslam, 2005). 
 
 
4.7.1 Optimisation of buffer compatibility and buffer : sample ratios 
 
Given the possibility for the buffer pH to denature the luciferase, the post-elution 
supernatant would require full rebuffering prior to the addition of the ADR. Two 
buffers: Tris and HEPES were assessed for their compatibility with the assay at 
high molarities (0.2 - 1 M) each containing 5 µl 25 µM ATP. As can be seen in 
figure 4.16, increasing the strength of either Tris or HEPES buffers leads to a 
corresponding decrease in assay sensitivity, though this decrease is greater in 
the case of Tris, which has previously been reported to inhibit other enzymatic 
processes (Oda et al., 1988; Desmarais et al., 2002; Ghalanbor et al., 2008). 
Both Tris and HEPES are known to inhibit carbamoyl-phosphate synthase activity 
(Lund and Wiggins, 1987), again with Tris leading to greater inhibitor than 
HEPES, though in these cases neither was tested at the high molar 
concentrations required here. It is also worth noting that at low buffer 
concentrations, i.e. below 10 mM HEPES-HCl or 5 mM Tris-acetate, sum 
luminescence was statistically indistinguishable from 5 µM ATP in water. 
 
0.2 M HEPES was decided upon, as this gave a high buffering capacity with a 
comparatively modest trade-off in sensitivity: ATP assayed in 0.2 M HEPES 
produced luciferase bioluminescence equivalent to 80.45 (SD = ± 0.9) % of an 
‘unbuffered’ control (the unbuffered ATP was assayed with ATP detection reagent 
working solution containing 0.625 mM Tris-acetate pH 7.8), while reducing the 
concentration of HEPES to 0.05 M only increased the bioluminescence to 87.75 
(SD = ± 2.44) % (see figure 4.16). 
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The elution buffers were then titrated against 0.2 M HEPES pH 7.8 to determine 
the optimum ratios of elution buffer : HEPES which would produce a pH of 7.8. A 
ratio of approximately 1 : 2 was found for the TMA-formate buffers, while the 
isotonic citrate-phosphate and sodium-formate buffers required approximately 1 : 
4 and 1 : 5 respectively, which was confirmed by pH probe. 
 
  
 
 
To ensure full rebuffering these were increased to 1:4 for the TMA-formate 
buffers and 1 : 9 for the citrate-phosphate and sodium-formate buffers. Short 
standard curves of ATP were assayed in the elution buffers following rebuffering 
with HEPES for linearity and sensitivity, and whilst the elution buffers did appear 
to effect assay sensitivity, linear standard curves were produced in all cases, all 
with R2 values greater were than 0.99 (see figure 4.17). The effect of osmotic 
balancing agents and supplements on the assay appeared to be negligible. 
 
 
Figure 4.16: Sum luminescence produced by firefly luciferase in the presence of ATP 
buffered in increasing molarities of Tris or HEPES pH 7.8. Five µl of 25 µM ATP was 
mixed with 75 µl of either buffer across a standard curve of molarity from 0.02 - 1 M 
Tris/HEPES at pH 7.8. To these 120 µl of ATP detection reagent was added and the sum 
luminescence read using a FluoStar OPTIMA fluorimeter / luminometer set to gain 6 over 
20 180-second cycles (60 minutes) at 22 °C. n = 5, error bars indicate SD, */** denote 
statistical significance to P < 0.05 / < 0.01 respectively, as measured by T-test. 
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4.7.2 Determination of relative intracellular ATP content 
 
Before loss of ATP during MHC elution could be studied, the intracellular ATP 
content of the four cell lines studies was investigated. Cells were heat-killed in 
5 % (v/v) acidified methanol, and supernatants clarified by centrifugation prior 
to being buffered and assayed as described in 2.3.4.5.1. 
 
A noticeable difference in ATP content was observed between the cell lines. The 
immortalised JY cell line and the hybridoma T2.Dr4 both exhibited intracellular 
ATP levels of 3.867 (± 0.13) and 3.779 (± 0.17) fmol/cell, whist the leaukaemic 
lines K562-A3 and THP-1 both contained a much higher concentration of ATP – 
17.189 (± 0.29) and 14.9 (± 0.35) fmol/cell (see figure 4.18). 
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Figure 4.17: Typical standard curves of ATP concentration against sum luminescence in 
the various MHC class-I and class-II elution buffers. Various concentrations of ATP  (n = 
4) were prepared in ddH2O, isotonic citrate-phosphate pH 3.3, 25 mM TMA formate pH 
3.3 (+/- osmotic agents and supplements) or 50 mM sodium-formate pH 2 (+/- osmotic 
agents and supplements), then rebuffered with 0.2 M HEPES pH 7.8 as described in 
2.3.4.5.5 producing ATP standard curves from 0.5 – 5 µM final concentration, and 
assayed in triplicate by the addition of 175 µl of ATP detection working reagent and the 
sum luminescence read using a FluoStar OPTIMA fluorimeter / luminometer set to gain 6 
over 20 x 120-second cycles (40 minutes) at 25 °C. Error bars indicate SD. 
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While somatic cells are commonly described as containing approximately 2 fmol 
ATP per cell (Wettermark et al., 1975; Harber, 1982; Lundin et al., 1986; Stanley 
et al., 1976) the actual value can vary greatly. Mouse embryo fibroblast cells 
contain 6.6 fmol ATP per cell (Bershadsky and Gelfand, 1981), while chick 
embryo spinal astrocytes and dorsal root neurons are known to contain 
approximately 7.9 and 11.9 fmol per cell (Schousboe et al., 1970). With regard 
to myeloid and lymphoid cells/cell lines, Tarnok and Tarnok (1987) report 1.22 
(S.D. ± 0.18) fmol ATP per human neutrophil, while murine perinoteal 
macrophages appear to contain only 0.5 fmol5 (Loike et al., 1979). Little data is 
available for suspension cell lines, however with regard to adherent lines when in 
log phase growth the HeLa cell line is known to contain 0.79 (± 0.09) fmol ATP 
per cell (Karu et al., 1995); the human breast-cancer cell line MDA-231 contains 
6 (± 0.8) fmol ATP (Geier et al., 1994); the human lung adenocarcinoma line 
A549 displays as much as 100 fmol ATP/cell (Chi and Pizzo, 2006); while the ATP 
content of the murine Erlich ascites tumour cell line ranges from ~ 7 to >30 
fmol/cell as the cell goes through the mitotic cycle (Skog et al., 1987). A Friend-
                                                 
5
 Though macrophages are thought to contain a second high-energy phosphate pool in the form of 
creatine phosphate from which the cellular ATP stores are rapidly replenished (Loike et al., 1970). 
 
Figure 4.18: Intracellular ATP content of four suspension cell lines. 5 x 106 cells were 
lysed by for 2 x ten minute incubations at 95 °C and the supernatant clarified by 
centrifugation at 20,800 r.c.f. for 30 mins. 5 µl supernatant was buffered by the addition of 
20 µl 5 mM Tris-acetate pH 7.8. To these 120 µl of ADWR was added and the sum 
luminescence read using a FluoStar OPTIMA fluorimeter / luminometer set to gain 6 over 
15 x 240-second cycles (60 minutes) at 25 °C. n = 3, error bars indicate SD, ** denotes 
statistical significance to P < 0.01, as measured by ANOVA. 
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virus induced erythroleukaemic murine cell line on the other hand has been 
recorded as containing 0.0357 fmol ATP per cell6 (Hobbs et al., 1995), while the 
Raji lymphoma7 cell line is recorded as containing only 0.0085 fmol ATP/cell8 
(Chignola et al., 2007). 
 
It is easy to conclude from this data that the levels of intracellular ATP may vary 
considerably between cell types, and likely across the cell-cycle, though some of 
the variations between cell types are undoubtedly a consequence of different 
approaches to cell lysis, as there is a trade-off to be made between maximum 
ATP release (Bagnara and Finch, 1972) and the effect of interefering substances 
(e.g. solvents, surfactants, detergents, buffers or antioxidants) (Betz, 2009) on 
the assay. Taking this into consideration it is still notable that the two leukaemic 
cell lines studied exhibit much higher ATP content than the EBV immortalised JY 
cell line and T2.Dr4 hybridoma. 
 
 
4.7.3 Effect of prewashing and buffer supplementation on ATP loss 
during MHC-elution 
 
Prior to analysis of the four cell lines, the effect of an isotonic citrate-phosphate 
prewash on MHC class-I elution of the K562-A3 cell line using either osmotically 
balanced or fully supplemented 25 mM TMA-formate pH 3.3. As previously 
observed, full supplementation of the elution buffer led to a statistically 
significant reduction (P value = < 0.05) in cellular ATP loss, as did prewashing 
the cells with isotonic citrate-phosphate pH 5.5. Either approach was found to 
reduce the level of ATP loss, while prewashing followed by elution with the fully 
supplemented TMA-formate buffer reduced ATP loss to 13.3 % of the osmotically 
balanced buffer alone (see figure 4.19). 
 
 
 
 
 
                                                 
6
 Based on the figure of 0.181 ng ATP (m.w. 507.18) per 104 cells. 
7
 Derived from a human B lymphoblastoid Burkitt’s lymphoma (Karpova et al., 2005) 
8
 Based on the figure of 4.32 fg ATP per cell. 
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4.7.4 Determination of comparative intracellular ATP loss during MHC 
elution 
 
After optimisation, ATP loss from the four cell lines during MHC elution with 
unsupplemented or fully supplemented buffers, or the isotonic citrate-phosphate 
buffer utilised by Storkus et al. (1993) was analysed. 5 x 106 cells were 
subjected to MHC elution, the eluates clarified by centrifugation and rebuffered 
with 0.2 M HEPES (in a ratio of 1:4 for TMA buffers and 1:9 for citrate-phosphate 
and sodium-formate buffers) as described in 2.4.4.5.4 before being assayed in 
replicates of 25 µl by the addition of 175 µl ADR working solution. ATP loss (amol 
per cell) was then calculated using a standard curve prepared in the same matrix 
(see figure 4.20) and expressed as a percentage of the total cellular ATP 
previously determined (see figure 4.21). 
 
Again, the supplementation of the 25 mM TMA-formate buffer appeared to have 
a large and statistically significant (P value = < 0.05) impact on cell permeability, 
 
Figure 4.19: Intracellular ATP loss from the CML cell line K562-A3 when eluted with 
either osmotically balanced or fully supplemented 25 mM TMA formate buffers at pH 3.3, 
with or without subjecting the cells to an isotonic citrate-phosphate pH 5.5 prewash prior 
to MHC elution. Data is expressed as amol ATP loss/cell. 5 x 106 cells were subjected to 
MHC elution as described in 2.4.4.5, the eluates rebuffered with HEPES and analysed in 
replicates of 25 µl, to which 175 µl of ADWR was added and the sum luminescence read 
using a FluoStar OPTIMA fluorimeter / luminometer set to gain 6 over 15 x 240-second 
cycles (60 minutes) at 25 °C. ATP concentration was calculated using a standard curve of 
ATP prepared in appropriate matrices. n = 5, error bars indicate SD, ** denotes statistical 
significance to P < 0.01, as measured by T-test. 
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Figure 4.20: Absolute ATP loss from four cell lines when subjected to different MHC 
elution protocols. 5 x 106 cells were subjected to MHC elution as described in 2.4.4.5, the 
eluates rebuffered with HEPES and analysed in replicates of 25 µl, to which 175 µl of 
ADWR was added and the sum luminescence read using a FluoStar OPTIMA fluorimeter 
/ luminometer set to gain 6 over 15 x 240-second cycles (60 minutes) at 25 °C. ATP loss 
per cell was determined using a standard curve prepared in identical matrices, and 
revealed a consistent reduction in ATP-leakage (to P < 0.01) from following 
supplementation of the TMA-formate buffer, while for the class-II elution, supplementation 
produced a drop in ATP loss (to P < 0.05) for all but THP-1. n = 4, error bars indicate SD, 
*/** denotes statistical significance between supplemented and unsupplemented buffers 
to P < 0.05 / < 0.01, as measured by T-test. 
 
Figure 4.21: Percentage cellular ATP loss from four cell lines when subjected to different 
MHC elution protocols. Data displayed in Figure 4.20 expressed as a percentage of the 
cellular ATP content of the four cell lines (as determined in Figure 4.18). n = 4, error bars 
indicate SD, */** denotes statistical significance between supplemented and 
unsupplemented buffers to P < 0.05 / < 0.01, as measured by T-test. 
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cutting ATP-loss to an average of one tenth that of the unsupplemented buffer. 
However as may be seen from figure 4.20, this effect varied significantly from 
cell line to cell line, with the permeability of the THP-1 cell line showing the 
greatest elasticity to supplementation (ATP loss fell to 0.93 % that produced by 
the unsupplemented TMA-formate buffer) and the K562-A3 cell line exhibiting 
the lowest elasticity (26.37 %); while the ATP loss from the JY and T2.Dr4 cell 
lines exhibited a reduction to 7.46 % and 3.11 % when compared to the 
unsupplemented buffer. 
 
Supplementation of the sodium-formate buffer on the other hand did not 
produce large shift in cell permeability; the JY and THP-1 cell lines showed the 
greatest reduction, with ATP falling to 79.07 and 81.42 % respectively (both to P < 
0.01).  However the K562 A3 line only showed a 5.37 % drop in ATP loss (P < 
0.05), while the ATP release from the T2.Dr4 hybridoma line remained 
statistically indistinct from treatment with the unsupplemented buffer. 
 
When the fully supplemented TMA-formate buffer is compared with the isotonic 
citrate-phosphate elution buffer (both pH 3.3), the results vary considerably, and 
mostly in the favour of the Storkus’ method. Whilst treating the T2.Dr4 and THP-
1 cell lines with the fully supplemented TMA-formate buffer leads to 128.6 % 
and 23.5 % ATP loss compared with the citrate-phosphate buffer, treatment of 
the K562-A3 cell line with fully supplemented TMA-formate results in 8.1 times 
the level of ATP loss than that caused by the pH 3.3 citrate-phosphate approach, 
while the ATP loss found in the JY cell line is four orders of magnitude higher 
than that caused by treatment with the isotonic citrate-phosphate buffer. The 
ATP loss caused by treatment with the fully supplemented pH 2 sodium-formate 
buffers ranges from a minimum of 25 x that caused by the pH 3.3 citrate-
phosphate buffer (K562-A3), up to a maximum of 29,000 x the ATP loss (JY), a 
somewhat suspect figure. 
 
When the luminometry data was examined however, it is notable that the lowest 
readings were in the low nanomolar range, possibly outside of the optimum 
range for the assay, and certainly outside of the determined linearity of the 
assay. To test this a second set of standard ATP curves were prepared in 0.9 % 
(w/v) saline, isotonic citrate-phosphate pH 3.3, and 25 mM TMA-formate pH 3.3, 
with or without supplementation. These were then diluted in 0.2 M HEPES 
producing a final concentration of ATP from 20 to 100 nM (see figure 4.22). It is 
notable that all of the standard curves retain linearity (R2 = > 0.99) with the 
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exception of the isotonic citrate-phosphate (R2 = > 0.96), which on inspection 
reveals that at 20 nM the sum luminescence is indistinguishable from 0 nM ATP. 
 
 
 
This lack of linearity and apparent ablation of the assay at low ATP 
concentrations may well be a consequence of the chelating properties of the 
citric acid, and calls into question the values of ATP loss recorded during 
treatment with the isotonic citrate-phosphate elution buffer, implying that cell 
permeability during MHC elution by the Storkus approach may be higher than 
the figures suggested by this experiment. However, the TMA-formate buffers 
appear to retain their linearity at these concentrations, suggesting that the low 
ATP losses recorded with the bioluminescent assay reflect an actual reduction in 
cell permeability when cells are treated with the fully supplemented TMA-formate 
MHC class-I buffer. In addition, the determination of ATP loss as a percent of the 
cellular pool depend on the lysis method producing close to 100 % ATP release, 
and whilst the cellular ATP content appears consistent between replicates 
(though different lysis methods were not compared), there remains the 
possibility that some lines may show greater sensitivity to heat-lysis than others. 
 
Figure 4.22: Standard curves of ATP concentration against sum luminescence in MHC 
class-I elution buffers (n = 5). Various concentrations of ATP were prepared in 0.9 % 
(w/v) NaCl, 25 mM TMA formate pH 3.3 (+/- osmotic agents and supplements) or isotonic 
citrate-phosphate pH 3.3. Each standard was rebuffered with 0.2 M HEPES pH 7.8 (as 
described in 2.4.4.5.4) producing ATP standard curves from 0.02 – 0.1 µM final 
concentration, and assayed in triplicate by the addition of 175 µl of ATP detection working 
reagent and the sum luminescence read using a FluoStar OPTIMA fluorimeter / 
luminometer set to gain 6 over 20 x 120-second cycles (40 minutes) at 25 °C. 
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4.8 Post MHC-elution population growth and potential for serial 
elutions  
 
Storkus et al., (1993) describe that following MHC class-I elution with isotonic 
citrate-phosphate, cells briefly downregulate MHC expression, within 10-18 
hours antigen presentation is fully restored, following which a second MHC class-
I elution may take place. 
 
In order to test the potential for serial elutions, it was required that post-elution 
population viability (c.f. death of membrane permeability) first be established. 
Cells were subjected to elution protocols as detailed in section 2.3.2, washed 
twice in PBS and twice in RPMI 1640 before being recultured in a small volume of 
complete RPMI 1640, under normal cell culture conditions. This was observed 
visually on a daily basis to record any colour change to the phenol red pH 
indicator present within the RPMI 1640 which would indicate a drop in pH due to 
media depletion/build up of waste products. In each case the PBS-treated 
cultures showed a change in media colour within 48 hours, while those treated 
with MHC class-I elution buffers (with or without supplementation) also 
demonstrated a pH change within the seven-day period (see table 4.4). However 
those treated with the MHC class-II elution buffers invariably failed to 
demonstrate any change in media colour, and upon inspection under the 
microscope at 100x magnification, appeared highly granulated with a significant 
degree of debris, an appearance consistent with non-viable populations.  
 
In order to further quantify the growth rates of cell populations following MHC 
class-I elution, the tritiated thymidine incorporation assay was employed. 
Following MHC class-I elution (as above) populations of JY, K562-A3 and THP-1 
were recultured in complete RPMI 1640 for 48 hours to allow a sufficient 
recovery window. They were then incubated for a further 18 hours in the 
presence of 37 MBq/µl [3H]-thymidine9, following which scintillation counts were 
taken. During mitosis the thymidine is incorporated into the DNA of the daughter 
strands (as unlike the other nucleotides, thymidine does not occur in RNA) and 
once the background is eliminated, the resulting radioactive signal from the 
cultured population correlates well with cell division (Hughes et al., 1958), it may 
also be influcenced though other factors such as mitochondrial replication 
(Parsons, 1965). 
                                                 
9
 Performed with the aid of Dr. Morgan Mathieu (NTU) and Dr. Stephanie Laversin (NTU). 
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In each case the results obtained indicated a massive decrease in cell 
proliferation following MHC class-I elution (Figure Table 4.5). While the isotonic 
citrate-phosphate buffer outperforms the TMA-formate buffers by far in this 
regard (with the exception of the K562-A3 cell line), the post-elution 
proliferation rate for each cell line is still below 6 % (S.D. = ± < 1.26) that of 
PBS-treated cells. Supplementation and osmotic balancing of the TMA-formate 
buffer appeared to have no significant impact on post-elution cell proliferation, 
with all three lines demonstrating less than 0.5 % (S.D. = ± < 0.09) of the 
proliferative capacity of their untreated counterparts (see Table 4.5). 
 
 Cell line 
 JY K562-A3 T2.Dr4 THP-1 
PBS-treated control + + + + 
Heat-killed control - - - - 
Isotonic citrate-phosphate pH 5.5 + + + + 
Isotonic citrate-phosphate pH 3.3 + + + + 
25 mM TMA-formate pH 3.3 + + + + 
25 mM TMA-formate pH 3.3 
(osmotically balanced) + + + + 
25 mM TMA-formate pH 3.3  
(fully supplemented) + + + + 
50 mM sodium-formate pH 2.0 - - - - 
50 mM sodium-formate pH 2 
(osmotically balanced) - - - - 
50 mM sodium-formate pH 2.0 
(fully supplemented) - - - - 
 
Table 4.4: Colour change observed in cultures of JY, K562-A3, T2.Dr4 and THP-1 cell lines 
when recultured in complete RPMI 1640 following treatment with MHC elution protocols (n = 
3). 2 x 106 cells were subjected to MHC elution as per 2.4.5. Isotonic citrate-phosphate pH 5.5 
was used as a prewash before eluting MHC class-I with TMA-formate buffers, while citrate-
phosphate pH 3.3 was used prior to eluting MHC class-II with sodium-formate buffers. 
Following elution cells were washed twice in PBS and twice in RPMI 1640 before being 
resuspended in 5 ml complete RPMI 1640 media and recultured in 6-well plates under 
standard conditions. Media colour was observed visually for a period of 7 days. 
 
Trypan-blue staining of cells 48-hours after MHC class-I elution demonstrated 
high population fragility in the unsupplemented TMA-formate treated cultures: 
73.49 – 83.88 % (S.D. = ± < 3.31) of each population failed to exclude the dye. 
However, in these cases osmotic balancing and further supplementation did 
appear to affect cell staining, and in each case led to a drop in trypan staining of 
23.98 – 29.18 % (± < 3.15) and of 35.87 – 37.45 % (± < 2.49) respectively (as 
a percentage of trypan blue stained cells derived from treatment with the 
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unsupplemented buffer). The isotonic citrate-phosphate on the other hand led to 
a much lower trypan staining of 15.09 – 19.42 % (± < 1.57) (see figure 4.23). 
 
 
An inverse Spearman’s correlation coefficient of -0.774 (to a P value of <0.01) 
was found between trypan staining and proliferation rate for the cell populations 
assayed, dropping to a weaker coefficient of -0.562 if the untreated controls 
were excluded. As would be expected from the [3H]-thymidine incorporation 
assay results, no correlation was found between trypan staining and proliferation 
rate when the data for cells treated with the TMA-formate buffers only were 
analysed. 
 
This lies somewhat at odds with the data reported by Storkus et al., (1993) 
which suggested that following elution with isotonic citrate-phosphate, full 
antigen presentation is restored within 10 – 18 hours, allowing serial elutions.  
Scintillation counts for each cell line following treatment (± S.D). 
Treatment JY K562-A3 THP-1 
PBS-treated cells 18737.33        
(±2538.97) 
68357 
(±13378.71) 
39532 
(±5172.10) 
Isotonic citrate-phosphate pH 3.3 703 
(±85.02) 
145 
(±62.22) 
2273 
(±499.22 
25 mM TMA-formate pH 3.3 68.33** 
(±17.47) 
61.33* 
(±10.41) 
72** 
(±3.61) 
25 mM TMA-formate pH 3.3 
(osmotically balanced) 
43** 
(±7.81) 
64.33* 
(±11.93) 
61.33** 
(±1.53) 
25 mM TMA-formate pH 3.3 
(fully supplemented) 
81.67** 
(±15.63) 
75 
(±21.00) 
66.33** 
(±20.55) 
 
Table 4.5: Scintillation counts of JY, K562-A3 and THP-1 cell line populations 48 hours 
after treatment with MHC class-I elution buffers, and following 18 hours culture in tritated 
thymidine-containing media. 1 x 106 cells were subjected to MHC elution as per 2.3.2. 
Isotonic citrate-phosphate pH 5.5 was used as a prewash before eluting MHC class-I with 
TMA-formate buffers. Following elution cells were washed twice in PBS and twice in 
RPMI 1640 before being resuspended in 10 ml complete RPMI 1640 media and 
recultured in 6-well plates under standard conditions for 48 hours. After this incubation 
cells were plated out in triplicate into a 96-well microplate, and treated with [3H]-thymidine 
to 37 MBq/µl and incubated for 18 hours prior to harvesting onto 96-well filter plate; to 
which 40 µl scintillation fluid was added per well, following which a Top-Count Scintillation 
counter was utilised to perform counts over 1 minute/well. n = 3, error bars indicate SD, 
*/** denotes statistical significance between supplemented and unsupplemented buffers 
to P < 0.05 / < 0.01, as measured by T-test. 
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This data suggests that even with the isotonic citrate-phosphate buffer, the 
proliferative capacity of eluted cells is severely impeded, and therefore any 
subsequent MHC-elutions may characterise an altered presentome. Furthermore 
it is conceivable that multiple elutions may lead to higher levels of cell lysis and 
contamination with intracellular peptides, and even should a return to log-phase 
growth be achievable through a prolonged return to culture, there remains the 
issue of potential selective pressure on the cultured population. The 
comparatively much lower proliferation rate of cells treated with the TMA-
formate MHC class-I elution buffers also therefore precludes any possibility of 
multiple elutions when these buffers are employed. 
 
 
Figure 4.23: Trypan-blue staining of JY, K562-A3 and THP-1 cell lines 48 hours after 
treatment with MHC class-I elution buffers. 1 x 106 cells were subjected to MHC elution 
as per 2.3.2. Isotonic citrate-phosphate pH 5.5 was used as a prewash before eluting 
MHC class-I with TMA-formate buffers. Following elution cells were washed twice in PBS 
and twice in RPMI 1640 before being resuspended in 10 ml complete RPMI 1640 media 
and recultured in 6-well plates under standard conditions for 48 hours, following which 
cells were pelleted and resuspended in PBS. To determine percentage cell death, 20 µl 
of each cell suspension was then mixed with 180 µl of 0.1 % (w/v) trypan blue, and the 
stained and total number of cells counted using a haemocytometer. n = 3, error bars 
indicate SD, ** denotes statistical significance when compared with osmotically balanced 
or fully supplemented TMA-formate buffers to P < 0.01, as measured by ANOVA. 
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It was therefore decided to avoid serial MHC elutions, especially given that in 
add7ition to the above factors, reculturing is not possible for populations which 
have also been subjected to elution of MHC class-II peptides with the sodium-
formate buffers. 
 
 
4.9  Discussion 
 
Though the pH-dependent disassociation of MHC-restricted peptides from the 
class-I complex has been utilised for almost 20 years (Storkus et al., 1993), little 
in the way of method development has occurred, and the technique presents 
largely the same problems for downstream analysis today as it did in the early 
nineties, namely limited compatibility with chromatographic methods, and the 
potential for acid-induced cell lysis or disassociation of membrane associated 
non-MHC peptides to lead to sample contamination. 
 
As this chapter demonstrates, a TMA-formate buffer may be used as an 
alternative to isotonic citrate-phosphate for elution of MHC class-I peptides, 
though as illustrated, the high water potential of the buffer leads to high cell 
lysis, though this may be abrogated to some extent by the inclusion of 0.3 M 
sucrose and 0.45 M KCl as osmoticants, which appear to reduce overall cell lysis 
(though to differing extents depending on the assay by which cell 
death/permeability is measured). Sucrose may confer a secondary benefit in the 
form of cushioning during centrifugation (a feature which often lends it to 
organelle preparations by ultracentrifugation) (Dr Alan Hargreaves and Dr 
Shakthi Dookie, NTU, Pers. Comm., 2008). Following on from this, the inclusion 
of 10 mM D-glucose, 2 mM myo-inositol and 1 mM reduced glutathione also 
allowed a reduction in cell staining/permeability to the point where by all 
measurements bar ATP-loss it led to less cell death/permeability than the 
isotonic citrate-phosphate elution buffer, and in several cases became 
statistically indistinguishable from the untreated (or prewashed-only) controls. 
 
The role that D-glucose plays in reducing cell permeability/lysis suggests that 
surviving low pH stress is an energy-dependent process. Locke’s solution, an 
early media for cell culture, often (though not always) contained glucose at 
varying concentrations (Rous and Turner, 1916), though sadly Pappenheimer 
(1917) did not state the components of his Locke’s solution used for culture of 
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lymphocytes. However the addition of sucrose and glucose to Locke’s solution is 
known to improve the long-term viability of erythrocytes, and dextrose is also 
known to confer a survival benefit, especially in samples with heavy handling 
(and which may also be of benefit here). 
 
In the case of erythrocytes, the inclusion of citric acid in Locke’s solution seems 
to confer a survival benefit, though this benefit is not consistent between species 
and may also heavily modulate the benefit or otherwise of other additives such 
as glucose or dextrose (Rous and Turner, 1916), possibly explaining why the 
addition of the non-osmotic supplements to the citrate-phosphate Storkus buffer 
or prewash buffer did not appear to reduce cell staining. Hendry (1951) noted 
that suspension of erythrocyes in solutions of 12 mM of glucose delayed 
haemolysis, especially when coupled with cooling below room temperature, and 
it is possible that that the inclusion of glucose merely delays a significant 
percentage of the cell lysis until after elution has taken place (a theory 
somewhat supported by the relatively high trypan staining of the fully 
supplemented buffer 48 hours post elution (see figure 4.23). It is possible that 
titrating the concentrations of the various supplements against cell staining 
might lead to reductions in isotonic citrate-phosphate elution mediated cell death, 
though given the downstream chromatographic requirements this might not 
facilitate the further aims. 
 
The role of inositol in minimising post-elution lysis is less clear. The best known 
role of the molecule is as the basis for the intracellular secondary messenger 
compounds of inositol phosphates (e.g. IP3), which have a number of functions, 
including modulation of membrane potential (Berridge, 1988) and intracellular 
Ca2+ levels (Gerasimenko et al., 2006). Silver et al. (2002) report that under 
hypertonic conditions the addition of myo-inositol to rat brains leads to a 
concomitant increase in intracellular myo-inositol, reducing osmotic stress. Each 
of these functions may be a potential source of the reduction in cell fragility 
during MHC elution when myo-inositol is added to the TMA-formate and sodium-
formate elution buffers. Additionally myo-inositol has been shown to reverse D-
glucose-induced reductions in cell proliferation (Ziyadeh et al., 1991); though in 
this case of this research cells underwent a far shorter exposure period (< 5 
minutes), it is possible that it may also contribute to a reduction in any glucose-
mediated cell-shock that may occur. 
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Like inositol, glutathione also has numerous functions, though it is known first 
and foremost as an antioxidant (Larbi et al., 2010), it is also capable of 
inactivating many toxins and carcinogens, both organic and inorganic, and acting 
as a cofactor for numerous peroxidases. It is one of the most abundant 
antioxidants, reaching cellular levels in the milimolar range in humans, though 
never higher than ~ 10 mM (in the liver) (Meister, 1995). Related to it’s 
antioxidant activity, it is a potent scavenger of free radicals, and donator of 
electrons and sulphydryls, and is also involved in glutamate synthesis and the 
conversion of ribonucleotides into deoxyribonucleotides (Kidd, 1997). As with 
glucose however, it is suggested that the most common role: the antioxidant 
activity, may provide the beneficial effect (though it may also be ameliorate the 
theoretical release of waste products as a response to pH stress). Glutathione 
has already proven its protective effects towards tumour cells (which are often 
glutathione rich) (Arrick et al., 1982), though it is interesting that the optimum 
concentration of this supplement was so low, given the far higher cellular 
concentrations discussed above (Kidd, 1997), and that the low pH of the MHC 
elution buffers would (at RT) be a pro-oxidative environment. Indeed, the yeast 
Candida utils up-regulates glutathione synthesis when exposed to low pH 
environments (Nie et al., 2005), though obviously this is a different biological 
system. 
 
Despite the efforts to minimise cell death/leakage it undoubtedly has not been 
eliminated entirely given the pH stress that it necessitates, and it is probable 
that alterations to the methodology may further drive down cell lysis (as well as 
potentially counteracting growth inhibition). For example inclusion of metal ions 
such as Ca2+ in low-pH buffers has been shown to reduce (PI determined) 
sensitivity to pH stress in Arabidopisis thaliana (Koyama et al., 2001). It is 
conceivable that similar effect might be achievable here, though complications to 
downstream chromatography must be avoided. Moore and Hood (1993) 
recommended the addition of Hetastarch (esterified amylopectin-containing 
starch) to their modified low-pH RPMI 1640 medium, and therefore the addition 
of it or other non-proteinaceous colloids such as dextrose to the elution buffers 
may further reduce cell death, especially given the extensive handling protocols 
detailed in the methodology. 
 
The use of the prewash step, while increasing the overall handling and 
experimental time involved in peptide elution also appears to reduce 
lysis/leakage during the peptide elution stage, further reducing the likelihood of 
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contamination by intracellular peptides. This coupled with the previously 
determined pH-dependent disassociation of membrane-associated (often serum) 
peptides (Barry, 2006) also aids decomplexing irrelevant peptides from the 
eluate. This is of particular note when the findings of Antwi, et al (2009) are 
taken into account – a mild acid elution of the PANC-1 pancreatic tumour cell line, 
produced 148 peptides, of which only 32 % were in the appropriate 7-13 amino 
acid mass range for MHC class-I presentation. Similarly Torabi-Pour et al., (2002) 
note that treatment of both MHC- class-I positive and negative Fen cells with a 
mild acid elution buffer will produce peptides in both cases. Depletion of these 
peptides by prewashing significantly reduces the complication they may present 
to antigen discovery. 
 
Indeed, there may be benefits to reducing the prewash pH closer to the β2-
microglobulin disassociation pH, as not only would this hypothetically decrease 
the remaining membrane associated peptides prior to MHC-elution, it would also 
aid removal of MHC class-II invariant chain peptides which might otherwise elute 
during the pH 3.3 stage (Urban et al., 1994). However, use of the prewash 
buffer on the murine CT26 cell line led to cellular disassociation from the 
polystyrene culture surface. Given that EDTA is also used to remove adherent 
cells, the higher citric acid concentration found in the isotonic Storkus buffer or a 
lower pH prewash buffer may lead to even greater disassociation of cells – a 
problem which the non-chelating TMA-formate buffers may avoid. 
 
The validity of prewashing cells with isotonic citrate-phosphate pH 5.5 to reduce 
intracellular ‘leakage’ during MHC class-I elution was validated by 
measuremement of ATP loss. However when an adherent CT26 cell line was 
treated with the elution protocol, the chelating properties of the buffer were 
found to partially disrupt cell adhesion, leading to disassociation of some, but not 
all of the cell population into the prewash buffer. It is possible therefore that an 
alternative buffer composition may be required for prewashing of adherent cell 
lines. With this said, the chelating properties of the citric acid may also provide 
the optimal disassociation of membrane-associated non-MHC peptides, and a 
change in prewash buffer may lead to a greater proportion of contaminating 
peptides in the final pH 3.3 MHC eluate. At this time it is unknown whether the 
cells which disassociated (or those that did not) represent any meaningful 
subpopulation of the CT26 cells (for example a certain point in the cell cycle), 
though their numbers (~ 20 % by visual mass) probably preclude the effect 
being limited to a stem cell subpopulation. 
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An alternative solution to this problem might be supplementation of the prewash 
with additional chelating agents (e.g. EDTA) to disassociate all cells, and then 
elute them in the same manner as non-adherent cells. As yet however the effect 
that this might have on MHC expression is also currently unknown. 
 
If however a serious commitment to further buffer optimisation were to be made, 
the first point of call might be the buffer itself, which was originally chosen for 
volatility and compatibility with M/S. Though the supplements added to reduce 
cell death compromise volatility, the loss of mass-spectrometric compatibility is a 
minor drawback given the complexity and likely impurities to be found in a MHC-
eluate (lipids being of particular concern to analytical column degredation). Of 
the two, TMA is an intermediate product in numerous metabolic pathways and 
should be readily broken down (Rehman, 1999), while formic acid is not 
tolerated as well, and is the ‘active’ agent in methanol intoxication (Seme et al., 
1999), inhibiting cytochrome oxidase (Eells et al., 2004) and degrading to 
carbon monoxide (Araña et al., 2001), all of which may damage mitochondria; 
as well as facilitating Ca2+ entry into cells and altered ATP production (Liesivuori, 
and Savolainen, 1991). 
 
Formic acid may therefore play a role in the growth retardation/arrest seen as a 
result of the MHC class-I / class-II elution protocols (though given that citrate-
phosphate elution also significantly ablates growth, it is certainly not the sole 
factor). Replacement of the acid with another, such as HCl, or further reduction 
in buffer concentration may both pay dividends in reduction in cell leakage/death. 
This mitochondrial damage may be caused/exacerbated by ATP depletion 
(Dorman et al., 1993; Wallace et al., 1997) and there may be a benefit to 
supplementing post- or pr-elution buffers with ATP, though if it were to be 
included in the elution buffers themselves it might increase kinase or protease 
activity, altering results.  
 
Interestingly Eells et al. (2004) found that red to near infra-red light (already 
known to speed wound healing) appears to stimulate cytochrome C function, and 
upregulation of gene pathways related to mitochondrial energy and antioxidant 
function. It is conceivable that such ‘light-therapy’ might improve post elution 
recovery, or if applied prior to MHC elution might even pre-condition the cells 
against damage, though doing so would further distance the cell line from a true 
in vivo blast crisis and may undermine the research. In any case the reasons for 
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not pursuing multiple MHC elutions from a single CML cell line population remain 
relevant. 
 
With regard to ATP, the relative differences in content between the cell lines 
warrants further examination. Loo et al., 2006 noted a positive correlation 
between ATP content and aggressiveness in invasive breast tumours. Similarly, a 
Spearman’s rho of 0.84 (to a P value of <0.01) was found between ATP content 
of the four cell lines, and their proliferation-assay determined growth rates (the 
data for the untreated controls), further highlighting the potential for ATP to be 
used as a marker for tumour prognosis/staging. Martin et al. (2000) reviews 
findings that depletion of ATP sensitised cancers to chemotherapy, while Fine et 
al. (2009) found that ATP uncoupling agents alone produced a tightly linked drop 
in both growth and ATP content. 
 
Despite optimisation, the MHC class-II elution buffer shows higher levels of cell 
death than the TMA-formate. This may be due to both the additional stress of a 
lower pH, and the toxic (relatively pH independent) effects of the comparatively 
much higher formic acid content. Again, this may be avoided by use of an 
alternative buffer, though Barry (2006) records that a glcyine-HCl composition 
was not suitable for cell surface elution. Nevertheless while the levels of cell 
death have been minimised to a point comparable (by most means of 
measurement) with that found in the widely accepted isotonic citrate-phosphate 
approach for class-I elution, it is likely that further optimisation is possible. 
 
Despite the advances in mild acid elution detailed here, the cell-surface elution 
method retains a number of complications. Firstly, a mild-acid eluate from cells 
naturally expressing MHC class-I will contain peptides derived from A, B and C 
alleles. As these may be found in many different combinations (though the 
expression of some alleles correlates to some extent with ethnicity), single 
peptides derived from a cell eluate cannot be considered viable therapeutic 
agents until the MHC-allele they bind is characterised. This may be considered 
an argument for using MHC-bound antibody columns as opposed to cell surface 
elution, or using homoallelic cell lines such as K562-A3. These too have their 
own drawbacks however: the former will include newly synthesised MHC 
molecules not expressed on the cell surface, potentially containing peptides with 
poor processing efficiency (Bonner et al., 2002); while the latter may be 
restrictive, and of potentially limited relevance to an in vivo malignancy). In 
addition given that the W6/32 antibody often used for MHC antibody columns 
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binds to an epitope including both the α-heavy chain and β2-microglobulin of the 
MHC class-I molecule, it is conceivable that this may in some instances stabilise 
the complex in acidic conditions, and that not all peptides may elute properly.  
 
Indeed, Gebreselassie et al. (2006) found that the mild acid elution and MHC-
immunoaffinity produce only mildly overlapping peptide populations, with the 
former skewed towards poor binding peptides, and the latter strong binders. It is 
conceivable that poor binding peptides failed to be retained during the 
chromatographic stage, and given that elution of peptides from immuno-
precipitated MHC molecules is usually performed by boiling the samples in 10 % 
(v/v) acetic acid for 10 minutes, a strong-binding subpopulation may indeed fail 
to elute at pH 3.3 (or pH 3 in the case of Gebreselassie et al., 2006). Though the 
data in figure 4.2 suggests that mild acid treatment is sufficient to elute the vast 
majority of peptides from MHC class-I-A2 and A3, Ciccone et al. (1995) report 
that a mild-acid elution of pH 2.2 is required to achieve 100 % disassociation of 
peptide from MHC class-I Cw3+ and Cw4+ CR-1 and 81.22 cell lines. Whilst this 
tightly bound peptide subpopulation was not characterised, nor were the pH 
required to achieve complete disassociation of the peptide from other MHC 
alleles investigated (Ermanno Ciccone, Université de Genève, Pers. Comm., 2010) 
together these data suggest mild acid elution at pH 3.3 is not be sufficient to 
analyse the total presentome of a culture, and that cell-surface elution and 
elution from immunoprecipitated MHC may be complementary methods rather 
than exclusive ones. Whether similar patterns may be seen for MHC class-II 
elution when compared to eluates from immunoprecipitates is currently 
uninvestigated. Yet it also implies that some MHC class-I peptides may 
contaminate class-II cell-surface eluates, complicating any cell-surface elution 
based research into cross presentation. 
 
The remaining drawbacks to mild-acid elution are primarily methodological: 
larger than ideal sample volumes and potential contamination with prewash-
resistant serum peptides may both be at least partially overcome by additional 
chromatographic methods; including rebinding peptides to immobilised MHC 
molecules (e.g. class-I or class-II tetramers) before re-elution. If the non-MHC 
contaminating peptides are characterised, determination of common 
characteristics may allow alternative/specific methods of depletion. 
 
Increasing reliance on serum-free media will also reduce the presence of serum 
peptides (this would also reduce intra-culture variation and the ethical issues 
Chapter 4.0: Results 
MHC cell-surface elution buffers 
 168
surrounding serum collection) (FoA, 2005) though in all probability at least a 
proportion of membrane-associated peptides are produced by the culture rather 
than derived from the FCS. 
 
It appears that despite the weaknesses of the Storkus et al. (1993a;b) approach 
to mild-acid elution it remains a part of the immunology toolkit, and that 
immunoprecipitation of MHC molecules may in fact be a complementary rather 
than a competing technique. With this in mind it is hoped that the modifications 
to the elution reagents and protocol suggested here may improve the efficiency 
of the approach, and though in of itself the method does not discriminate 
between immunogenic and nonimmunogenic peptides, that the use of these 
methods may aid in the search for novel T-cell epitopes in cancer 
immunotherapy. 
Chapter 5.0: Results 
Optimisation of Chromatography 
 169
5.0: Optimisation of chromatography.  
 
5.1  Introduction 
 
Once a heterogeneous population of MHC-bound peptides have been eluted from 
the cell surface as putative vaccines their sequences require identification. While 
a variety of chromatographic approaches have been applied to MHC-eluted 
peptides prior to mass spectrometry (MS), decomplexing or fractionation of 
samples along a first dimension (1-D) prior to analysis on a second dimension 
(which may be LC or TOF) and identification by MS is a common feature of many 
latter direct immunology publications (Clark et al. 2001; Gebreselassie et al., 
2006; Fortier et al., 2008), for the simple reason that complex samples such as 
MHC-eluates require simplification/fractionation to reduce the high background 
signal caused by multiple co-eluting peptides; while low abundance peptide 
populations (e.g. phosphopeptides) must be concentrated and isolated from the 
non-phosphorylated majority if they are to be confidently identified.  
 
Various forms of chromatography have been used for over a century to separate 
components of a heterogeneous solution by passing them in solvent through a 
stationary phase (Tswett 1906). The most basic method, paper chromatography 
was rapidly supplanted by thin layer chromatography (later found to be capable 
of isolating serine-phosphorylated (pSer) peptides from threonine- or tyrosine-
phosphorylated (pThr/pTyr) peptides at low pH) (Martensen, 1984), which in 
turn fell out of favour with the arrival of techniques such as poly-acrylamide gel 
electrophoresis (PAGE) (in both 1-D and 2-D) and HPLC, both of which show 
improved resolution and reproducibility (Martensen, 1984; Görög, 2004). 
 
Along with column fractionation, PAGE is one of the most common proteomic 
methods of analysis (Minden, 2007), with staining either done in-gel, or by 
western blotting following transfer to nitrocellulose/PVDF, or alternatively spots 
may be excised (and usually trypsinised) for identification by mass-spectrometry. 
Due to the limitations of resolution and identification methods, 1-D PAGE is 
rarely utilised for complex unknown samples except in conjunction with western 
blotting (Ahmad et al., 2005), and despite its limitations in resolution has major 
advantages over its 2-D counterpart in terms of reproducibility, throughput, and 
the timescale involved (Ahmad et al., 2005; Minden, 2007). Nevertheless, 2-D 
PAGE (typically using immobilised pH gradient strips) in conjunction with MS is 
now the gold-standard for the majority of proteomic investigations (Gorg et al., 
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1988; Kubota et al., 2005), and is capable of determining the net acidic/basic 
weighting of a protein, as well as differentiating between isoforms. However, 
despite advances in solubilisation methods, large (>100 kDa) or membrane-
bound proteins remain difficult to run (Ong & Pandey, 2001) and proteins and 
peptides below 10 kDa remain outside the range of the technique (Kubota et al., 
2005). There have however been some efforts to utilise iso-electric focusing 
followed by 2-D PAGE for peptides (Gatti and Traugh, 1999), though high-
acrylamide concentrations (15-50 % w/v) are vital for any meaningful separation 
of peptides, which may differ from each other by only a few kDa. A wide 
variation in methods exists for 1-D PAGE for peptides, e.g.: Andersen et al. 
(1983); West et al. (1983); Fling and Gregerson (1986); Schagger & von Jagow 
(1987); Ahn et al. (2001); and Yim et al. (2002) and the use of peptide PAGE for 
analytical purposes is constrained by the limited facility for western-blotting of 
peptides onto PVDF (Xu et al., 2004)1, and the competition of MS (especially 
MALDI-TOF) to rapidly determine peptide masses with high throughput. 
 
As previously discussed (see 1.2) protein phosphorylation is a relatively common 
post-translational modification, however, as proteins are typically hundreds of 
amino acids in length, often with only one or two phosphorylation sites, and that 
the phosphorylated form of a protein is often (though not always) of low 
abundance (Wagner et al., 2007), phosphopeptides are expected to make up the 
minority of the presentome. Isolation/enrichment of phosphopeptides is 
therefore an important requirement for analysis, without which a ‘drowning out’ 
of the modified peptides by higher abundance non-phosphorylated peptides may 
be observed, leading to very poor signal strength (by both gel-based analyses or 
mass-spectrometry) (Steen et al., 2006; D’Ambrosio et al., 2006). 
 
Enrichment of phosphorylated proteins and peptides is achievable by a variety of 
methods, but the majority of approaches use one of the following three: 
antibody-affinity; immobilised metal affinity chromatography (IMAC) or more 
recently metal oxide (typically titanium dioxide/TiO2) affinity (MOAC). Antibody-
based methods were highly limited as though global anti-pTyr antibodies were 
available, global anti-pSer/anti-pThr antibodies were not until the last decade.  
Antibodies against Ser- or Thr-phosphopeptides had to be raised using synthetic 
peptides or purified proteins, and were usually specific for the peptides in 
                                                 
1
 Kuhar and Yoho (1999) found a lower limit of 4 kDa for blotting of CART peptides (involved 
in the neuroendocrine control system), while Xu et al. (2004) and Ghosh et al. (2004) both 
found it necessary to ligate small (10-20 amino acid) peptides to carrier proteins prior to 
western blotting. 
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question (Patton, 2002), rendering them unusable for purification of 
heterogeneous phosphopeptides from MHC eluates and the vast majority are 
also not compatible with immunoprecipitation (Rush et al., 2005). Furthermore 
as Tyr is by far the least common site of O-phosphorylation in mammals (a ratio 
of 1:200:1800 pTyr : pThr : pSer is often cited) (Hunter, 1998) the use of anti-
pTry antibodies alone excluded a large proportion of phosphorylated peptides, 
only remedied by the advent of global anti-pSer and anti-pThr antibodies in the 
early 2000’s (Grønbørg et al., 2002; Stannard et al., 2003; D’Ambrosio et al., 
2006), though even these are usually of limited applicability to 
immunoprecipitation, constraining their use (Han et al., 2008a). Furthermore, 
disassociation of the peptide from the antibody often requires harsh 
temperatures and/or incubation with detergents and reducing agents, producing 
a suspension far from compatible with electrospray mass spectrometry (Patton, 
2002), as well as risking peptide oxidation which may complicate the analysis. 
 
Immobilized metal ion affinity chromatography (IMAC) (reviewed extensively in 
Chaga, 2001) was first described for protein chromatography by Porath et al. 
(1975) who employed zinc and copper ions to isolate proteins from plasma. It 
has since proven to be highly selective, and operates on the basis of differential 
affinity arising between the metal ions and the functional groups on the amino 
acids; allowing a protein to be isolated from a sample and eluted under non-
denaturing conditions. Whilst not as stringently selective as immunoaffinity 
chromatography, IMAC allows great flexibility with a low number of columns, as 
well as high recovery, milder elution conditions and lower cost, and may be 
applied independently to; or on-line with electrospray mass spectrometry 
(D’Ambrosio et al., 2006; Kaur-Atwal et al., 2007). 
 
The metal ions employed vary depending on the proteins to be isolated, and are 
typically classified by Pearson’s (1963) three-tier “hard and soft acids and bases” 
system (HSAB); determined by reactivity with nucleophiles. At a low pH, “hard” 
ions such as Fe3+, Ga3+, and Al3+ co-ordinate unprotonated oxygen ions 
(Sulkowski, 1985), and depending on running conditions may be used to target 
carboxylic amino acids, Tyr residues or, crucially, phosphorylated amino acids 
(Andersson and Porath, 1986). The ability of IMAC to isolate and enrich 
phosphorylated proteins/peptides using hard ions such as Fe3+ and the more 
selective Ga3+ (Posewits & Tempst, 1999) has become increasingly important in 
proteomic research, though there is on goinging research into the utilisation of 
intermediate ions for investigation of other PTMs (Chaga, 2001). Once optimised 
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however, Fe3+ IMAC may be utilised to strongly enrich phosphopeptide fractions 
from heterogeneous samples, though the approach has a higher affinity for 
multiply phosphorylated peptides (Scanff et al. 1991). Additionally, Zn2+ ions 
(normally be thought of as “intermediate” under the Pearson system) may also 
be used to isolate phosphoproteins (Ueda et al., 2003; D’Ambrosio et al., 2006). 
However, the resins commonly used for IMAC may also inadvertently select out 
peptides containing acidic residues (aspartic acid [Asp], glutamic acid [Glu]) or 
electron donors (e.g. histidine (His))2. 
 
The intermediate metal ions (e.g. Cu2+, Ni2+, Zn2+, and Co2+) co-ordinate 
nitrogen and sulphur ions as well as oxygen, and have an optimum adsorption in 
neutral pH. Cu2+ and Ni2+ may also be used to target His and cysteine (Cys) 
residues, though Cys residues are typically rarer (Hansen et al., 1996). Finally 
the soft ions (Cu+, Hg2+, and Ag2+) preferentially retain sulphur – and may be 
used to isolate methionine, Cys and sulphated Tyr. As the hard and soft ions 
interact with different side chains, they may be used in tandem to improve 
separation/isolation. Indeed IMAC techniques have also been used in conjunction 
with other separation methods such as HPLC to achieve impressive levels of 
isolation (Chaga 2001). Over 50 % of recombinant proteins are now routinely 
isolated through the use of IMAC, aided by either the addition of terminal poly-
His tags to improve isolation (Hochuli et al., 1987 and 1988) using Cu2+, Ni2+, 
Zn2+ and Co2+ ions (in increasing order of His affinity) (Sulkowski, 1985), or via 
the generation of novel binding sites through point mutation (Smith, 1991; 
Yilnaz et al., 1995). 
 
The choice of metal ion may strongly impact the efficiacy of any column. For 
example, Cu2+ columns will retain approximately 50 % of proteins from any 
biological sample, while Ni2+, Co2+ or Zn2+ will retain a far smaller proportion, 
due to a higher stringency for binding (Chaga, 2001) (Cu2+ binds exposed His, 
which makes up approximately 1 % of the average protein [Klapper, 1977]). 
Conversely, Fe3+ will adsorb over 30 % of proteins from any biological mixture at 
below pH 5.0, though a proportion of this may be non-specific interactions 
between proteins and the resin rather than the metal ion (Thingolm and Jensen, 
2009). The choice of resin may also therefore be expected to impact on 
purification efficiency, though currently only a small variety of adsorbent resins 
are commonly used in IMAC: IDA (iminodiacetic acid) [e.g. as produced by GE 
Healthcare]; NTA (nitrilotriacetic acid) [e.g. Quiagen] and CM-Asp 
                                                 
2
 This is obviously less of an issue when Cu2+ IMAC is used to enrich His-containing peptides. 
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(carboxymethylated aspartic acid) [e.g. Clontech]; or TED (tris-carboxymethyl 
ethylene diamine) [e.g.: Inovata], offering the formation of tri-, tetra- and 
penta-dentate metal-ion complexes respectively (as most metal ions can co-
ordinate between four to six ligands, the choice of resin-metal complex may 
have large effects on sample binding) (Kaur-Atwal et al,. 2008). While other 
adsorbant resins have been synthesised, these are rarely used due to lack of 
commercial availability (Chaga, 2001). 
 
Any IMAC protocol consists of 6 key steps: (1) charging the column with metal 
ion; (2) removing the excess metal; (3) equilibration of the adsorbant; (4) 
loading of the sample; (5) washing away unbound protein and; (6) eluting the 
enriched material. However no standard methods exist for the majority of these 
steps. As stated the metal chosen varies depending on the target in question, 
but may be loaded in a small concentrated volume, or a more dilute one, and 
unbound metal may be washed away using glycine, ultrapure water, weak acids 
or imidazole. Similarly, equilibration (bringing the column to the required loading 
pH) may be performed with a wide range of buffers (e.g. Na2HPO4 and MOPS for 
intermediate metal ions, and sodium acetate, MES, PIPES for hard ions). 
Kinoshita-Kikula et al. (2006) were even able to both selectively bind and elute 
phosphoprotein at a constant pH of 7.5 from a zinc(II)-based resin (the Phos-
Tag system), disassociating the bound material with Na2HPO4 and NaCl. At the 
same time reductions in pH have also been shown to allow at least partial elution 
of phosphopeptides (Thingolm and Jensen, 2009) and Imanishi et al. (2007) 
demonstrated elution in an acetonitrile (ACN)/phosphoric acid mobile phase, 
while Hart et al. (2002) were able to elute Fe3+ IMAC using 2’, 5’-
dihydroxybenzoic acid (DHB), which is now commonly utilised in conjunction with 
TiO2 approaches, but which is of limited LC-MS/MS compatibility (Imanishi et al. 
2007).  Though Tris is commonly utilised as a mobile phase it should be avoided 
(despite many manufacturers recommendations), as weak co-ordination of the 
ions by the buffer results in decreased adsorbancy and even weak metal leakage 
from the column3, though in the case of high affinity ligands low concentrations 
of Tris may reduce non-selective binding (Proteus, 2004; GE Healthcare, 2005). 
Similarly, chelators such as EDTA should be avoided for all stages except 
removal of metal ions from the column. For the isolation of phosphorylated 
proteins and peptides, pH extremes should also be avoided, as O-
phosphorylations (especially pSer and pThr) are succeptible to β-elimination in 
basic conditions (pTyr residues show higher stability), while N- phosphorylations 
                                                 
3
 Though this is a greater issue with intermediate metal ions. 
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are labile at a low pH (as determined by 32Pi loss) (Mecham and Olcott, 1949; 
Martensen, 1984; D’Ambrosio et al., 2006).  
When samples are loaded onto the column, there are three possible outcomes: 
(1) the peptide of interest binds to and is retained by metal ion; (2) the peptide 
of interest is not retained by the metal ion; or (3) the peptide of interest co-
ordinates and removes the metal ion from the resin (metal ion transfer). 
Obviously leakage of metal ions during column operation will seriously affect 
both column efficiency and capacity, and for this reason columns are typically 
underloaded with metal ion (often by ~20 %) or a second uncharged column is 
placed in-line with the first, leaving room for disassociated ions to rebind (Kaur-
Atwal et al., 2008). Certain buffers may exacerbate metal ion leakage, especially 
at high concentrations, therefore Yruela et al. (2003) and Pingoud et al. (2005) 
recommend a maxiumum concentration of 50 mM MES in conjunction with IMAC. 
This said, IMAC adsorption matrices have excellent regenerative properties, and 
old ions are easily removed with strong chelators (e.g. EDTA), following which 
the column may be rapidly washed and recharged with fresh metal ions. 
 
Previous work at NTU entailed the comparative use of Cu2+ IMAC as a 
prefractionation step before HPLC, where it allowed identification of low-
abundance peptide peaks and the isolation and identification of His-containing 
peptides from tryptic digests of K562 cell line protein (Barry, 2006); as well as 
the use of on-line Cu2+ IMAC for decomplexing of samples and simplification of 
mass spectra during ESI-MS/MS. Preliminary investigations were also carried out 
into the use of Cu2+ IMAC for fractionation of MHC class-I presented peptides, 
using either the isotonic citrate-phosphate MHC elution buffer developed by 
Storkus et al. (1993) with IMAC following sample cleanup by C18, or by Ga
3+ 
IMAC following elution with the unsupplemented 25 mM TMA-formate pH 3.3 
buffer. 
 
A related technology; metal oxide affinity chromatography (MOAC) (Han et al., 
2008a) is advocated by some as cheaper, more readily optimisable and with 
greater selectivity than IMAC (D’Ambrosio et al., 2006). The most common form 
utilises TiO2 (occasionally referred to as ‘titania’) which had previously been 
utilised for binding of organic phosphates (Matsuda et al., 2000) and 
phospholipids (Ikeguchi and Nakamura, 2000), and like IMAC (often) involves 
binding at low pH and eluting with a intermediate-high pH buffer (e.g. Sano and 
Nakamura, 2004). This similarity between the two methods is all the more 
striking when it is considered that as well as zirconium, oxides of gallium and 
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aluminium have all also been utilised at some stage (Dunn et al., 2010), and 
that both appear to involve interaction between the metal ion and the oxygen or 
hydroxyls of the phosphate group (Leitner, 2010), along with electrostatic 
repulsion at the higher elution pH. Unlike IMAC however little data is available on 
comparable specificity between different ions (Leitner, 2010) and there are 
conflicting reports on the applicability of iron(III)-oxide for phosphopeptide 
enrichment (Han et al., 2007; Shan et al., 2008; Lee et al., 2008). Again, non-
specific binding is primarily due to interactions with acidic residues (Glu/Asp) 
though unlike IMAC, these can be reduced by inclusion of 2,5-dihydroxybenzoic 
acid (a potent chelator), or reducing the loading pH beyond that typically 
employed for IMAC (Pinkse et al., 2004), and the methodology is far more 
tolerant of detergents, higher buffer strengths, and salts (etc). 
 
The majority of proteins contain a number of hydrophobic patches on their 
exterior (Hochuli, 1992), a feature which is exploited by reversed-phase (RP) 
approaches4, the simplicity, broad binding capacity and strong reproducibility 
(Hengström and Irgum, 2006) of which have for several decades made them the 
most popular method for peptide and protein fractionation, either for sample 
cleanup/concentration or for analytical purposes along an increasing solvent 
gradient. Adjustment of loading, washing and elution conditions can allow 
selective isolation and/or elution of particular fractions, e.g. for removal of 
abundant serum proteins such as albumin (Freeman et al., 2006; Matharoo-Ball 
et al., 2007). These resins contain silica beads to which long hydrophobic alkyl 
hydrocarbon chains are bound, the resin name being dependent on the number 
of carbon molecules per chain: C8 corresponding to an octyl-carbon chain, C12 to 
a duodecyl-carbon chain, etc. While C4, C12 and C18 are the most commonly used 
resins, largely due to commercial availability, resins of up to C60 have been 
developed (Vallant et al., 2007). 
 
Samples are typically loaded at an acidic pH (2 or below) to protonate the side 
chains, minimising overall charge, and bind by primarily hydrophobic interations 
with the resin. The column is then washed, and subjected to increasing solvent 
concentration(s), allowing either fractionation across a hydrophobic gradient 
(though charge and size also play a role), or concentration into a small volume 
by a rapid increase in solvent. Unlike hydrophobic interaction chromatography 
(an earlier method), the presence of salt is not required to encourage peptides to 
                                                 
4
 Derived from hydrophic interaction chromatography (HIC) methods first described by Porath et al. 
(1973) and Hjerten et al. (1974) 
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bind to the column; hence C18 is frequently used to desalt samples prior to MS. 
Furthermore, as identification of MHC peptides by LC-MS/MS is almost always 
performed using C18 columns they are also ideal for sample concentration and 
clean-up, as peptides which bind poorly to the SPE resins will typically also be 
poorly retained by the analytical column, leading to inferior spectra. 
 
Though well investigated, the effect of phosphorylation on reversed-phase 
binding is complex; though in general the addition of an anionic phosphate group 
is believed to increase the polarity and the hydrophilicity of a peptide, data is at 
times contradictory (Steen et al., 2006; Kim et al., 2007). Ohguro and 
Palczewski (1995) found that when a variety of phosphopeptides were studied by 
RP chromatography, each eluted prior to, or with the nonphosphorylated forms, 
with differences of up to 20 minutes found between elution times (though this 
corresponded to an increase in solvent concentrations of only 4.22 % v/v), with 
the ion pairing agent heptafluorobutyric acid (HFB) found to provide the greatest 
difference in elution times. Matsumoto et al. (1997) on the other hand found no 
difference between phosphorylated and nonphosphorylated forms using either a 
C4 or a POROS 20R2 reversed-phase resin (analogous to a C8 silica resin) when 
acidified with either TFA or HFB, but found that on the 20R2 system increasing 
the pH to 11.5 (silica resins are not alkaline stable) phosphopeptides were 
resolvable from their naked counterparts and again were found to elute prior to 
the nonphosphorylated form (though the low alkaline stability of O-
phosphorylation required samples to be neutralised with TFA as soon as they 
eluted from the column). However, Steen et al. (2006) found that each of the 
fifteen monophosphorylated peptides (varying from 7-17 amino acids in length 
and with a range of physical characteristics) tested on a C18 resin (acidified with 
formic acid) eluted after the nonphosphorylated form, and that two of the three 
doubly phosphorylated peptides eluted after both the singly or non-
phosphorylated peptides (the third peptide eluted before either the non- or the 
mono-phosphorylated form), and postulated that peptides with basic amino acids 
might experience net reduction in charge from phosphorylation, increasing 
retention. 
 
Matsumoto et al. (1997) also noted that as monophosphorylated peptides 
increase in size, the difference in retention times decreases; presumably due to 
a fall in the net effect of a single phosphate group. This was mirrored by Kim et 
al. (2007), but the opposite was found by Steen et al. (2006), who found that 
the smallest of their peptides demonstrated the greatest overlap between peaks. 
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Kim et al. (2007) studied 33 peptides from 4-35 amino acids in length with 
single, double and in one case quadruple phosphorylation, and found mixed 
results. In general phosphorylation was found to decrease retention on the RP 
column, however there were several exceptions, for which they implicated 
hydrogen bonding and stearic hindrances from adjascent residues. They also 
found that phosphorylation of Tyr lead to the greatest reduction in peptide 
retention time, which may be of special importance given the relatively low 
abundance of Tyr phosphorylation (Hunter, 1998). 
 
The use of a porous graphitic carbon column to both desalt and separate 
hydrophilic phosphopeptides from their nonphosphorylated counterparts along an 
increasing solvent gradient as developed by Chin and Papac (1999) may be 
thought of as a loose analogue of reversed-phase approaches, though it likely 
also involved additional interactions, as peptides which normally bind poorly to 
C18 may be retained. Vallant et al. (2007) compare their C60 reversed-phase 
resin favourably with the porous graphite approach, though there are concerns 
about column reusability (Larsen et al., 2002). The method has also been used 
(with MALDI-MS) by Vascratis et al. (2002) and Larsen et al., (2002; 2004). 
 
Hydrophilic Interaction Liquid Chromatography (HiLIC) (sometimes termed 
Hydrophilic Interaction Chromatography), is a normal-phase approach often 
considered as an orthoganal counterpart to the reversed-phase resins such as 
C18. Unlike reversed-phase, HiLIC requires samples be loaded onto a polar 
stationary phase in non-polar conditions, and eluted along an increasingly polar 
gradient; and as would be expected from such an approach, much greater 
retention and fractionation of polar molecules are possible (Bai and Wang, 2009). 
Though methods employing a polar stationary phase, including HiLIC have been 
in use since the 1970’s, these were primarily applied to small molecules, 
metabolites and carbohydrates (Yoshida, 2004); at the time normal phase 
approaches to protein biochemistry were limited by poor reproducibility when 
compared to reversed-phase (Hengström and Irgum, 2006) - HiLIC as a method 
for peptide fractionation was therefore not introduced until 1990 by Alpert (1990) 
who was able to fractionate proteins, peptides, amino acids, oligonucleotides, 
and carbohydrates. 
 
As well as direct hydrogen bonding and ionic interactions between the analyte 
and the resin (Bai and Wang, 2009), the mechanism depends on partitioning of 
sample into the stationary aqueous layer associated with the hydrophilic 
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(typically silanol) groups present within the resin (Yoshida, 2004) (as suspected 
by Alpert, 1990), and must therefore not be confused with other normal phase 
approaches, which may allow samples to be loaded in the absence of H2O.
5 As 
well as resin and sample composition, binding efficiency is known to be affected 
by salt and solvent concentrations, and by pH and ionicity. The potential for 
HiLIC for the study of phosphorylation was noted by Alpert (1990), and Linder et 
al. (1997) were able to isolate phosphorylated histones from the Raji cell line. 
The use of HiLIC for phosphopeptides did not gather pace until 2008, when 
Albuquerque et al. (2008) and McNulty and Annan (2008) both used it as part of 
a multidimensional phosphopeptide enrichment strategy. The latter later found 
that prefractionation of samples with HiLIC (as opposed to the post IMAC 
methodology they previously employed) improved phosphopeptide selectivity of 
IMAC to >95 % (McNulty and Annan, 2009). 
 
Alternate technologies for phosphopeptide enrichment often involve chemical 
derivatization (Patton, 2002): examples include binding phosphopeptides to 
thiol-containing compounds (subsequent to amino-group tert-butyloxycarbonyl 
modification and amidation of the carboxylate-groups), which were then 
covalently bound to glass beads and released through an acid wash (Zhou et al., 
2001); or β-elimination of phosphate groups under alkali conditions, followed by 
the Michael addition of ethanedithiol and subsequent tagging of the thiol group 
with biotin (via the resulting sulphydryl group), which may then be isolated via a 
captavidin column (Oda et al., 2001, as described in Araces et al., 2004). Knight 
et al. (2003) were able to convert pSer/pThr to lysine analogues, and then 
identify these sites by differential proteolytic cleavage (though this method is far 
less applicable to MHC eluates). These approaches also circumvent the issue of 
Ser/Thr phosphate-loss during mass-spectrometric fragmentation (Wolshin & 
Weckwerth, 2005), however, they are also limited to phosphorylation of these 
residues, and therefore overlook pTyr events (Bai and Wang, 2009).  
 
Similarly, chemical modification of samples prior to IMAC or TiO2 
chromatography can be used to reduce non-specific binding (typically by Asp and 
Glu), and such methods typically improve the quality of the resultant mass-
spectra (He et al., 2004; Simon et al., 2008). However, they can also 
significantly complicate peptide sequencing and render unbound fractions 
unusable, as incomplete/partial sample modification, combined with secondary 
or non-specific reactions (e.g.: esterification of arginine; β-elimination of O-
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 Depending on sample solubility in nonaqueous conditions. 
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linked glycosylations producing intermediates with similar molecular weights to a 
phosphate group) can produce numerous molecular weights from a single 
peptide, greatly increasing mass spectrometric analysis time, and potentially 
reducing concentrations of many modified peptide isoforms below the levels 
required for confident identification (Ficarro et al., 2002; McLachlin and Chait, 
2003; Karty and Reilly, 2005; D’Ambrosio et al., 2006). Furthermore the 
chromatography may be complicated by increases in sample volume or the 
presence of low-compatibility reagents during modification. A third alternative, 
32P-labelling followed by Edman-sequencing (De Carvalho et al., 1996), while 
highly accurate carries both the complications associated with beta-emitter 
isotope work (e.g. inapplicability to patient samples) and long analysis times/low 
throughput (Bai and Wang, 2009). Additional chromatographic methods for 
isolation of phosphopeptides include thin-layer chromatography as already 
mentioned (Martensen, 1984), and more recently the use of soluble 
nanopolymers which may be used in conjunction with or distinct from TiO2 (Iliuk 
and Tao, 2009) 
 
A single pSer peptide was found by Hogan et al. (1998) in an eluate from 
immunoaffinity-purified MHC class-I molecules from the VBT2 carcinoma cell line, 
following fractionation on HPLC (without any phosphopeptide-enrichment stage), 
noting at the time the potential phosphorylation may have to influence the CD8+ 
T cell response. Since then investigations into MHC-presented phosphopeptides 
have primarily been carried out by Zarling et al., (2000; 2006; Mohammed et al., 
2008; Depontieu et al., 2009) using Fe3+ IMAC of peptides eluted from 
immunopurified MHC molecules. The IMAC protocol utilised however varies 
notably, with the initial approach using a 100 mM NaCl in 25 % ACN, 1 % (v/v) 
acetic acid wash to minimise non-specific binding, and the column eluted with 
Na2HPO4 (pH 9.0); and later using Ficarro et al. (2003)’s methylation protocol 
(Zarling et al., 2006; Mohammed et al., 2008). In both cases they use POROS 
20MC resin and peptides were sequenced using LC-ESI-MS/MS. Meyer et al. 
(2009) on the other hand used a similar MHC class-I and -II isolation procedure, 
with the exception that phosphopeptide enrichment took place using TiO2, and 
peptides were characterised by LC-ESI Q-TOF. 
 
The MHC class-I / class-II peptides acquired by mild acid elution are contained in 
a semi-volatile low-pH matrix (TMA-formate or sodium-formate, plus salts, 
sugars and other supplements) that is not directly compatible with mass 
spectrometry or quantification of peptide content by peptide BCA. Furthermore 
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the peptides are highly heterogeneous, with the phosphorylated component 
expected to make up the minority of the sample. This chapter primarily deals 
with improving the use of IMAC and reversed-phase approaches to retain and 
concentrate model phosphopeptides, and to elute them in a matrix-compatible 
with quantification, secondary chromatographic fractionation, and identification 
by mass spectrometry. There is also some investigation into the use of HiLIC for 
phosphopeptide selection/retention, and ion exchange chromatography as an 
alternative to reversed-phase. A descriptive flowchart (Figure 5.1) below 
illustrates the main concerns at each stage. 
 
 
 
Figure 5.1: Major concerns at each stage of the chromatographic process. Low 
concentration and high complexity of the MHC peptides and poor compatibility may be 
rectified by chromatographic concentration and enrichment, though this may be affected 
by a range of factors. Eluates should be quantifiable and compatible with all downstream 
approaches. 
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5.2 Use of IMAC for fractionation/selection of peptide subpopulations 
 
By nature the peptide populations derived from MHC eluates are highly 
heterogenous, and unlike protein digests, rarely contain two or more abundant 
peptides from the same protein. In order to reduce background noise and 
improve identification of peptides, decomplexing of samples by chromatographic 
fractionation is highly desirable. While the use of LC-MS/MS includes separation 
of peptides along a hydrophobic gradient, prefractionation by a second 
dimension typically reduce sample complexity dramatically and may lead to 
identification of lower abundance peaks than the original unfractionated sample 
might allow. As deregulation of kinase activity has a strong link with malignancy 
(Capra et al., 2006) and MHC-presented phosphopeptides are known to 
modulate the immune response (Zarling, 2006), identification of MHC 
phosphopeptides may be key to novel immunotherapeutic vaccines. It was 
therefore sought to improve the use of IMAC as a preparative-chromatographic 
stage for MHC phosphopeptides prior to MS analysis. 
 
 
5.2.1 Isolation of phosphopeptides using Fe3+ IMAC – proof of principle 
 
To confirm the potential for IMAC to isolate phosphorylated peptides from a 
heterogeneous mix, a casein digest was subjected to the Fe3+ IMAC protocol 
previously utilised at NTU6. The peak unbound and eluted fractions were then 
quantified by peptide BCA (Kapoor et al., 2009) as per chapter 3, analysed by 
peptide-PAGE along with unfractionated casein and BSA digests, and stained 
with the Pro-Q diamond phosphoprotein stain (see figure 5.2). This confirmed 
that IMAC was capable of producing a heavily phosphopeptide-enriched fraction, 
and that the unbound material was depleted of casein phosphopeptides to a level 
below the detection limits of the stain). This enrichment was significant when 
compared with an un-enriched casein digest which was loaded at double the 
concentration of the IMAC material, while as expected a BSA digest failed to 
show any staining. Compatibility of the DEA-HCl buffer with peptide PAGE was 
also demonstrated. 
 
                                                 
6
 Loaded in 25 mM TMA-formate pH 3.3, washed with five column volumes, and eluted with five 
column volumes 0.1 M DEA-HCl pH 8.4. 
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When the peak IMAC eluate fraction was subjected to LC-MS/MS (as per 2.6.2) 
analysis by MASCOT indicated that 9 of the 12 casein peptides confidently 
identified were phosphorylated (data not shown).  
 
5.2.2 Modification of Fe3+ IMAC protocol to increase peak fraction 
concentration 
 
While analytical chromatography usually depends on fractionation of a sample 
across a steady gradient, the generation of numerous samples from each 
chromatographic step complicates analysis by RP-mass spectrometry, 
dramatically increasing analysis time. Therefore, using IMAC as a prep-
chromatograpic method, the bound material should be concentrated into as 
small a sample volume as feasible. This also allows increased dilution of the 
sample prior to analysis, reducing background noise and any buffer compatibility 
issues. 
 
An increase in elution buffer pH from 8.4 to 9 was investigated with the aim of 
increasing the pH gradient across the five column volumes used to elute bound 
material (in this case a tryptic digest of casein) from the column. This led to an 
increase in peak fraction concentration from ~ 43.1 (S.D ± 2.61) % to 59.89 % 
 
 
 
Figure 5.2: Peptide PAGE of BSA and casein digests (+/- IMAC) stained with Pro-Q 
Diamond phosphoprotein stain. Lanes are as follows: A – casein digest subjected to Fe3+ 
IMAC, peak fraction from eluate (~ 6 µg); B - casein digest subjected to Fe3+ IMAC, peak 
unbound fraction (~ 6 µg); C – casein digest (~ 6 µg); D – casein digest (~ 12 µg); E – 
BSA digest (~ 12 µg). Digestion was performed as per 2.3.2.2, IMAC as per 2.5.1.1, 
peptide quantification as per 2.3.4, and peptide PAGE and staining as per 2.5.5. 
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(S.D ± 3.46) of total eluted material, as well as altering the shape of the elution 
profile, bringing the peak forward to the second fraction (see figure 5.3). 
 
The effect of reducing the wash buffer molarity was also tested, under the 
hypothesis that a lower molarity would present lower buffering capacity when 
confronted with the pH 9 elution stage. The addition of a second wash stage of 5 
column volumes 5 mM TMA-formate pH 3.3 (following the 25 mM wash) was 
found to increase peak fraction content even further, to 74.36 % (S.D ± 3.17) 
total eluted material  (see figure 5.3), without any sign of protein or metal ion 
leakage during the additional stage (data not shown). 
 
Following these alterations to the protocol, the effect of dropping the elution 
buffer molarity from 100 mM to 50 mM DEA-HCl (pH 9.0) was also tested, 
theoretically doubling the compatibility of the buffer and halving any dilutions 
required for downstream analysis. This was achievable with a mild-trade-off in 
peak fraction concentration, which dropped to 67.85 % (S.D ± 1.6) total eluted 
material.  
 
 
 
 
Figure 5.3: Typical peptide BCA-determined elution profiles (1 m / fraction) for casein 
digests subjected to Fe3+ IMAC. Samples were loaded in 25 mM TMA-formate pH 3.3, 
washed with at least 5 column volumes of TMA buffer (+/- low molarity 5 mM TMA wash 
stage), and eluted with DEA 50/100 mM pH 8.4/ 9.0. Each alteration to the method led to 
a change in peak fraction concentration (significant to a P value < 0.01, n = 4). Error bars 
indicate SD. 
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The use of a second charged Fe3+ IMAC column, in line with the first was also 
investigated. By providing an increase in bed volume, a greater charged surface 
is available to interact with the phosphopeptides, increasing the total eluted 
material from 7.18 mg (S.D ± 0.22) to 10.97 mg (S.D ± 0.528) (see figure 
5.4.A). However, the peak fractions only rose from 4.54 mg/ml (S.D ± 0.2) to 
5.0143 mg/ml (S.D ± 0.16), which represented a drop in percentage bound 
material per peak fraction from 66.79 % (S.D ± 2.92) to 45.73 % (S.D ± 1.48) 
(see figure 5.4.B), which may reduce the potential for a single fraction to be 
representative of the total bound material, a consequence of the broader peaks 
produced by two columns in tandem. This may also be in part an artefact from 
the points at which fractions were collected, the peak fraction may be divided 
between fractions 5 and 6, and may possibly be remedied by staggering fraction 
collection by 0.5 ml. In either case however the use of a second column required 
slower flow rates (from 0.5 to 0.2 ml/min) to mitigate for increased back-
pressure and leakage of mobile phase, leading to longer run-times, and on 
occasion appeared to exhibit greater metal ion loss. 
 
 
 
 
 
               
 
Figure 5.4: (A) Peptide BCA-determined elution profiles for casein digests subjected to 
Fe3+ IMAC on a single or dual column set-up. Samples were loaded in 25 mM TMA-
formate pH 3.3, washed with 5x 2-column volumes of 25 mM then 5 mM TMA-formate pH 
3.3, then eluted with 10 ml 50mM DEA pH 9.0. While the dual column approach nearly 
doubled the amount material bound and eluted, peak fraction concentration only 
increased by ~ 10 %  (significant to a P value of < 0.05), which when expressed as a 
percentage total eluted material (B) indicated a drop from 66.79 % (S.D ± 2.92) to 
45.73 % (S.D ± 1.48), significant to P  < 0.05, n = 4. Error bars indicate SD. 
 
A B 
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5.2.3  Modification of Cu2+ IMAC methodology 
 
The applicability of these modifications to the Cu2+ IMAC protocol were also 
investigated using a BSA digest, with the addition of a 5 mM HEPES wash stage 
found to increase peak fraction concentration from 37.12 % (S.D ± 1.82) to 
59.11 % (S.D ± 1.18). In this case however increasing the pH gradient 
(normally 0.1 % v/v TFA) was incompatible with reducing concentration of the 
solution; however increasing TFA to 0.5 % (v/v) led to an increase in peak 
fraction concentration to 72.64 % (S.D ± 5.4) of the total eluted material (see 
figure 5.5). 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Peptide BCA-determined elution profiles for BSA digests subjected to Cu2+ 
IMAC by the standardised method, or by modifications similar to those previously utilised 
for Fe3+ IMAC. Samples were loaded and washed with 100 mM HEPES-NaOH pH 7.2, 
with or without a second low-molarity wash stage (5 mM HEPES-NaOH), prior to bound 
material being eluted with 0.1 or 0.5 % (v/v) TFA in 1 ml fractions. Again each alteration 
to the method produced a statistically significant (to P <0.01 , n = 4) increase in peak 
fraction concentration. Error bars indicate SD. 
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5.3  Alternative chromatographic methods 
 
The use of alternative SPE-chromatographic resins for sample cleanup and/or 
selective phosphopeptide capture was also investigated. Again, as these were to 
be used primarily for sample clean-up/concentration, the emphasis was on peak 
sharpness and recovery of sample in as small a volume as feasible. 
 
 
5.3.1  Reversed-phase SPE resins 
 
Whilst the fractionation of phosphopeptides from their unphosphorylated 
counterparts has been extensively documented using reversed-phased columns 
such as C18, there is little data available regarding increasing phosphopeptide 
binding to reversed-phase resins. The choice of resin and modification of loading 
conditions was therefore investigated to maximise phosphopeptide recovery, 
with the aim of coupling this method with IMAC. 
 
 
5.3.1.1 Choice of optimum reversed-phase resin 
 
Three different reversed-phase resins: Bond-elut C18 (Varian), Strata C18 and 
Strata C8 (Phenomenex) were tested for their potential to capture and retain two 
phosphorylated peptides with differing hydrophilic characteristics, SQK(p), HPS = 
1.1; and YIS(p), HPS = -0.5. Peptides (0.2 mg) were loaded onto a column 
containing 30 mg resin in 0.1 % (v/v) TFA, unbound material washed away, and 
the peptides eluted in 1.5 ml volumes. Eluates were then spiked with 20 µl 
DMSO7 and concentrated by rotary evaporation. Once significantly reduced in 
volume they were brought back to 200 µl with ddH2O and the peptide content 
assessed by peptide BCA as per (as per chapter 3) quantified against standards 
subjected to the same rotary evaporative process (without the addition of DMSO) 
(see figure 5.6). While recovery of YIS(p) was consistent at ~ 22 % (S.D ± 
<1.21) between the resins, SQK(p) recovery dropped from ~25 (S.D ± 
<1.26) % binding to the C18 resins to 16.6 % (S.D ± <0.75) binding to Strata C8. 
It was therefore decided to utilise a C18 SPE resin for any sample cleanup, and 
the Varian Bond-elut C18 cartridges were chosen for reasons of availability. 
                                                 
7
 Chosen for it’s low volatility and preference as a solvent for dissolving peptides, as well as it’s 
presence in the non-chromatographic standards. 
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Given the hydrophilic score of SQK(p), the higher recovery when compared with 
YIS(p) was surprising. While the lower BCA reactivity of the YIS(p) peptide may 
play a role in this result, or potentially higher volatility/adsorption of the 
hydrophobic peptide, the use of peptide standards not subjected to reversed-
phase chromatography makes this unlikely. As stated, the presence of a 
phosphate group is generally believed to alter the interaction between the 
peptide and the resin. However, in this case there does not seem to be a 
distinction between serine or tyrosine phosphorylation, as the 25.2 % of the 
ALR(p) peptide (HPS = 0.3) was recovered from an eluate of a Varian Bond-Elut 
SPE column when subjected to the same procedure (see Figure 5.7, column 1). 
If one is to follow the data of Steen et al. (2006), it is conceivable that the 
phosphate group aids retention of a hydrophilic peptide, and that the effects 
balance out in the loss in binding that would normally be seen by such a 
hydrophilic peptide, but further data would be required before this could be 
proven. As each peptide was supplied at > 80 % purity, it also is possible that 
retention and quantification of mis-synthesised sequences may also have had an 
effect. These would be expected to be shorter than the sequences stated, and 
might be expected to present lower BCA reactivity unless they also possessed 
fewer hydrophobic residues. 
 
Figure 5.6: BCA-determined recovery of two peptides in eluates from three reversed-
phase resins following concentration by rotary evaporation. 0.2 mg of each peptide was 
loaded in 0.1 % (v/v) TFA and eluted in 1 ml 80 % (v/v) ACN before being spiked with 
DMSO and further concentrated by rotary evaporation. While binding of the YIS(p) 
peptide remained constant, the C8 showed poor recovery of the hydrophilic SQK(p) 
peptide. ** Indicates statistical significance to P < 0.01 when compared with other resins 
as determined by ANOVA (n = 5). Error bars indicate SD. 
Chapter 5.0: Results 
Optimisation of Chromatography 
 188
5.3.1.2  Sample acidification with TFA, HCl or Phosphoric acid 
 
In order to determine the optimum acidification protocol for maximum retention 
of phosphopeptides on the Varian Bond-Elut C18 columns, three different acids 
were tested at different concentrations (see figure 5.7). It was found that neither 
HCl nor phosphoric acid were a suitable alternative for TFA. However increasing 
the TFA concentration from 0.1 to 0.5 % (v/v) lead to an increase in peak 
fraction concentration to approximately 33 %, statistically higher (to P <0.01) 
than any other protocol investigated (with the exception of 1 % (v/v) TFA, which 
was statistically indistinct from both 0.5 and 0.1 % TFA). 
 
 
 
 
5.3.1.3 Inclusion of KCl 
 
In order to determine whether the inclusion of neutral salts might affect recovery 
from the C18 SPE columns, KCl was tested at various concentrations, on the basis 
that it was the primary supplement in the minimal-lysis MHC class-I and class-II  
 
Figure 5.7: The effect of three different acids at different concentrations on BCA-
determined recovery of synthetic peptide ALR(p) in eluates from Varian Bond-Elut 
reversed-phase SPE columns. 0.2 mg peptide was loaded in trifluoroacetic (TFA), 
hydrochloric (HCl) or phosphoric acid (PA) (all % v/v), and washed with the same before 
elution in 1 ml 80 % (v/v) ACN and 0.5 ml 100 % (v/v) ACN, before being spiked with 
DMSO and concentrated by rotary evaporation. Acidifying with 0.5 % TFA allowed the 
greatest recovery, and was statistically distinct (to P < 0.01, n = 5) from all other protocols 
bar 1 % (v/v) TFA when assessed by ANOVA. Error bars indicate SD. 
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elution buffers. Tryptic digests of casein were loaded in 0.5 % (v/v) TFA 
containing 0.0, 0.1, 0.2, or 0.5 M KCl. The columns were then washed with the 
same, and then again with 0.5 % (v/v) TFA (no salt), before being eluted in 1 ml 
80 % (v/v), and then 0.5 ml 100 % ACN. Fractions were then assayed by 
peptide BCA (as per chapter 3) with appropriate standards. While the inclusion of 
0.1 and 0.2 M KCl failed to produce a statistically significant change in peptides 
recovered, 0.5 M lead to a decrease in peptide recovery from 42.1 (S.D ± <2.8)  
to 36.4 (S.D ± <2.4). In no case was bound material found to elute in the 
second (salt-free) wash (data not shown). 
 
 
 
5.3.2  Mixed mode SPE resins 
 
Two recently-developed SPE resins from Phenomenex were also tested for their 
ability to bind phosphopeptides. Strata X, a mixed mode resin with both 
hydrophilic and hydrophobic binding properties; and Strata X-AW, a weak anion-
exchange resin with reversed-phase properties (methodologies based on 
personal communication between P.L.R. Bonner and Phenomenex). Again the 
 
Figure 5.8: The effect of the inclusion of salts in the loading phase on BCA-determined 
recovery of a casein digest in eluates from Varian Bond-Elut C18 SPE columns. 0.3 mg of 
digest was loaded in 0.5 % (v/v) TFA containing varying concentrations of KCl and, 
washed with 1 ml 0.5 % TFA (no KCl) and eluted in 1 ml 80 % and 0.5 ml 100 (v/v) ACN. 
Eluates were then spiked with 0.2 ml DMSO and subjected to rotary evaporation prior to 
quantification by peptide BCA. With the exception of 0.5 M, the inclusion of KCl was 
found to have no statistically significant effect (to a P value of <0.05, n = 4). Error bars 
indicate SD. 
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phosphopeptides SQK(p) and YIS(p) were utilised to assess the resins’ abilities 
to retain dissimilar phosphopeptides. The results (see figure 5.9) indicate that 
the two resins show divergent selectivity - the Strata X showed a high selectivity 
for the YIS(p) peptide, 30.33 % recovery (S.D ± <4.9) (total recovery 
31.769 %); while the peak fraction recovery of the SQK(p) peptide was below 
10.29 % (S.D ± <0.6) (total recovery 18.84 %). 
 
 
 
 
The Strata X-AW resin on the other hand showed some selectivity for both 
peptides, with greater amounts of the SQK(p) peptide eluting in each fraction, 
peaking at 38.25 (S.D ± <1.8) in the third (ammonium bicarbonate and TFA in 
MeOH) wash (total recovery 75.25 %), while the YIS(p) peptide eluted primarily 
in the second wash (MeOH only) at 32.9 % (S.D ± <0.9). This resulted in a 
higher total recovery (46.97 %), and though the multiple elution points are 
 
Figure 5.9: Recovery of two synthetic peptides in the three wash and elution stages of 
Strata X and X-AW. While the Strata X resin appeared to have little affinity for the 
hydrophilic SQK(p) phosphopeptide, YIS(p) was retained and selectively eluted in the 
second fraction (50 % (v/v) MeOH in ddH2O). Strata X-AW showed a more even 
selectivity for both peptides. 
 
Strata X: samples were loaded in 2 % (v/v) phosphoric acid and washed with 1 ml of the 
same (fraction 1) before being eluted with 1 ml 25 % (fraction 2) and 50 % (fraction 3) 
(v/v) MeOH in ddH2O. Strata X-AW: samples were also loaded in 2 % (v/v) phosphoric 
acid. They were then washed with 1 ml 20 mM Na acetate pH 5 (fraction 1), followed with 
1 ml MeOH (fraction 2), and finally with 1 ml 2 % (w/v) ammonium bicarbonate, 0.5 % 
(v/v) TFA in MeOH (fraction 3). 
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unexpected for a single peptide, it should be noted that SQK(p) also eluted in 
several fractions when applied to the Strata X resin, and 6.13 and 7.93 % of 
YIS(p) was found in the first and third elution conditions. As this 
chromatography was performed by hand, it is conceivable that these variations 
might stem to some extent from changes in flow-rate or pressure, but it was 
decided not to pursue this approach. 
 
 
5.3.3 Hydrophilic Ligand Interaction Chromatography (HiLIC) resins 
 
Though in the simplest terms HiLIC resins may be considered normal-phase 
counterparts to the reversed-phase resins such as C18, their mechanisms of 
action are still somewhat unresolved, and along with hydrophilic partitioning of 
sample from the mobile to the stationary phase, the approach is also known to 
overlap to some extent with reversed-phase and ion-exchange chromatography, 
with interaction between resin and sample usually being a combination of 
hydrogen bonding, dipolar interactions and electrostatic effects, as most resins 
exhibit a charge within some regions of the pH scale (Sequant, 2009). The use of 
HiLIC to isolate phosphopeptides, either alone or in conjunction with IMAC/TiO2 
is a recently developing field, and no work into it’s applicability to MHC peptide 
fractionation exists in the literature. 
 
Two resins from Pall Biosciences: HEA (hexylamine) HyperCel and PPA 
(phenylpropylamine) HyperCel, were assessed, each is normally utilised for 
industrial feed stock preparation. Both are mixed-mode resins with a 
combination of both HiLIC and hydrophobic-interaction chromatographic (HIC) 
properties, though lacking the latter’s need for high salt concentrations. The 
Strata-NH2 HiLIC resin (Phenomenex) was also investigated. 
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5.3.3.1  Assesment of various HiLIC resins for retention of a standard 
phosphopeptide 
   
In order to determine which of the three HiLIC resins (HEA HyperCel, PPA 
HyperCel and Strata-NH2) tested demonstrated the best potential for 
phosphopeptide retention, the ALR(p) peptide (HPS = 0.3) was employed as a 
standard; 0.2 mg peptide was loaded in 2 ml 90 % (v/v) ACN and the HiLIC 
columns (HyperCel columns constructed in-house using spent Varian Bond-Elut 
C18 cartridges, Strata-NH2 cartridge as supplied) washed/eluted with a stepwise 
gradient from 90 to 75, 50, 25 and 0 % ACN. While neither the PPA-HyperCel 
nor the Strata-NH2 resins retained a high proportion of the peptide, the HEA 
resin bound and eluted up to 53 % of the peptide in the 90 % ACN wash phase 
(see Figure 5.10). As the loading phase contained 0.1 mg/ml peptide which was 
derived from a 10 mg/ml stock in DMSO, it was speculated that the loss of 
DMSO from the mobile phase may have led to elution of the peptide. 
 
 
 
Figure 5.10: Typical peptide BCA-determined elution profiles of synthetic 
phosphopeptide ALR(pS)NFERI in fractions obtained from three HiLIC resins: HEA-
HyperCel and PPA-HyperCel (both Pal Biosciences), and Strata NH2 (Phenomenex) in 
SPE column setups.  0.2 mg peptide was loaded in a 2 ml volume of 90 % (v/v) ACN, and 
the columns washed and eluted with a stepwise gradient of 90; 75; 50; 25; and 0 % (v/v) 
ACN, with fractions of 6-drops collected (= ~0.3 - 0.4 ml). Fractions were vortexed mixed, 
diluted 1:5 with ddH2O and the diluted samples assayed by peptide BCA (as per section 
3.1.4). The HEA appeared to retain and elute up to 53 % (to P < 0.01, n = 3) of the 
phosphopeptide during the 90 % ACN wash (which unlike the loading phase lacked 1 % 
(v/v) DMSO), while both HyperCel resins showed smaller comparable peaks at 75 % (v/v) 
ACN. Error bars indicate SD. 
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5.3.3.2 Effect of DMSO on retention of peptides 
 
In order to determine the effect DMSO might have on ligand-column interaction, 
as well as determine whether other peptides would also elute at the same point 
on the solvent gradient, a tryptic digest of casein was prepared in 90 % (v/v) 
ACN. Precipitated material was removed by centrifugation at 20,800 r.c.f. for 
fifteen minutes and the supernatant applied to a HEA-HyperCel SPE cartridge 
and washed/eluted along the same stepwise gradient in the presence or absence 
of 1 % (v/v) DMSO in the mobile phase (see figure 5.11). The presence of DMSO 
was found to exert an increase in peak area, and at the lower end of the 
ACN:H2O gradient to produce peaks not found within the DMSO-free 
chromatographic runs. As casein is primarily serine phosphorylated (as is ALR(p)) 
phosphorylation of different amino acids (threonine/tyrosine) is unlikely to be 
responsible for the multiple elution peaks, though it could be hypothesised that 
the multiple phosphorylation sites within casein (which upon tryptic digestion 
usually lead to multiply-phosphorylated peptides) might be responsible for the 
multiple elution peaks. However, the binding of casein phosphopeptides to the 
column remained unproven. 
 
 
Figure 5.11: Typical peptide BCA-determined elution profiles of casein digests following 
SPE-fractionation with the HEA-HyperCel HiLIC resin with or without the inclusion of 
DMSO in the mobile phase (excluding H2O). 5 mg tryptic digest was prepared in 2 ml 
90 % (v/v) ACN, and (following removal of precipitate by centrifugation) the supernatant 
applied to the column. The columns were washed and eluted with a stepwise gradient 
and the 330 µl fractions collected and assayed by peptide BCA (see figure 3.3.9). Multiple 
peaks were observed, and the inclusion of DMSO was found to increase the amount of 
bound material and create additional peaks in the 25 % (v/v) ACN (1 % DMSO) and H2O-
only (DMSO-free) final phase. 
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Following on from this a 1 ml column was packed with HEA Hypercel resin and 
attempts made to replicate this data using a HPLC setup, with the aim of 
confirming the presence of phosphorylated material by peptide-PAGE and Pro-Q 
Diamond staining. However issues with pressure fluctuation (possibly linked to 
the precipitation observed at 90 % (v/v) ACN and highly exacerbated in the 
presence of DMSO) proved impossible to resolve (data not shown). Given this, 
and the relative incompatibility of DMSO with ESI-MS/MS, it was also decided to 
shift focus away from using DMSO to alter retention on the column. 
 
 
5.3.3.3 Binding studies of undigested casein and BSA protein to HEA 
HyperCel HiLIC. 
 
In order to simplify the analysis and compare phosphorylated with 
unphosphorylated material, undigested BSA and casein were prepared in 70 %; 
50 % and 25 % (v/v) ACN8 and applied to a 1 ml HEA HyperCel column with a 
similar stepwise gradient as per 5.3.1 with the addition of a 0.1 % (v/v) TFA 
wash following 0 % ACN (see Figure 5.12). It is notable that as the 
concentration of solvent in the loading conditions decreases, selectivity for 
casein also falls, while selectivity for BSA rises. At 50 % (v/v) ACN a double peak 
is observed for BSA which may correspond to (e.g.) the monomeric and dimeric 
isomers of the protein or differential sulphydryl content (Janatova et al., 1968). 
However the most significant result is that without the TFA wash the majority of 
sample does not disassociate from the column, though it is unclear whether this 
effect is due to the acidic conditions or whether the ion-pairing effect TFA is 
commonly employed for may be facilitating disassociation. 
 
 
5.3.3.4 Potential to retain a Post-IMAC phosphopeptide-enriched fraction 
 
In order to determine the potential for the two HyperCel resins to retain and 
fractionate a heterogeneous phosphopeptide population, a pre-enriched IMAC 
eluate from a casein digest was applied to each resin. Unlike the single synthetic 
ALR(p) peptide, with the exception of a minor peak at 50 % (v/v) ACN, elution of 
bound material did not occur until the column wash flushed with 0.1 % (v/v) TFA. 
Unlike the ALR(p) peptide, similar binding was found between both resins, 
though a sharper elution peak was obverved for HEA HyperCel (see figure 5.13). 
                                                 
8
 Casein would not dissolve in 90 % (v/v) ACN. 
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Figure 5.12: Typical peptide BCA-determined elution profiles of 
undigested casein and BSA loaded in (A) 70 %; (B) 50 %; (C) 25 % (v/v) 
ACN, and eluted along a stepwise gradient, followed by a final elution 
with 0.1 % (v/v) TFA. As the solvent concentration of the loading stage 
dropped, selectivity for casein followed, while BSA selectivity increased. 
It is notable that the 0.1 % TFA wash stage is crucial for full elution of 
bound material from the column, though the cause of this is unknown.  
  
B A
C 
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5.3.3.5 Inclusion of TFA in mobile phase 
 
Given the effect of 0.1 % (v/v) TFA on bound material, the inclusion of 0.1 % 
(v/v) TFA in the mobile phase on casein protein retention was investigated. 
Casein was loaded at 75 % (v/v) ACN and the stepwise elution carried out with 
the presence or absence of 0.1 % (v/v) TFA, following which five column 
volumes of 1 % (v/v) TFA was applied to elute any remaining bound material 
(see figure 5.14). However, no binding/elution was observed, and therefore 
inclusion of a steady TFA concentration along a solvent:H2O gradient would 
require a lower TFA concentration, if at all. 
 
 
  
 
 
Figure 5.13: Typical peptide BCA-determined elution profiles (1 ml/fraction) of HEA and 
PPA HyperCel resins (1 ml columns packed in-house) when loaded with phosphopeptide-
enriched casein IMAC eluates at 75 % (v/v) ACN and eluted by a stepwise gradient 
followed by a 0.1 % (v/v) TFA wash. Fractions were assayed by peptide BCA (as 
previously described). HEA HyperCel was found to elute in a tighter peak than PPA, but 
peak areas did not appear to differ between resins. ** denotes statistical significance to P 
<0.01 (n = 3). Error bars indicate SD. 
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5.3.3.6 Elution along an acid gradient / elution with alternative acids 
 
As elution seemed dependent on acidification (known to reduce hydrophilic 
interactions [Hjertén, 1973]), yet TFA seemed less than ideal for downstream 
purposes (given that it absorbs strongly in the UV at 210 nm precluding use of 
UV peak identification, and as an ion pairing agent it may suppress LC-MS/MS 
ionisation (Apffel, et al., 1995; Kuhlmann et al., 1995) the potential for 
alternative acids/concentrations was investigated by way of a stepwise gradient 
applied to a post-IMAC casein digest collected in 1 ml fractions and assayed by 
peptide BCA. HCl, formic, and phosphoric acid were all assayed alongside TFA to 
determine if they were suitable substitutions. Each column was finally flushed 
with 1 % TFA to determine if any material remained bound (see figure 5.15).  
 
Unfortunately only HCl was able to provide full elution of bound material, but in 
this case signs of resin damage rapidly became evident upon re-dehydration to 
70 % ACN, limiting re-use if these elution conditions were required in future. 
 
Figure 5.14: Typical peptide BCA-determined elution profiles (1 ml/fraction) of 
phosphopeptide-enriched casein IMAC eluates loaded onto HEA HyperCel resin at 75 % 
(v/v) ACN and eluted by a stepwise gradient in the presence or absence of 0.1 % (v/v) 
TFA, followed by a 1 % (v/v) TFA wash. Fractions were vortexed mixed, diluted 1:5 with 
ddH2O and the diluted samples assayed by peptide BCA (as per chapter 3). Presence of 
0.1 % (v/v) TFA in the mobile phase was found to prevent peptide binding. Error bars 
indicate SD. 
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Fortunately formic acid only produced a minor peak at 1 % (v/v), raising the 
potential for unbound R-P C18 or Fe
3+ IMAC fractions to be retained by HEA 
HyperCel as a secondary chromatographic pathway (though in the case of IMAC 
these may be depleted of phosphopeptides). Phosphoric acid produced peaks at 
0.1 % and 1 % (v/v) but did not fully elute at this concentration. It is possible 
that higher levels of phosphoric acid may allow full disassociation of bound 
material, but as a non-volatile acid, high concentrations must be avoided in 
conjunction with LC-MS/MS. Interestingly the column subjected to a TFA 
gradient did not fully elute at 0.1 % (v/v) TFA, suggesting that if TFA is used for 
fractionation a gradient will be required (i.e. a steady concentration of TFA along 
a solvent:H2O gradient may not allow full elution). 
 
 
5.3.7 Assessment of phosphopeptide selectivity 
 
Once elution conditions were optimised, the preference of the resin for 
phosphopeptides was reassessed. A mixture of four synthetic phosphopeptides 
or their non-phosphorylated counterparts were loaded at 0.2 mg/peptide onto 1 
ml HEA HyperCel columns in 75 % (v/v) ACN, and a short stepwise gradient to 
50 % (v/v) ACN, H2O, and then 0.5 % (v/v) TFA applied. Again, eluates were 
collected in 1 ml fractions and assayed by peptide BCA as previously described 
(see figure 5.16). No significant difference in binding was observed between the 
phosphorylated and non-phosphorylated, both of which appeard to elute 
between 50 – 0 % (v/v) ACN. Despite the variation in peptide’s physical 
characteristic multiple peaks were not observed, and the introduction of 0.5 % 
(v/v) TFA to the column similarly produced no effect. It is unknown however if all 
four peptides bound to the column, or whether a gradient between 50 – 0 % 
might resolve the unmodified peptides from the phosphorylated, however, these 
data suggests that any difference in binding may well be a matter of relative 
retention rather than true selectivity under the current conditions. 
 
The nature of the strongly bound post-IMAC casein peptides remains unresolved, 
however if they are phosphorylated they may be a distinct subpopulation of 
phosphopeptides. Given the failure of the synthetic peptides (each of which’s 
non- phosphorylated form was chosen for a high MHC class-I binding score) to 
bind and elute at this point, they may not be representative of MHC eluted 
nonphosphorylated peptides, however as the effects of phosphorylation on MHC 
binding are only currently being elucidated (Mohammed et al., 2008), the 
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overlap between MHC eluted phosphopeptides and HEA HyperCel-binding 
peptides may only be determined by direct experimentation. 
 
 
 
 
5.4   Discussion 
 
Phosphopeptide isolation, enrichment and fractionation is crucial for proper 
characterisation of this typically sub-stochiometric peptide population, and while 
a number of methods are available, immunoaffinity, IMAC and TiO2 are by far 
the most commonly utilised (Bai and Wang, 2009). As with all chromatographic 
approaches, IMAC may be utilised as either an analytical or a preparative 
chromatography approach, the former involving long run times, slow gradients 
and high separation into a large number of (dilute) fractions; while the latter 
involves rapid gradient changes with the aim of producing a single concentrated 
bound fraction which may then be taken on for downstream analysis. While the 
established IMAC protocol previously used at NTU has been shown to isolate 
phosphorylated peptides from a heterogenous mixture; by including a low-
molarity wash stage and increasing the elution pH to 9 a significant increase in 
 
Figure 5.15: Typical peptide BCA-determined elution profiles (1 ml/fraction) of 
phosphopeptide-enriched casein IMAC eluates loaded onto HEA HyperCel resin at 75 % 
(v/v) ACN and eluted by a stepwise gradient of acid (all v/v) followed by a 1 % (v/v) TFA 
wash and a short TFA-ACN gradient. Fractions were vortexed mixed, diluted 1:5 with 
ddH2O and the diluted samples assayed by peptide BCA (as per chapter 3). TFA remains 
the optimum acid for sample disassociation. 
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peak fraction concentration may be achieved, and the molarity of the elution 
buffer halved (thus doubling downstream compatibility) without a punitive trade-
off in peak height. These developments are also applicable to other IMAC 
procedures, as may be seen from the improved peak fraction concentration for 
Cu2+ IMAC (Fig 5.5). 
 
The analysis of phosphopeptides in the mass range of MHC eluates are much less 
restricted by the steric hindrances that complicate IMAC work with 
phosphorylated proteins and polypeptides (Han et al., 2008a), and while the 
technique carries a reasonable selectivity for phosphorylated peptides, IMAC is 
however not considered as robust as MOAC/TiO2 chromatography, which has 
seen a boom in use over recent years (D’Ambrosio et al., 2006). Like IMAC, 
acidic residues are the primary cause of non-specific sample binding, however 
this may be reduced by the inclusion of low DHB concentrations, or by reducing 
the loading pH (Pinkse et al., 2004; Larsen et al., 2005; Thingholm and Larsen, 
2009), as at pH 2 and below carboxyl groups such as the side chains of acidic 
amino acids are largely uncharged (Bai and Wang, 2009). While reductions in 
 
Figure 5.16: Typical peptide BCA-determined elution profiles (1 ml/fraction) of 
phosphorylated or non- phosphorylated peptide mixtures loaded onto HEA HyperCel 
resin at 75 % (v/v) ACN and eluted by a stepwise gradient to 0.5 % (v/v) TFA. Fractions 
were vortex-mixed, diluted 1:5 with ddH2O and the diluted samples assayed by peptide 
BCA (as per section 3.1.4). No significant distinction in binding was observed between 
the phosphorylated peptides or their nonphosphorylated counterparts. Error bars indicate 
SD. 
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the IMAC loading pH are capped at pH 1.7 or above, below which multiply-
phosphorylated peptides begin to disassociate from the column (Thingolm and 
Jensen, 2009)9, lowering the loading pH from 3.3 to 2 may reduce non-specific 
binding. Alternatively including wash stages of varying pH or solvent 
concentration may also aid disassociation of nonphosphorylated peptides, though 
this may require scaling up of the chromatographic setup to guarantee detection 
by peptide BCA10. Under-loading of sample onto the columns should also be 
avoided as this may lead to non-specific interactions which would normally be 
outcompeted by the phosphate groups (Dunn et al., 2009). The effect of salts or 
solvent on selectivity (as opposed to gross binding) is also worth investigating, 
as either may further reduce non-specific interactions or possibly even metal ion 
leakage. However care must be taken as it is unknown whether these 
improvements in selectivity, or indeed the higher stringency some have found 
TiO2 to have over IMAC (Larsen et al., 2005) may result in a decrease in the 
population of phosphopeptides which are retained on the column. Methods may 
be further optimised by the inclusion of low concentrations of Tris to reduce 
binding (Proteus, 2004; GE Healthcare, 2005). While our own data suggests 
ascorbic acid can cause metal ion loss from the column, very low concentrations, 
or another antioxidant may be included to minimise metal-catalysed oxidation on 
the column 11  (Krishnamurthy, et al., 1995) which would complicate mass 
spectrometric analysis 12 , though these in turn must be compatible with 
downstream analysis. Loss of metal ions may be adjusted by using higher-
affinity resins such as the tetradentate NTA (Hochuli et al., 1987; Holmes and 
Schiller, 1997), though as already mentioned this may affect column capacity 
and peptide binding/selectivity (Kaur-Atwal et al,. 2008). A new variation on 
IMAC using GMA-EDMA polymer beads as a resin, which operates by the 
coordination of free phosphonate to in turn immobilise metal ions was found to 
produce a higher specificity for phosphopeptides than TiO2 or ZrO2 (reviewed in 
Han et al., 2008a). 
 
                                                 
9
 Though inter-resin variations may also play a role here, as they found full elution of all 
phosphorylated peptides did not occur until pH 10-11, when multiply phosphorylated peptides also 
disassociated  from the column. 
10
 An alternative approach would be to concentrate unbound fractions by freeze-drying (if their matrix 
is volatile) or by another chromatographic method, however this may have implications for accuracy 
of quantification. 
11
 It is conceivable that the 1 mM glutathione content of the MHC elution buffers may do just this, but 
this has not been assessed at the time of writing. 
12
 Araña et al.,  (2001) note that formic acid may be degraded by Fe 2+/3+, or by TiO2. If this leads to 
carbon monoxide production a formic acid based buffer may promote metal ion loss or sample 
oxidation. 
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As previously mentioned, another method to reduce non-specific binding involves 
chemically modification of samples prior to IMAC. Methylation is the most 
common approach, and in 2002 Ficarro et al., (2002; Salomon, 2003) developed 
a novel method for methylation of acidic residues involving incubation with 2N 
HCl in methanol. An alternative which seems to have been mostly overlooked 
with regard to IMAC is carbodiimide-catalysed methyl-esterification of carboxylic 
groups13. Using the improved protocol published by Staros et al. (1986) the 
addition of N-hydroxysuccinimide may be used to increase the efficiency of 
reaction with the methyl-ester. However, as with all modifications, conditions 
must be carefully chosen to avoid both incomplete modification (which can 
significantly complicate mass spectra, reducing the clarity of results and 
inhibiting analysis) and cross reactivity with other residues, or functional groups 
(D’Ambrosio et al., 2006; Han et al., 2008a)14. Preliminary work in this area 
carried out at NTU appeared not to have any negative effects on the phosphate 
groups, but was found to significantly dilute samples. However pre-IMAC sample 
concentration, either by HiLIC (McNulty and Annan, 2009) or by reversed-phase 
may compensate for these changes in volume, be they prior to or following 
modification. Indeed, it has been suggested that the reaction might be carried 
out in an organic solvent such as ACN (Dr Ray Wallace, Nottingham Trent 
University, Pers. Comm., 2007), similar to the methylation protocol developed 
by Ficarro et al. (2002), and this would also leave the samples compatible with 
the high-solvent loading/washing buffer used by Ndassa et al. (2006). 
 
However the largest stumbling block to proper method development remains the 
limited understanding of both TiO2 and IMAC’s mode of action (Thingolm et al., 
2008), there is evidence that IMAC may yet prove as robust as TiO2 (Liang et al., 
2007). Furthermore, both IMAC and TiO2 chromatography are still undergoing 
continuous and highly fractured method development, and while the lack of 
standard methods allows flexibility and tailoring of methods to specific samples 
and analytes, it also produces a highly heterogeneous body of literature, which 
renders comparisons between publications challenging to say the least. A 
standardisation effort between multiple research groups using a large panel of 
phosphorylated peptides (+/- nonphosphorylated peptides with acidic amino 
acids) with a range of different physical properties (not to mention the 
                                                 
13
 Note that this modification may render the aspartic acid residues trypsin-cleavable (Wang & Young, 
1978), and that a secondary reaction may also (irreversibly) modify the sulphydryl group of cysteine 
(Carraway and Koshland, 1968 in Timkovich, 1977) at approximately the same rate as the carboxyl 
groups and the hydroxyl group of tyrosine (Hoare & Koshland, 1966) (though this is a slower reaction 
and is reversible by addition of hydroxylamine) (Carraway & Koshland, 1972). 
14
 For examples of carboxymethylation of alternative residues see Gurd (1967).  
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underexplored world of N-, S- and acyl linked phophorylation) would go a long 
way towards determining the relative advantages of each methodology, as well 
as possibly further elucidating the mechanisms by which both methods operate, 
and why neither will bind the full range of phosphopeptides. 
 
Reversed–phase resins have been the most commonly utilised peptide 
concentration/fractionation method for over twenty years, and (unlike IMAC and 
TiO2) have a simple methodology which is relatively homogenous between 
research groups 15 . However despite the recognised importance of 
phosphorylation in signalling pathways, the binding kinetics of phosphopeptides 
to reversed-phase columns are not fully understood. While we did not compare 
binding between phosphorylated and nonphosphorylated peptides, the 
hydrophilic (C-terminal) tyrosine-phosphorylated SQK(p) peptide and the 
hydrophobic (mid-peptide) serine-phosphorylated YIS(p) both showed 
comparable binding to C18 reversed-phase SPE cartridges despite their divergent 
physical properties, but recovery for both peptides was not high. While this could 
be increased by raising the TFA concentration, the increased ion-pairing effect 
may dampen the resulting M/S signal, although acids which did not ion-pair to 
the same extent did not provide the same effect. However these approaches 
may still be fruitful for HPLC fractionation or use of RP as a first dimension 
before applying to IMAC, peptide-PAGE or simply drying under vacuum (e.g. 
prior to MALDI-TOF MS/MS). 
 
Through the mixed mode work indicated a variation in selectivity for the two 
peptides tested, the Strata X-AW anion exchange resin appeared to be capable 
of binding both peptides (though a greater amount of SQK(p) was recovered 
than YIS(p), and was split between two elution conditions. Nevertheless, Dai et 
al. (2007) note that cation exchange resins struggle to isolate phosphopeptides 
with a pI lower than 4.5, while anion exchange resins are capable of capturing 
these peptides, which is to some extent borne out by our data: SQK(p) has a pI 
of 4.3, while YIS(p) is much higher at 9.5. Han et al. (2008b) report that the use 
of strong anion exchange chromatography (SAX) to isolate and fractionate 
phosphopeptides may be as effective as Fe3+ IMAC, though the extent to which 
their selectivities overlap is as yet unknown. 
 
                                                 
15
 Acidification and loading solvent concentration (typically 0 – 10 %) are the factors most likely to 
vary, the majority of HPLC takes place using either MeOH or ACN. 
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HiLIC show some promise as a method to concentrate phosphorylated peptides 
either prior to or following IMAC. While the preliminary data in figure 5.16 
suggests that HEA HyperCel does not appear to have any true selectivity for 
phosphopeptides under the current conditions, this is similar to the results found 
by Albuquerque et al., 2008; and McNulty and Annan, 2009; both of whom state 
that HiLIC alone does not appear to be suitable for phosphopeptide purification. 
Ideally utilisation of HiLIC with a HPLC setup would have provided rapid and 
reproducible results for method development in this area. Unfortunately such a 
marriage of technologies was not achieved during this research period, issues 
with pressure were especially prevalent, and perhaps expected once the primary 
use of the resins (industrial feedstock seperation) are taken into account. It was 
however possible through careful packing and low flow rates to generate a HPLC 
setup within the pressure tolerance of the resins in the absence of analyte or 
DMSO. The inclusion of either, especially injection of a tryptic casein digest led to 
pressure increases, possibly due to micellular formations and low solubility even 
at 75 % ACN. Furthermore, even if one were willing to accept the damage to the 
resin from exceeding pressure tolerance, the research to date suggested TFA 
was required to fully elute a heterogeneous digest from the resin, however TFA 
absorbs strongly in the UV at 210 nm, complicating peak identification, hence 
research was restricted to the more laborious BCA assay approach, as it has 
greater accuracy for biological samples. Crucially the effect of loading pH and 
salt concentration were not investigated fully, samples were merely loaded in 
differing solvent concentrations, however it is possible that the higher pH of the 
tryptic digests (pH 8.0) and IMAC eluates (pH 9.0) may explain the difference in 
peak elution points between these and the synthetic peptides, which were loaded 
without buffering. Whilst there is little literature available for either HEA or PPA 
Hypercel, Pezzini et al. (2009) and Brenac Brochier et al. (2009) both noted a 
benefit to eluting along a pH gradient when utilising HEA Hypercel for purification 
of recombinant protein. 
 
Nevertheless it is hoped that the mixed-mode aspects of HEA (or even PPA) 
HyperCel might allow better selectivity for phosphopeptides with further method 
development. Even utilising the methods as they are in combination with RP and 
Fe3+ IMAC should allow significant decomplexing of resultant mass spectra, 
though again, ion pairing agents such as TFA are widely regarded as problematic 
for ESI-MS/MS due to the resulting neutralisation of cation charge, masking 
analytes from positive-mode mass spectrometers (Apffel, et al., 1995; Kuhlmann 
et al., 1995), and it may be beneficial to employ vacuum drying or application 
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onto a second chromatographic dimension (such as IMAC) prior to LC-MS/MS. 
Furthermore the current methodology for Cu2+ IMAC may not be downstream 
compatible with HEA/PPA HyperCel HiLIC, though figure 5.15 indicates that 
formic acid would be a suitable loading matrix in place of TFA (especially 
following sample dilution in ACN), this may require some optimisation as a Cu2+ 
IMAC elution buffer. With this exception, care has been taken to maintain inter-
method compatibility as far as is possible, therefore an eluate from any method 
should be capable of fractionation by a subsequent approach, or by LC-ESI-
MS/MS, if room for sample dilution prior to loading is allowed, and peptides are 
decomplexed and concentrated to the point that supression effects of remaining 
ion pairing agents (e.g. TFA) are tolerated. 
 
It must be remembered however that each chromatographic step reduces the 
material left for the next stage. At the 2 * 109 suspension cell number used for 
MHC class-I elution, stochiometric concentrations of at least 10 copies of each 
peptide are expected per cell, resulting in at least fmolar concentrations of each 
peptide following MHC elution (Bonner, 2002), though how these figures relate 
to phosphorylated peptides (and/or class-II phospho/peptides) is much less clear. 
Chromatographic losses must be weighed up against poor signal/noise ratios, or 
effective underloading of the final analytical approach due to low interaction 
between peptide fractions and the method in question. Furthermore comparisons 
of chromatographic methods, especially with regard to IMAC are plagued by the 
lack of standardisation within the field, and the complementary (and only partly 
overlapping) binding profiles between the main phosphopeptide isolation 
methods also complicate inter-chromatographic comparisons (Bodenmiller et al., 
2007). Nevertheless the above data indicates that IMAC, already well regarded 
as a LC-MS/MS compatible approach for phosphopeptide enrichment can be 
further tailored as a prep-chromatographic stage, and that HiLIC appears 
capable of binding a subpopulation of phosphorylated peptides following IMAC 
enrichment. 
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6.0  Mass spectrometry 
 
6.1  Introduction 
 
 
Following sample fractionation and phosphopeptides enrichment, peptide 
sequences require identification by mass spectrometry, followed by a BLAST to 
determine their likely protein of origin.  
 
It is something or an irony that mass spectrometry (MS), based on approaches 
developed by Thomson (1913) and Aston (1933), has existed since the mid 
1950’s, as long as the Edman sequencing method, yet while the former is far 
more common for determining peptide sequencing today, it did not achieve this 
status until the late 1970’s, and far more recently. The reasons behind this are 
primarily technological; early MS methods used a gas chromatographic mass 
spectrometer (Biemann, 1995), and while small molecules were ‘easily’ ionisable 
using electron-impact, polar/thermally labile molecules such as peptides required 
extensive and laborious chemical modification to render them volatile and readily 
ionisable. These methods also required relatively abundant samples, and 
struggled to sequence peptides of greater than 8 amino acids accurately 
(Griffiths et al., 2001); while the Edman method was rapidly automated, and 
capable of dealing with larger polypeptides, and much less concentrated samples. 
However, pioneering research across the globe (including both sides of the Iron 
Curtain) gradually eroded these problems; the 1980’s saw the advent of soft 
ionisation approaches, such as fast atom/ion bombardment (FAB-/FIB-MS), 
electrospray ionisation (ESI) and matrix-assisted laser desorption-ionisation 
(MALDI) (usually with a time-of-flight [TOF] detector), rapidly increasing 
ionisation rates. These, along with improvements in mass detector sensitivity 
allowed the sample requirements to fall to the pico and femtomolar 
concentrations commonly used today. Indeed, the miniaturisation of LC-ESI-
MS/MS was to some extent driven by the requirements for analysis of MHC 
peptides, which typically display high heterogeneity and sample scarcity 
(Biemann, 1995). 
 
Though mass spectrometers may be divided into numerous subtypes (e.g.: ESI, 
MALDI, ion mobility mass spectrometry), all involve the ionisation of a sample 
(“source”), the fractionation/isolation of analyte within that sample by 
mass/charge (m/z) by a mass analyser, and the determination of ion abundance 
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values (mass detector). While this gives limited information, combining it with a 
tandem mass spectrometric approach (MS/MS), where the precursor ion is 
further fragmented (usually by collision-induced disassociation) (Wells and 
McLucky, 2005), allows peptide sequences to be determined from the daughter 
ions (Griffiths et al., 2001).  
 
The majority of mass spectrometric based peptidomic approaches rely on either 
MALDI (e.g. MALDI-TOF-MS or MS/MS16) or ESI (frequently LC-ESI-MS/MS1) as 
their ion source. MALDI involves the complexing of volatile sample (often 
tryptically digested and desalted by RP) with a matrix such as α-Cyano-4-
hydroxycinnamic acid (α-CHCA) or sinapinic acid on a MALDI plate. This mixture 
is allowed to co-crystallise, and the resultant spot targeted with a laser pulse. 
The matrix absorbs the energy of the laser, transferring it to the sample, which 
is ionised and launched towards the detector (which in modern models almost 
always utilises an ion trap). Smaller, strongly ionised peptides travel faster, and 
the time-of-flight may then be used to determine the peptide m/z. 
 
Electrospray ionisation (ESI) is commonly used with a liquid chromatography (LC) 
setup, typically an HPLC with a RP column. Unlike MALDI it is a semi-continuous 
approach, samples are concentrated onto an analytical column and eluted along 
an acidified aqueous to solvent (ACN) gradient. As these elute they are pumped 
through a charge which is subjected to a high voltage, imparting a (usually 
positive) charge to the sample which exits the needle into a vacuum. The 
positive charge of the ionised analyte molecules repel one another, which 
combined with the low pressure forms an ionised gas (“Coulomb explosion”); 
this enters the MS analyser (typically an ion trap) as a beam of ions, which may 
then be fragmented by collision with electrons or an inert gas to determine 
peptide sequence (Cole, 1997; Griffiths et al., 2001).  
 
Whilst MALDI allows high throughput and efficient ionisation of peptides, the 
fractionation approach of LC-ESI MS/MS (along both hydrophobicity and m/z) 
provides a greater resolution for peptides of similar masses (e.g. MHC-eluates). 
Quadropole setups such as the Thermo Fisher Finnegan LTQ (Linear Trap 
Quadropole) are among the most common mass analysers used in conjunction 
with ESI (El Aneed, 2009), especially with regard to MHC-associated peptides 
(Lemmel and Stevanovi, 2003; Bonner et al., Zarling et al., 2006; 2002; Milo et 
                                                 
16
 These are common combinations, though in theory any MS source should be combinable with any 
mass analyser. 
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al., 2007) though MALDI is used by some groups (Butterfield et al., 2001; 
Ramos et al., 2004). 
 
 
 
 
 
6.2 Comparison of citrate-phosphate and TMA-formate MHC 
class-I eluates by MALDI-TOF/TOF mass spectrometry 
 
Cultures of 2 x 109 K562-A3 and LAMA-84 cells were subjected to MHC class-I 
elution using either the isotonic citrate-phosphate (K562-A3 only) or 
supplemented TMA-formate (K562-A3, LAMA-84) elution buffers (both pH 3.3) 
by the methods outlined in 2.4.2. 10 % of each eluate was subjected to SPE 
sample cleanup by two rounds of chromatography by C18 (as per 2.5.2.4) and 1 
µl of eluate assayed by MALDI-TOF (CHCA matrix) using methods optimised by 
Matharoo-Ball et al. (2007) and Vafadar-Isfahani et al. (2010) in a mass range 
from 600 to 3500 Da (see figure 6.2). When analysed these indicated similar 
spectra for both citrate-phosphate and TMA-formate eluted K562-A3 samples. 
The spectra obtained from the LAMA-84 cell line was distinct from all four from 
K562-A3, indicating that the peaks identified are linked to the cell line in 
question (i.e. not a product of the culture conditions, which were identical for all 
five samples). 
 
The major peak in the K562-A3 samples (1308.702 Da) was sequenced by 
tandem mass spectrometry (see figure 6.3) and the sequence compared to the 
Figure 6.1: Schematic design of a Fisher Thermo LTQ ESI MS/MS (adapted from Fisher 
online).  
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human proteome (SwissProt database). It was subsequently found to be a ten 
amino acid peptide (LVVYPWTQRF), which lies in a region of the haemoglobin 
sequence common to the β, γ-1; γ-2; and ε subunits. Though sequence data 
alone cannot rule out the potential for contamination with serum peptides, again 
the presence of this peptide in all five K562-A3 eluates (and as they major peak 
in all but one) but apparent lack within the LAMA-84 eluate implies that it is 
restricted to the K562-A3 cell line, which is known for haemoglobin synthesis 
(Zuhrie et al., 1988).  
 
Of note is the relative signal strength between the peptides. A signal intensity of 
2.5 x 104 a.u. was observed for both K562-A3 samples eluted in isotonic citrate 
phosphate. However for the TMA-formate eluted K562-A3 this ranged from 2.5 - 
5 x 104 a.u., while the LAMA-84 cell eluate was only 1 x 104 a.u.. It is important 
to consider that while mass spectrometry is a concentration-dependent 
technique, the apparent abundance of this peptide may not be reflected in the 
original samples, but may instead be a product of ionisation or chromatographic 
retention. It is possible that the LVVYPWTQRF peptide may have been 
preferentially retained on the C18 columns to a greater degree than other 
peptides, and that some enrichment may have taken place, a possibility which is 
supported by the peptides predicted hydrophilicity (-1.0)17. 
 
In terms of the peptide’s origin, the SYFPEITHI MHC-binding prediction algorithm 
(Rammensee et al., 1999) assigned a MHC class-I A3 binding score of 14 to the 
LVVYPWTQRF peptide; below that normally considered for reverse immunology, 
while the stringency of the algorithm may incorrectly exclude peptides which do 
bind (Pers. Comm., Dr Roger Horton, 2006, Nottingham Trent University). Lin et 
al., (2008) found the algorithm to have a success rate of 80-90 %, and therefore 
again, a serum/membrane-associated origin for the peptide cannot be ruled out.  
However a near-identical peptide LVVYPWTQRY (HBB33-42) was recently under 
investigation (in a murine sarcoma model) by Komita et al. (2008), lending 
weight to the possibility of presentation by the MHC18. 
 
 
                                                 
17
 Determined as per 2.3.2.1. 
18
 Tyrosine and phenylalanine share similar structures, and each are coded for by two codons. An A/T 
SNP can lead to the conversion of one to in respective codon pair (Tan et al., 2005; Schneider et al,. 
2008). 
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Figure 6.2: MALDI TOF-TOF mass spectra (600 – 3500 Da) for MHC class-I eluates from ~ 
2 * 109 K562-A3 (A-D) and LAMA-84 (E) cell lines eluted with isotonic citrate-phosphate (A, 
B) or supplemented TMA-formate (C-E) as per 2.4.2. Of particular note were the peaks 1195, 
1308 and 3330 present in all K562-A3 samples, but absent in LAMA-84 (see Figure 6.2 for 
MS/MS analysis of 1308 Da peak). 
 
E 
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Figure 6.3: Tandem mass spectra (MALDI-TOF/MS) for major peak (1308 Da) from 
K562-A3 MHC class-I eluate (this peak was common to all K562-A3 samples, this spectra 
was generated from sample D in Figure 6.1). A MASCOT search against the SwissProt 
Human database revealed it to be LVVYPWTQRF, with a proposed origin in the 
Haemoglobin sequence (β, γ-1; γ-2; or ε subunit), closely matching the HBB33-42 peptide 
(LVVYPWTQRY) presented by the CMS-4 sarcoma cell line, and against which a CD8+ 
CTL response may be generated (Komita et al., 2008). 
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6.3 LC-ESI MS/MS mass spectrometry of phosphopeptides from 
MHC class-I eluates 
 
MHC class-I peptides were eluted from 2 x 109 cells of the cell lines JY, K562-A3, 
and THP-1 (cultured as per section 2.2) using the supplemented 25 mM TMA-
formate buffer (pH 3.3) as detailed in 2.4.2. The phosphopeptide subpopulation 
was enriched by Fe3+ IMAC as per 2.5.1.1.4 and peak fraction subjected to ESI-
MS/MS following RP (C18) fractionation in the second dimension by HPLC (as per 
2.6.2). 
 
Some typical mass spectra are presented in figure 6.3, in this case 
supplemented TMA-formate eluted MHC class-I peptides from the K562-A3 cell 
line. Similar spectra (though different peptides) were observed in MHC eluates 
from the EBV immortalised JY cell line and the AML cell line THP-1. Some notable 
examples are listed in Table 6.1. 
 
 
6.3.1 Identification of MHC class-I restricted peptides from a 
transfected cell line 
 
MHC class-I peptides were eluted (as per 2.4.2.2.1) from cultures of 2 x 108 
murine CT26 cells transfected with the immunogenic GP63 protein4 (expressed 
by way of a CMV promoter) from L. mexicana, a strain of parasite responsible for 
the Leishmaniasis (Ali et al., 2009) and subjected to two rounds of SPE sample 
cleanup using a C18 RP column as per 2.6.2. 
 
Three GP63 peptides in the 7-12 mass range were putatively identified: 
AGSAGSH; CTAEDILTDEK and TDEKRDTLVKHL, though only one (CTAEDILTDEK) 
with a confident score (for spectra see figure 6.4). No evidence of hydrophobic  
peptide enrichment was seen (peptide hydrophilic scores are 0.1, 0.8 and 1 
respectively), though sample decomplexing was observed as an attempt to 
subject the sample to ESI-MS/MS following a single round of C18 SPE showed far 
higher background signal (data not shown). However, as no prewash step was 
used higher contamination of non-MHC peptides would be expected, and the 
presence of these peptides must therefore be validated, and following on from 
this their immunogenicity assessed. While the 7- and 12-amino acid peptides are 
outside of the mass range found for most MHC class-I peptides (typically 8-11  
                                                 
4
 Kindly donated by Dr Selman Ali and Ms Anisha Bannerjee (Nottingham Trent University) 
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Figure 6.4: Typical tandem mass spectra (ESI-MS/MS) for phosphopeptides from MHC 
class-I eluates of the K562-A3 CML cell line. Sequences determined by ESI-MS/MS 
following C18 fractionation of a Fe3+ IMAC eluate. (A) [Q13467] (pS)APQLLLLLLL from 
Frizzled 5; (B) [Q9UI38] LLLLLLLLR(pS) from Testis-specific protease-like protein 50; (C) 
[Q16825] SNP(pS)ITGS from Tyrosine-protein phosphatase non-receptor type 21. 
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Peptide(s) Protein Name and 
Accession No 
Details  
FIQQRL(pS)Q(pT)EP (Q8WZ42) Elastic titin Involved in chromosomal 
condensation. 
(pT)AAKPRQKALP (Q12934) Filensin,  Cytoskeletal protein. 
(pY)REV(pS)RAFHLN 
(P55160)  Membrane-
associated protein HEM1/ 
NCKAP1L 
Hematopoietic protein 
LLLLLLLLR(pS) 
(Q9UI38) Testis-specific 
protease-like protein 50 
(TP50) (Cancer/testis 
antigen 20) 
Expression formerly considered 
testis-specific, but now known in 
kidney, liver and pancreas (Scanlan 
et al., 2004). Expressed in breast 
cancer and regulated by p53 (Xu et 
al., 2007). 
LIAMK(pT)EKEE (Q15596) Nuclear 
receptor coactivator 2 
Fuses with MOX in AML and results 
in P53 inhibition. 
KKKKEKVLA(pT) (Q02878) Ribosomal protein HL6, cytosolic 
Associated with human T-cell 
leukemia virus 
LEFHEAILRL(pS) (Q99871) UCHL5-interacting protein Part of the 26S proteasome 
(pS)GGGGGLLL 
(P78426) Homeobox 
protein Nkx-6.1, NKX6A, 
NKX6-1 
Involved in β cell development. 
Gene methylated/downregulated in 
number of cancers. 
LLLLLPLS(pS)(pS) 
(Q16270) Insulin-like 
growth factor-binding 
protein 7 
Proto-oncogene differentially 
expressed in many cancers. Known 
expression in K562 cell line (Jin et 
al., 2007). 
KPNLDV(pT)(pS)(pT) (P12821) Angiotensin 
converting enzyme 
Overexpressed in AML, and in 
K562 cell line. Linked to tumour 
progression. Inhibition may have 
anti-leukaemic effect (De la Iglesia 
Iñigo et al., 2009) 
(pS)APQLLLLLLL (Q13467) from Frizzled 5 (FZD5) 
Linked to Wnt / β-catenin  signalling 
(both proto oncogenes) (He et al., 
1997; Lai et al., 2009) 
KVRFQA(pS)IHL (P56499) Mitochondrial 
uncoupling protein 3 Involved in thermostasis. 
LVQLP(pS)GQ(pT)I 
(Q03060) Indiucible 
cAMP-early repressor 
(ICER/CREM) 
Often downregulated in cancer, 
often by phosphorylation in 
leukaemia, leading to proteasomic 
degredation (Pigazzi et al., 2008) 
LLLLLLL(pY)K(pY)K 
(P07333) Macrophage 
colony stimulating factor 
1 receptor (M-CSF-1R) 
(aka cFMS proto-
oncogene) 
Membrane Y-kinase involved in 
myeloid-development. Implicated in 
many cancers and sensitive to 
Imatinib (Dewar et al., 2005). 
SNP(pS)ITGS 
(Q16825) Tyrosine-
protein phosphatase non-
receptor type 21. 
Regulator of Tec kinase family. 
Binds Src (Jui et al., 2004). 
Frameshift mutations common in 
colorectal cancer (Korff et al., 2008) 
Figure 6.1: MHC class-I phosphopeptides eluted from the CML cell line K562-A3 and 
isolated by Fe3+ IMAC. Where references are not indicated, details are adapted from 
UniProtKB (http://www.uniprot.org/uniprot/), OMIM (http://www.ncbi.nlm.nih.gov/omim/) and 
iHOP (http://www.ihop-net.org/UniPub/iHOP/) databases. 
 
Chapter 6.0: Results 
Mass spectrometry 
 217
 
Peptide(s) Protein Name and 
Accession No 
Details  
(pS)EGA(pS)SD 
(P26442) Autocrine 
motility factor (AMF) 
receptor 
Involved in tumour metastasis, AMF 
release is induced by EBV infection. 
(Baumforth et al., 2005)  
IINLG(pS)LVIED 
(O15164) Transcription 
intermediary factor 1-
alpha (TIF1-alpha) 
Transcription factor that interacts 
with estrogen receptors. Fusion with 
RET produces the PTC6 oncogene.  
IPIQINVG(pT)(pT) 
(P46379) Large proline-
rich protein BAT3 
(Protein G3) 
Involved in DNA damage stimulated 
P53 acetylation (Sasaki et al., 
2007). Transcription induced by 
EBV protein LMP2A (capable of 
circumventing p53) in lymphoma 
(Bieging et al., 2009. 
Figure 6.2: MHC class-I phosphopeptides eluted from the EBV-immortalised JY cell line 
and isolated by Fe3+ IMAC. Where references are not indicated, details are adapted from 
UniProtKB (http://www.uniprot.org/uniprot/), OMIM (http://www.ncbi.nlm.nih.gov/omim/) and 
iHOP (http://www.ihop-net.org/UniPub/iHOP/) databases. 
 
Peptide(s) Protein Name and 
Accession No 
Details  
FSPCAEK(pS)P 
(P35916) Vascular 
endothelial growth factor 
receptor 3 (VEGFR-3) 
Receptor Y-kinase implicated in 
leukaemia proliferation/resistance to 
therapy and MAPK activation 
(reviewed in Su et al., 2007; 2008) 
(pS)SSTPSSLPQSF 
(borderline score) 
(O60732) Melaloma-
associated antigen 
(MAGE) C-1 
C-T antigen with unknown function, 
expressed in multiple myeloma 
(Jungbluth et al., 2005). 
Figure 6.3: MHC class-I phosphopeptides eluted from the AML cell line THP-1 and 
isolated by Fe3+ IMAC. Where references are not indicated, details are adapted from 
UniProtKB (http://www.uniprot.org/uniprot/), OMIM (http://www.ncbi.nlm.nih.gov/omim/) and 
iHOP (http://www.ihop-net.org/UniPub/iHOP/) databases. 
 
amino acids in length5), immunogenic septomeric and duodecomeric peptides are 
known (e.g. Fu et al., 1994; Chen et al., 1992) and so they remain potential 
candidates for further investigation. However given that the cell population from 
which this eluate was sourced was an order of magnitude below that normally 
used for direct immunology, the immunogenic peptide within GP63 may be none 
of the above, and a larger sample may be required. 
 
While no 3000 / 5000 w.m. cutoff filters have been applied to the MHC class-I 
elutates prior to chromatographic fractionation, it is possible that doing so (or 
including a size-exclusion chromatographic stage) may be worthwhile, especially 
in this case. Though for post Fe3+ IMAC analysis of phosphopeptides, the non-
phosphorylated β2-microglobulin molecule is not expected to be retained, in this 
instance no phosphopeptide enrichment stage was performed, and it is possible  
                                                 
5
 Though MHC class-I H2-Kd (one allele expressed by the CT26 cell line)  shows a high preference 
for nonamers, with only 16% of peptides found by Suri et al. (2006) exceeding this length. 
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Figure 6.5: Tandem mass spectra (ESI-MS/MS) for three peptides from MHC class-I 
eluates of the GP63 transfected murine ALC cell line. Peptide sequences: (A) 
CTAEDILTDEK; (B) AGSAGSH; and (C) TDEKRDTLVKHL. Determined by ESI-MS/MS 
following serial C18 fractionation (2x C18 SPE, 1x HPLC). 
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that the 12 kDa β2M molecules (which should be in a 1:1 ratio with MHC class-I 
peptides) have drowned out the MHC peptides, both in terms of BCA 
quantification (ceteris paribus, β2M may lead to a 10-fold overestimation of 
peptide content) and in terms of chromatographic retention.6 
 
 
 
6.4   LC-ESI MS/MS mass spectrometry of phosphopeptides from    
 MHC class-II eluates 
 
MHC class-II peptides were eluted from 2 x 109 cells of the THP-1 (known to 
present low levels of MHC class-II DRB0101, DRB1501, DQB05, DQB06, 
DQA0101, and DQA0102) (Berges et al., 2005) and JY (DR4+, DR6+) (Kaufman 
and Strominger, 1979) cell lines using the supplemented MHC class-II elution 
buffer (as per 24.2.3); and subjected to Fe3+ IMAC, from which the peak 
fractions were further concentrated and desalted by C18 RP SPE, following which 
samples were subjected to LC ESI-MS as per 6.3. 
 
In this case however poor spectra were found in almost all cases. LC-ESI-MS/MS 
of the IMAC eluates prior to C18 concentration were indistinguishable from 
background in every case (peak ion intensities of as low as 17 counts were 
observed). When peak fractions from IMAC eluates were subjected to 
concentration by C18 RP SPE, the majority of all samples failed to bind to the SPE 
column, but the signal strength rose by one order of magnitude. Despite this no 
confident spectra were found in MHC class-II eluates from the JY cell line, while 
a number of borderline spectra were found in the THP-1 cell eluate. 
 
Of these, three represented peptides within the 14-26 amino acid MHC class-II 
range (see figure 6.5), however only two (Protocadherin Fat 1 and Nuclear 
receptor corepressor 1) could be identified in the Homo sapiens proteome. The 
third was found to correspond to cell division protein zipA homolog in the 
bacterial Pseudomonas putida proteome.  
 
A MCH class-II eluate of the CML MHC class-II negative LAMA 84 cell line 
processed in the same fasion failed to present any confident spectra, and the top 
                                                 
6
 Though the BCA figure may be an overestimate given the low (-0.2) HPS of the β2M polpeptide, 
this low hydrophilicity may lend itself to C18 binding, reducing the capacity for MHC peptide 
retention except by way of any secondary interactions with the β2M itself. 
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10 peptides listed were all over 27 amino acids in length, with a mean peptide 
length of 37.33 amino acids. This supports the hypothesis that the above 
peptides from the THP-1 cell line have a MHC class-II origin, though whether 
they originated in extracellular material or from the intracellular proteome by 
way of cross-presentation is unclear, and their immunogenicity is currently 
uninvestigated. 
 
 
6.5  MHC peptide database design 
 
The mass spectrometry of MHC eluates rapidly led to a build up in lists of peptide 
sequences. In order to maintain a high level of order a database was required to 
contain sequences, protein source data and cell line data. It was decided to 
utilise Microsoft Access (ver 2003) to generate and manage the database for a 
number of reasons primarily related to speed and convenience. Chief amongst 
these were prior experience in database design using this facility, flexibility of 
the software to accept changes in the structure of an existing database (allowing 
the addition of new fields, or deletion of pre-existing ones) and the availability of 
the software, being present on all machines within NTU. 
 
To prevent duplication of data, the SwissProt accession number of each protein 
was chosen as the key field (/unique record identifier). This allowed peptide 
sequences to be stored by parent protein, along with details on the protein’s 
function, distribution and potential links to malignancy. In order to facilitate 
searches, a range of Boolean check-boxes were utilised, allowing exclusions of 
extraneous records as well as sorting by alphabetic or numeric fields (e.g. 
accession number or common titles). Secondary research was carried out 
regarding each protein, and a brief literature review of relevant information 
composed (the check-boxes conveying additional information). Depending on the 
protein’s function and the information found in the literature review, a ‘potential 
significance’ score was assigned manually from 0-9. A screen-capture of the 
database can be found in figure 6.6. 
 
While data entry into the database is an ongoing effort (currently it contains 
approximately 200 records), the end result is a tool which allows a user to 
search for peptides from proteins by their sequence, the protein’s role (e.g.  
receptors, transcription factors, kinases), or links to cancer in general, or specific 
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forms of malignancy. The search may also be restricted to include or exclude 
posttranslationally modified peptides, or peptides from a single cell line. It also  
 
 
 
 
 
 
 
 
Figure 6.6: Tandem mass spectra (LC-ESI-MS/MS) for three peptides in the MHC class-
II mass range from eluates of the AML cell line THP-1 following Fe3+ IMAC and C18 RP 
SPE cleanup. Sequences: (A) (Q14517) GKLVYAVSGGNED(pS)CFMIDMET from 
Protocadherin Fat 1; (B) (O75376) K(pS)LITGPSKLSRGM from Nuclear receptor 
corepressor 1; and (C) (ZIPA_PSEP1) (pS)DDDFAADNNRSSGAAPASSSVKE from Cell 
division protein zipA homolog (from P. putida). 
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allows novel fields (text or check-boxes) to be applied as required, as well as 
their content to be automatically applied retroactively to all previous records 
(though if this content is non-uniform, it must be entered/amended manually). 
 
However if this database is considered as a prototype, further versions may 
require additional features. Currently the primary limitation is the manual nature 
of data entry. For maximum efficiency, future versions should be compatible with 
Proteome Discoverer, and allow importing of mass-spectrometric data directly 
into the database. The ability for keyword-searching of online protein/gene 
databases such as Expasy and OMIM (and possibly iHOP) would also allow 
autopopulation of the checkboxes and an automatic generation of significance-
score, avoiding any user bias, or complications from multiple user scoring. 
 
 
6.5   Discussion 
 
While it has been demonstrated that it is possible to elute MHC restricted 
peptides from the surface of suspension and adherent cell lines using the 
minimal lysis buffers, and following fractionation and sample 
concentration/cleanup by chromatography to identify sequences related to 
malignancy and EBV immortalisation, the results are often restricted to a small 
pool of high quality spectra, especially in the case of phosphopeptides and MHC 
class-II peptides. 
 
There are numerous reasons which may lie behind this observation. First and 
foremost the sample size may not be adequate: the figure of 2x109 cells used for 
these elution (Bonner 2002) may not be sufficient for a sub-stochiometric 
population such as phosphorylated peptides, especially given the transient 
nature of this modification (Ishiai et al., 2003), and that peptide phosphorylation 
alters MHC binding (Mohammed, 2008). Zarling et al. (e.g.: 2000; 2006; 
Depontieu; 2009) typically employed up to 5 x 109 cells for both MHC class-I and 
class-II analysis, indicating that higher numbers may be required. This may be 
especially true for MHC class-II phosphopeptides, which given their greater 
length may allow greater sequence variation and therefore even lower 
stochiometric concentrations of each peptide. Higher confidence spectra may 
also be found by the increased sensitivity of the latest ESI and MALDI mass 
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Figure 6.67: In-house MHC peptide database (form view) with the record for TIF1-alpha417-427 (‘@’ denotes phosphorylation). While this protein is known to 
undergo multiple serine phosphorylation events in response to DNA-damage, the point in question (pSer422) has not yet been documented. This 
phosphopeptide was found in duplicate cultures of the same cell line (JY), but not in subsequent elutions. 
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spectrometry technology, which are > 2 orders of magnitude more sensitive 
than the Thermo LTQ ESI model (Pers. Comm. Dr. David Boocock, Nottingham 
Trent University, 2010). 
 
As has been shown no one method is capable of isolating the full range of 
phosphopeptides within the proteome (Bodnar et al., 2007); in all probability 
therefore, Fe3+ IMAC therefore only enriches a proportion of MHC-presented 
phosphopeptides, and whether this proportion differs from tryptic peptides is not 
known at this time. As when MHC class-II peptide Fe3+ IMAC eluates were 
subjected to C18 SPE cleanup the total sample material was found to drop 
significantly, it is believed that there is a poor overlap between C18 and Fe
3+ 
IMAC binding which may significantly hinder a concentration dependent method 
such as mass-spectrometry, and may have lead to an effective underloading of 
the RP HPLC set-up. As MHC-eluates show high scarcity and long lead-times, 
method optimisation has largely been performed using tryptic digests of single 
standard proteins; it is possible that greater optimisation may be achievable 
using proteolytic digests of cell material.  
 
While it might be argued that there is therefore a strong argument for 
performing C18 SPE concentration prior to Fe
3+ IMAC, reducing the sample to 
those which will interact with a C18 resin prior to enriching the phosphorylated 
subcomponent, doing so may remove a high proportion of Fe3+ IMAC binding 
peptides from the sample, and encourage non-specific binding during the IMAC 
stage. It is believed that merely increasing the concentration of the material 
loaded onto the LC-ESI-MS/MS will produce improvements in spectra quality, 
though the use of RP SPE following Fe3+ IMAC may allow the selection of 
phosphopeptides with stronger C18 binding properties, and exclude the unbound 
population, the corresponding chromatographic losses may prove prohibitive. 
 
A simple, though crude method of estimating the increase in concentration 
required might be to determine the proportion of peptides which bind to a C18 
SPE column, and multiply the sample loading concentration by this amount (with 
perhaps a 10-20 % safety margin), though this assumes good inter-resin 
compatibility and inter-sample variation might lead to overloading of the column. 
 
A preferable option would be to perform the LC stage prior to ESI-MS/MS using a 
nanoflow Fe3+ IMAC HPLC system in a manner similar to Kaur-Atwal et al. (2007), 
though this would require a dedicated HPLC-ESI-MS/MS set-up which was not 
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available during the current research period, and would of course require its own 
optimisation.  
 
It is worth noting that many peptides that appeared in earlier MS/MS analyses 
(analysed with Bioworks Browser/SEQUEST) were not found when those same 
files were reanalysed by MASCOT, and for the purposes of clarity these are not 
currently included in the database (Wan et al. [2008] noted that MASCOT is 
superior to SEQUEST in assigning phosphorylation sites). Furthermore, 
numerous peptides present multiple candidate proteins as parents. For some this 
is due to identical or near-identical sequences (or masses, leucine and isoleucine 
are particularly difficult to distinguish from one another by mass). Others have 
missing ions, requiring the MASCOT algorithm to predict missing amino acids 
from the net remaining mass (total peptide mass minus the mass of the ions 
identified). With single absent ions this is easily resolved, as few amino acids will 
exactly match the net remaining mass. However, two or more missing ions may 
lead to misidentification as these amino acids may produce different proteome 
matches when exchanged. The lack of these ions may be due to poor ionisation 
or fragmentation, or PTMs that were not included in the MASCOT search, yet a 
greater number of modifications allow a larger number of mass permutations 
that must be eliminated prior to a putative sequence and protein source, and 
thus each modification adds an exponential increase to the demands in terms of 
computing power/time.  
 
The mass spectrometric analysis of phosphopeptides has long been considered 
more challenging than that of unmodified peptides (Steen et al., 2005). While 
the effect of phosphorylation on binding to reversed-phase columns has already 
been discussed (see 5.3.1), it is often also stated that the negatively charged 
phosphate groups hinder positive ionisation of the peptide for mass spectrometry 
(Barnouin et al. (005) (termed lower ionisation efficiency), though work by Steen 
et al. (2005) indicates that this may be less true than is thought, and is a highly 
variable effect dependent on running conditions, especially for multiply-charged 
ions (Steen et al., 2005). Barnouin et al. (2005) and Edelson-Averbukh et al. 
(2006) recommend the use of negative ion mode rather than the classic positive 
ion approach for improved ionisation efficiency, though this may not be suitable 
for all phosphopeptides, and may result in reduced efficiency for 
nonphosphorylated peptides (Gunawardena et al., 2006). 
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Under the collision induced disassociation (CID)7 approach to ion-fragmentation, 
phosphate groups on serine and threonine show higher lability, and may be lost 
from the parent mass as phosphoric acid (-98 Da) prior to full fragmentation 
(Boersema et al., 2009). This neutral loss event (determined by the division of 
the 90 Da mass between doubly- or triply- charged ions) (Wagner et al., 2006; 
2007) can be measured to identify phosphorylation sites that would otherwise be 
missed (Schroeder et al., 2004; Syka et al., 2004; Wolshin & Weckwerth, 2005). 
Though this approach currently requires semi-manual data analysis, recently 
improvements in spectral analysis software (often combining data from multiple 
mass spectra), used in conjunction with phospho-site prediction algorithms have 
shown a significant improvements in phosphopeptide identification accuracy 
(reviewed in Han et al., 2008). 
 
Many however have found it simpler to chemically modify the phosphate groups 
to one with greater durability/convenience for mass spectrometry, often by β-
elimination and Michael addition 8  (e.g. Steen and Mann, 2002; Wolshin and 
Weckwerth, 2005; Xu et al., 2007b), though as always reaction efficiencies may 
play an important role. It has also been suggested that samples processed using 
reverse-phase set-ups (for either MALDI and ESI-based MS/MS) may be acidified 
using phosphoric acid (0.1-1%) to reduce hydrophilicity and minimise resultant 
sample loss (Kim et al., 2004; Liu et al, 2005). Though the data collected on 
acidification of (albeit a single phosphopeptide) samples with phosphoric acid 
prior to C18 concentration do not reflect these findings (see Figure 5.7), the 
addition of phosphoric acid and ammonium salts to the matrix for MALDI-
TOF/MS may minimise ionic suppression of phopsphopeptides (Kjellsgtrom et al., 
2004; Asara et al., 1999; Yang et al., 2004). 
 
More recently it has been suggested that metal-ion adsorption onto analytical 
columns may lead to phosphopeptide retention in an IMAC-related manner, and 
washing columns with, or even inclusion of chelating agents may improve 
phosphopeptide mass spectra (Winter et al., 2009). This actually opens up the 
possibility of using a step-wise solvent against pH gradient on a reversed-phase 
or mixed mode resin charged with (e.g.) Fe3+, to perform 2-D LC interfaced ESI-
MS/MS for maximum fractionation of a phosphopeptide sample, though the 
                                                 
7
 Or collision activated disassociation (CAD) 
8
 Not only is this not applicable to Y-phosphorylation, but it may also result in β-elimination of O-
linked glycosylations, and the resulting intermediates may be falsely identified as phosphosites 
(D’Ambrosio et al., 2006). 
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effect of metal ion loss (especially co-ordinated by the phosphate group) on the 
spectrometry (and spectrometer) would require investigation.  
 
To conclude, these results indicate the potential for peptides eluted from the 
MHC by way of the novel IMAC compatible class-I and class-II elution buffers to 
be characterised by mass spectrometry following chromatographic fractionation, 
revealing peptides which may be linked to the origins of the cell line in question, 
and in one instance may represent a known cancer epitope. Nevertheless the 
frequency of poor spectra suggest that further method development is required 
in this area (starting with increasing the concentration of samples loaded onto 
the LC-ESI-MS/MS). 
 
Following on from mass spectrometric identification of a candidate peptide, the 
next logical stage would be validation of the antigen-of-interest’s expression by a 
MS-independent approach (e.g. PCR, followed by western blotting) before 
investigation into confirmation of processing and immunogenicity. In the case of 
phosphopeptides, identification of the kinase responsible for peptide 
phosphorylation and determination of phosphorylation status in normal tissues 
are in all likelihood both desirable. 
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7.0  General Discussion 
 
 
Previously of minor interest outside of immunology and hormone signalling, the 
burgeoning field of peptidomics is in no small way linked to the boom in mass-
spectrometric approaches to the biomedical/proteomic sciences (as is partly 
evidenced by the relative under-use of 1D peptide PAGE compared to the 
standard protein-PAGE method). One has only to study the range of known 
tumour epitopes today, compared to that two decades ago to see the impact 
that mass spectrometric identification has had on the discovery of candidate 
antigens. 
 
It is hoped that the modification of the BCA assay for improved accuracy in 
peptide measurement will make some modest contribution towards this field. 
Though the increasing drive towards miniaturisation may render the assay 
obsolete on its current scale, miniaturisation of colorimetric/absorbance based 
assays (e.g. NanoDrop® spectrophotometers) indicate that it may continue to 
play a role in a nano, or even pico-assay set-up (though whether the BCA assay 
is truly linearly scaleable is unknown). As it may be considered only semi-
destructive (the reaction between peptide and reagent is ionic only, though it 
takes place in a pro-oxidative environment), the assay may also see continued 
use as a quantification method prior to chromatographic cleanup (though this 
would likely result in post-quantitative losses). In current usage the modified 
assay has allowed both the relative quantification of peptide/protein loss from 
MHC eluted cell lines, as well as improved accuracy in quantification of 
chromatographic fractions, and applicability to peptide quantification under 
conditions not suitable for UV absorbance. 
 
While identification of cancer antigens may be by direct or reverse immunology, 
the prediction algorithms for MHC binding do not as yet take phosphorylation 
into account, and so the discovery of phosphopeptide epitopes is currently 
restricted to sampling of peptides from the MHC and sequencing by mass 
spectrometry. 
 
As discussed, the method for eluting MHC class-I peptides has changed little in 
two decades, apart from the addition of protease inhibitors, and a general drift 
away from a strictly isotonic formulation. Though historically contamination of 
cell surface eluates with non-MHC presented peptides has been the primary 
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weakness of the approach, more recent findings suggest that the alternative, 
lysis, immunoprecipitation and elution from immobilised MHC molecules may 
produce a different, but complimentary peptide population. Using a combination 
of novel, non-chelating elution buffers, supplemented to minimise cell lysis, and 
a prewash stage to encourage pH-dependent disassociation of non-MHC 
presented peptides from the cell surface, this research aimed to produce cleaner 
MHC class-I eluates, with less contamination by non MHC-presented peptides. 
 
Progress in direct immunology for MHC class-II peptides is something of a 
younger field, and correspondingly fewer epitopes have been found. The 
methodology is restricted to elution of peptides from immunoprecipitated class-II 
molecules (Röhn et al., 2005), no viable cell surface method appears to exist in 
the literature. 
 
Optimisation of a recently developed cell-surface elution buffer for MHC class-II 
was performed along similar lines as the class-I buffer above, producing levels of 
cell death/leakage comparable to the isotonic citrate-phosphate widely used for 
class-I elution. If, as with MHC class-I elution, cell surface elution of class-II 
reveals an only partially overlapping series of peptides, these may provide a 
range of new vaccines to stimulate CD4+-mediated immunity by way of MHC 
class-II leukaemia cells themselves.  
 
Given the relative similarities in structure between the MHC class-I and CD1 
complex, another potential source of contamination lies with glycolipid material 
eluted during peptide elution. Like MHC class-I, β-2 microglobulin has been 
shown to disassociate from CD-1 in a pH-dependent manner, with CD1b showing 
the strongest binding, up to pH 3.0 (Polakova et al., 1993; Moody and Porcelli, 
2003). While the amount of glycolipid contamination of class-I or class-II eluted 
peptides has not been assessed, the presence of such may affect quantification 
and chromatographic fractionation (and potentially also mass spectrometric 
analysis). Removal of these contaminants might be achievable through the 
addition of (e.g. 10 % v/v) chloroform to eluted peptide material, and would 
likely have the additional advantage of denaturing any protein contaminants 
(including proteases, peptidases, kinases and phosphatases). However the 
proportion of eluted peptide material which would partition into the chloroform, 
or to the interphase boundary is unknown, and may require investigation with 
model peptides and glycolipids prior to implementation. 
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While tumour-specific antigens are the gold-standard for immunotherapeutic 
agents, these are often difficult to identify. With the exception of novel 
proteomic entities such as frame-shifted proteins and gene-fusion products, it is 
difficult to be fully confident that what may appear to be a tumour-specific is not 
in fact expressed by somatic tissue under any other conditions. Furthermore, in 
the case of frame-shifts1, expression of the protein may not be required for 
malignancy and an immune response may simply leave behind an 
immunosculptured tumour refractory to that antigen. As abberant kinase activity 
drives the proliferation of many cancers though signalling networks, 
downregulation of the proteins involved in these networks can compromise the 
malignant phenotype. Simultaneously, phosphorylation of proteins not normally 
co-expressed with these kinases can theoretically create novel tumour specific 
antigens which are immunologically distinct from their nonphosphorylated 
counterparts. 
 
Identification of MHC-presented phosphopeptides by mass spectrometry 
combines the challenges of highly heterogenic samples with that of identifying a 
sub-stochiometric phosphopeptide population. Therefore sample fractionation 
and enrichment of the phosphopeptide subcomponent is key to successful 
characterisation. Both Fe3+ IMAC and TiO2-MOAC have been shown as capable of 
MHC-presented phosphopeptide enrichment, though in a wider context it is 
accepted that the phosphopeptide populations they enrich only partly overlap 
(few options are available for the enrichment of non-N phosphorylated peptides). 
Various chromatographic approaches were investigated, primarily with regard to 
selective and nonselective phosphopeptide enrichment/retention. While the 
recently developed mixed-mode HiLIC resin HEA Hypercel showed some promise 
with regard to phosphoprotein/peptide retention (research ongoing), only Fe3+ 
IMAC showed true selectivity. Following minor method development of the 
running conditions; including a debuffering wash with a lower molarity version of 
the loading/wash buffer2 (enabling a subsequent halving of the elution buffer 
                                                 
1
 Additionally mass spectrometric identification relies heavily on (though is not totally restricted to) 
proteomic databases. Novel frame-shifts and gene fusions may not appear in these databases unless 
they have been previously characterised, whereas the same is not true for the determination of a 
phosphosite. 
2
 The use of an isotonic saline wash before treatment with MHC class-I and class-II elution buffers 
follows the same logic; by debuffering the void volume/intercellular media, achievement of MHC 
peptide elution may be confidently achieved without concern that the wash buffers may alter the final 
pH. This may also allow reduction in elution buffer volume, though in the case of suspension cells 
there is a trade-off, as smaller elution volumes result in loss of a greater proportion of eluted material 
into the (relatively constant) intercellular space. 
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molarity / doubling of downstream compatibility, while still rendering a sharp 
increase in peak fraction concentration) IMAC was applied as a preparative 
chromatographic stage to concentrate phosphorylated MHC-presented peptides 
prior to (RP)LC-ESI-MS/MS. 
 
As can be seen, only a limited population of MHC phosphopeptides were 
sequenced with any confidence (especially true with regard to MHC class-II 
phosphopeptides), though the predicted protein sources for many of these can 
be tied back to leukaemia, and in the case of the JY cell line, EBV-linked 
malignancies. Subsequent research has also indicated that poor chromatographic 
binding of Fe3+ IMAC-isolated MHC-phosphopeptides to C18 resins may be at 
least partly responsible for this, with effective underloading of the C18 analytical 
column as a result. Continuing research aims to increase the loading 
concentration of peptides and determine if there is a corresponding improvement 
in the number of confidently identified peptides. Depending on these results the 
use of RP SPE to concentrate/retain C18 binding peptides from the IMAC eluates 
may also be utilised, though chromatographic losses may prove prohibitive. 
 
Of course phosphorylation is not the only post-translational modification 
presented by the MHC. Glycosylation, disulphide bridges, deamidation, 
trifluroacetylation and many other PTMs have been reported (reviewed in 
Engelhard et al., 2006; Petersen et al., 2009). However, in terms of cancer 
immunotherapy and antigen recognition only glycosylation has received 
significant attention; both O- and N-linked glycopeptides have been found to be 
presented by both MHC class-I and –II (Haurum et al., 1999; Xu, et al., 2004b; 
Dengjel et al., 2005; Ostankovitch et al., 2009), and like phosphorylation, 
changes in glycosylation has known associations with cancer (Brooks et al., 2008) 
(though the complexity of the carbohydrate chains can significantly complicate 
analysis) (Freeze, 2003). This is not to imply that changes in other post-
translationally modified peptide expression is not a likely outcome of some 
cancers, but that for most part these modifications lack both the impact and the 
direct and obvious links to malignancy that phosphorylation has. 
 
Following on from peptide identification by mass spectrometry, it is 
recommended that the presence of the target gene/protein is confirmed by PCR, 
western blotting or ELISA, first in the cell line of origin, and then the level of 
expression in leukaemic patient samples. In the case of phosphopeptides the 
picture is more complicated; if the kinase responsible is known then its 
Chapter 4.0: General Discussion 
 232
expression must also be assessed, however if, as is the case for many of the 
phosphopeptides encountered, the phosphorylation site is not in the literature, 
this may require confirmation by proteomic means, including immunoaffinity and 
mass spectrometry of tryptic digests. 
 
Existence and presentation do not however necessarily mean that the 
(phospho)peptide is immunogenic. While there are efforts to develop in silico 
models to predict peptide immunogenicity (e.g. Tung and Ho, 2007), 
inmmunogenicity is a product of peptide-TCR interactions and peptide-MHC 
interactions (as well as the resulting TCR-MHC interactions) and requires 
experimental confirmation (Yu et al., 2004). IF a CTL population specific for the 
peptide(s) in question can be generated, the immunogenicity of the peptides 
may be assessed by CTL mediated killing of the cell line of origin (e.g. K562-A3). 
Again in the case of phosphorylated peptides, the immunogenicity of the non-
phosphorylated form should also be assessed. 
 
When activated, the immune system is capable of rapidly and effectively 
destroying cells and tissues that are recognised as non-self, as evidenced by the 
reaction against mismatched transplants, or by GvHD, where tissue measuring in 
kilograms may be rejected (Robson et al., 2010). However, the history of T cell-
mediated cancer immunotherapy contains many vaccines which appeared highly 
promising in the laboratory, but which failed to deliver significant effects during 
clinical trial (Rosenberg et al., 2004). This, combined with the relatively recent 
discovery of a regulatory cell population within each effector immune cell class, 
and our slowly improving understanding of the role stem cells play in 
malignancies, suggest that new antigens alone will not be the key to successful 
cancer immunotherapy. Instead improved understanding of immuno-modulation 
by cytokines and regulatory cells; how cross-presentation effects immune 
activity; the immunosuppressive effects of tumours; and the role of cancer stem 
cells in tumour growth (and how tolerance/immunoprotection of these stem cells 
operates) are also in all probability required if current efforts into cancer 
immunotherapy are to be improved upon. As several studies have investigated, 
in vivo priming of cells may be less effective than vaccination of ex vivo cell 
preparations (including allogenic bone marrow transplants) (Barrett and Rezvani, 
2007), and multiple peptide or single-peptide-multiple-epitope vaccines may be 
required to generate large numbers of anti-leukaemic CD4+ and CD8+ 
lymphocytes, though an effective peptide-only vaccine would have the 
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advantages of relative stability, lower complexity/risk of pathogen transmission, 
shorter lead times and far lower cost per patient. 
 
The increasing awareness of the benefits to successful therapy of patient 
stratification, and classification of tumours based on their genetic and proteomic 
characteristics (as well as that of the patient), rather than simple morphology or 
tissue of origin suggest a potential role for cell surface-elution in personalised 
medicine. It has been shown that responses to peptide vaccines are highly 
individual (Reynolds et al., 1998), and it is possible that even in MHC allele-
matched patients all suffering an early stage malignancy with a consistent 
mutation (e.g. bcr:abl) multiple peptides may be required to elicit a response in 
all patients. It is conceivable that in the not too distant future the MHC peptide 
repertoire of leukaemic patients might be sampled using cell surface elution 
upon presentation (ideally prior to the prescription of kinase inhibitors), and in 
conjunction with (e.g.) microarray data, potential immunotherapeutic peptides 
may be identified and used in conjunction with imatinib/dasatinib (etc)3 (which 
despite not being capable of clearing a leukaemia when used in isolation, may 
inhibit bcr:abl dependent recruitment of CD4+, CD25+ Treg cells) (Larmonier et al., 
2008). Though obviously such an approach would be significantly aided by 
further improvements in mass spectrometric sensitivity and reductions in 
computational analysis time. Additionally, recent years have seen a large 
increase in the range of software that may be used to analyse MS/MS data 
(including some specifically for phosphopeptide identification), either in isolation 
or integrated with data from other (often high-throughput) methods (Han et al., 
2008). These may be aided by alterations to method workflow, such as that of 
Imanishi et al. (2007) who divided their phosphopeptide enriched fraction into 
two, and dephosphorylated one, significantly increasing the number of correctly 
identified phosphopeptides. Such approaches may of course be aided by 
improvements in the selectivity of existing chromatographic techniques, and 
conversely, improvements in mass spectrometry also allow the use of additional 
chromatographic dimensions, improving sample fractionation and selectivity. 
 
There is therefore still much work to accomplish and many false leads to be 
eliminated before immunotherapy for cancer becomes an effective and routine 
aspect of patient treatment. MHC-presented class-I and class-II peptides appear 
                                                 
3
 A WT-1 vaccine was recently shown to render a previously imatinib-resistant patient sensitive to 
imatinib, and lead to a complete molecular response (Narita et al., 2010 (in a timeframe consistent 
with an effect at the stem cell level (Rojas et al., 2007).  
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to be a strong candidate for achieving total remission in patients, ideally without 
the necessity of a stem-cell transplant, and the aberrant phosphorylation 
patterns found in all cancers may generate tumour specific antigens at the 
epigenetic level. It is hoped that the methods developed herein aid in the 
discovery of successful therapeutic agents. 
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